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Background: Although hip and knee arthroplasties are considered to be common elective cost-effective
operations, up to one-quarter of patients are not satisfied with the operation. A number of risk factors for
implant failure are known, but little is known about the predictors of patient-reported outcomes.
Objectives: (1) Describe current and future needs for lower limb arthroplasties in the UK; (2) describe
important risk factors for poor surgery outcomes and combine them to produce predictive tools (for hip
and knee separately) for poor outcomes; (3) produce a Markov model to enable a detailed health
economic analysis of hip/knee arthroplasty, and for implementing the predictive tool; and (4) test the
practicality of the prediction tools in a pragmatic prospective cohort of lower limb arthroplasty.
Design: The programme was arranged into four work packages. The first three work packages used the
data from large existing data sets such as Clinical Practice Research Datalink, Hospital Episode Statistics
and the National Joint Registry. Work package 4 established a pragmatic cohort of lower limb arthroplasty
to test the practicality of the predictive tools developed within the programme.
Results: The estimated number of total knee replacements (TKRs) and total hip replacements (THRs)
performed in the UK in 2015 was 85,019 and 72,418, respectively. Between 1991 and 2006, the estimated
age-standardised rates (per 100,000 person-years) for a THR increased from 60.3 to 144.6 for women and
from 35.8 to 88.6 for men. The rates for TKR increased from 42.5 to 138.7 for women and from 28.7
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to 99.4 for men. The strongest predictors for poor outcomes were preoperative pain/function scores,
deprivation, age, mental health score and radiographic variable pattern of joint space narrowing. We found
a weak association between body mass index (BMI) and outcomes; however, increased BMI did increase the
risk of revision surgery (a 5-kg/m2 rise in BMI increased THR revision risk by 10.4% and TKR revision risk by
7.7%). We also confirmed that osteoarthritis (OA) severity and migration pattern of the hip predicted
patient-reported outcome measures. The hip predictive tool that we developed performed well, with a
corrected R2 of 23.1% and had good calibration, with only slight overestimation of Oxford Hip Score in the
lowest decile of outcome. The knee tool developed performed less well, with a corrected R2 of 20.2%;
however, it had good calibration. The analysis was restricted by the relatively limited number of variables
available in the extant data sets, something that could be addressed in future studies. We found that the
use of bisphosphonates reduced the risk of revision knee and hip surgery by 46%. Hormone replacement
therapy reduced the risk by 38%, if used for at least 6 months postoperatively. We found that an increased
risk of postoperative fracture was prevented by bisphosphonate use. This result, being observational in
nature, will require confirmation in a randomised controlled trial. The Markov model distinguished between
outcome categories following primary and revision procedures. The resulting outcome prediction tool for
THR and TKR reduced the number and proportion of unsatisfactory outcomes after the operation, saving
NHS resources in the process. The highest savings per quality-adjusted life-year (QALY) forgone were
reported from the oldest patient subgroups (men and women aged ≥ 80 years), with a reported
incremental cost-effectiveness ratio of around £1200 saved per QALY forgone for THRs. In the prospective
cohort of arthroplasty, the performance of the knee model was modest (R2 = 0.14) and that of the hip
model poor (R2 = 0.04). However, the addition of the radiographic OA variable improved the performance
of the hip model (R2 = 0.125 vs. 0.110) and high-sensitivity C-reactive protein improved the performance of
the knee model (R2 = 0.230 vs. 0.216). These data will ideally need replication in an external cohort of a
similar design. The data are not necessarily applicable to other health systems or countries.
Conclusion: The number of total hip and knee replacements will increase in the next decade. High BMI,
although clinically insignificant, is associated with an increased risk of revision surgery and postoperative
complications. Preoperative pain/function, the pattern of joint space narrowing, deprivation index and level
of education were found to be the strongest predictors for THR. Bisphosphonates and hormone therapy
proved to be beneficial for patients undergoing lower limb replacement. The addition of new predictors
collected from the prospective cohort of arthroplasty slightly improved the performance of the predictive
tools, suggesting that the potential improvements in both tools can be achieved using the plethora of
extra variables from the validation cohort. Although currently it would not be cost-effective to implement
the predictive tools in a health-care setting, we feel that the addition of extensive risk factors will improve
the performances of the predictive tools as well as the Markov model, and will prove to be beneficial in
terms of cost-effectiveness. Future analyses are under way and awaiting more promising provisional results.
Future work: Further research should focus on defining and predicting the most important outcome to
the patient.
Funding: The National Institute for Health Research Programme Grants for Applied Research programme.
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Plain English summary
In this project we collected data on the number of hip and knee replacements across the UK. To helphealth-care planning, we have estimated the rapidly growing demand for hip and knee replacements.
We also investigated patient outcomes and developed a new way of measuring the success of surgery
for individual patients. We identified the factors that predict poor results of knee and hip replacements,
postoperative complications and the need for further surgery. We have found that patients who have
severe pain and poorer joint function before surgery experience more unsatisfactory outcomes after
operation. Poor surgery outcomes were associated with older age, deprived socioeconomic background
and poor mental health. Although the association between increased weight and poor outcomes was
weak, we found that overweight patients are more likely to need revision surgery.
We combined risk factors and designed statistical tools separately for hip and knee to identify patients
likely to have unsatisfactory outcomes. We then tested the tools for practicality in two NHS trusts, in
Oxford and Southampton. Although the predictive tools slightly underperformed, inclusion of additional
risk factors in the tools improved their performance. Better results would be likely if we used a wider
spectrum of risk factors.
Economically, hip and knee replacements are, in general, undoubtedly cost-effective in improving the
long-term quality of patients’ lives. It is important, therefore, that any measure that directs patients away
from surgery because of likely poor outcomes is accurate and offers good alternatives. Further work is in
progress to help both patients and their doctors make reliable decisions about future treatment in
individual cases.
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Scientific summary
Background
Hip and knee replacements are considered clinically successful and cost-effective. Revision surgery has
historically been used to measure the outcome of primary total joint replacements; however, this indicated
that up to one-quarter of patients are not satisfied after their operation. Moving towards patient-reported
outcome measures (PROMs), therefore, seems warranted.
Several clinical determinants of poor patient outcome have been published, but they have not been used
as a combined risk score to guide the clinicians, patients and health commissioners. The results of this
programme will help plan future services, educate patients and doctors about benefits and risks of surgery
at patient level, and inform the NHS with its planning.
Objectives
1. To describe current and future rates of primary and revision lower limb joint replacement surgery.
2. To describe regional variation in hip and knee replacement surgery in the UK.
3. To confirm the operational, clinical, biological and other important risk factors for poor outcomes.
4. To combine the risk factors to produce a clinically relevant instrument to predict poor outcomes.
5. To perform detailed health economic analyses of the statistical tools developed.
6. To test, and refine, the prediction tool on a pragmatic, prospective lower limb cohort to predict
patient-specific outcomes at 12 months postoperatively.
Methods
This report describes the findings and outputs from the 5-year programme of health research into the
outcomes of hip and knee arthroplasty. Work packages are displayed in Figure a. The programme identifies
the current rates of primary and revision arthroplasty, and predicts the future requirements for health-care
provision using routinely collected data, for example the Clinical Practice Research Datalink (CPRD), Hospital
Episode Statistics (HES), PROMs and the National Joint Registry (NJR). It identifies and combines preoperative
characteristics that predict poor patient-reported outcomes and produces a predictive model using a
collection of extant UK cohorts. It evaluates the use of this model in a new prospective study of 3000 hip
and knee replacement patients recruited in two hospitals in England (Southampton and Oxford). Finally, it
evaluates the cost-effectiveness of implementing this model using all of the above sources of data.
Findings
Lower limb arthroplasty: the burden on the health service, present and future
In work package 1 we describe current rates of total hip replacements (THRs) and total knee replacements
(TKRs) in the UK and regional variations in hip and knee replacements, and estimate projected future
trends in these operations in the UK. We also describe, for the first time, the lifetime risk of THR and TKR.
We used the CPRD, in addition to the NJR, HES and Health Survey for England, to identify all male and
female patients who underwent THR or TKR from 1991 to 2006. The rates of both procedures increased
substantially over this period but with different trends. The rate of THR increased steadily, whereas the rate
of TKR increased slowly initially but then more rapidly after 2000. We estimate the lifetime risk of TKR to
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be 8.1% for 50-year-old men and 10.8% for 50-year-old women, and the lifetime risk of THR to be 7.1%
for 50-year-old men and 11.6% for 50-year-old women. The popularity of unicompartmental knee
replacement (UKR) has also increased, with the ratio of TKRs to UKRs falling from 250 : 1 in 1999 to 40 : 1
in 2006. We found considerable variation in the rates of THR and TKR between regions included in the
General Practice Research Database (GPRD).
We found that the rates of revision surgery are low. The rates of hip revision remained essentially stable for
the last 10 years, whereas the rates of knee revision increased substantially. This may partially reflect the
recent increase in the rates of primary TKR, but also the established techniques and prostheses for THR.
We have demonstrated that increasing body mass index (BMI) is a risk factor for revision surgery of both
the hip and the knee. This is an important piece of information, but it has to be considered along with the
effect of BMI on PROMs and of complications for which the adverse effects of obesity on outcome are
more obvious.
We predict that the number of THRs and TKRs performed will increase dramatically over the next 20 years.
The different methodologies used give very different estimates. For THR, we feel that the model using
rates fixed at 2010 levels and varying BMI is the most sensible one, and this suggests an annual figure of
95,877 THRs in 2035, a 32% increase in the number of procedures than in 2015. For the knee, we feel
that the rates in 2010 do not represent a balance between need and provision, and that the rates will
continue to rise. The real number required will therefore be greater than the fixed rates and varying BMI
model (118,666), but less than the estimates produced using the log-linear model (1,219,362).
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Lower limb arthroplasty: can we produce a tool to predict outcome and
failure and is it cost-effective?
• To describe the current and future need for primary and
   revision lower limb joint replacement surgery in the UK,
   using the general practice database
• To perform detailed health economic analyses of hip and knee
   arthroplasty and arthroplasty failure using a large
   representative collection of cohorts
• To confirm the important operational, clinical and
   biological risk factors for poor outcomes and prosthesis failure
• To combine the risk factors, using decision analysis, to produce
   a clinically relevant instrument to predict poor outcome and
   replacement failure
• To establish a dual-site pragmatic prospective lower limb
   arthroplasty cohort and use the data to test and refine the
   practicality and effectiveness of the prediction instrument
FIGURE a Summary of work programme. WP, work programme.
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Risk factors and predictive models for poor patient-reported outcome
In work package 2 we describe the predictors of poor patient-reported outcome of THR and TKR at
12 months and combine them into a statistical tool that could be used to identify, prior to lower limb
replacement surgeries, patients who are likely to experience a poor outcome.
First, using existing cohorts from the South West London Elective Orthopaedic Centre, with PROMs at 6, 12
and 24 months, we defined values of the Oxford Hip Score (OHS) and Oxford Knee Score (OKS) that were
associated with patient satisfaction with the operation at 12 months. We used two different statistical
methods to identify the cut-off points: the receiver operating characteristic curve and the 75th percentile
approach. The values were 30 units for TKR and 33 units for THR; however, a single score is not
recommended, as stratified analyses demonstrated varying values depending on age, sex and baseline
score. We propose a new score, percentage of potential change (PoPC), in order to assess the outcome of
surgery. PoPC is computed as the actual change divided by the potential improvement multiplied by 100.
PoPC is a measure to express relativity of an actual change in PROMs in relation to a potential change,
that is, what could have been attained. It demonstrated less heterogeneity when stratifying for important
baseline characteristics of the patients.
We then used these scores to identify predictors of patient-reported outcome. We identified a number
of important variables that could be used to predict outcomes following THR and TKR. These include
preoperative Oxford scores, age, sex, BMI, deprivation index, indication for surgery, anxiety and depression,
and radiographic variables. Age had a variable association, with PROMs being worse in both the youngest
and oldest patients, whereas the risk of revision surgery was higher in younger patients. Increasing BMI
was associated with a higher rate of revision and, although it was associated with a poorer PROM, the
effect size was very small, suggesting that it should not be a barrier to surgery. A radiographic pattern of
joint space narrowing was found to be a strong predictor of outcome following THR, with outcomes being
better in patients in whom joint space loss showed a superolateral pattern than in those with medial,
superomedial or concentric patterns of joint space loss.
We have demonstrated for the first time that the use of bisphosphonates reduces the risk of revision
knee and hip surgery by 46%. Furthermore, we found that hormone replacement therapy reduced the
risk by 38% if used for at least 6 months postoperatively. We have since validated these findings in a
Danish registry. In addition, we found an increased risk of postoperative fracture, which is prevented by
bisphosphonate use.
We have developed separate predictive models for the hip and knee. For the hip model we used data from
two prospective cohorts of patients undergoing primary THR for osteoarthritis (OA), the European
Collaborative Database of Cost and Practice Patterns of Total Hip Replacement study and the Exeter Primary
Outcomes Study, and for the knee model we used the data from Knee Arthroplasty Trial. We identified risk
factors to predict poor outcomes at 12 months after the hip and knee replacements. We used multivariate
imputation to combine data from two studies and allow for missing variables. To validate, and to allow
for overoptimism of, the model we applied automatic backward selection per 200 bootstrap samples of
imputed data sets. The variables retained were those consistently selected for at least 70% of the analyses.
The hip predictive tool included age, sex, baseline OHS, BMI, education, Short Form questionnaire-36 items
(SF-36), SF-36 mental component summary score, number of joints with OA, number of joints with
surgery, radiographic pattern of OA and two surgical variables (femoral offset size and surgical approach).
The model performed well, with a corrected R2 of 23.1%, and had good calibration, with only slight
overestimation of OHS in the lowest decile of outcome.
The knee predictive tool included age, sex, baseline OKS, BMI, deprivation score, Short Form questionnaire-12
items (SF-12), SF-12 mental component summary score, American Society of Anaesthesiologists grade, other
conditions affecting mobility, previous knee surgery, fixed flexion deformity, valgus/varus deformity at baseline
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and preoperative anterior cruciate ligament state (intact yes/no). The model performed less well than the hip
model with a corrected R2 of 20.2%; however, it had good calibration.
Validation of predictive models
Work package 4 evaluated the performance of the models produced above to predict PROMs at 12 months.
We recruited a large unique cohort of approximately 3000 patients from two hospitals (in Southampton and
Oxford) with very comprehensive phenotyping and biological samples collected at baseline. All patients
are followed up annually by means of a postal questionnaire designed to elicit data on PROMs, complications
of surgery and health service utilisation.
The cohort confirmed the excellent PROMs of each operation: the THR preoperative OHS was 18.63 units
[standard deviation (SD) 8.05 units] and the postoperative OHS was 41.06 units (SD 8.96 units), 92%
satisfied; and the TKR preoperative OKS was 20.31 units (SD 7.69 units) and the postoperative OHS was
37.46 units (SD 9.74 units), 87% satisfied. It provided essential data on health resource use, both pre- and
postoperatively. The performance of the knee model was modest (R2 = 0.14) and that of the hip model poor
(R2 = 0.04). However, when the same variables used to develop the original model from the Knee
Arthroplasty Trial (KAT) were used to produce a new model using Clinical Outcomes in Arthroplasty Study
(COASt) data, the performance was improved for the knee model (R2 = 0.216) as opposed to the levels of
performance as the development model (R2 = 0.202). Both models performed better in predicting good
rather than poor outcomes. The addition of radiographic OA severity improved the performance of the hip
model (R2 = 0.125 vs. 0.110) and high-sensitivity C-reactive protein improved the performance of the knee
model (R2 = 0.230 vs. 0.216), demonstrating the importance of expanding the number of patient-based
predictors, a large number of which have been collected in this cohort.
Several factors that affect the performance are discussed in detail, but the degree of imputation required
in the development cohorts, the different case mix and non-comparability of the variables collected in the
development and validation cohort are the most important.
Cost-effectiveness of predictive models
Work package 3 described the costs and utility outcomes of THR and TKR and assessed the cost utility of
implementing the predictive model in clinical practice. We produced a novel Markov model that started at
the orthopaedic surgeon’s assessment and distinguished between outcome categories following primary
and revision procedures. It was populated with the best-quality patient-level data available from numerous
sources (such as GPRD, PROMs and HES), in addition to the cohorts involved in this project. We mapped
the OHS onto the EuroQol-5 Dimensions (EQ-5D) index to enable production of health utilities estimates
from the Oxford scores.
At 12 months post surgery, mean EQ-5D scores were substantially higher among both patients who
underwent hip replacement and those who underwent knee replacement (0.44 and 0.32 units, respectively).
Even patients who were defined as having poor outcomes in this programme experienced a substantial
improvement in score (0.28 units and 0.19 units, respectively). As the cost of surgery is £4000–6000, the
operations are cost-effective interventions, setting a high hurdle for the predictive tool to be cost-effective.
The developed outcome prediction tool for THRs and TKRs did reduce the number of unsatisfactory and
poor outcomes; however, the tool would deny surgery to patients who would have improved significantly,
thereby producing fewer quality-adjusted life-years (QALYs) than current practice.
The highest savings per QALY forgone for THRs were in the oldest patients (aged ≥ 80 years), with an
incremental cost-effectiveness ratio (ICER) of around £1200 saved per QALY forgone. In the case of
TKRs, the highest ICER was reported by younger women (entering the model at 45 years of age), with
£637 saved per each QALY forgone. Keeping patients from surgery, therefore, appears unlikely to be
cost-effective for any tool applied to such a highly successful operation, unless the tool is extremely
sensitive and specific.
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The Markov model produced will now be extremely useful for assessing the impact of current strategies
aimed at restricting access to lower limb arthroplasty, including those based on BMI thresholds. It will also
be essential for modelling new interventions produced.
Conclusions
This programme has calculated the number of hip and knee replacement operations performed in the
past and projected to be performed in the future, which will help in planning services. It has defined a
poor outcome using PROMs and identified a number of important predictors of PROMs. Increased BMI is
statistically significantly associated with poorer PROMs, but the effect size is small and almost certainly not
clinically significant. It is, however, associated with an increased risk of revision surgery and postoperative
complications, something that needs to be considered when making a decision to operate. We found
that bisphosphonates reduce postoperative fractures and the need for revision surgery, and subsequently
validated this finding.
Although we have produced a predictive tool for outcome, it cannot be cost-effectively implemented in
its current form. However, we have demonstrated that the addition of extra variables to the previously
described list of predictors does improve the performance of the predictive tools. Further work is being
performed to refine and improve the predictive tools using more extensive and novel risk factors. We
believe that the work will prove to be very useful as part of patient decision aids in the future.
The Markov model and the collection of cohorts produced in this programme will prove beneficial for
assessment of any future therapeutic or health-care delivery interventions.
Several areas of future research would use this programme as a foundation. This could involve:
l developing and testing a potential postoperative prediction model
l exploring novel potential predictors such as bone mineral density, vitamin D, bone markers and better
phenotyping of mental status
l producing a new bespoke model in the validation cohort with external validation in a contemporary
Geneva Arthroplasty Registry
l obtaining annual follow-up scores from the validation cohort for a longer period with a view to having
long-term PROMs and also revision rates
l exploring the economic effects of new therapeutic and care delivery interventions (e.g. BMI restriction
criteria) using the Markov model.
Funding
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Chapter 1 Introduction
Background
Osteoarthritis (OA) is one of the most common musculoskeletal conditions worldwide and accounts for
> 90% of total knee replacement (TKR) and total hip replacement (THR) procedures in the UK.1 There is
currently no acceptable medical therapy for reducing the onset or progression of OA and the current
treatments are aimed at symptom relief and increasing mobility.2,3 The only successful treatment for
patients with OA of the lower limbs is arthroplasty.
A wide range of high-quality support measures and treatments are needed for individuals suffering from
musculoskeletal conditions. Choice of treatment is based on type of condition, severity of symptoms
and access to health-care services and professionals. An estimated 30% of general practitioner (GP)
consultations4 and 40% of visits to NHS walk-in centres are for musculoskeletal-related conditions.5,6
Currently, lower limb arthroplasty is the most common and most successful elective orthopaedic procedure
undertaken in the UK in patients with OA affecting the hip and knee joints.7,8 It provides substantial relief
from pain and improves physical function,2,8–10 and is considered the most successful and cost-effective
operation for end-stage disease.2,9,11,12 It is therefore not unexpected that the workload of trauma and
orthopaedic surgical services has intensified.
Musculoskeletal conditions are a major cause of ill health, pain and disability, placing a significant burden
on the NHS.13 Evidence suggests that this burden will only increase as a result of a growing elderly
population and an increase in obesity.14 A combination of these factors, in association with related
comorbidities,15 highlights an urgent need for accurate and reliable data to ensure effective long-term
planning and equitable resource allocation across all regions in the UK. It is therefore essential that the
current needs for surgery are accurately described and future trends estimated for effective planning of
health-care services.
Surgical trends
It has been estimated that a total of 52,048 THRs and 44,645 TKRs were performed in 2002, and
the number of elective procedures increased markedly in the period 1989–2004.16 These surgical
interventions remain the top elective procedures performed by orthopaedic surgeons in the NHS and,
in the 12 months to April 2012, a total of 75,366 hip replacements and 76,497 knee replacements were
performed17 in the NHS.
The reasons for the increase in demand are widely debated and suggested explanations include improved
instrumentation and prostheses survival rates, but also increasing numbers of patients with OA (related
or unrelated to comorbid chronic conditions such as obesity) and the significant increase in total joint
replacements (TJRs) among individuals aged > 55 years.18
Patient choice is important to understand and may be a factor affecting demand, as suggested by a Canadian
study assessing OA patients’ perception of total joint arthroplasty as an intervention, which found that the
willingness to undergo surgery was inversely associated with misperceptions about its appropriateness.19
The same team also found low rates of willingness among those with disabling arthritis.20 Women seemed
to be less willing than men to undergo surgery21 and less willing to undergo TKR than THR22 as a suitable
intervention. Jüni et al.23 previously reported that 32% of patients considered for TKR, for a variety of
reasons, did not consider surgery an option. The group conducted a population-based study of TKR in the
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south-west of England, using an assessment of need based on the New Zealand Score,24 and found that
differences in the perception of disease severity may account for some of the underprovision reported by the
study team.
Some estimates have been produced from historical rates of arthroplasty but up-to-date information is
essential to estimate future rates. Historically, published findings were often based on small data sets
unrepresentative of a general population and administrative codes lacked specificity. The potential of these
codes in providing accurate and clinical descriptions was recognised, and revision codes were updated in
October 2005.25 Furthermore, published results have used simplistic models to predict changes in future
rates and have produced unrealistic information.22
Predictors of surgery outcomes and prediction tool
Although the majority of patients improve after hip and knee arthroplasty, an important group of patients
continue to experience some pain and functional disability after THRs and TKRs, and some experience no
improvement or get worse.26–35 This especially applies to TKR surgeries, as a number of studies have
identified that a small minority of patients are not satisfied with their knee replacements.26,34,36
Arthroplasties are successful interventions for end-stage disease and have been known to provide pain relief
and improved physical function.8 However, for years, the approach has tended to focus on revision as an
outcome, with few data on patient-reported outcomes. In more recent years, the government has accepted
the importance of patient-reported outcomes for this operation and introduced the patient-reported
outcome measures (PROMs) for monitoring the outcomes of such patients.
There is consistent evidence in the joint arthroplasty literature that up to 30% of patients are dissatisfied
with their outcomes.37,38 It still not entirely clear from the available evidence what factors contribute to
dissatisfaction. For example, Gandhi et al.38 and Hawker et al.26 found that preoperative pain and function
were not associated with patient satisfaction and, yet, Kim et al.39 and Scott et al.40 demonstrated that less
preoperative pain is suggestive of increased satisfaction.
As a result of advances in arthroplasty devices and improvements in technical surgical skills and expertise,
a successful long-term outcome is now achieved in the majority of patients undergoing hip or knee
replacements. It has, however, also become evident that prosthesis survival may not be an accurate or true
measure of success when patient satisfaction is taken into account and, by this criterion, a small but
important group of patients do not improve or even get worse.27 Following this understanding, the focus
has moved away from implant survival to patient-reported outcomes that concentrate on the patient’s
experience and level of satisfaction with the operation.41 The difficulty lies with identifying the
determinants of outcome, as well as using the most appropriate and accurate method for collecting and
interpreting the patient-reported outcomes. A successful joint replacement should result in pain relief,
function improvement and patient satisfaction.42
Total hip replacement is successful in the majority of patients. However, there is growing evidence that a
small, but important, minority of patients show no improvement or get worse.27,32,33,35 PROMs are now
commonly used to determine the result of knee and hip surgical interventions. However, little work has
been done to establish the predictors of good or bad patient-reported outcomes after THR.43
Determinants of outcomes for THR have been widely researched and include baseline levels of pain and
function,32,44–47 severity of clinical disease,45 age,45,47,48 sex,45,46,49 radiographic grade,45,50 education,32,44,49,50
obesity,46,48 comorbidities,32,46 living alone,46,51 mental health47 and patients’ expectation of surgery.52 The
results in literature are conflicting. For example, some studies have found that age, sex, body mass index
(BMI) and comorbidities are not predictive of outcome,26,37–40 whereas others have found that a lower level
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of education and higher BMI are associated with dissatisfaction,26 and Noble et al.53 found an association
between age and satisfaction.53
Validation of some key issues about age, sex, rates and indication for surgery is needed for a better
understanding of these surgical interventions in order to effectively target treatment. Of the patient factors
for poor outcome, there is ongoing controversy as to the role of obesity.54 Although some have found no
difference in clinical outcome after THR6 or TKR,55 others have demonstrated that obesity is a recognised
risk factor for poor outcome after TKR.6,56
Surgical technique and implant type are important factors in the outcome of hip and knee arthroplasty.
However, in a recent systematic review, Kynaston-Pearson et al.57 reported that there is no clinical evidence of
effectiveness in one-quarter of available hip prostheses in the UK. The relationships between implant users,
manufacturers and suppliers have been in development over a number of years, as implant costs contribute
appreciably to the overall cost of surgery. Lack of implant regulation became an area of focused concentration
recently as a result of the adverse outcomes in metal-on-metal resurfacings and large-bearing-surface implants.58
It is only recently that regulatory frameworks have started to focus on the safety regulations around
implants, and much more needs to be done to ensure that tested prosthetics are both safe and clinically
effective.3 Other technical factors include case volume, technique and choice of prosthesis. Technical
factors in performing surgery, such as component alignment,59 influence both the short- and long-term
success rates. The technical ability of the surgeon also plays a vital role in the successful outcome of hip
and knee replacements, and continues to drive the ongoing development and refinement of implants,
surgical techniques, skills and training.
Historically, most research has focused on implant failure as the main outcome. There are three main
causes of implant failure: aseptic osteolysis, infection and inflammation. Osteolysis results, in part, from
resin wear, leading to local inflammation and accelerated bone resorption.60 Differences between implant
design, resin storage and type affect resin wear and osteolysis.61,62 Currently, radiographic assessment
has poor sensitivity for detecting osteolysis, requiring at least 50% of demineralisation to occur before
osteolysis can be detected. However, osteolysis may be better detected using structural measurements,
such as fractal analysis, than changes in density.63,64 Although initially considered a purely degenerative
disease, there is increased inflammation in both synovial fluid and cell membranes of osteoarthritic joints,
and this may play a key role in arthroplasty failure.65
Other common complications of arthroplasties include infection, vascular or thrombotic compromise,
dislocation, instability and fracture. Infection is a common cause of early failure and can lead to
significantly poorer clinical outcomes, such as amputation or revision surgery. Deep-seated infections may
be the leading cause of implant failure over the next 20 years.66 The diagnosis of surgical site infection
following TJR requires a balance between quality and practicality. Revision after septic failures has a higher
failure rate than revision after aseptic failures, highlighting the importance of accurate identification
of sepsis.60
Extensive research into the diseases commonly associated with degenerative changes in joints has been
conducted, as an understanding of the underlying causes could assist with predicting the outcome of
surgery. One of the most common musculoskeletal conditions, OA, accounted for > 90% of the total knee
and hip arthroplasties (153,000 procedures) in the UK up to 2010.1 OA is the major cause of health, pain
and disability and increased mortality. Two main risk factors for OA are age and obesity, both of which are
increasing in the population in the West.67 For this reason, it is almost inevitable that the prevalence of OA
will increase substantially in the next 20 years.68
Osteoarthritis has been recognised as a global burden and is the most frequent primary indication for
total hip and knee replacements in the UK,69 accounting for 93% of hip replacements and 97% of knee
replacements in England and Wales.70 In the UK, 550,000 people have moderate to severe knee OA and
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210,000 moderate to severe hip OA. Each year approximately 2 million people consult their GP for OA
and 115,000 are admitted to hospital. The prevalence of hip and knee OA is particularly high in the
population aged > 60 years.71–74 The lifetime risk of hip OA has been calculated at 25%75 and of knee OA
has been calculated at 45%.14,71,76 Changes in the reported prevalence of OA, such as the overall increase
and increased prevalence in younger patients found by Kim,14 have to be substantiated and validated to
inform new treatment algorithms for local services.
Patient selection,3,77 implant design and surgical technique are all key factors that could affect the durability
of a prosthetic implant.78 Historically, outcome studies used continuous variables at population levels to
identify statistically significant predictors; however, their clinical relevance is less clearly understood,
especially by patients. Understanding and identifying patients at risk of poor patient-reported outcomes and
presenting these in a clinically meaningful way to an individual patient will enable clinicians to evaluate the
risks and benefits of surgery on an individual level.
The lack of information led to well-publicised decisions by primary care trusts (PCTs) in Suffolk to
temporarily withhold hip and knee arthroplasty from obese subjects.79 This decision was overturned
because of a lack of supporting evidence. We urgently need data to identify patients at a high risk of poor
outcome both before surgery, in order to minimise risk factors, and in the early postoperative period, to
initiate urgent interventions to improve outcomes and prioritise resources.
A number of individual determinants of implant failure have been described in the literature; however, the
majority of patients exhibit more than one cause of failure,59 and the benefit of combining risk factors are
not known. The current literature describes a wide range of risk factors in a prognostic model,80,81 including
age, sex, education, obesity, mental health status, preoperative level of pain and function, indication for
surgery, coexisting conditions, radiographic variables (radiographic grade) and surgery-related risk factors
(i.e. femoral component offset). In this programme we aimed to develop similar prognostic models for the
knee and hip, and to include a wider range of risk factors to predict pain and function outcomes.
As personalised medicine becomes increasingly common, it is essential that the correct patients are chosen
to undergo hip and knee arthroplasties, which are important but complex procedures. This emphasises the
importance of understanding the predictors of patient-reported outcomes of satisfaction and pain or function
scores. This programme aims to address these issues. Previous work on outcomes focused very heavily
on prosthesis and little attention was paid to surgical- and patient-related factors that predict outcomes.
It is important to look at all three components and their interactions to predict surgery outcomes accurately.
The information then can be used to identify patients with good or poor outcomes and form the clinical
decision-making tool to allow stratification of patients for surgeries with patient-informed consent.
With increasing restrictions on funding in the NHS, it is critical to have accurate and reliable data from
practice, alongside current and future population-based estimates, for a better understanding of these
surgical interventions. This would aid our understanding of the clinical effectiveness and cost-effectiveness
of lower limb arthroplasty and help to target resources more efficiently.
Cost-effectiveness of implementation of the tools
Lower limb arthroplasties are a considerable burden on NHS resources. Estimations by Jenkins et al.82
suggest the cost per procedure to be in excess of £7000. In the USA, TJR is a cost-saving or cost-effective
procedure in those with significant functional limitation as it avoids high care costs resulting from the
disability of OA.83 Early improvements in the management of patients, such as decreasing length of stay,
resulted in overall reduced costs.84,85 Although the overall costs of primary TJR have decreased, the
procedural costs of revision surgery continue to increase.86 In the UK implant survival data are impressive,
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with a 5-year revision rate of 4.5% for THR and 5.1% for TKR.7 Yet, although it may be a technically
successful replacement, up to 20% of knee replacement patients still have a poor outcome and a small,
but important, proportion of patients who have had hip replacements do not achieve a clinically
meaningful symptomatic improvement or their symptoms get worse.27,87
Accurate cost-effectiveness data are essential for the appropriate evaluation within the NHS of the
incremental cost-effectiveness ratio (ICER) of using more expensive prosthetic components that may
improve implant survival.88,89 As well as validated predictors of poor outcome following TJR outcome,
cost implications are important for informing patient expectations.90
In addition to optimising the outcome of patients undergoing arthroplasty, it is important for NHS
commissioners to have accurate data on the cost-effectiveness and cost–utility of these operations. Current
health economic data are limited for several reasons. The main limitations of the data on utility gains post
surgery are that they are from small cohorts, they do not differentiate between different patient profiles,
they are limited to outcomes at 10 years, with limited data on short-term gains, and, importantly, they use
revision surgery and not ongoing health-care utilisation as a result poor functional outcomes.
In this programme we aimed to design a clinical tool to predict patients who will experience poor
outcomes following THR and TKR. Taking into account the fact that these procedures are costly and exert
a significant burden on the NHS, we need to ascertain if the additional cost of the implementing tools
would be worthwhile in terms of benefits to an already overstretched current health-care system; that is,
if the tools would be a cost-effective use of resources in the UK health-care system. With this in mind, we
aim to provide an economic evaluation of the implementation of the tool in the health-care setting. The
availability of predictive tools, and detailed cost-effectiveness and cost–utility data will help to produce a
coherent strategy for the provision of a clinically effective and cost-effective strategy for the provision of
lower limb arthroplasty in the NHS. The information collected and analysed in the development of a
predictive tool for hip and knee replacement will also support the development of patient-based, informed
decision-making programmes.91
External validation of the tool
As part of the programme we aimed to test the productiveness, practicality and cost-effectiveness of the
developed tool in the pragmatic cohort of NHS setting. This required us to recruit a cohort of patients
undergoing hip and knee arthroplasties in which the productiveness, practicality and cost-effectiveness of
the tools would be tested.
Aims of the programme grant
We aimed to inform the policy-makers of the current health-care system in the UK about predicting
the outcomes and failure of lower limb arthroplasty, and give advice on the cost-effectiveness of
implementation of predictive tools. We set out to achieve this through four work packages (1–4),
as described in the subsequent chapters (see Chapters 2–5) of this report.
In Chapter 2 (work package 1) we describe the current and future needs for primary and revision lower
limb joint replacement surgeries in the UK using a national longitudinal prospective database.
In Chapter 3 (work package 2) we look at the predictors of poor outcome following lower limb arthroplasties
using extant databases. We report on combining these databases to produce predictive tools separately for
knee and hip for patient-reported outcomes at 12 months.
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In Chapter 4 (work package 3) we describe the detailed body of work looking at the cost-effectiveness of
implementing the tool to predict the outcomes following knee and hip arthroplasties using the extant
databases, nationally available routine data and our prospective cohort of patients who were recruited in
work package 4.
In Chapter 5 (work package 4) we describe our prospective new cohort and the steps performed in this
prospective pragmatic cohort to detail the external validation of the tools developed in work package 2.
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Chapter 2 Work package 1: current and future
rates of lower limb arthroplasties
This chapter describes the current and future needs for primary and revision lower limb joint replacementsurgeries in the UK using a national prospective database.
The chapter contains information covered in work package 1. The objectives in this work package were to:
1. describe and estimate the rates of THR, TKR and unicompartmental knee replacement (UKR) in the UK
2. describe regional and national variation in hip and knee replacement surgery in the UK
3. describe the mechanics of revision for hip and knee arthroplasty and quantify the rates in the UK
4. predict future trends in hip and knee surgery in the UK, accounting for projected changes in age
and obesity.
Design and setting
In order to quantify the rates of lower limb arthroplasty in the UK we used a prospective cohort from the
Clinical Practice Research Datalink (CPRD), formerly known as the General Practice Research Database
(GPRD). The CPRD is a recognised and frequently utilised database in epidemiological studies,92 and is
validated.69,93 It is a computerised medical records system that is representative of the UK population and has
been validated for a wide range of medical conditions.94 The CPRD database has data from over 6 million
patients across more than 600 practices and has been collecting data since 1987. The data set has been
validated and audited, and only practices providing good-quality data are admitted. Every patient is registered
with one general practice. GPs are responsible for providing primary care and referral services to their patients
and keep comprehensive records that contain prescription data, clinical events, specialist referrals, hospital
admissions and their major outcomes. These systems are commonly used in general practice for the
classification of diseases. Personal details are encoded and all patients are provided with clinic identifiers to
ensure confidentiality. The database is administered by the Medicines and Healthcare products Regulatory
Agency. The CPRD database provides a unique resource to examine the outcome of joint arthroplasty.
The CPRD database is accepted as being broadly representative of the UK population with respect to age,
sex, socioeconomic circumstances and region; the data and Read codes for diseases (see Appendix 1),
which are cross-referenced to the International Classification of Diseases, Ninth Edition,94–96 are stored in
the Oxford Medical Information System (OXMIS).
The CPRD data were used to answer several research questions within different outputs, which contributed
to the results described in this chapter. The design details of the bespoke computer programs written to
manipulate and post-process the raw CPRD data are not provided. The methods used in the published
articles,67,97–99 produced as part of work package 1, are described in general terms.
The CRPD data are routinely gathered for contributing practices and are not explicitly censored, other than
when patients die or when they leave a general practice. The data delivered to our research team were
truncated at 31 December 2006 for practical purposes, as the data ‘cut’ were taken from the main CPRD
database shortly thereafter. No minimum contribution time was imposed, but the CPRD does impose a
practice-level requirement that the data delivered to the database by each practice should be ‘up to standard’
according to the CPRD’s definitions, which in effect means that each practice submits data for up to 6 months
before the data were confirmed as being up to standard. Other than this exclusion criterion, which is applied
to all CPRD studies, we applied no further inclusion/exclusion criteria other than those reported in the
individual research outputs written. Consequently, studies using CPRD data are ‘real world’, in the sense that
the data recorded in general practice are used as research data, and therefore constitute a sensible sample
from which to make population-level inferences about the UK population of GP-registered patients.
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Sets of Read codes (see Appendix 1) (including remapped OXMIS codes, which have been phased out)
were used for all of the data selection from the CPRD. Two or more clinicians validated the code lists for
replacement procedures and clinical consensus was reached. Regarding the potential miscoding of primary
THR/TKR, we took the first code match as the date of primary replacement.
A small number of subjects were found to have more than two primary operations, which is not strictly
possible according to the usual definition, and without linkage to register data it is impossible to know which
are genuine and which are not. Similarly, sidedness (left or right) of the procedure is not identifiable from Read
codes. We took a pragmatic but consistent approach by identifying the first primary encountered as the one to
use. In addition, we acknowledge that, without detail on sidedness, we cannot be sure that, for example, a
left-sided revision was matched with a left-sided primary, but register data suggest that the effect of these
potential mismatches on estimated incidence rates, lifetime risks and hazard ratios (HRs) would be small.
The first phase of using the data set for this work package involved the construction and validation of the
GPRD data set with internal checks for consistency. During the analyses we also compared the summary
data set with other available and appropriate data sets such as the National Joint Registry (NJR) for England
and Wales, Hospital Episode Statistics (HES) and Health Survey for England (HSE), and population forecast
data from the Office for National Statistics (ONS) in order to establish external validity.
Main exposure
The main exposure is primary arthroplasty. The selected cohort contains all of the patients with a code for
primary or revision hip or knee replacement surgery and meets the criteria for each particular analysis.
Outcome measures
This work package centres on describing the epidemiology of hip and knee replacements. The relevant
outcome measures are incidence rates, estimates of revision risk and future projections of procedure counts.
Rates of total hip replacement, total knee replacement and
unicompartmental knee replacement in the UK
Temporal trends
Temporal trends in hip and knee replacement in the UK67
Total joint arthroplasty is a successful surgical intervention and is considered reliable and effective for
pain relief and improved function and quality of life, with 90% prosthesis survival at 10 years.3,8 In total,
160,000 hip and knee replacements were carried out in England and Wales in the 12 months prior to
April 2010.70 This number is expected to rise, and studies from the USA predict an increase in hip
replacements (174%) and knee replacements (673%) to nearly 3.5 million per annum by 2030.66 More
than 650,000 knee replacements alone were carried out in the USA in 2008,100 and almost 80,000 in the
UK in 2009.17 The USA saw the number of knee surgeries increase from 31.2 per 100,000 person-years
[95% confidence interval (CI) 25.3 to 37.1 per 100,000 person-years] in 1971–1976, to 220.9 per 100,000
person-years (95% CI 206.7 to 235.0 per 100,000 person-years) in 2008.101
For the analysis we selected the patient data with a medical diagnosis code for THR (n = 27,113) or TKR
(n = 23,843) between 1991 and the end of 2006. Patients were included if they were aged > 18 years
at the time of operation. Evidence suggests that 20% of THR/TKRs in England are carried out in private
institutions102 and the impact of this on arthroplasty provision needs further investigation. However, as the
CPRD database had not been validated at this time, private practice codes were not included in the
analysis. The NHS rates were validated using the HES (2005–6)103 and NJR.104
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Directly age- and sex-standardised replacement rates for calendar years were calculated using 10-year
age groups with the mid-year population estimates for 2003 as the reference standard, as published by
the ONS,105,106 the General Register Office for Scotland and the Northern Ireland Statistics and Research
Agency. The 95% CI was computed using the Poisson model appropriate for directly standardised rates.
The mean age at total replacement was calculated for the hip and knee for each calendar year and
95% CIs computed. To investigate patterns over time we calculated age distribution at operation by sex
for three consecutive 5-year periods for the hip and knee.
The estimated age-standardised rate of THR increased from 60.3 per 100,000 person-years (95% CI 53.7 to
67.0 per 100,000 person-years) to 144.6 per 100,000 person-years (95% CI 138.1 to 151.1 per 100,000
person-years) for women (Figure 1a), and from 35.8 per 100,000 person-years (95% CI 30.4 to 41.3 per
100,000 person-years) to 88.6 per 100,000 person-years (95% CI 83.4 to 93.7 per 100,000 person-years)
for men (Figure 1b). The increase in rates over time for THRs were steady between 1993 and 2005. The rate of
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TKR increased from 42.5 per 100,000 person-years (95% CI 37.0 to 48.0 per 100,000 person-years) to 138.7
per 100,000 person-years (95% CI 132.3 to 145.0 per 100,000 person-years) for women (see Figure 1a), and
from 28.7 per 100,000 person-years (95% CI 23.9 to 33.6 per 100,000 person-years) to 99.4 per 100,000
person-years (95% CI 93.9 to 104.8 per 100,000 person-years) for men (see Figure 1b). The temporal trend
for knees showed a marked plateau from the mid-1990s, followed by a sharp rise from 2000.
The mean age at operation was significantly higher for women than for men for all years after 1991: the
mean age at THR was 70.3 years (95% CI 69.8 to 70.8 years) for women and 67.6 years (95% CI 66.9 to
68.2 years) for men; and the mean age at TKR was 70.1 years (95% CI 69.6 to 70.5 years) for women and
69.2 years (95% CI 68.6 to 69.7 years) for men. The highest rates of THRs and TKRs were for women
aged between 70 and 79 years, with a mean rate of THR of 541.8 per 100,000 person-years (95% CI
501.0 to 582.5 per 100,000 person-years) and of TKR of 555.3 per 100,000 person-years (95% CI 514.1
to 596 per 100,000 person-years).
The final results showed that the rates of hip and knee arthroplasty continued to increase, but that the
rise was more marked for knees than for hips. Women were 67% more likely than men to undergo THR,
and 45% were more likely to undergo TKR, but sex ratios have been consistent over time, as demonstrated
in Figure 2.
Women were, on average, 3 years older than men at THR, but the age difference between men and
women undergoing knee replacements was only half as great. BMI was significantly higher for patients
undergoing TKR than for those undergoing THR (p < 0.0001) and was higher for women than for men.
There was little sex difference in the number of replacements carried out in patients between the ages of
60 and 79 years, who made up almost two-thirds of the total number of patients undergoing arthroplasty
during 1991–2006.
Unicompartmental knee replacements are also becoming more popular, and the rates have increased over
the last decade. We, again, used CPRD data and Read/OXMIS codes to identify all patients who underwent
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primary TKR or UKR between 1986 and 2006. However, the final analysis was restricted to the use of data
between 1999 and 2006, as very few UKRs were carried out before this time.
The results of the statistical analysis give the number of TKRs and UKRs performed in each year; the mean
age [and standard deviation (SD)] of patients of each sex and undergoing each type of operation was
calculated to explore the profile for each intervention. The total numbers of TKRs and UKRs performed in
the UK in 2006 were estimated by applying the CPRD rates to the population of the UK in that year.
There were substantially more TKRs (n = 18,450) than UKRs (n = 266) in 2006. The rate of TKRs increased
from 55.4 per 100,000 person-years in 1999 to 123.5 per 100,000 person-years in 2006. The rate of UKRs
increased from 0.25 per 100,000 person-years in 1999 to 3.0 per 100,000 person-years in 2006. Both
men and women undergoing UKR were, on average, younger than those undergoing TKR (p < 0.0001).
Men who underwent TKR were, on average, younger than women undergoing TKR (p < 0.0001). There
was no statistically significant difference between the mean age of men and women undergoing UKRs
(p = 0.74). TKR was performed more often in women (n = 10,836) than in men (n = 7614), but UKR was
performed less often in women (n = 126) than in men (n = 140). The ratio of TKRs to UKRs fell from
250 : 1 in 1999 to 40 : 1 in 2006. The estimated numbers of operations performed in 2006 were 74,800
TKRs and 1800 UKRs.
The results showed a 12-fold increase in UKRs since 1999, and that this was still significantly less than
TKRs, and UKRs are performed on a younger age group than TKRs.
Regional and national variation for hip and knee replacement surgery
in the UK
Geographical and sociodemographic variations play an important role in the provision of, and access to,
health care. Estimates of the mismatch of need and provision have been published by Judge et al.107 and
were found to be greater for TKR than for THR. There seems to be a wide variation in intervention rates
for revision surgery across PCTs and the reasons need to be understood more clearly.
We looked at regional variations in the UK using CPRD data for 1986–2006 and found inter-regional
differences in joint replacement rates. Using Read/OXMIS codes we identified 28,068 THRs and
24,364 TKRs.
Incidence was calculated by dividing the number of replacement operations by the number of person-years
in the GPRD population. The rates were directly age and sex standardised, and computed by region,
using a reference population (mid-2003 ONS population estimates). A 95% CI was calculated using a
Poisson model.
Marked temporal changes were observed within and between certain regions. The reason for these
differences is not clear, but factors such as medical indications and contraindications, personal and social
perceptions of surgery as well as the availability of orthopaedic services should be considered. Figure 3
shows the example of regional differences in hip replacement rates between south-west England and
London, standardised by age.
The GPRD data showed significant inter-regional differences in joint replacement rates in the UK in the
period 1991–2006. Marked temporal changes were observed within and between certain regions, and
the differences are larger for hips than for knees. This is supported by other studies also using national
databases and registries within the UK. Inequities and inequalities currently exist within the UK health-care
system,109 but the reasons need further investigation.
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Describing the revision rates for hip and knee arthroplasty, and
quantifying the rates in the UK
Total joint replacements are very successful operations, but a number of patients continue to have problems
or are not satisfied with the outcome. Hawker27 estimated that up to 30% do not have symptomatic
improvement after surgery. A further 20% of patients report unfavourable long-term pain.87 There are many
types of implants, and they are likely to be revised within the lifetime of a patient; for example, it is expected
that a metal-on-polyethylene implant will need to be replaced after 20 years because of wear or prosthetic
loosening. This is one of the reasons why THR and TKRs were indicated for mainly older patients. Even more
modern prosthetics, making use of the latest technological advances, are not routinely recommended for
younger patients. A UK population-based survey of patients after TKR found that 20% were not satisfied.36
TJRs have, on average, a prosthesis survival rate of 90% at 10 years,110 and none has an indefinite lifespan.17,111
They are considered economical because of the low failure rate,78,112,113 but surgical intervention is
recommended when they do fail. Revision surgery is a high-risk procedure with a significantly higher mortality
and morbidity than primary joint replacement, and is more costly than primary replacements.114,115
The revision rate is expected to increase as the population that requires hip and knee surgery increases
because of an increase in lifespan in developed countries and changing demographics. Dixon et al.116
examined the trend in primary and revision TJRs in England and found a rapid increase in the proportion of
hip surgeries requiring subsequent revision between 1991 and 2000, from 1 in 12 to 1 in 5; the number
of knee revisions tripled over the same period, from 1 in 33 to 1 in 11.116 The increase in revision rates is
expected to continue in parallel with the steady increase of primary joint replacements.117 Kurtz et al.66
predicted an increase of 137% in hip revisions and of 601% in knee revisions in the USA by 2030 than
2005. Evidence from the Scandinavian National Joint Registries118 further demonstrates that the mean age
for joint replacement is also decreasing.
An understanding of the reasons for failure, and success, of arthroplasty surgery is essential for guidance
with implant design and clinical decision-making. Revision surgery is primarily indicated by implant
loosening, instability through implant wear, or osteolysis and complications.
National and international registry data have been used extensively to estimate time to revision119 and to
model prosthesis survival time in order to assess which specific demographic, clinical and prosthetic-specific
factors are associated with time to failure.120,121 Appropriate commissioning of services will reduce waiting
times by matching demand with capacity and improved health-care delivery. Compared with primary TJR,
revision TJR is more costly and more technically difficult, and results in only a 65% improvement in symptoms,
although it remains a cost-effective method for improving function, pain relief and quality of life.117
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Revision rates continue to increase despite advances in surgical technique and implant design and the reasons
for this remain unclear. Without this understanding it is difficult to address implant survival and long-term
patient outcomes.122
To determine the revision rates for the UK, we obtained data between 1991 and 2006 from the CPRD
database. We used Read/OXMIS codes to identify all revisions to hip and knee replacements. Patients aged
> 18 years at the time of operation were included in the analysis. Private practices were excluded because
of lack of validation within the CPRD at this time.
For the analysis we calculated directly age- and sex-standardised rates for the incidence of revision for each
calendar year. We used 10-year age groups, with 2003 mid-year population estimates as the reference
standard. These rates have been constructed to represent the incidence of revision in the overall UK population
and do not reflect the risk of revision for those already having undergone hip or knee replacement. The
population estimates used for standardisation were as published by the ONS,106 the General Register Office for
Scotland and the Northern Ireland Statistics and Research Agency. We computed 95% CIs using a Poisson
model appropriate for directly standardised rates.
Mean age at revision was calculated for hips and knees for each calendar year and 95% CIs computed.
The distribution of age at revision was calculated for three consecutive 5-year periods, separately for hip
and knee by sex, to investigate patterns over time.
A total of 1689 hip revisions and 634 knee revisions were identified in the CPRD database. During the
period 1991–2006, women underwent 59% more hip revisions and 6% more knee revisions than men.
Women were, on average, > 3 years older than men at hip revision and approximately 2.5 years older in
the case of knee revisions. Since 1994, the female-to-male ratio among patients undergoing revision
surgery has remained reasonably stable, with ratios for hips varying around 2 : 1 and for knees 1.4 : 1,
with further variation by age group, showing higher ratios for 70- to 79-year-olds (Figures 4 and 5).
Patients undergoing TKR had a significantly higher BMI than those undergoing THR (p < 0.0001) and the
difference in BMI was greater for women than for men (Table 1).
Between 1991 and 2006, the estimated age-standardised rates of hip revision arthroplasty increased from
2.3 per 100,000 person-years (95% CI 1.2 to 3.8 per 100,000 person-years) to 7.7 per 100,000 person-years
(95% CI 6.2 to 9.2 per 100,000 person-years) for women and from 1.3 per 100,000 person-years (95% CI
0.5 to 2.5 per 100,000 person-years) to 6.3 per 100,000 person-years (95% CI 5.0 to 7.8 per 100,000
person-years) for men. The majority of the increase occurred between 1991 and 1994, with rates stabilising
between 1994 and 2006. When the rates of revision hip replacement in 2006 were applied to the mid-2006
population estimates for the UK, we obtained an estimated total number of primary THRs (excluding private
practice) of 1887 (95% CI 1538 to 2270) for women and 1447 (95% CI 1148 to 1780) for men.
Over the same period, the estimated age-standardised rates of knee revision arthroplasty increased from
0.9 per 100,000 person-years (95% CI 0.3 to 1.9 per 100,000 person-years) to 5.0 per 100,000 person-years
(95% CI 3.9 to 6.3 per 100,000 person-years) for women and from 0.2 per 100,000 person-years (95% CI
0.0 to 3.1 per 100,000 person-years) to 4.1 per 100,000 person-years (95% CI 3.1 to 5.3 per 100,000
person-years) for men. The temporal trend in rates of knee revision shows a marked increase, with a steep
rise after 1995. Estimated rates for women increased almost fivefold between 1996 and 2006. When we
apply the 2006 rates for knee replacement to the mid-2006 UK population estimates, we obtain an
estimated total number of revision TKRs (excluding private practice) of 1225 (95% CI 946 to 1540) for
women and 942 (95% CI 706 to 1211) for men.
In 2006, the mean age at operation for hip revisions was 72.7 years (95% CI 70.3 to 75.0 years) for
women and 69.5 years (95% CI 67.3 to 71.7 years) for men, and for knee revisions it was 71.0 years
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(95% CI 68.8 to 73.2 years) for women and 67.8 years (95% CI 65.3 to 70.3 years) for men. Among
women, the highest incidence rate of hip revision is in the 80–89 years age group and of knee revision is
in the 70–79 years age group. The rates in these groups are 35.1 (95% CI 22.1 to 48.1) for hips and 19.9
(95% CI 12.1 to 27.8) for knees. The number of replacements for those aged 60–79 years comprises
almost two-thirds of the total for knees (64.7%) and a similar proportion for hips (61.0%), with men
having a higher proportion than women in this age group for both hips and knees.
The mean age at hip revision was higher in women than in men for almost all years after 1991 (Figure 6a),
but the difference was statistically significant in only 2 of the years. For knee revision (Figure 6b), the sex
difference in mean age at operation is much narrower than for hip revision. Since 1999, the sex-specific
mean ages at knee revision have been very similar, with women slightly older than men, but by 2006 there
is virtually no discernible difference between the sexes.
To explore the possibility that there had been a change in the distribution in age of people undergoing
revision surgery, we examined the distribution of age in 10-year age bands over three time periods:
1991–5, 1996–2000 and 2001–5. For the two earlier periods the counts of revision operations were
generally too low to enable an effective comparison between age distributions over time. However, in the
period 2001–5 it was observed that the distributions were similar between the sexes and also between hip
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and knee revisions. During the same period, the 10-year age group at which most revisions were carried
out was 70–79 years (between 37% and 39% of revisions, whether for hips or knees for either sex).
The ratio of knee-to-hip revision incidence rates (Figure 7) was low for both men and women during the
mid-1990s, at around 0.15 : 1. This ratio then began to rise steeply in both sexes in 1996 such that, by
2006, the incidence of knee revision was two-thirds of that of hip revision.
When we compared our estimated revision incidence rates for 2006 with the corresponding rates for
primary operations using the same GPRD data set, we found that the ratio of primary operations to
revisions was approximately 17 : 1 for hips and 25 : 1 for knees.
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TABLE 1 Baseline clinical variables for THR and TKR
Variable
Surgery
THR TKR
Female (n= 17,560) Male (n= 10,508) Female (n= 14,462) Male (n= 9902)
Age (years), mean (range) 70.4 (18–103) 67.5 (19–100) 70.9 (18–99) 69.4 (19–98)
BMI (kg/m2), mean (IQR) 27.0 (23.3–30.1) 27.5 (24.6–29.9) 29.1 (25.2–32.5) 28.4 (25.4–30.9)
Smoker (%) 11.3 14.4 8.1 12.3
Deprivation (% from
practices in the most
deprived quintile)
17.3 17.1 18.8 19.8
IQR, interquartile range.
Reproduced from oral presentation by David Culliford, Faculty of Health Sciences, University of Southampton, at the British
Society for Rheumatology in 2008. Copyright David Culliford.
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Analysis of the UK national database over a 10-year period revealed that knee revision rates increased
more than fivefold over this period in both men and women. The rate of THR revision has remained
relatively static, with no significant increase identified between 1994 and 2006.
The fivefold increase in knee revision rates may be multifactorial and a reflection of the increased number
of primary replacements over this 10-year period as well as rapid advances in implant technology alongside
improved surgical experience.66 Clinicians may be much more likely to intervene at an earlier stage,
especially in complex cases that in the past would have been considered beyond salvage. Another
contributing factor may be the increased usage of unicompartmental knee arthroplasty, which has been
associated with higher revision rates.
The picture looks different for hip replacements, as the results showed a marginal increase in revision rates.
Technological advances, such as improved bearing surfaces and fixation methods, should have decreased the
need for revision but may not have had the predicted impact on primary total hip arthroplasty (THA) longevity.
Registry data from Scandinavia120,121 demonstrate that the longevity of more conventional cemented implants
is superior to that of modern cementless or resurfacing designs. In 1996 there was good evidence to support
THA in < 30% of primary cases in the UK; in 2010 there was good evidence for their use in < 40% of cases.
This is an important observation, as newer implants tend to be more expensive and may in fact be adding to
the revision burden if they are not introduced in a co-ordinated manner. Significant demographical differences
were found, with women 59% more likely to require hip revision than men.
In comparison with our findings, Kurtz et al.66 have previously reported a 79% increase in revision THA and a
200% increase in revision total knee arthroplasty (TKA) in the USA between 1990 and 2002.66 This group
also looked at future projections between 2006 and 2030 and estimated that revision THA would increase
by 137% and revision TKA by 601% by 2030. These findings confirm the predicted trends in revision
arthroplasty in the UK, with dramatic increases in knee revisions and a smaller, but still significant, increase in
hip revisions. The cost implications for this increase would be significant, and accurate modelling of revision
THA and TKA demand is therefore required for adequate and appropriate long-term health planning.
We have further investigated the role of a risk factor, particularly the role of BMI, on the time of revision
for hip and knee arthroplasties. We used methods from survival analysis to present population-based
estimates for the risk of revision following TJR of the hip and knee. We described these associations and
published the results.97
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Association of body mass index with time of revision
A population-based survival analysis describing the association of body mass index
on time to revision for total hip and knee replacements: results from the UK General
Practice Research Database97
For this task we selected 63,162 THR and 54,276 TKRs from the CPRD database. The average age at
replacement was similar in both groups and the proportion for women in both procedures was greater
(Table 2).
Table 2 also describes the baseline characteristics of the cohort, including summary statistics and missing
data percentages for all explanatory variables for which complete data were not observed.
Eighty per cent of preoperative BMI values used were recorded within 5 years of the primary operation;
among those with a recorded BMI, the proportion of obese patients (BMI ≥ 30 kg/m2) was 26.2% for THR
and 39.8% for TKR, and of morbidly obese patients (BMI ≥ 40 kg/m2) was 1.6% for THR and 3.6% for TKR.
In a single-predictor (univariable) survival model allowing for the competing risk of death over the entire
period of follow-up, we estimated that THR participants had a 3% increase in the subhazard of revision
[subhazard ratio (SHR) 1.030, 95% CI 1.020 to 1.041; p < 0.001] for each extra unit (kg/m2) of BMI, with
TKR participants showing a 2.6% increase per unit (SHR 1.026, 95% CI 1.013 to 1.038; p < 0.001]. The
SHR was significantly greater for men than for women for both THR (SHR 1.35, 95% CI 1.23 to 1.48;
p < 0.001) and TKR 2 (SHR 1.54, 95% CI 1.37 to 1.72; p < 0.001).
Age at TJR was also a significant univariable predictor of both hip and knee revision surgery, with THR
participants estimated to have a 3% reduction (SHR 0.970, 95% CI 0.967 to 0.973; p < 0.001) for each
extra year of age, and TKR participants showing a 4.3% reduction (SHR 0.957, 95% CI 0.952 to 0.961;
p < 0.001). The effects for all three variables (sex, age and BMI) were then estimated in multivariable
TABLE 2 Clinical and demographic characteristics, all participants undergoing hip and knee replacement
Characteristic
Surgery
THR (N= 63,162) TKR (N= 54,276)
Female (n= 39,292) Male (n= 23,870) Female (n= 31,682) Male (n= 22,594)
Age (years), mean (SD) 70.5 (11.1) 67.7 (11.0) 70.7 (9.6) 69.4 (9.4)
Sex (%) 62.2 37.8 58.3 41.6
BMI (kg/m2), mean (SD) 27.2 (5.1) 27.7 (4.3) 29.6 (5.6) 28.8 (4.4)
Missing BMI (%) 19.1 19.3 13.8 14.0
Revisions, n (%) 1000 (2.55) 811 (3.40) 572 (1.8) 614 (2.7)
Deaths pre revision, n (%) 6615 (16.8) 4201 (17.6) 4110 (13.0) 3349 (14.8)
Number of comorbid conditions (%)
0 42.8 48.1 37.5 43.7
1 34.2 31.0 37.4 35.8
≥ 2 23.0 20.9 25.2 20.6
Note
Reproduced from Culliford et al.97 This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 3.0) licence, which permits others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the
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competing risks regression models after adjusting for smoking status, drinking status and the number of
comorbid conditions over the entire period of follow-up. For age, the estimates were almost exactly the
same as those from the univariable model for both hip and knee, but for sex (SHR 1.23 for hip and 1.51
for knee) and BMI (SHR 1.020 for hip and 1.015 for knee) the estimates were smaller. Nevertheless, all
three variables remained statistically significant for both hip and knee in the presence of adjustment.
For a 5-kg/m2 and 10-kg/m2 increase in BMI, this represents an increase in THR revision risk of 10.4% and
21.9%, respectively (7.7% and 16.1% for TKR). Testing for two-way interactions between age, sex and
BMI did not produce any significant effects. All subhazard estimates (with 95% CI and p-values) from the
univariable and multivariable models are given in Tables 3 and 4.
To further explore the effect of estimates for BMI, we ran the same adjusted age–sex–BMI model described
but used categorical rather than continuous BMI. For morbidly obese TKR participants (BMI > 40 kg/m2)
there was a 43.9% increase (95% CI 2.6% to 103.9%; p = 0.040) in the rate than those with a normal
BMI (18.5–25 kg/m2), but the effect for THR was larger (an increase of 65.5%) and stronger (95% CI
15.4% to 137.3%; p = 0.006).
The effect sizes were similar to those obtained when using the adjusted SHR estimate of continuous BMI for
a participant with a BMI of 45 kg/m2 relative to one with a BMI of 22 kg/m2 (an increase of 57.7% for THR
and 40.8% for TKR). For obese patients in the range 30–40 kg/m2 compared with those with a normal BMI,
the estimated SHR for revision was weakly significant for THR (15.7% increase, 95% CI 0.2% to 33.7%;
p = 0.048) but not for TKR (17.9% increase, 95% CI –1.9% to 41.6%; p = 0.079). As a sensitivity analysis,
we also performed standard Cox regressions with revision surgery as the event of interest, and when no
distinction was made between death and other censoring events. Univariable models for age, sex and BMI
gave very similar results to the competing risks analysis, as did the multivariable models that adjusted for the
same factors as in the competing risks regression. Results from the Cox regression models are given in
Tables 5 and 6.
In addition, we also calculated that it would take 175 patients with TKR to reduce their baseline BMI from
obese to normal in order to prevent one revision operation after 5 years. For patients with THR this
number reduces to 152.
TABLE 3 Estimated subhazard of revision for total hip and knee replacements: competing risks analysis – hip
Variable
Analysis
Univariable Adjusteda
HR 95% CI p-value HR 95% CI p-value
BMI (kg/m2) (per additional unit)b 1.030 1.020 to 1.041 < 0.001 1.020 1.009 to 1.032 < 0.001
Sex
Female (reference) 1.00 1.00
Male 1.35 1.23 to 1.48 < 0.001 1.23 1.10 to 1.38 < 0.001
Age (years at THR) (per additional year) 0.970 0.967 to 0.973 < 0.001 0.971 0.966 to 0.975 < 0.001
a Adjusted for smoking (yes/no/ex), drinking (yes/no/ex) and number of comorbid conditions.
b BMI available in 86.1% of patients.
Note
Reproduced from Culliford et al.97 This is an Open Access article distributed in accordance with the Creative Commons
Attribution Non Commercial (CC BY-NC 3.0) licence, which permits others to distribute, remix, adapt, build upon this work
non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the
use is non-commercial.
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
19
Finally, we assessed whether or not the higher incidence of hip revision surgery during the first year
following THR might compromise the proportionality assumption and, therefore, suggest the inclusion of
time-dependent effects. Separate univariable piecewise competing risk models for hip revision were fitted
for sex, age (≤ 65 years vs. > 65 years) and BMI (> 40 kg/m2 vs. ≤ 40 kg/m2). A single change point at
1 year was used to simultaneously estimate two SHRs for revision (before and after 1 year following THR).
The only model that provided some evidence for a different SHR during the first year was with BMI
(> 40 kg/m2 vs. ≤ 40 kg/m2) as the predictor (SHR 2.619, 95% CI 1.502 to 4.560; p = 0.001), but this was
not matched with a statistically significant estimate for revision after the first year (SHR 0.575, 95% CI
0.238 to 1.170; p = 0.130).
TABLE 4 Estimated subhazard of revision for total hip and knee replacements: competing risks analysis – knee
Variable
Analysis
Univariable Adjusteda
HR 95% CI p-value HR 95% CI p-value
BMI (kg/m2) (per additional unit)b 1.026 1.013 to 1.038 < 0.001 1.015 1.002 to 1.028 0.023
Sex
Female (reference) 1.00 1.00
Male 1.54 1.37 to 1.72 < 0.001 1.51 1.32 to 1.73 < 0.001
Age (years at THR) (per additional year) 0.957 0.952 to 0.961 < 0.001 0.957 0.951 to 0.962 < 0.001
a Adjusted for smoking (yes/no/ex), drinking (yes/no/ex) and number of comorbid conditions.
b BMI available in 80.9% of patients.
Note
Reproduced from Culliford et al.97 This is an Open Access article distributed in accordance with the Creative Commons
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TABLE 5 Estimated hazard of revision for THR: univariable and adjusted Cox regression analysis with death as a
censoring event
Variable
Analysis
Univariable Adjusteda
HR 95% CI p-value HR 95% CI p-value
BMI (kg/m2) (per additional unit)b 1.029 1.017 to 1.040 < 0.001 1.019 1.008 to 1.031 0.001
Sex
Female (reference) 1.00 1.00
Male 1.36 1.24 to 1.49 < 0.001 1.26 1.13 to 1.41 < 0.001
Age (years at THR) (per additional year) 0.978 0.974 to 0.983 < 0.001 0.977 0.972 to 0.982 < 0.001
a Adjusted for smoking (yes/no/ex), drinking (yes/no/ex) and number of comorbid conditions.
b BMI available in 86.1% of patients.
Note
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Cumulative incidence rates of revision were higher for men than for women and higher for hips than for
knees. Age, sex and BMI were estimated to be significant predictors of time to revision in an adjusted
model allowing for the competing risk of death. Severely obese patients undergoing THR had a higher risk
of revision surgery during the first year following replacement, but the same effect was not observed for
knee replacement.
Projected future trends for total hip replacement/total knee
replacement accounting for projected changes in age and obesity
Estimating the lifetime risk of total knee and hip arthroplasties
The lifetime risk of total hip and knee arthroplasty: results from the UK General Practice
Research Database99
Lifetime risk is a patient-centred measure of risk for the onset of disease or the occurrence of specific events.
The concept is easily understood by clinicians and policy-makers, and can be made even more informative
by also calculating interval risks (e.g. 10 years) at different ages to establish the periods of greatest lifetime
risk. Population-based estimates are needed for effective and efficient health-care planning and resource
allocation. No lifetime risk estimates were available in the literature for patients who were undergoing these
surgical procedures, but published incidence rates existed for hip and knee replacement in the UK67,116
and internationally.119,123,124
The primary aim of this analysis was to use the CPRD database combined with the ONS mortality data to
provide estimates for the lifetime risk of undergoing a primary THR or TKR in the UK. OXMIS/Read codes
were used to identify THRs and TKRs for the period 1991–2006 in the CPRD database. Patients were
included if aged ≥ 50 years at the time of replacement. Sex-specific all-cause mortality data from the ONS
were obtained for the same period.125
The analysis was done with CPRD data that were aggregated into single-year age intervals, with the age
label defined as age at last birthday at the end of a calendar year, starting at the age of 50 years. We used
data for the time period 1991–2006 and identified 49,105 patients who had undergone a THR (n = 25,845)
or TKR (n = 23,260). Consistent definitions were applied to death data and exposure to risk. Incidence rates
for joint replacement were computed by dividing the count of primary THRs and TKRs in the CPRD data by
TABLE 6 Estimated hazard of revision for TKR: univariable and adjusted Cox regression analysis with death as a
censoring event
Variable
Analysis
Univariable Adjusteda
HR 95% CI p-value HR 95% CI p-value
BMI (kg/m2) (per additional unit)b 1.024 1.012 to 1.037 < 0.001 1.015 1.003 to 1.028 0.019
Sex
Female (reference) 1.00 1.00 < 0.001
Male 1.58 1.41 to 1.77 < 0.001 1.55 1.36 to 1.77
Age (years at THR) (per additional year) 0.962 0.956 to 0.967 < 0.001 0.961 0.955 to 0.968 < 0.001
a Adjusted for smoking (yes/no/ex), drinking (yes/no/ex) and number of comorbid conditions.
b BMI available in 80.9% of patients.
Note
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the corresponding amount of person-time spent by those in the entire CPRD population who matched
the age band, sex and time interval of interest. This was achieved by a life table method similar to that
described by Kim et al.39 CIs at the 95% level were estimated under a Poisson model.126 Risks were
estimated separately for sex and hip/knee. This was repeated with 60, 70 and 80 years of age as the
starting point for the risk of replacement. We further computed 10-year risk percentages from age 50 years
up to the age of 80 years. All estimates for single calendar years used mortality data matched to the same
calendar years, but for the estimates based on the entire study period we used 2006 mortality rates with
a sensitivity analysis. Lifetime risks of THR and TKR, stratified by sex for individual calendar years, were
estimated in order to compare temporal trends.
The results, using rates from 2005, showed that the estimated mortality-adjusted lifetime risk of THR at
age 50 years was 11.6% for women and 7.1% for men. For the aggregated data over the period
1991–2006, the mortality-adjusted lifetime risk of THR at age 50 years was estimated at 8.3% for women
and 5.2% for men. The lifetime risk of THR at age 50 years rose from 4.0% (95% CI 3.0% to 5.0%) to
11.1% (95% CI 9.9% to 12.2%) for women and from 2.2% (95% CI 1.4% to 3.0%) to 6.6% (95% CI
5.7% to 7.5%) for men. Therefore, our findings estimated that, between 1991 and 2006, the lifetime risk
of THR at age 50 years rose from 4.0% (95% CI 3.0% to 5.0%) to 11.1% (95% CI 9.9% to 12.2%) for
women and from 2.2% (95% CI 1.4% to 3.0%) to 6.6% (95% CI 5.7% to 7.5%) for men.
Again, using the rates from 2005, we estimated that the mortality-adjusted lifetime risk of TKR at age
50 years was 10.8% for women and 8.1% for men. The aggregated data for the period 1991–2006
estimated the mortality-adjusted lifetime risk for TKR at age 50 years at 7.0% for women and at 5.2% for
men. The same time period for TKR saw an increased risk for women from 2.9% (95% CI 2.1% to 3.8%)
to 10.6% (95% CI 9.5% to 11.7%) and for men from 1.8% (95% CI 1.1% to 2.6%) to 7.7% (95% CI
6.8% to 8.7%). As with hips, TKR estimates of risk also increased, for women from 2.9% (95% CI 2.1%
to 3.8%) to 10.6% (95% CI 9.5% to 11.7%) and for men from 1.8% (95% CI 1.1% to 2.6%) to 7.7%
(95% CI 6.8% to 8.7%).
As a sensitivity analysis these estimates were recalculated using 1991 mortality data, but this resulted in
only small reductions in the lifetime risk estimates of between 0.6 and 0.8 percentage points at age 50
years and of 0.2 and 0.3 percentage points at age 80 years. These reductions were seen for both THR and
TKR, and for men and women.
The lifetime risk decreases with increasing age for both THR and TKR in men and women. At age 80 years,
the sex gap in risk of THR reduced to 40% higher for women than for men (22% higher for TKR).
Estimated risk percentages at ages 50, 60, 70 and 80 years are presented in Table 7.
The sex gaps in the estimates obtained for the whole study period were similar to those for the 2005 estimates.
Our results showed that between 1991 and 2006 the lifetime risk of THR at age 50 years increased from
4.0% (95% CI 3.0% to 5.0%) to 11.1% (95% CI 9.9% to 12.2%) for women and from 2.2% (95% CI
TABLE 7 Estimated lifetime risk (95% CI) of undergoing primary TKR or THR based on age- and sex-specific
incidence rates adjusted for mortality. Data from GPRD in 200599
Current age (years)
Risk of primary TKR, % (95% CI) Risk of primary THR, % (95% CI)
Female Male Female Male
50 10.8 (9.7 to 11.9) 8.1 (7.1 to 9.1) 11.6 (10.4 to 12.7) 7.1 (6.2 to 8.0)
60 10.1 (9.0 to 11.2) 7.9 (6.9 to 8.9) 10.8 (9.7 to 12.0) 6.7 (5.8 to 7.7)
70 7.8 (6.7 to 8.8) 6.2 (5.2 to 7.2) 8.1 (7.1 to 9.2) 5.3 (4.3 to 6.2)
80 3.3 (2.6 to 4.1) 2.7 (1.8 to 3.6) 3.8 (3.0 to 4.7) 2.7 (1.8 to 3.6)
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1.4% to 3.0%) to 6.6% (95% CI 5.7% to 7.5%) for men. For TKR, the risk increased for women from
2.9% (95% CI 2.1% to 3.8%) to 10.6% (95% CI 9.5% to 11.7%) and for men from 1.8% (95% CI
1.1% to 2.6%) to 7.7% (95% CI 6.8% to 8.7%) (Figure 8).
The lifetime risks of hip and knee replacements are estimated to be between 5% and 10%, which is
substantially below the estimated lifetime risk of hip and knee OA. Our estimates based on UK GPRD data
from 2005 suggest a lifetime risk of THR and TKR for women or men aged 50 years living in the UK of
10–11% and 6–7%, respectively.
Future projections of total hip and knee arthroplasties
Future projections of total hip and knee arthroplasty in the UK: results from
the UK Clinical Practice Research Datalink98
Future predictions for lower limb arthroplasty in the UK are limited,116,123 and international predictions
are mainly concentrated around the USA and Europe.34,68,127,128 With the steady increase in rates of hip
and knee surgery, up-to-date future predicted rates are necessary as part of our understanding of this
treatment intervention. The most recent published future projections of the UK covered England only,116
were based on a 10-year period of HES data and did not account for BMI changes or other important risk
factors for arthroplasty.
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FIGURE 8 Estimated lifetime risk at age 50 years of undergoing (a) THR; or (b) TKR based on age- and sex-specific
incidence adjusted for mortality. Data from the GPRD.99
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Deciding on the correct method for forecasting is important and dependent on high-quality research data.
More sophisticated modelling approaches require at least one population-based cohort or survey data set
with long-term follow-up.129
We produced and published the national future projections for THR and TKR.98 We used three national
data sets that were representative of age, sex and BMI in the UK population. Using the CPRD database,
in combination with national population forecasts from the ONS, we aimed to calculate age- and sex-
specific forecasts for the number of THR and TKR operations per year in the UK between 2010 and 2035.
Secondary analysis aimed to produce forecasts that reflect the changing distribution of BMI during the
same period. To project estimated THR and TKR rates, HSE data were used. We constructed a denominator
to estimate BMI-specific rates and obtained sex-specific population projections from the ONS for the period
2011–35.106 The methods of Kurtz et al.66 were further extended to incorporate the inclusion of BMI, in
addition to age and sex.
Analysis: estimation
The CPRD data (1991–2010) were used to estimate annual incidence rates for THR/TKRs, and standard
log-linear regression models were used to produce calendar year-, age- and sex-specific rates, but were
extended to include BMI-specific rates. Unweighted aggregated data from the HSE, for the same period,
were used as a proxy for the change in the distribution of BMI in the UK population. The CPRD data were
remodelled by calendar year, age, sex and BMI. Age and BMI were grouped in categories, and rates for
hips and knees were estimated separately. The calendar year-/age-/sex-specific values of BMI in the HSE
were used to partition the calendar year-/age-/sex-specific denominator values in the CPRD to further
break them down by BMI. Regarding the numerator for the rate (i.e. the counts of TJRs), the counts were
weighted by BMI for those TJR patients with an observed preoperative BMI in their record. This was the
case for approximately 80%. We made the decision not to use missing data methods (such as multiple
imputation) because of a high rate of observed BMI. If preoperative BMI had been available in, for
example, 50–60% of cases, we could have reconsidered and use multiple imputation methods. Our
BMI-specific projections were in categorical bandings; therefore, fewer concerns were raised about
sensitivity to missingness.
The ONS data were split into age- and sex-specific forecasts, by BMI group, prior to applying the estimated
incidence rates obtained from the HSE. Two methods were used: BMI proportions fixed at 2010 levels and
BMI proportions increasing linearly based on ordinary least squares (OLS) regression estimates derived from
the HSE BMI data from 1991 to 2010. A hyperbolic tangent function, similar to the method described in
the Foresight report, was used to smooth the proportions over the forecasting time frame.130
Analysis projection
Two different projections methods were used on each of the two future UK population scenarios. Hips and
knees were analysed separately. The first method used THR/TKR incidence rate estimates held at 2010
levels, applied to the two population scenarios. The second used an exponential extrapolation directly
from the log-linear model-estimated rates for THR/TKR. The two population forecast data sets76 contained
exactly the same population growth estimates by age and sex over time, as forecast by ONS, with a
difference that one population data set assumed a static BMI distribution (held fixed at 2010), whereas the
other reflected HSE- and CPRD-based estimates of forecast BMI distribution change in the UK.
The results from analysis of the CPRD database contained 50,000 THRs and 45,609 TKRs between 1991
and 2010, and all sets included age, sex and BMI. The average age at time of operation was similar for
THR and TKR, and the proportion of women was greater for both TKR and THR (Table 8).
Preoperative BMI was slightly higher for TKR than for THR. There was little sex-specific difference in counts
when comparing fixed or varying future estimates of BMI category distribution in hips. Knee estimates,
however, suggested a 9% higher rate when using the varying BMI distribution.
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Hospital Episode Statistics data (1991–2010) were used to estimate future BMI distribution and contained
186,174 subjects with measured BMI. The breakdown of this distribution by age, sex and BMI values is
depicted in Tables 9 and 10.
TABLE 9 Health Survey for England 1991 to 2010 showing number of female and male subjects by BMI98
BMI group (kg/m2)
Total number of subjects (N= 186,174)
Female [n= 100,576 (54.0%)] Male [n= 85,598 (46.0%)]
n % n %
< 20 6117 6.1 2933 3.4
20 to 25 39,261 39.0 27,347 31.9
25 to 29 33,361 33.2 38,681 45.2
30 to 39 19,688 19.6 16,216 18.9
≥ 40 2149 2.1 421 0.5
Reprinted from Osteoarthritis and Cartilage, vol. 23, Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D,
Arden NK, COASt Study Group, Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical
Practice Research Datalink, pp. 594–600, 2015,98 with permission from Elsevier.
TABLE 8 Demographic characteristics of CPRD subjects used to construct incidence rates98
Variable
Surgery
TKR (N= 45,609) TKR (N= 50,000)
Female (n= 26,623) Male (n= 18,986) Female (n= 31,148) Male (n= 18,852)
Sex (%) 58.4 41.6 62.2 37.8
Age (years), mean (SD) 70.3 (9.5) 69.4 (9.2) 69.9 (10.9) 67.8 (10.7)
BMI (kg/m2), mean (SD) 29.6 (5.4) 28.8 (4.4) 27.2 (5.1) 27.7 (4.2)
Reprinted from Osteoarthritis and Cartilage, vol. 23, Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D,
Arden NK, COASt Study Group, Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical
Practice Research Datalink, pp. 594–600, 2015,98 with permission from Elsevier.
TABLE 10 Health Survey for England 1991 to 2010 showing number of female and male subjects by age98
Age group (years)
Total number of subjects (N= 186,174)
Female [n= 100,576 (54.0%)] Male [n= 85,598 (46.0%)]
n % n %
18–39 37,664 37.4 32,527 38.0
40–49 18,503 18.4 15,704 18.3
50–59 15,620 15.5 13,640 15.9
60–69 13,813 13.7 12,433 14.5
70–79 10,430 10.4 8504 9.9
≥ 80 4546 4.5 2790 3.3
Reprinted from Osteoarthritis and Cartilage, vol. 23, Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D,
Arden NK, COASt Study Group, Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical
Practice Research Datalink, pp. 594–600, 2015,98 with permission from Elsevier.
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The static rate projection method, with BMI distribution held fixed at levels estimated for 2010, forecasts
an annual number of THRs of up to 97,516 and of TKRs of up to 110,306 by 2035. Using the same
projection method, but with changing BMI distribution, the estimated rates are expected to grow by up to
95,877 for hips and 118,666 for knees.
Using the log-linear projection method, with BMI distribution held fixed at levels estimated for 2010, the
annual number forecast for hips is up to 437,708 and for knees is up to 1,071,790 by 2035. Using the
same method, but with changing BMI distribution, the rates are exponential and increase to 439,097 for
hip and 1,219,362 for knees by 2035. Five-yearly projections for all four scenarios up to 2035 are shown
in Table 11.
The results that follow present counts split by sex, BMI and age, all of which are estimated using the static
projection method (see Table 11).
Hip and knee projected counts by sex are shown in Table 12. There is little sex difference in counts at
2035 when we compare projections, with fixed or varying future estimates, of BMI category distribution
for hips. Knees results are different, however, especially for women, whose TKR count at 2035 is estimated
to be 9% higher when using varying BMI distribution as opposed to fixed.
Discussion
The increasing trends in THR and TKR up to the year 2000 have continued and are more marked in knees
than in hips. Although there is a marked increase in the number of knee replacements being carried
out per year, the number of TKRs are similar to those for THR. The increase in knee surgery may be because
the burden of OA of the knee is more easily identified in radiographs.131 The number of TKRs per year is
similar to the number of THRs, despite the much higher prevalence of OA of the knee.75,76 It is possible that
the level of provision of THR is appropriate to the burden of OA of the hip, whereas the level for the TKR is
still below that required by surgeons operating on patients with lower levels of pain and disability.
TABLE 11 Projected UK counts for total hip and knee replacements in adults to the year 203598
Year
Projection
THR incidence rates TKR incidence rates
Estimated rates fixed at
the 2010 level
Estimated rates
increasing log-linearly
Estimated rates fixed at
the 2010 level
Estimated rates
increasing log-linearly
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
2015 72,762 72,418 96,314 95,945 82,610 85,019 128,944 133,063
2020 79,716 79,048 141,626 140,945 90,555 94,783 221,653 234,244
2025 85,988 85,026 205,464 204,793 97,780 103,657 376,384 407,400
2030 91,496 90,202 296,354 296,106 103,810 111,015 632,257 701,052
2035 97,516 95,877 437,708 439,097 110,306 118,666 1,071,790 1,219,362
Reprinted from Osteoarthritis and Cartilage, vol. 23, Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D,
Arden NK, COASt Study Group, Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical
Practice Research Datalink, pp. 594–600, 2015,98 with permission from Elsevier.
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The reason for the mismatch between lifetime risk of OA75,76 and the established intervention (THR/TKR)
is not clear, but could be in part a result of the lack of consensus on the type or severity of symptoms.132
The mismatch may also be a result of the difference between the need for and provision of hip and knee
arthroplasty in the UK, as described by Judge et al.107,133 Attempts have been made to understand the
geographical and sociodemographic characteristics of different countries,30 and UK-based studies from the
late 1990s22,23,134 found little mismatch in THR provision but a large mismatch between the estimated need
for TKR and provision. Data from the NJR70 show that, for England and Wales, growth in provision was
much slower over the period 2007–10 than in 1995–2005,67 suggesting that the perceived gap between
need and provision is unlikely to have been substantially narrowed in the time since the end of our analysis
in 2006. This would depend on there being no change in the risk of developing OA over the same period.
Surgical thresholds are also important and hold their own implications for access and provision of care.
There have been a number of strategies to cope with this increase in demand, for example national
waiting list initiatives, but without accurate and reliable information long-term planning is difficult. It is
therefore essential to have up-to-date and accurate disease-specific information available to estimate the
future burden of the interventions, as well as the underlying diseases that are indications for hip and knee
arthroplasty. This information also needs to be substantiated and validated for an accurate consensual
agreement of the changing trends within the surgical community. Estimates from the USA are useful but
not always consistent with epidemiological findings from the UK.
Accurate and reliable evidence of the demand and need for hip and knee arthroplasty is necessary for
future planning. However, estimating rates for forecasts is difficult because surgical capacity is influenced
and limited by governmental planning. Nevertheless, in the absence of supply-side forecasts, future
projections based on the extrapolation of observed data98 suggest that modest increases in the number of
arthroplasties are to be expected in the UK, and that the dramatic increases forecast for the USA up to
203066 are unlikely to be matched in this country.
We estimated the high rates of THR and TKR using the log-linear model. We think that simply using a
straight log-linear model (which projects exponentially) to estimate future projections is not helpful as a
TABLE 12 Projected UK counts for total hip and knee replacements respectively by sex to the year 2035, with
estimated TKR incidence rates fixed at 2010 level98
Year
Surgery
THR TKR
Women Men Women Men
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
BMI
category
proportions
fixed at
2010
estimates
BMI
category
proportions
changing
over time
2015 45,143 44,905 27,618 27,513 47,703 49,207 34,908 35,812
2020 49,207 48,752 30,509 30,296 51,931 54,638 38,624 40,145
2025 52,949 52,307 33,039 32,719 55,785 59,604 41,995 44,054
2030 56,255 55,426 35,241 34,776 58,919 63,665 44,891 47,350
2035 59,909 58,850 37,607 37,026 62,493 68,082 47,813 50,584
Reprinted from Osteoarthritis and Cartilage, vol. 23, Culliford D, Maskell J, Judge A, Cooper C, Prieto-Alhambra D,
Arden NK, COASt Study Group, Future projections of total hip and knee arthroplasty in the UK: results from the UK Clinical
Practice Research Datalink, pp. 594–600, 2015,98 with permission from Elsevier.
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substantive analysis, particularly over such a long projection period. Given the rise in the temporal trends in
the incidence rates (1991–2010) on which the projections are anchored, it is not surprising that the
curvature on a log-linear scale will eventually (by 2035) produce a very large number. Therefore, we did
not major on this simple log-linear extrapolation but took a more refined and considered approach.
From the CPRD database we considered the first primary replacement for each subject to be the one of
interest, and for the survival study we ignored subsequent primaries, even though the second primary may be
a genuine contralateral primary. Likewise, we took the first revision encountered as the one that matches up
with the primary. This approach, although arbitrary, is consistent, and is not likely to be biased with respect to
any other important factors of interest in our studies (e.g. age, sex and BMI). For survival analyses, taking the
first revision recorded is less of an issue, given that multiple revisions on the same-side joint are not only
possible but quite common, over and above those revision procedures that are designed to be performed in
two separate stages. We found the distributions of certain event coding to be good, considering that the
CPRD is derived from routinely recorded data; however, the coding is not always perfect.
The main limitation of the work performed in this work package was the lack of individual validation of
events in the data of the CPRD. However, several studies have shown the data to be accurate and complete
for the clinical codes corresponding to OA, fracture and other crucial variables. The diagnosis of OA in
general practice is often based on clinical symptoms without radiological support. This is because current
general practice guidelines do not recommend radiographs to make a diagnosis of uncomplicated OA.
Furthermore, we have examined a random sample of patients from general practice with a clinical diagnosis
of knee OA to validate the diagnosis. We found that > 75% of GP diagnoses were confirmed using
validated criteria. Moreover, there is an increasing need to study the epidemiology and management of the
more clinically relevant diagnosis of clinically diagnosed hip OA.
The provisional number of patients identified in the GPRD is consistent with the expected number of patients
for hip and knee joint replacements, which are less likely to be a result of misclassification or under-reporting.
The CPRD data are routinely gathered for all contributing practices and are not explicitly censored when
requested, including left-censoring. The CPRD has a practice-level requirement that the data delivered
to the database by each practice should be ‘up to standard’, but this does not affect patient-level data.
Similar to most users of CPRD data, we used only data from practices after the point at which the CPRD
deemed them to be ‘up to standard’. Although a subject may have had a primary THR/TKR event after
his/her practice began submission of data but before that practice was deemed to be ‘up to standard’, we
used only the up-to-standard data. Therefore, if a subject satisfying the study selection criteria is registered
with a valid CPRD practice for any length of registration period, he/she will be in the data set so long as
that period coincides with the time during which the practice is supplying up-to-standard data.
Another limitation of our work was that it was possible for us to encounter revisions whereby the matching
primary was carried out before the up-to-standard date, before the practice began submission or even
before the patient registered with that practice. Once again, our consistent and conservative approach was
not to use revision events in our survival or lifetime risk analyses unless we had a valid preceding primary
replacement event for the same subject.
Conclusion
In conclusion, rates of hip and knee replacement rose between 1991 and 2006. Projections of future
growth in the number of procedures to 2035 suggest a slower increase than that observed since the early
1990s. The long-term risk of revision for hip and knee replacements is slightly higher for subjects with
higher BMI, but the effect is small.
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Chapter 3 Work package 2: designing the
statistical tool to predict surgery outcome
This chapter describes the important risk factors for poor outcome and combine them to produce aclinically relevant instrument (tool) to predict poor outcome and replacement failure.
The chapter contains information from publications that were based on work package 2.
Our objectives for work package 2 were to:
1. describe the risk factors for primary and revision surgery using the data from existing national and
hospital prospective arthroplasty cohort studies
2. combine these risk factors to produce a clinically meaningful panel of predictors for poor outcome.
Predictors of outcome
Identification of operational, clinical and biological predictors of poor outcome after TJR is urgently
required for a balanced provision of services and avoidance of unjustified use of resources when there is a
high risk of implant failure. Identification of risk factors for poor outcome will guide translational research
in terms both of the specific interventions and specific patient group selection. In addition, this will provide
vital information to clinicians, patients and their carers, as those with a high risk of revision may wish to
forgo surgery whereas those with a lower risk would be reassured.
Baker et al.36 used a NJR to determine the role of pain and function in postoperative patient satisfaction
and found that pain was a significant factor in patients not being satisfied with their operation.
Aims and objectives
In this work package we identify the important operational, clinical, biological and other important risk
factors for poor outcome for lower limb joint replacements. We then combine previously described risk
factors in order to develop a statistical tool for identification of patients with poor outcomes following
THRs and TKRs. To achieve this goal, the work has been done to:
1. initially define the good and bad PROMs
2. identify the role of univariable as well as multivariable risk factors in patient-reported outcomes
3. develop a statistical tool to predict poor outcomes following THR and TKR surgeries.
We have completed further work to confirm the role of individual predictors for hip and knee replacement
surgeries, particularly BMI, age and sex, patient’s preoperative expectation, premorbidities (such as OA)
and the type of implant. We have summarised our findings on the potential risk factors of good or bad
patient-reported outcomes after THR and TKR, and revision results from the GPRD, currently known as the
CPRD, in a number of publications.135,136
In this chapter we discuss each individual risk factor and its association with surgery outcomes, as
described in published papers. At the end of each subsection for risk factors we will summarise the
publications when these associations were reported.
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Design and setting
Cohorts and databases
The list of databases and cohorts we used in work package 2 is outlined in this section.
European Collaborative Database of Cost and Practice Patterns of Total
Hip Replacement137,138
The European Collaborative Database of Cost and Practice Patterns of Total Hip Replacement (EUROHIP)
study consists of 327 patients receiving THR treatment across 20 orthopaedic centres in Europe. Patients
completed self-administered questionnaires on demographic variables and baseline of pain, stiffness,
mobility and quality of life. In addition, they were asked about their expectations of surgery 1 year after
the operation. We also collected preoperative radiographs and data on operative procedure, including the
prosthesis type used. Patients undergoing primary hip replacement in whom the indication for surgery was
OA were included, but those with hip disease other than OA, severe mental conditions and/or dementia
were excluded.
Exeter Primary Outcomes Study139
In the Exeter Primary Outcomes Study (EPOS), participants were recruited between January 1999 and
January 2002 from seven centres in England and Scotland. Patients received primary THR using a
cemented Exeter femoral stem component (Stryker Howmedica Osteonics, Mahwah, NJ, USA).140 A variety
of cemented and uncemented acetabular components were used in included patients. Ethics approval was
obtained from the North Western Multiple Centre Research Ethics Committee and the local research ethics
committees. The cohort was representative of a wider orthopaedic cohort, as the participating hospitals
(both teaching and district general hospitals) covered a wide geographical area including urban and rural
locations; thus, it covered both affluent and somewhat deprived inner-city suburban areas with an overall
population of 1 million.
Elective Orthopaedic Centre141
The Elective Orthopaedic Centre (EOC), also known as the South West London Elective Orthopaedic Centre
(SWLEOC), is a purpose-built orthopaedic treatment centre that was opened in 2004. The centre serves a
population of 1.5 million people in south-west London and it performs TKR surgeries across four acute
NHS trusts: Kingston, St George’s, Mayday, and Epsom and St Helier. In this work package we included
patients who received either primary UKR or TKR.
Knee Arthroplasty Trial142
Participants in the Knee Arthroplasty Trial (KAT) received primary TKR across 34 centres in the UK between
July 1999 and January 2003. The primary outcome was the Oxford Knee Score (OKS) at 12 months after
surgery. For this work package we used a wide range of preoperative predictors such as patient
characteristics, as well as clinical and surgical factors.
Portsmouth and North Staffordshire143
We used the data on patients undergoing THR from two districts in England, Portsmouth and North
Staffordshire, with a population of approximately 1 million. The districts were selected for our work
because, first, they were specialised in the assessment and treatment of hip OA; second, there was much
support from the local orthopaedic surgeons; and, third, the district had a diverse socioeconomic profile.
The orthopaedic surgeons recorded all men and women aged > 45 years who were listed for primary THA
between 1993 and 1995. For our work we excluded the patients who had sustained a hip fracture within
the past year, with a diagnosis of rheumatoid arthritis (RA) or ankylosing spondylitis, and those with
secondary OA.
Clinical Practice Research Datalink77,94
The CPRD, formerly known as the GPRD, is an English NHS observational data and interventional research
service. It is jointly funded by the NHS National Institute for Health Research (NIHR) and the Medicines and
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Healthcare products Regulatory Agency. The database is designed to facilitate the linkage of anonymised
patients’ clinical data, thus enabling a number of epidemiological studies which would subsequently be
beneficial for improved health-care services. The CPRD has become a gold standard in utilising data by
observational researches. Currently over 890 clinical reviews and publications have benefited from the
service. More information about the database has been previously detailed in Chapter 2.
A summary of the cohorts and data sets used in work package 2 is provided in Table 13.
Outcome measures
We used two scoring systems as a measure of surgery outcome:
1. PROMs, which are a condition-specific instrument jointly made up of the condition-specific Oxford
score, a generic instrument EuroQol-5 Dimensions (EQ-5D) and general patient-specific questions144
2. the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).
Oxford Hip Score/Oxford Knee Score
Two of the most commonly used and nationally recommended scores are the Oxford Hip Score (OHS) and
OKS,145 incorporated into PROMs as described but also used as stand-alone questionnaires. They were
originally designed as joint-specific scores for use in clinical trials to measure population-based changes,146
and widely assessed for reliability and validity145–147 for this intended purpose. The OHS and OKS consist
of 12 questions asking patients about their joint-specific pain and function in the preceding 4 weeks.
Questions are scored on a Likert scale from 0 to 4, with the results added up to give a total score. The
overall score maximum is 48 units, with 0 the worst possible score, indicating poor function and/or severe
pain; and 48 representing the best score, suggesting no adverse symptoms and excellent joint function.
Overall satisfaction of Oxford scores is measured by a visual analogue scale (VAS) with scores from 0 to
100 units.
EuroQol-5 Dimensions
The EQ-5D is joint non-specific questionnaire asking patients about their general health state, mobility,
self-care, usual activities, pain and anxiety/depression.148
TABLE 13 Cohorts and data sets used in work package 2
Cohort/database
Year of
inception Arthroplasty
Number of
patients
Longest
duration of
observation
(years)
Pain
outcome
Joint
failure
CPRD 1987 Hip 27,155 18 N Y
Knee 23,536
EPOS 1999 Hip 1411 5 Y Y
KAT 2000 Knee 2000 5 Y Y
Portsmouth and
North Staffordshire
1993 Hip 643 8 Y Y
St Helier 1995 Hip 4089 12 Y Y
EOC 2004 Hip and knee Still recruiting –
> 10,000
3 Y Y
N, no; Y, yes.
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Satisfaction
In a number of cohorts, patients were asked about their satisfaction with surgery. In many cohorts, the
measure of satisfaction is split between satisfaction with the procedure and satisfaction with the service.
Satisfaction in some cohorts is a dichotomous variable, whereas in others it measured on a VAS.
Western Ontario and McMaster Universities Osteoarthritis Index
The WOMAC consists of 24 items with three domains: pain, stiffness and physical function. The scores
range from 0 (no symptoms) to 100 (symptoms with extreme severity). The total score is created by adding
the scores from each domain, multiplying by 100 and then dividing by the maximum score. Combination
of these three domains adds up to a total score of 96, which is then converted into a normalised score.
In order to classify whether or not patients improved 1 year after their surgery, we used the Outcome
Measures in Rheumatology Clinical Trials/Osteoarthritis Research Society International (OARSI) responder
criteria. For statistical analysis we used logistic regression to describe association between preoperative
expectations and response to surgery.
Short Form questionnaire-12 items
The Short Form questionnaire-12 items (SF-12) consists of 12 questions and is the shorter version of the
Short Form questionnaire-36 items (SF-36) health survey. The questionnaire is designed to collect the data
on patients’ mental and physical functioning, and also overall quality of life related to health. SF-12 is not
age or disease specific, but is a general measure of health. The physical and mental component summary
scores are combined and range from 0 to 100, in which 0 is indicative of the lowest possible status of
health and 100 of the best possible status of health.
Main exposure
Primary and revision hip and knee replacement surgery.
Sample size
For a diagnostic (predictive) model to be of use in predicting outcomes it needs to have a sensitivity of at
least 90% and a specificity of at least 75%. The power calculations are based conservatively on having
data for 32,500 hip arthroplasties and 27,300 knee arthroplasties. It is assumed that we have complete
data for only 80% of the patients and that 16% will experience arthroplasty failure, as defined by poor
functional outcome at 2 years. This would result in there being 5200 patients with whom to estimate
sensitivity and 27,300 patients with whom to estimate specificity for THR. With 5200 patients, a true
sensitivity of 90% can be estimated to within 1% (95% CI 89% to 91%), and a true specificity of 75%
can be estimated to within 0.5% (95% CI 74.5% to 75.5%). For TKR, there would be 4370 patients with
whom to estimate sensitivity and 22,930 patients with whom to estimate specificity for knee arthroplasty,
giving similar precision for the estimated sensitivity of 90% (95% CI 89% to 91%) and specificity of 75%
(95% CI 74.4% to 75.6%).
Variables
A detailed literature search was conducted for an up-to-date list of potential risk factors for poor outcome. Our
a priori list of factors can be grouped into three main groups: (1) technical factors, including type of prosthesis
and cemented compared with uncemented; (2) other non-patient-related factors, such as the hospital where
the surgery took place (size, throughput and expertise) and year of surgery; and (3) patient-related factors,
such as age, sex, obesity, underlying arthritic condition, comorbid medical problems, radiographic parameters,
intraoperative findings, postoperative complications and medication, such as non-steroidal anti-inflammatory
drugs, bisphosphonates, hormone replacement therapy, statins and corticosteroids.
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Preoperative radiographs were graded for severity using the Kellgren and Lawrence (K/L)149 grading system
for OA and the Sharpe score for RA. Grading of radiographs was done by trained research assistants and
in cases of disagreement a formal consensus reading was performed. Radiographs were digitally scanned
for a more detailed assessment of bone quality and shape.
The early postoperative radiographs (approximately 6 weeks post surgery) were assessed for joint
alignment and the quality of subchondral bone as early predictors of joint failure.
Statistical methods
For identifying and combining predictors we have used various statistical methods. The list of such
methods is detailed for each work/publication in Appendix 2. Statistical methods for designing predictive
tools are detailed in Developing a predictive model.
Defining good and bad patient-reported outcome measures
Patient-reported outcome measures have been in development over a number of years for different reasons,
and often for use as outcomes in clinical trials. They are now increasingly being used to assess a patient’s
satisfaction with hip or knee replacements.150,151 They are also increasingly considered as a potential tool to
prioritise patients for surgery. This has raised some methodological concerns as these scoring systems
traditionally accounted for the mean improvement of population group by using pre- and postsurgical
scores as a continuous variable, with little validation for use as an outcome measure in individuals.
Some of the most commonly used PROMs include OHSs146 and OKSs,147 all validated to assess pain, stiffness
and function. However, the scores have historically been used mostly as continuous outcome measures.
The government has introduced the PROM, as the recognised PROM for all patients having a hip or knee
replacement,152 and attempts have been made to use PROMs to prioritise patients for surgery, limiting
those with lower (worse) scores. The intention is that all data collected as part of the PROM programme
are published and used towards the patient choice agenda. This kind of access to data provides patients
and health-care professionals with the opportunity to discuss the information available regarding their care
options, and results in shared informed decision-making.153
Initially, the routine collection of PROMs has been brought in to clinical trials and national audits followed by
the government initiative in 2009 to introduce PROMs throughout the NHS as a measure of improvement
of clinical quality within the health-care system.150 OHSs and OKSs, which form part of PROMs, were not,
however, designed to be utilised in this way. Moreover, little work has been done to suggest that Oxford
scores can actually predict surgery outcome. We therefore investigated how preoperative Oxford scores
can be used for the definition of patient-reported outcomes, a prerequisite for prioritising patients to
access surgery.
What is a good patient-reported outcome after total hip replacement?154
To assess the suitability of the Oxford scores, we investigated the possibility of defining a postoperative
OHS threshold anchored on patient satisfaction, as described in Arden et al.154 As OHS is a continuous
variable ranging from 0 units, as the worst possible score, to 48 units, as the best possible score, it is
unclear which score on this continuous scale would define a cut-off point indicating patient satisfaction
with surgery. To explore this, we used the St Helier Hospital Outcome Programme data for defining a
postoperative OHS threshold anchored on patient satisfaction. To investigate patients’ satisfaction at
12 and 24 months after the surgery, patients were asked ‘are you satisfied with the result of your hip
replacement?’, to which patients would answer yes or no.
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From baseline characteristics, we included BMI, sex, age, OHS and duration of pain. Table 14 shows the
median values of these characteristics for the full cohort (799 patients).
A total of 799 patients who had THR were eligible in the period 1986–2007. Of those, 77.5% (n = 619)
completed the 12-month follow-up questionnaires and 80.0% (n = 639) completed the 24-month
follow-up questionnaires. The underlying diagnosis was OA in 95.4% of selected patients. Outcome
measures included age, height, weight, sex, expectation and satisfaction questions, and OHS.
Indication for surgery was available for only 239 patients, which was a limitation of this data set. Within
this group, 95.4% of operations were carried out because of OA/coxarthrosis. The remaining 4.6% of
cases were a result of avascular necrosis (n = 4), failed postfracture fixation (n = 3), acetabular erosion
secondary to hemiarthroplasty (n = 1), unspecified arthritis (n = 1), hip dysplasia (n = 1) and joint pain
(n = 1). Only 487 patients had a baseline BMI measurement and, among these patients, the median BMI
was 27 kg/m2 [interquartile range (IQR) 24–30 kg/m2]. The duration of pain measurement was available in
630 patients, and sex and baseline OHS were present in all.
TABLE 14 Baseline characteristics of patients154
Baseline characteristics
Median (full cohort,
n= 799)
Non-respondents
12-month follow-up
(n= 180)
24-month follow-up
(n= 160)
BMI (kg/m2)
All, median (IQR) 27 (24–30), n= 487 27 (24–30), n = 106 27 (23–30), n= 93
Low tertile, median (range) 23 (15–25), n= 197 23 (15–25), n = 42 22 (15–24), n= 32
Medium tertile, median (range) 27 (26–29), n= 143 27 (26–29), n = 33 27 (25–29), n= 34
High tertile, median (range) 32 (30–43), n= 147 33 (30–42), n = 31 33 (30–39), n= 27
Sex
Female, frequency (%) 480 (60.1) 107 (59.4) 96 (60.0)
Male, frequency (%) 319 (39.9) 73 (40.6) 64 (40.0)
Age (years)
All, median (IQR) 68 (58–76), n= 797 65 (54–74), n = 179 67.5 (56–77), n= 158
Low tertile, median (range) 54 (20–62), n= 269 51 (20–60), n = 65 53 (20–60), n= 54
Medium tertile, median (range) 68 (63–73), n= 275 65 (63–71), n = 56 68 (61–74), n= 52
High tertile, median (range) 79 (74–100), n= 253 78.5 (72–100), n= 58 80 (75–100), n= 52
OHS (units)
All, median (IQR) 17 (11–23), n= 799 17 (12–24), n = 180 17 (12–23), n= 160
Low tertile, median (range) 9 (0–13), n = 278 10 (1–15), n= 71 10 (1–14), n = 57
Medium tertile, median (range) 17 (14–21), n= 277 18 (16–21), n = 51 17 (15–20), n= 50
High tertile, median (range) 27 (22–41), n= 244 26.5 (24–30), n= 58 25 (21–36), n= 53
Duration of pain, median (IQR) 1–3 years (1–3 years,
3–5 years), n= 630
1–3 years (1–3 years,
3–5 years), n = 83
No observations
IQR, interquartile range.
Note
Reprinted from Osteoarthritis and Cartilage, vol. 19, Arden NK, Kiran A, Judge A, Biant LC, Javaid MK, Murray DW, et al.
What is a good patient reported outcome after total hip replacement? pp. 155–162, 2011, with permission from Elsevier.154
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Two different statistical methods were used to identify the cut-off points, which were anchored on patient
satisfaction: one was the receiver operating characteristic (ROC) curve technique, which was used to
identify the thresholds to maximise sensitivity and specificity; and the other was the 75th percentile
approach. The OHS, which is quoted to patient satisfaction, at 12 months was ≥ 38 units using the ROC
curve technique and ≥ 38 units by the 75th percentile approach. At 24 months, the figures were 33 units
and 40 units, respectively (Figure 9). Using changing OHS as the outcome of choice, the ROC curve
revealed that the value of satisfaction was 15 at 12 months and 14 at 24 months.
We took the 75th percentile from the top end of the OHS curve, leaving the cut-off point at 25%. At follow-up,
91.9% were satisfied at 12 months and 92.8% at 24 months, whereas 24 patients were unsatisfied at
24 months.
To assess whether or not these cut-off points varied according to important baseline characteristics, we
performed a stratified analysis. The characteristics were sex, age (tertiles), BMI (tertiles), baseline OHS
(tertiles), preoperative expectation of pain (‘not at all painful’ vs. ‘any pain’) and expectations for function
(‘not limited at all’ vs. ‘any limitation’).
We demonstrated that the cut-off points, when using the change in OHS between the baseline and
24 months, have greater variation across patients than when using only 24-month OHSs (Figure 10). The
value associated with satisfaction was greater in women than men. There were also greater variations
accounting for BMI and patients’ preoperative expectations. The patients who had the highest
preoperative OHS required the lowest change in the score in order to be satisfied.
Using the 12-month data, we demonstrated the heterogeneity in the cut-off points, particularly when
stratified for BMI and age. The greatest discrepancy was seen for change and baseline OHS, but with the
lesser changes seen in percentage for potential improvement.
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This study below confirms that we could identify the cut-off point for outcome of hip replacement surgery,
which could be used for our research. This was based on the patient-accepted symptom state (PASS)
methodology. In view of the heterogeneity discovered on stratification, however, this was not acceptable
for clinical decision-making as a single outcome measure and more work would be required to stratify
outcome measures if this was to be the case.
Interpretation of patient-reported outcomes for hip and knee replacement surgery155
Having identified a cut-off score for outcome of hip arthroplasty at 12 months, we then used a second
cohort, the EOC, to produce a PASS score for the OHS but also to validate the OHS. This purpose-built
EOC performs hip and knee replacement surgeries for four acute NHS trusts (Mayday, Kingston, St
George’s, and Epsom and St Helier) serving 1.5 million people. The database routinely collected OHS and
OKS preoperatively and 6 months after surgery.
We obtained baseline and 6-month postoperative Oxford scores from 1523 patients undergoing hip
replacement and 1784 patients undergoing knee replacement. Six months after the surgery, patients were
asked to complete their overall satisfaction with surgery using a VAS. On a VAS, 0 depicts no satisfaction
and 100 shows a complete satisfaction (very satisfied). We identified a threshold value of ≥ 50. This cut-off
point was observed with 93% patients who had hip arthroplasty and with 89% who had knee arthroplasty.
A ROC curve was used to identify PASS score thresholds for absolute changes in OHS and OKS. For OHS
this cut-off point was 14 when 97.6% patients declared satisfaction with surgery, and for OKS the cut-off
point was 11 when 95.4% said that they were satisfied with surgery.
Table 15 shows these results at the baseline and follow-up at 6 months scores in tabular format.
The mean improvement (the absolute change) in OHS was 19 units (10.5 units) and in OKS was 14.5 units
(9.8 units). Of interest, 80 patients undergoing THR had no change or worsening of OHS at 6 months, of
whom 56.3% still declared themselves satisfied with surgery. Of the 143 patients whose OKS remained
unchanged or deteriorated, 54.6% reported that they were satisfied with surgery. Of those whose pain
score improved, 94.9% of hip replacement patients and 92.2% of knee replacement patients were
satisfied. Using ROCs, the OHS associated with satisfaction at 6 months was 35 units (95% CI 32.9 to 37.1
units) and, of the patients achieving this score, 98% were satisfied with their surgery compared with 78.6%
of those not meeting the threshold. The same figures for OKS were 96.7% and 70.1%, respectively.
Figure 11 shows the thresholds according to baseline Oxford scores. Overall, it can be seen that patients
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starting with a higher baseline score, not surprisingly, have higher thresholds for satisfaction. Patients with
worst pain/function baseline scores require higher change in Oxford scores to achieve the highest level of
satisfaction, in contrast to patients with the better preoperative scores. However, patients with low
preoperative scores (severe symptoms) require lower 6 months’ postoperative Oxford scores to achieve a
higher state of satisfaction.
A PROMs score on its own does not translate into a clinically meaningful outcome for either clinicians or
patients. We aimed to describe how absolute changes in Oxford scores can relate to patients’ satisfaction
with surgery. We used PASS156 to identify the cut-off points for the difference between the scores at baseline
and 6 months after surgery. PASS depicts the value of OHS/OKS beyond which a patient’s consideration of
his or her own health status is good. These cut-off points for the change, as well as 6-month scores, are
useful for both patients and clinicians as they improve the understanding of representation of a ‘very good
outcome’ as opposed to a ‘good outcome’ and of the expectations of the operation.
TABLE 15 Descriptive statistics of satisfaction with surgery: OKS and OHS preoperatively and at 6 months
Time point
Surgery
OKS OHS
Preoperative
Mean (SD) 19.9 (8.0) 19.7 (8.8)
Median (IQR) 20 (14–25) 19 (13–26)
6 months
Mean (SD) 34.5 (9.1) 38.8 (8.7)
Median (IQR) 36 (29–42) 41 (34–46)
Patients satisfied with surgery, n (%) 1591 (89.2) 1415 (92.9)
Note
Reproduced with permission and copyright © of the British Editorial Society of Bone and Joint Surgery.155
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Overall, this study demonstrated that thresholds for satisfaction could be identified for use in this research
programme. The value obtained for the knee was not dissimilar from the previous study and a new value
for the OKS was identified. This was substantially, and significantly, lower than the hip score.
Novel methodological approach for measuring symptomatic change following total
joint arthroplasty157
There has been confusion in the orthopaedic literature owing to the different methods used to define
patient-reported outcomes. Some papers have used the score as the main outcome with or without
adjustments for baseline score. Others have used the changes in score. This has often caused discrepant
results in predictors of outcome, most notably when using baseline functional score and pain score as
predictors. Harmonising the outcome measure is needed in current research. Both of these functional and
pain scores have had limitations. We propose a new score – percentage of potential change (PoPC). PoPC
is computed as the actual change divided by the potential improvement multiplied by 100. Thus, PoPC is a
measure to express relativity of an actual change in PROMs in relation to a potential change, that is what
could have been attained (Figure 12).
We have used the data from the EOC of patients who underwent THA and TKA between 2004 and 2009.
Patients had completed OHS and OKS questionnaires both preoperatively and 6 months postoperatively.
For the analysis, 1523 OHS and 1784 OKS completed questionnaires were used. In addition to Oxford
scores, patients were also asked to complete a short questionnaire about their satisfaction with surgery on
a VAS. A threshold of ≥ 50 units was used to generate a binary variable to identify whether or not patients
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FIGURE 12 Percentage of potential changes. Reprinted from The Journal of Arthroplasty, vol. 29, Kiran A,
Hunter DJ, Judge A, Field RE, Javaid MK, Cooper C, Arden NK. A novel methodological approach for measuring
symptomatic change following total joint arthroplasty, pp. 2140–5, 2014, with permission from Elsevier.157
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were satisfied with surgery. Patients with potential improvement have a PoPC of > 0 units, with a potential
worsening PoPC of < 0 units and patients with no actual change have a PoPC value of 0 units. PoPC
allows the expression of how much a patient’s symptoms have improved or worsened.
Kiran et al.,157 again, demonstrated excellent improvements following knee and hip replacement surgeries.
Correlation (Spearman’s rank-order correlation) of patient satisfaction score with each of the outcome
measures was greatest for PoPC and lowest for the relative change (Table 16).
The results showed that the ROC analysis, anchored on satisfaction as the outcome area under the curve
(AUC) for hip replacement were follow-up score of 0.86 units, PoPC of 0.86 units, actual change of 0.83
units, relative change of 0.75 units, and for knee replacement were 0.85, 0.85, 0.8 and 0.72 units,
respectively.
Kiran et al.157 have demonstrated the importance of defining outcome measures. Different outcome
measures identified different numbers of patients as being responders and non-responders, which has
major implications in terms of health economics and health-care planning. It also demonstrates that
outcomes for individual subjects differ depending on the outcome measures. This is critically important
when trying to define outcome in an individual patient, as in this programme.
In summary, so far we have demonstrated that the OHSs and OKSs can be used to define patient-reported
outcome following hip and knee replacement surgery. We have defined cut-off points for the OHSs and
OKSs that equate to patient satisfaction with the procedure for use in the following sections to identify
predictors of outcome.
Value-added publication
Assessing patients for joint replacement: can preoperative Oxford Hip and
Knee Scores be used to predict patient satisfaction following joint
replacement surgery and to guide patient selection?50
In response to increasing moves to use the Oxford scores to ration access to lower limb joint replacement,
we investigated the predictive nature of preoperative OHS and OKS in determining patient satisfaction
postoperatively. We used the database from the SWLEOC, in which OHS or OKS were routinely collected
with the addition of a satisfaction questionnaire both preoperatively and 6 months postoperatively. A total
of 1523 THR patients and 1784 TKR patients were selected. Patients were asked routinely to complete the
questionnaires with OHSs and OKSs at baseline, preoperatively and 6 months after their surgery. They
were also asked to measure their overall satisfaction with surgery using a VAS, with scores from 0 to 100.
We used scatterplots to identify, and describe, the associations between participants’ preoperative Oxford
scores and satisfaction 6 months postoperatively. We found no such association, as shown in the
scatterplots (Figure 13).
TABLE 16 Spearman’s rank-order correlation of satisfaction with surgery (95% CI)157
Surgery
OHS OKS
Follow-up score 0.49 (0.45 to 0.53) 0.57 (0.54 to 0.60)
Actual change 0.43 (0.40 to 0.47) 0.49 (0.46 to 0.53)
Relative change 0.30 (0.25 to 0.34) 0.34 (0.30 to 0.38)
PoPC 0.52 (0.49 to 0.56) 0.58 (0.55 to 0.61)
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Spearman’s rank-correlation coefficients between Oxford scores and satisfaction at 6 months
postoperatively were –0.04 units for the OHS (95% CI –0.09 to 0.01 units) and 0.04 for the OKS (95% CI
–0.01 to 0.08 units). We also found no differences in median satisfaction scores by baseline OHS (Table 17)
or OKS (Table 18) with the Kruskal–Wallis test. Interestingly, TKR results suggested that TKR patients with
the lowest preoperative scores were most dissatisfied with their surgery at 6 months after their operation;
conversely, scores were not predictive in patients undergoing THR.
This study suggests that, based on 6-month outcomes, preoperative Oxford scores should not be used to
predict patient satisfaction after surgery. We conclude that it is unlikely that PROMs can be used on their
own to predict patient satisfaction, but it is likely that a combination of multifactorial elements would play
an important factor. Such a multidimensional instrument would incorporate a wide range of risk factors in
the assessment of pain, function, satisfaction and health-related quality of life (HRQoL).
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FIGURE 13 Scatterplots showing relationship between (a) baseline OKS; and (b) baseline OHS compared with
satisfaction at 6 months after surgery. Reproduced with permission and copyright © of the British Editorial Society
of Bone and Joint Surgery.50
TABLE 17 Patient satisfaction with surgery 6 months after THR, stratified by baseline scores
OHS
Number of
patients
Number of
satisfied patients
at 6 months after
surgery (IQR)
Kruskal–Wallis
p-value
Patients satisfied
at 6 months
after surgery (%)
Chi-squared
p-value
Total 1523 100 (90–100) 1415 (92.9)
Baseline OHS of ≤ 26 units 1170 100 (90–100) 0.45 1085 (92.7) 0.63
Baseline OHS of > 26 units 353 100 (90–100) 330 (93.5)
Baseline OHS of 0–15 units
(low)
533 100 (90–100) 0.36 496 (93.1) 0.97
Baseline OHS of 16–24
units (medium)
546 100 (90–100) 506 (92.7)
Baseline OHS of 25–46
units (high)
444 100 (90–100) 413 (93.0)
Note
Reproduced with permission and copyright © of the British Editorial Society of Bone and Joint Surgery.50
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Identifying the role of univariable as well as multivariable risk
factors in patient-reported outcomes
In this work package we report on the identification of the operational, clinical, biological and other
important risk factors for poor outcome, and on the combining of risk factors, with the aim of producing a
clinically relevant instrument to predict poor outcome. We have summarised our findings on the potential
risk factors of good or bad patient-reported outcomes after THR and TKR, and revision results from GPRD
and the new CPRD.135,136
Data from a number of cohorts were used to inform the analysis. In particular, four data sets, which have
been reported in detail elsewhere, were used extensively:
1. EUROHIP137
2. EPOS139
3. EOC database155
4. St Helier Hospital outcome programme.154
In this section, we will discuss each individual risk factors and its association with outcomes, as described in
published studies.
Preoperative Oxford Hip Score and Oxford Knee Score
Introduction
In the UK, within the NHS, PROMs have been routinely used as the outcome measure. PROMs comprise
the OHS, the OKS, the EQ-5D and several questions asking patients about their satisfaction with surgery,
services and expectations. The OHS was developed in 1996 mainly for use in clinical trials.146 The OHS and
OKS are joint-specific measures,145,158 whereas EQ-5D is non-specific, asking patients about their general
health state, mobility, self-care, usual activities, pain and anxiety/depression.148
As previously described, the OHS and OKR score patients’ satisfaction between 0 and 48 units, with 0
describing the worst possible pain and function, and 48 indicating the best possible outcomes. These
scales have been used to identify patients with surgery failure; however, scores alone are not sufficient to
inform clinicians and patients of the outcome. For this reason, we introduced a dichotomous variable, the
TABLE 18 Patient satisfaction with surgery 6 months after TKR, stratified by baseline scores
OKS
Number of
patients
Number of
satisfied patients
at 6 months after
surgery (IQR)
Kruskal–Wallis
p-value
Patients satisfied
at 6 months
after surgery (%)
Chi-squared
p-value
Total 1784 90 (80–100) 1591 (89.2)
Baseline OKS of ≤ 20 units 954 90 (75–100) 0.079 834 (87.4) 0.01
Baseline OKS of > 20 units 830 90 (80–100) 757 (91.2)
Baseline OKS of 0–16 units
(low)
623 90 (75–100) 0.36 540 (86.7) 0.037
Baseline OKS of 17–23
units (medium)
568 90 (80–100) 511 (90.0)
Baseline OKS of 24–47
units (high)
593 90 (80–100) 540 (91.1)
Note
Reproduced with permission and copyright © of the British Editorial Society of Bone and Joint Surgery.50
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PASS score.156 The PASS score is a necessary measure to translate the continuous Oxford score variable
into a binary variable, that is, to calculate a cut-off point as an indicative score for surgery satisfaction or
dissatisfaction. It is a useful variable that provides clinicians and patients with more meaningful information
about outcomes of surgery. In addition to PROMs, we have also used the WOMAC, which assesses pain,
stiffness and function.159
Findings
Knee
We investigated the baseline OKS from the EOC database. We included patients undergoing total and
UKR surgeries, but excluded those with previous knee surgeries and bilateral operations. Judge et al.138
investigated the OKS at baseline and 6 months after surgery, as well as the absolute change in OKS.138 The
histogram shows a relatively normal distribution of the baseline OKS (Figure 14a). The OKS distribution
after 6 months is skewed to the right, indicating that pain and function improved in the majority of
patients (Figure 14b).
We established a PASS score using the ROC curve in order to produce the outcome for this study. A score
of 30 units was used as a PASS score, which identified 71.7% of the patients (OKS ≥ 30 units) as satisfied
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FIGURE 14 Distributions of OKS at (a) baseline; and (b) 6 months after surgery. Reproduced from Judge A, Arden NK,
Cooper C, Kassim Javaid M, Carr AJ, Field RE, Dieppe PA. Predictors of outcomes of total knee replacement surgery.
Rheumatology, 2012, vol. 51, pp. 1804–13, with permission of Oxford University Press.141
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at 6 months postoperatively. A higher baseline OKS predicts better outcome, defined by the PASS score,
at the 6-month follow-up [odds ratio (OR) 1.52, 95% CI 1.40 to 1.66]. It also predicted a higher follow-up
OKS (β = 1.70, 95% CI 1.43 to 1.96).
In another study, Sánchez-Santos et al.142 used the data from 1967 patients from the KAT across 34 UK
centres in the UK.142 The results showed a baseline OKS mean of 18.2 units (SD 7.5 units) among patients
who completed both pre- and postoperative questionnaires. The study found an association between the
OKS at baseline and the OKS 12 months after surgery; patients with a better preoperative OKS achieved
better pain and functional outcome following TKR (β = 0.35, 95% CI 0.29 to 0.42).
Hip
Our work confirmed that a higher PROMs score was associated with a better outcome.139,160 The mean
baseline OHS was 16.5 units (SD 7.6 units) in patients from the EPOS cohort139 and 16.49 units (SD 7.7
units), 15.67 units (SD 8.61 units), 19.51 units (SD 8.77 units) and 17.52 units (SD 8.30 units) in a
meta-analysis combining responders at 12 months of the four cohorts.160 Baseline SF-36 physical function
score, collected from responders of two England health districts, was 20 units (SD 5.35 units).
Primary hip replacement for OA was assessed by using the EPOS prospective cohort.139 The study showed
that better preoperative pain/function was associated with a higher postoperative score. Figure 15a shows
the left-skewed histogram of baseline OHS. Figure 15b depicts the 1-year OKS distribution, indicating
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FIGURE 15 The distribution of OHSs at (a) baseline; and (b) 1 year postoperatively. Reproduced from Judge et al.139
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that the majority of patients exhibited better outcomes at 1–5 years using a repeated measures linear
regression model (baseline OHS 10 units; β = 2.68, 95% CI 2.16 to 3.21).
More importantly, this study found that, regardless of the preoperative OHS, participants attained a
statistically significant improvement in pain and function after THR.139 We observed that the patients with
the worst baseline scores attained the greatest improvements in pain and function (patients with a
preoperative OHS of < 5 achieved a 28.8-point change in the score). However, the patients with the best
baseline scores still attained a substantial improvement (patients with a baseline OHS of > 30 achieved a
10.6-point change) (Figure 16).
We have investigated the association of the baseline OHS and BMI.160 We observed that the baseline OHS
decreased as BMI increased; that is, patients of normal weight (BMI 18.5–25 kg/m2) had an OHS of 17.02
units (IQR 15.69–18.34 units), whereas patients with the highest weight (BMI ≥ 40 kg/m2) had an OHS of
12.25 units (IQR 9.02–15.49 units). Underweight patients (< 17.02 kg/m2) also had a low OHS (14.01
units, IQR 9.54–18.48 units). A higher baseline OHS was associated with a better outcome.
Interestingly, a further study investigating patients from two England public health districts (Portsmouth and
North Staffordshire districts) demonstrated that patients reporting better baseline physical function were at
higher risk of a bad postoperative outcome.143 This can be explained by the fact that the study used a
different measure from the OHS, that is, the SF-36. Functional improvement was classified as change in
SF-36 physical function score in the upper quartile. The cut-off point for improved outcome on the SF-36
was defined as ≥ 30 units, which falls in the upper quartile. Patients with better preoperative scores had
also improved outcomes, although they achieved a lesser change between pre- and postoperative scores.
Finally, we observed that the increased baseline OHS was associated with a greater OHS.138 This study
emphasises the importance of classifying outcome similarly across all studies.
Conclusion
Preoperative pain/function was one of the strongest predictors of outcome. A high baseline preoperative
score was related to a better postoperative score. It has been established that patients with lower
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preoperative pain and better preoperative function attain the highest postoperative pain and function,
whereas patients with the worst baseline scores achieve the highest change between baseline and
follow-up.32,44–47 We also need to consider floor and ceiling effects when we estimate change because the
level of satisfaction attained differs according to the baseline degree of functional disability. It is also known
that patients with the lower preoperative scores never obtain the original functional and pain levels, although
this outcome is possible in patients with better preoperative scores. Table 19 summarises our findings.
TABLE 19 Associations found between pre- and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month PASS
score
High OS
predicts better
outcome
Adjusted ORtotal OKS:
1.52 (95% CI
1.40 to 1.66)a
Judge et al.141
EOC Knee PROMs 6-month OKS High OS
predicts better
outcome
Linear model
coefficienttotal OKS:
1.70 (95% CI
1.43 to 1.96)a
Judge et al.141
KAT Knee PROMs 12-month OKS High OS
predicts better
outcome
Linear model
coefficientlog total OKS:
5.6 (95% CI
4.4 to 6.7)b
Sánchez-Santos
et al.142
EPOS Hip PROMs 1- to 5-year OHS High OS
predicts better
outcome
Δ linear model
coefficientOHS (10 units):
2.68 (95% CI
2.16 to 3.21)c
Judge et al.139
EPOS, EUROHIP,
EOC and
St Helier
Hip PROMs 12-month OHS High OS
predicts better
outcome
Linear model
coefficientOHS (10 units):
1.48 (95% CI
0.62 to 2.34)d
Judge et al.160
Portsmouth
and North
Staffordshire
Hip PROMs 6 months, with
≥ 30 points in
the SF-36
High OS
predicts lower
risk of good
functional
outcome
Adjusted OROHS (10 units):
0.73 (95% CI
0.60 to 0.89)e
Judge et al.143
EPOS and
EUROHIP
Hip PROMs 12-month OHS
and WOMAC
score
High OS
predicts better
outcome
Linear model
coefficientOHS (10 units):
2.23 (95% CI
1.68 to 2.79)f
Judge et al.161
OS, Oxford Score.
a Predictor variables were age, sex, BMI, Index of Multiple Deprivation 2004, side (left or right), diagnosis (primary OA, RA
or other), operation type (TKR or UKR), American Society of Anesthesiologists grade (1, 2, 3 or 4), preoperative EQ-5D
anxiety/depression question, year of surgery and aged < 60 years.
b Predictor variables were age, sex, age × sex, Index of Multiple Deprivation 2004, BMI, SF-12 mental component summary
score, American Society of Anesthesiologists grade (1, 2, 3 or 4), other conditions affecting mobility, previous knee
surgery, fixed flexion deformity, preoperative valgus/varus deformity and preoperative anterior cruciate ligament.
c Predictor variables were 1- to 5-year postoperative OHS, age, sex, BMI, occupation, comorbidities, SF-36 mental
component summary score and femoral component offset size.
d Confounding variables included age, sex, SF-36 mental component summary score, comorbidities, fixed flexion, analgesic
use, college education, OA in other joints, expectation of less pain, radiographic K/L grade, American Society of
Anesthesiologists grade (1, 2, 3 or 4) and years of hip pain.
e Predictor variables were age, sex, BMI, Index of Multiple Deprivation 2004, side of surgery, primary diagnosis (OA, RA,
other), operation type (TKR or UKR), American Society of Anesthesiologists grade (1, 2, 3 or 4), preoperative OKS,
preoperative EQ-5D anxiety/depression question and year of surgery.
f Predictor variables were age, sex, BMI, education, SF-36 mental component summary score, pattern of OA
(superolateral, superomedial/medial/concentric) no reduction, number of joints with OA, number of joints with surgery,
surgical approach (anterolateral or posterior) and femoral component offset size.
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Age
Introduction
Previous research on the association of age with the outcome of TJR has been heterogeneous. Some
authors have found an association between age and outcome, but others have found no such
evidence.44–49,51,162 Literature reviews suggest that age is not a strong predictor of outcome.43
Findings
Knee
Data from the EOC database showed no association with age overall but a minor effect on OKS function,
with younger patients having a better outcome.141 However, despite the statistical significance, the effect
size observed was small. We further explored this association using the KAT data and found that patients
aged < 60 years and ≥ 80 years presented a worse pain and functional status at 12 months after knee
surgery.142 We observed that younger women (aged < 60 years) had a better outcome than men, whereas
in the oldest age group (aged ≥ 80 years) women had a worse outcome than men.
Age at TJR was also a significant predictor of revision for knee. Importantly, Culliford et al.97 found that the
patients undergoing TKR had a 4.3% reduction in revision rates for each extra year of age.97 Figure 17
illustrates that patients aged between 55 and 65 years had up to 10% revision rates at 15 years after
primary knee replacement; patients aged > 85 years had a < 2% revision rate; interestingly, the youngest
group of patients had the highest revision rate.
Hip
Judge et al.30 investigated the association between age and patient outcomes following THR surgery in the
EUROHIP cohort. Age was grouped at baseline as < 50, 50–69 or ≥ 70 years. The results showed that there
were no statistically significant differences across the age groups, although the youngest responders presented
better outcomes.30 In another study, Judge et al.143 collected data from 282 patients from two England health
districts: Portsmouth and North Staffordshire. The primary outcome was the long-term functional improvement
after THR. Patients included in the study were aged ≥ 45 years and were listed for THR for primary OA. To
identify the risk factors to predict functional improvement in the long term (≈8 years), we used the logistic
regression modelling. The results showed that older patients were less likely to have an improvement in
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FIGURE 17 Cumulative incidence estimate for revision of TKR by age. Reproduced from Culliford et al.97 This is an
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physical function; however, the association found in the study was weak.143 Furthermore, data analysis
from EPOS and EUROHIP cohorts revealed a non-linear association between age and outcome in patients
undergoing THR.138 In those patients aged ≥ 75 years, increasing age was associated with worse outcomes.
In addition, a worse outcome was found in those patients aged 50–60 years than in those who are younger
(aged < 50 years) and older (aged > 60 years),139 although there was a small, statistically significant change in
achieved postoperative outcome associated with patient age (Figure 18).
Among patients aged > 65 years, revision rates 15 years after the primary hip replacement were up to
10%97 (Figure 19). Among THR patients, the revision rate fell by 3% for each extra year of age, after
adjusting for the competing risk of death.
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FIGURE 18 The change in OHS over time, layered by age, from Judge et al.139 This is an open-access article
distributed under the terms of the Creative Commons Attribution-Noncommercial license, which permits use,
distribution, and reproduction in any medium, provided the original work is properly cited and the use is
non-commercial and is otherwise in compliance with the licence.
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FIGURE 19 Cumulative incidence estimate for revision of THR by age. Reproduced from Culliford et al.97 This is an
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Conclusion
We have demonstrated that increasing age reduces the risk of revision surgery.97 Different, and heterogeneous,
results were seen when using PROMs as the primary outcome. Some of our work showed that the effect of
age on joint replacement surgery outcome is not significant,30,141,160 whereas other work showed the effect
of age to be non-linear, with the youngest and oldest patients having the worst outcomes.138,139,142 Age was
associated with functional outcome following TKR and THR, although size effect of the association was small.
Overall, the small statistically significant differences relating to patient age at the time of surgery were
greatly outweighed by the substantial change in PROMs achieved by these patients.139 Table 20
summarises associations found between age and outcomes.
Sex
Introduction
The work carried out in work package 1 showed that the lifetime risk of THR in the UK is higher among
women than among men.98,99 It was observed that, at the age of 50 years in 2005, the risk of THR was
11.6% (95% CI 11.1% to 12.1%) for women and 7.1% (95% CI 6.7% to 7.5%) for men. Similarly, the
risk of TKR was also greater among women (10.8%, 95% CI 10.3% to 11.3%) than among men (8.1%,
95% CI 7.6% to 8.5%).99 In work package 2 we aimed to confirm sex, as previously described in the
literature, as a predictor of surgery outcome following THR and TKR.
Findings
Knee
Judge et al.141 found that, among the EOC cohort patients undergoing TKA, functional outcomes were
worse in women. The attained 6-month OKS was 0.88 units lower in women than in men (95% CI 0.08 to
1.68 units). In the KAT cohort, the responders showed strong evidence of an interaction between age and
sex: younger women (aged < 60 years) and older men (aged ≥ 80 years) had better outcomes.142 This
difference of sex was not found on OKS outcome in the middle age groups (60–80 years).
Conversely, Culliford et al.97 showed that the revision risks were significantly higher among men than
among women following TKR. The adjusted overall SHR was greater in men than in women in the
adjusted competing risk analysis (SHR 1.51, 95% CI 1.32 to 1.73).
Hip
In hip arthroplasty patients we did not find an association between sex and surgery outcomes.30,139,143,160
Slight improvements were observed in the EUROHIP and Portsmouth and North Staffordshire Health
districts’ cohorts, although this difference was found to be non-significant.30,143 On the other hand,
Culliford et al.97 described a significantly higher risk of revision THR in men than in women: men had a
23% higher risk of revision arthroplasty than women (1.23, 95% CI 1.10 to 1.38). Although women and
men did not present differences in the OHS, WOMAC and SF-36 scores at 12 months, 1–5 years and close
to 8 years after surgery,30,139,143,160 it was found that men had a greater risk of revision THR.97
Conclusion
The results from the knee and hip studies show that sex may have small effects in knee arthroplasty patients
with little effect on hip arthroplasty when using PROMs as the outcome. In general, women had a worse
PROMs outcome (of minor clinical significance),141,142 whereas men were at a higher risk for prosthesis failure
resulting in the revision arthroplasties.97 Our results are summarised in Table 21.
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TABLE 20 Associations found between age and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month PASS
score
NS pain effect.
Weak function
effect: younger
Adjusted ORpain:
0.98 (95% CI
0.92 to 1.05)
Judge et al.141
Higher likelihood
of improvement
Adjusted ORfunction:
0.93 (95% CI
0.87 to 0.99)
EOC Knee PROMs 6-month OKS NS pain effect.
Weak function
effect: younger
Linear model
coefficientpain: 0.01
(95% CI –0.10
to 0.12)
Judge et al.141
Higher likelihood
of improvement
Linear model
coefficientfunction:
–0.21 (95% CI
–0.3 to –0.08)
GPRD Knee Revision 15 years Increasing age
reduces risk
SHR: 0.957 (95%
CI 0.951 to 0.962)a
Culliford et al.97
KAT Knee PROMs 12-month OKS Younger
(< 60 years)
and older
(> 80 years)
worst outcome
Linear model
coefficient(>80):
–2.8 (95% CI
–5.6 to 0.1)
Sánchez-Santos
et al.142
EPOS Hip PROMs 1- to 5-year OHS Very old
(> 80 years)
worst outcome,
but NS worse for
young
Δ linear model
coefficient(>80):
–3.81 (95% CI
–5.29 to –2.33)
Δ linear model
coefficient(50–60):
–1.87 (95% CI
–3.22 to –0.53)
Judge et al.139
GPRD Hip Revision 15 years Increasing age
reduces risk
Adjusted OR(1 year):
0.971 (95% CI
0.966 to 0.975)
Culliford et al.97
EPOS,
EUROHIP, EOC
and St Helier
Hip PROMs 12-month OHS NS Linear model
coefficient:
–0.28 (95% CI
–1.12 to 0.57)
Judge et al.160
EUROHIP Hip PROMs 12-month
WOMAC score
NS effect, but
young did better
ORreturn to normal (<50):
1.7 (95% CI
0.6 to 4.6)
Judge et al.30
Portsmouth
and North
Staffordshire
Hip PROMs 6 months, with
≥ 30 points in
the SF-36
Weak significant
effect, younger
age higher
likelihood of
improvement
Adjusted OR(10 unit):
0.94 (95% CI
0.90 to 0.98)
Judge et al.143
EPOS and
EUROHIP
Hip PROMs 12-month OHS
and WOMAC
score
Increasing age.
When aged
> 75 years worst
outcome
Linear model
coefficient(≥75):
–2.00 (95% CI
–3.55 to –0.45)
Judge et al.161
NS, not significant.
a Risk of THR and TKR revision associated with BMI, age and sex, after adjusting for the competing risk of death.
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Body mass index
Introduction
The World Health Organization recommends that BMI is classified into four categories: underweight
(< 18.5 kg/m2), normal (between 18 and 25 kg/m2), overweight (> 25 to 30 kg/m2) and obese (class I, > 30
to 35 kg/m2; class II, > 35 to 40 kg/m2; and class III, > 40 kg/m2). BMI is widely recognised as an important
predictor for many conditions, including OA, and, as such, a number of patients referred for lower limb
arthroplasty will have a raised BMI. Although some studies identified a positive relationship between
increased BMI and susceptibility to knee and hip OA, and the need for replacement surgeries,163–165 there is
increasing concern that obesity could be seen as an obstacle to accessing replacement surgeries. We aimed
to confirm an association between BMI and patient-reported outcomes of THR surgeries. A number of
detailed studies investigating the BMI effects on surgery outcomes have been carried out. This section will
detail the results from several publications.
TABLE 21 Associations found between sex and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month PASS
score
NS Adjusted ORfemale:
0.92 (95% CI
0.72 to 1.17)
Judge et al.141
EOC Knee PROMs 6-month OKS Female worse Linear model
coefficientfemale:
–0.88 (95% CI
–1.68 to –0.08)
Judge et al.141
GPRD Knee Revision 15 years Higher risk in
men
Adjusted ORmale:
1.54 (95% CI
1.37 to 1.72)
Culliford et al.97
KAT Knee PROMs 12-month OKS High predicts
better outcome.
Younger women
and older men
had a better
outcome
Linear model
coefficientmale:
–4.6 (95% CI
–7.7 to –1.4)
Sánchez-Santos
et al.142
EPOS Hip PROMs 1- to 5-year OHS NS – Judge et al.139
GPRD Hip Revision 15 years Higher risk in
men
Adjusted ORmale:
1.35 (95% CI
1.23 to 1.48)
Culliford et al.97
EPOS,
EUROHIP, EOC
and St Helier
Hip PROMs 12-month OHS NS Linear model
coefficient:
–0.88 (95% CI
–0.67 to 2.43)
Judge et al.160
EUROHIP Hip PROMs 12-month
WOMAC SCORE
No significant
difference, but
women had a
slightly better
improvement
Adjusted
OROMERACT/OARSI (female):
1.6 (95% CI
0.9 to 2.8)
Judge et al.30
Portsmouth
and North
Staffordshire
Hip PROMs 6 months, with
≥ 30 points in
the SF-36
NS Adjusted OR(female):
0.37 (95% CI
0.19 to 0.72)
Judge et al.143
NS, not significant.
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Knee
We used the GPRD data to describe the association of BMI with revision rates.97 The data were collected
from patients who had undergone hip and knee replacement surgeries between 1998 and 2011. From this
cohort we then identified those with subsequent revision surgeries. We investigated the effects of BMI on
the time of revision surgery. We estimated cumulative incidences of TKR revisions at 1, 5, 10 and 15 years.
The results showed that at 5 years the estimated cumulative revision rate for TKR was 1.9% (95% CI 1.8%
to 2.1%). The cumulative incidences across all BMI groups are shown in Figure 20. For each increased unit
of BMI the estimated risk of TKR revision increased by 1.015 (95% CI 1.002 to 1.028).
Our results suggested that BMI appears to be a significant risk factor of time to revision of TKR. The risk of
revision for morbidly obese TKR patients was found as high as 6% after 10 years following surgery. Up to
approximately 7 years there was a more even distribution across all BMI categories; however, there was a
much higher risk for the morbidly obese patients between 7 and 10 years.
In Judge et al.,141 a high BMI was related to a worse outcome at 6 months after TKR (coefficient total OKS
–0.44 units, 95% CI –0.86 to –0.01 units), although BMI was not found to be a clinically important
predictor of outcome taking into account the PASS score binary variable (OR total OKS 0.90 units, 95% CI
0.80 to 1.01 units) (Table 22). Patients who had a higher BMI showed worse functional outcomes
(coefficient function OKS –0.33 units, 95% CI –0.57 to –0.09 units). Cohort analysis by Sánchez-Santos
et al.142 showed that a high BMI was a determinant factor associated with a decreased OKS at 12 months’
follow-up. Although statistically significant, the effect sizes are small and below the minimal clinically
important difference of the OKS.
Wallace et al.77 further investigated the association between BMI and the risks of complications 6 months
following TKR. We used the CPRD to collect baseline BMI measurements, as recorded by GP practices, on
patients who had undergone primary TKR between 1995 and 2011. We selected 32,485 TKR patients
(including those who died within 6 months of their surgery) and, of those, < 1% were underweight, 17%
were of normal weight, 38% were overweight, 29% were obese class I, 12% were obese class II and 4%
were obese class III. The following outcomes were recorded following their surgeries: myocardial infarction,
stroke, deep-vein thrombosis (DVT) or pulmonary embolism (PE), respiratory infection, anaemia, urinary
tract infection, wound infection and death.
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FIGURE 20 Estimated cumulative incidence for TKRs by BMI. Reproduced from Culliford et al.97 This is an Open
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The study analysis showed that a higher BMI was associated with a significantly higher risk of developing
wound infections, up from 3% to 4.1% (adjusted p < 0.05), in TKR patients. An association was also
found between increased BMI and DVT/PE risk, up from 2.0% to 3.3% (adjusted p < 0.01), in TKR
patients. Interestingly, no association was found between BMI and other confounders, particularly
myocardial infarction, stroke and mortality.
Hip
We have published several studies investigating associations between BMI and THR outcomes.97,160,166
Table 23 shows these associations. The results of the study by Culliford et al.97 show that at 5 years
the estimated cumulative rate of revision surgery for THR was 2% (95% CI 1.8% to 2.1%). Figure 21
depicts cumulative incidences across all BMI groups for patients undergoing THR. BMI was a significant
predictor of revision. Severely obese THR patients seem to have an increased risk of revision surgery in the
first year. For each additional unit of BMI, the estimated risk of THR revision rises by 1.02 units (95% CI
1.009 to 1.032 units).
Batra et al.166 used the analysis from four prospective cohort studies of patients who had undergone THR
for OA: EPOS, SWLEOC, St Helier and EUROHIP. We determined the relationship between BMI and OHS at
1 year following THR. This was adjusted for the baseline OHS. We used a meta-analysis to combine the
results from separately built models in all four cohorts. All models were adjusted for common variables
such as sex and age. The analysis showed that, for every 5-unit rise in BMI, the 1-year OHS fell by 0.81
units (95% CI 0.55 to 1.08 units)166 (Figure 22).
TABLE 22 Associations found between BMI and postoperative knee score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month PASS
score
NS Adjusted ORtotal OKS: 0.90
(95% CI 0.80 to 1.01)
Judge et al.141
EOC Knee PROMs 6-month OKS High BMI, worse
outcome
Linear model
coefficienttotal OKS: –0.44
(95% CI –0.86 to –0.01)
Judge et al.141
KAT Knee PROMs 12-month OKS High BMI, worse
outcome
Linear model
coefficientBMI (10 units): –1.5
(95% CI –2.4 to –0.6)
Sánchez-Santos
et al.142
GPRD Knee Revision 15 years Increasing BMI
increases risk
(small)
Adjusted ORTKR: 1.015
(95% CI 1.002 to 1.028)
Culliford et al.97
CPRD Knee PROMs DVT/PE 6 months
after surgery
Increasing BMI
increases risk
Adjusted ORTKR (obese): 1.59
(95% CI 1.26 to 1.99)
Wallace et al.77
CPRD Knee PROMs Anaemia 6 months
after surgery
Obesity decreases
TKR risk
Adjusted ORTKR (obese): 0.74
(95% CI 0.58 to 0.94)
Wallace et al.77
CPRD Knee PROMs A wound infection
6 months after
surgery
Increasing BMI
increases risk
Adjusted ORTKR (obese): 1.23
(95% CI 1.01 to 1.50)
Wallace et al.77
CPRD Knee PROMs A UTI 6 months
after surgery
TKR NS Adjusted ORTKR (obese): 0.93
(95% CI 0.74 to 1.17)
Wallace et al.77
CPRD Knee PROMs Death 6 months
after surgery
Underweight
increases risk
Adjusted ORTKR (underweight):
4.61 (95% CI 1.64 to
13.01)
Wallace et al.77
DVT, deep-vein thrombosis; NS, not significant; PE, pulmonary embolism; UTI, urinary tract infection.
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TABLE 23 Associations found between BMI and postoperative hip score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
GPRD Hip Revision 15 years Increasing BMI
increases risk
(small)
Adjusted ORTHR:
1.020 (95% CI
1.009 to 1.032)
Culliford et al.97
EPOS Hip PROMs 1- to 5-year OHS High BMI worse
outcome but
small effect
Δ linear model
coefficientBMI (10 units):
–1.54 (95% CI
–2.45 to –0.64)
Judge et al.139
EPOS,
EUROHIP, EOC
and St Helier
Hip PROMs 12-month OHS Higher BMI
worse outcome
Linear model
coefficientBMI (5 units):
–0.81 (95% CI
–1.08 to –0.54)
Batra et al.166
EPOS,
EUROHIP, EOC
and St Helier
Hip PROMs 12-month OHS Higher BMI
worse outcome
but not clinically
significant
Linear model
coefficientBMI (5 units):
–0.78 (95% CI
–1.28 to –0.27)
Judge et al.160
EUROHIP Hip PROMs 12-month
WOMAC score
The obese
improved less
than the
non-obese
ORreturn to normal (obese):
0.8 (95% CI 0.5 to
1.3)
Judge et al.30
Portsmouth
and North
Staffordshire
Hip PROMs 6 months, with
≥ 30 points in
the SF-36
NS. No influence
of BMI on
functional
outcome
Crude OR: 1.00
(95% CI 0.93 to
1.07)
Judge et al.143
EPOS and
EUROHIP
Hip PROMs 12-month OHS
and WOMAC
score
High BMI, worse
outcome
Linear model
coefficientBMI (5 units):
–0.66 (95% CI
–1.10 to –0.22)
Judge et al.161
CPRD Hip PROMs DVT/PE 6 months
after surgery
Increasing BMI
increases risk
ORTHR (obese): 1.64
(95% CI 1.34 to
2.00)
Wallace et al.77
CPRD Hip PROMs Anaemia
6 months after
surgery
THR NS ORTHR (obese): 1.03
(95% CI 0.83 to
1.28)
Wallace et al.77
CPRD Hip PROMs A wound
infection
6 months after
surgery
Increasing BMI
increases risk
ORTHR (obese): 1.52
(95% CI 1.21 to
1.90)
Wallace et al.77
CPRD Hip PROMs A UTI 6 months
after surgery
Obesity increases
THR risk
ORTHR (obese): 1.25
(95% CI 1.02 to
1.55)
Wallace et al.77
CPRD Hip PROMs Death 6 months
after surgery
Underweight
increases risk
ORTHR (underweight):
2.71 (95% CI 1.67
to 4.39)
Wallace et al.77
NS, not significant; UTI, urinary tract infection.
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We then combined the data from all cohorts and used multiple imputations for missing data. With this
analysis, when the sex and age variables were adjusted, every 5-unit rise in BMI was associated with a
1-year fall in OHS of 0.72 units (95% CI 0.46 to 0.99 units); when adjusting for all potential confounders,
this reduction was decreased to 0.51 units (95% CI 0.09 to 0.92 units). The results suggest that, for each
5-unit increase in BMI, the difference in 1-year OHS becomes more significant.
Following these preliminary results, Judge et al.160 further expanded the investigation and used the same
cohorts, exposure, primary outcome OHS and confounding variables to reinvestigate whether or not BMI is
a clinically significant predictor of patient-reported outcomes in patients with THR. Tables 24 and 25 show
that patients achieved significant improvement in their OHS, regardless of their baseline BMI value.
The results confirmed the following associations between BMI and OHS: for each 5-kg/m2 increase in BMI,
the OHS at 1 year decreased by 0.78 units (95% CI 0.27 to 1.28 units; p < 0.001). Obese class II patients
would have a 1-year OHS 2.34 units lower than that of people with a normal BMI.
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FIGURE 21 Figure showing estimated cumulative incidence for THRs by BMI. Reproduced from Culliford et al.97
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Study Effect size (95% CI)
EPOS – 0.90 (– 1.27 to – 0.53)
EUROHIP – 1.15 (– 1.95 to – 0.35)
SWLEOC – 0.52 (– 1.05 to 0.01)
St Helier – 0.69 (– 1.48 to 0.11)
Overall – 0.81 (– 1.08 to – 0.54)
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FIGURE 22 Fixed-effects meta-analysis from Batra et al.166 Osteoarthritis and Cartilage, vol. 20, Batra RN, Judge A,
Javaid MK, Thomas GE, Beard D, Murray D, et al. Pre-operative BMI as a predictor of patient reported outcomes of
primary hip replacement surgery: a combined analysis of 4 prospective cohort study, pp. S152–3, 2012, with
permission from Elsevier.
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Our results confirmed that the effect of BMI on 1-year postoperative OHS is statistically significant,
although the degree of significance is low: patients who are obese class II would have an OHS 2.34 units
lower than patients with a normal BMI. In addition, patients who are rated as obese class II achieved a
22.2-unit change in their OHS following THR. As suggested by Murray et al.,145 the smallest change in OHS
that can be regarded as clinically important is approximately 5 units. Therefore, although a difference of
2.34 units is statistically significant, a difference of this magnitude in OHS at 1 year across all categories
of BMI will have clinical significance only in patients who are rated as obese class II or III. This effect is
greatly outweighed by a significant change in OHS in obese class II people (22.2-unit change), indicating
substantial improvement in outcomes in this patients over the year. Thus, we conclude that BMI should not
be indicative to deny patients access to hip replacement surgery.
Judge et al.138 analysed the data from the EPOS cohort preoperatively and every year up to 5 years after the
patients’ THR surgery. The analysis showed that a 10-kg/m2 increase in BMI was associated with decrease
in OHS of 1.54 units (95% CI 0.64 to 2.45 units) averaged between the 1- and 5-year follow-ups, although
these differences were small compared with the overall benefit of the operation (Figure 23).139 Similarly,
patients from the EUROHIP cohort presented similar results at 1 year after their THR [OR return to normal
(obese) 0.8 units, 95% CI 0.5 to 1.3 units].30 In contrast, there was no association found between BMI and
functional outcomes in THA patients from Portsmouth and North Staffordshire districts.143
TABLE 24 Repeated measures regression model: estimates of pre- and postoperative OHS adjusted for age and sex
BMI categories (kg/m2)
OHS, mean (95% CI)
Baseline 12 months
Underweight (< 18.5) 14.01 (9.54 to 18.48) 39.31 (34.93 to 43.68)
Normal (18.5–25) 17.02 (15.69 to 18.34) 40.04 (38.72 to 41.36)
Overweight (25–30) 16.65 (15.38 to 17.91) 39.01 (37.75 to 40.28)
Obese class I (30–35) 14.23 (12.81 to 15.64) 36.95 (35.54 to 38.37)
Obese class II (35–40) 13.69 (11.82 to 15.57) 35.90 (34.01 to 37.79)
Obese class III (> 40) 12.25 (9.02 to 15.49) 36.43 (33.10 to 39.76)
Reprinted from Osteoarthritis and Cartilage, vol. 22, Judge A, Batra RN, Thomas GE, Beard D, Javaid MK, Murray DW, et al.,
Body mass index is not a clinically meaningful predictor of patient reported outcomes of primary hip replacement surgery:
prospective cohort study, pp. 431–9, 2014,160 with permission from Elsevier.
TABLE 25 Repeated measures regression model: estimates of pre- and postoperative OHS adjusted for adjusted for
all confounders
BMI categories (kg/m2)
OHS, mean (95% CI)
Baseline 12 months
Underweight (< 18.5) 14.04 (9.56 to 18.52) 39.34 (34.97 to 43.71)
Normal (18.5–25) 16.83 (15.25 to 18.40) 39.85 (38.25 to 41.45)
Overweight (25–30) 16.79 (15.22 to 18.36) 39.15 (37.56 to 40.75)
Obese class I (30–35) 14.93 (13.13 to 16.72) 37.66 (35.93 to 39.39)
Obese class II (35–40) 14.71 (12.51 to 16.91) 36.92 (34.72 to 39.11)
Obese class III (> 40) 13.66 (10.24 to 17.07) 37.83 (34.25 to 41.41)
Reprinted from Osteoarthritis and Cartilage, vol. 22, Judge A, Batra RN, Thomas GE, Beard D, Javaid MK, Murray DW, et al.,
Body mass index is not a clinically meaningful predictor of patient reported outcomes of primary hip replacement surgery:
prospective cohort study, pp. 431–9, 2014,160 with permission from Elsevier.
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Wallace et al.77 investigated the association between BMI and the risks of complications 6 months after
THR surgery using the CPRD.77 We collected the baseline BMI measurements from the CPRD for THR
patients between 1995 and 2011. For THR we selected 31,817 patients. From this cohort, BMI distribution
was as follows: 1.5% underweight, 28% normal weight, 40% overweight, 21% obese class I, 7% obese
class II and 2% obese class III. The results showed that in THR patients increased BMI was associated with
a significantly higher risk of wound infections, ranging from 1.6% to 3.5% (adjusted p < 0.01). The
association between increased BMI and DVT/PE risk was significant, with increased BMI from 2.2% to
3.3% (adjusted p < 0.01) in THR patients.
Conclusion
We found weak associations between increasing BMI and worse PROMs outcome. In accordance with
other studies,167 however, the effect sizes were small and often below the minimal clinically important
difference for the Oxford scores. BMI was found not to be a strong predictor of functional outcomes.
Therefore, high preoperative BMI should not be a deterrent to knee or hip replacement surgeries.26,43
Obese patients have a high risk of developing of DVT, PE, wound infection and urinary tract infection
following knee and hip replacement surgeries.
We cannot advocate selecting patients for joint replacement surgeries without consideration of BMI, but
we do suggest that denial of surgery based on high BMI is unwarranted.
Deprivation
Introduction
Historically, deprivation was measured using the Index of Multiple Deprivation (IMD) 2004.53 This index was
extracted from the residence area where the patients lived at the time of surgery. The index is a compound
of seven deprivation indices, employing the indicated weightings: income (22.5%), employment (22.5%),
health deprivation and disability (13.5%), education, skills and training (13.5%), barriers to housing and
services (9.3%), crime (9.3%) and living environment (9.3%). Poorer areas attract a higher deprivation score
and more prosperous areas have a lower score. In addition, educational level was considered in some of our
studies as a proxy of socioeconomic,30,161 as well as employment, status.30 Table 26 shows postoperative
scores in relation to deprivation indices.
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FIGURE 23 Change in OHS over time, stratified by BMI from Judge et al.139 This is an open-access article distributed
under the terms of the Creative Commons Attribution-Noncommercial license, which permits use, distribution, and
reproduction in any medium, provided the original work is properly cited, the use is non commercial and is
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Findings
Knee
The data analysed from the EOC and KAT cohorts showed that deprivation is one of the main predictors of
worse outcome in knee patients.141,142 The IMD 200453 score in the KAT cohort showed that, for each
10-unit increase in deprivation index, the 12-month OKS was reduced by 0.5 units (95% CI 0.1 to 0.9 units),
whereas increased deprivation was associated with a lower OR of achieving a 6-month PASS score (OR 0.73,
95% CI 0.62 to 0.87) (see Table 26).
Hip
We did not identify any THR cohorts for which IMD data were available,53 and so we used data on
educational level and occupation as imperfect surrogates. The data showed that patients who had higher
levels of education had better outcomes.30,160,161 There was no significant difference between employed
and retired patients.30
Conclusion
Higher levels of deprivation were associated with worse patient outcomes following TKR. A higher attained
educational level was associated with better postoperative reported outcomes following THR.
Indication for surgery
Introduction
The most frequent indication for THR and TKR in the UK is OA, which is the most common type of arthritis
in developed countries and for which TJR is the only effective therapy in severe cases.2 The total number of
TABLE 26 Associations found between deprivation and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month PASS
score
Deprived worse
outcome
Adjusted ORtotal OKS: 0.73
(95% CI 0.62 to 0.87)
Judge et al.141
EOC Knee PROMs 6-month OKS Deprived worse
outcome
Linear model
coefficienttotal OKS: –1.40
(95% CI –1.96 to
–0.85)
Judge et al.141
KAT Knee PROMs 12-month OKS Deprived worse
outcome
Linear model
coefficient: –0.5
(95% CI –0.9 to –0.1)
Sánchez-Santos
et al.142
EPOS,
EUROHIP,
EOC and
St Helier
Hip PROMs 12-month OHS College/
university better
outcome
Linear model
coefficient: 3.39
(95% CI 0.12 to 6.67)
Judge et al.160
EPOS and
EUROHIP
Hip PROMs 12-month OHS
and WOMAC
score
College/
university better
outcome
Linear model
coefficient: 2.08
(95% CI 0.59 to 3.57)
Judge et al.161
EUROHIP Hip PROMs 12-month
WOMAC score
Employment no
significant effect,
but employed
not significantly
better
Adjusted
ORreturn to normal (employed): 0.8
(95% CI 0.5 to 1.5)
Judge et al.30
EUROHIP Hip PROMs 12-month
WOMAC score
Education better
for dichotomous
outcomes but
not continuous
Adjusted
ORreturn to normal (university degree):
2.9 (95% CI 1.4 to 5.9)
Judge et al.30
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hip procedures reported in the UK in 2013 was 89,945. Of these, 80,194 were primary procedures and
9751 were revision replacements.168 The indication for primary hip replacement was OA in 91% of cases.
The total number of knee procedures reported in the UK in 2013 was 91,703. Of these, 85,920 were
primary procedures and 5783 were revision replacements. The indication for primary knee replacement
was OA in 97% of cases.
Another important disease for THR and TKR indication is RA. RA is a chronic autoimmune disease affecting
joints. Severe RA also requires surgical intervention. RA indication for THR and TKR in 2013 was 1%.168
Since the licensing of biological agents for the treatment of RA, the number of arthroplasties in patients
with RA is declining. Association between the indication for lower limb joint replacement (OA or RA) and
postoperative score is shown in Table 27.
Findings
Knee
The data analysis from EOC showed that patients diagnosed with RA had a better outcome than those
diagnosed with OA.141 Clinical outcomes in patients with RA were more than twice as better than in those
TABLE 27 Associations found between indication for OA or RA and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month
PASS
score
RA better
outcome
Adjusted ORtotal OKS: 2.17
(95% CI 1.02 to 4.60)
Judge et al.141
EOC Knee PROMs 6-month
OKS
Not significantly
(RA better for
pain)
Linear model coefficienttotal OKS pain:
1.75 (95% CI 0.61 to 2.89)
Judge et al.141
KAT Knee PROMs 12-month
OKS
No model
differences in
OA vs. OA + RA
analysis
– Sánchez-Santos
et al.142
EPOS,
EUROHIP,
EOC and
St Helier
Hip PROMs 12-month
OHS
More joints with
OA, worse
improvement
Linear model
coefficient(number of joints with OA):
–1.24 (95% CI –1.71 to –0.77)
Judge et al.160
Portsmouth
and North
Staffordshire
Hip PROMs 6 months
with ≥ 30
points in
the SF-36
OA worse
preoperative
radiograph
grade, higher
improvement
Adjusted OR: 2.15 (95% CI
1.17 to 3.93)
Judge et al.143
EPOS and
EUROHIP
Hip PROMs 12-month
OHS and
WOMAC
score
OA,
superomedial,
medial or
concentric
disease, had
worse outcomes
Linear model
coefficient(superomedial, medial or concentric):
–1.44 (95% CI –2.79 to –0.09)
Judge et al.161
EPOS and
EUROHIP
Hip PROMs 12-month
OHS and
WOMAC
score
More joints with
OA, worse
improvement
Linear model coefficient:
–1.11 (95% CI –1.48 to –0.74)
Judge et al.161
EPOS and
EUROHIP
Hip PROMs 12-month
OHS and
WOMAC
score
More joints with
surgery, worse
improvement
Linear model coefficient:
–0.78 (95% CI –1.50 to –0.06)
Judge et al.161
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with primary OA, as indicated by the 6-month PASS score (OR 2.17, 95% CI 1.02 to 4.60), and patients
with RA had a better PASS pain score than those with OA (OR 2.33, 95% CI 1.03 to 5.29). There was no
difference in PASS function scores between patients with RA and OA (OR 1.56, 95% CI 0.73 to 3.31).
However, the result using the continuous OKS was not statistically significant (see Table 27).
Hip
We collected data on the number of joints affected by OA, apart from the hip.160 The adjusted multivariable
analysis showed that, for each additional joint affected by OA, the 12-month OHS fell by 1.24 units
(95% CI 0.77 to 1.71 units) (see Table 27).
Baseline data on preoperative radiographic severity were collected from OA patients in two health districts
in England (Portsmouth and North Staffordshire).143 Radiographic grades (Croft grading system) of hip for
surgery were grouped as 0–3, 4 and 5. Patients with worse preoperative radiographic grades had greater
improvement (OR 2.15, 95% CI 1.17 to 3.93). In another study we collected data from preoperative
anteroposterior radiographs of the pelvis and its intra-articular pattern of disease distribution (superolateral,
superomedial, medial or concentric).161 The pattern of OA was strongly associated with the outcome.
Patients with superomedial, medial or concentric disease presented with a lower improvement than those
with a superolateral pattern of OA or no reduction in joint space. Furthermore, the number of additional
joints affected by arthritis and the number of joint replacements was also related to worse outcomes.
Therefore, for each extra joint affected by OA, the 12-month OHS was reduced by 1.11 units (95% CI
0.74 to 1.48 units), and for each extra joint with surgery the OHS was reduced by 0.78 units (95% CI 0.06
to 1.50 units).
Conclusion
Most of the patients undergoing lower limb joint replacements have been diagnosed with OA. In only one
study did patients diagnosed with RA have better outcomes than those diagnosed with OA.141 We adjusted
the model by the confounding factor age, as the patient population diagnosed with RA is younger than
that diagnosed with OA141,169 Similar results were also observed for OKS pain score. The other studies were
related to OA patterns. These studies unveiled better TKR outcomes in patients with a superolateral pattern
of OA or no reduction in joint space, any or a low number of other joints affected by OA, as well as any or a
low number of previous interventions on other joints. In summary, fewer baseline OA complications were
related to better outcomes.
American Society of Anesthesiologists/comorbidities
Introduction
The American Society of Anesthesiologists (ASA) status classification system is a standard measure of
fitness for surgery, scored from 1 (normal, healthy) to 6 (brain-dead patients whose organs are being
removed for donor purposes). Our studies included patients up to ASA 4 (severe systemic disease that is a
constant threat to life).
In addition, we considered some coexisting diseases that could affect surgery outcomes. We take into
account DVT and PE, urinary tract infection, other musculoskeletal diseases and neurological, respiratory,
cardiovascular, renal or hepatic disease. ASA status and number of comorbidities were analysed in several
cohorts, listed in Table 28. Some of these coexistent diseases were also related to BMI (see Tables 18 and 20).
Findings
Knee
The data analysis in EOC cohort study showed that the ASA grade was not statistically significant when
normal healthy patients (ASA 1) or those with severe systemic disease (ASA 3) were compared with
patients with mild systemic disease (ASA 2).141 On the other hand, the KAT cohort study142 showed that a
worse ASA grade was linked to a worse OKS outcome (see Table 28).142
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
Hip
In the EUROHIP cohort, there was no statically significant association between ASA grade and change in
WOMAC score at 12 months: the median OHS for ASA 1 patients was 40.6 (95% CI 35.2 to 46.0), for
ASA 2 patients was 35.4 (95% CI 32.8 to 38.1), for ASA 3 patients was 33.3 (95% CI 27.8 to 38.9) and
for ASA 4 patients was 38.5 (95% CI 30.9 to 46.2) (p = 0.13).30 We did not find differences between
preoperative ASA grades and the OHS 12 months after hip surgery.160
In EPOS, the number of coexistent diseases was statistically significantly associated with outcome, that is,
for each additional preoperative disease the OHS between 1 year and 5 years was reduced by 0.90 units
(95% CI 0.54 to 1.27 units)139 (Figure 24).
Conclusion
We can conclude that ASA grade is not an important predictor of outcomes, although healthier preoperative
conditions could relate to better outcome. On the other hand, the number of other coexisting diseases is a
predictor of worse outcome, although the effect size was small and it would be necessary to identify the
weight for each illness in the final outcome.
Anxiety/depression
Introduction
We employed several scoring systems to assess mental health. For instance, patients from EUROHIP, the
EOC, St Helier and EPOS cohorts completed a SF-36 questionnaire. This tool measures quality of life
through eight health concepts, from which we selected mental health (psychological distress and
psychological well-being).170,171 In the KAT cohort, quality of life was assessed using a subset of those in
TABLE 28 Associations found between ASA score and number of extra comorbidities and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month PASS
score
ASA NS Adjusted ORtotal OKS (ASA 1 vs. 2):
1.30 (95% CI 0.81 to 2.08)
Judge et al.141
EOC Knee PROMs 6-month OKS ASA NS Linear model
coefficienttotal OKS (ASA 1):
1.00 (95% CI –0.29 to 2.29)
Judge et al.141
KAT Knee PROMs 12-month OKS Worse ASA
grade worse
outcome
Linear model
coefficient(ASA 3/4 vs. ASA 1):
–2.6 (95% CI –4.1 to –1.1)
Sánchez-Santos
et al.142
EPOS Hip PROMs 1- to 5-year
OHS
Increasing
number of
comorbidities
associated with
worse outcome
Δ linear model
coefficient(number of comorbidities):
–0.90 (95% CI –1.27 to –0.54)
Judge et al.139
EPOS,
EUROHIP,
EOC and
St Helier
Hip PROMs 12-month OHS ASA NS Linear model
coefficient(number of joints with OA):
–0.56 (95% CI –3.24 to 2.12)
Judge et al.160
EUROHIP Hip PROMs 12-month
WOMAC score
Continuous no
effect
p = 0.13 Judge et al.30
NS, not significant.
Note
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
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the SF-36 (SF-12). Both questionnaires score from 0 (the worst possible health) to 100 (best possible
health). In addition, we estimated anxiety and depression among EOC participants using the EQ-5D.148
Findings
Knee
In the EOC cohort, those patients with moderate or extreme anxiety and/or depression presented a worse
TKR outcome, that is, worse EQ-5D scores were related to worse outcome using the continuous OKS as
outcome.141 We observed lower OKS in anxious or depressed patients, with moderate anxiety or
depression being associated with a reduction of 0.85 units (95% CI 0.03 to 1.68 units), and extreme
anxiety or depression a reduction of 2.21 units (95% CI 0.09 to 4.34 units), compared with non-anxious or
depressed patients. In the KAT cohort, the SF-12 questionnaire was used and demonstrated that worse
mental health is found in those with poor outcomes.142 These results highlight the clinical relevance of
mental health in relation to outcome.
Hip
In the EPOS cohort, lower preoperative SF-36 mental health scores were associated with reduced
postoperative improvement in OHS between 1 and 5 years (Table 29).139 The differences in achieved
postoperative OHS among categorised mental health levels were not substantial, although they were
statistically significant when we followed up between 1 and 5 years (Figure 25). We observed the same
results when we followed up patients at 12 months and we used the same questionnaire (coefficient 0.76
units, 95% CI 0.18 to 1.33 units).160 Finally, we obtained a similar increase in the OHS outcome (coefficient
0.59 units, 95% CI 0.24 to 0.94 units) in patients from the EPOS and EUROHIP cohorts followed up at
12 months.161
Conclusion
Our results show an association between preoperative mental health and the PROM. Therefore, patients
having worse preoperative mental health were more likely to have worse postoperative outcome scores.
This is concordant with other studies in the literature which used detailed measures of mental
health28,29,172,173 or more specific ones, for example the Beck Depression Inventory.174 However, there were
no clinical important differences among mental health categories and the outcome found after surgery.
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FIGURE 24 Change in OHS over time, stratified by number of coexisting diseases, from Judge et al.139 This is an
open-access article distributed under the terms of the Creative Commons Attribution Noncommercial license, which
permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is
non commercial and is otherwise in compliance with the licence.
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FIGURE 25 Change in OHS over time, stratified by SF-36 mental health categories from Judge et al.139 This is an
open-access article distributed under the terms of the Creative Commons Attribution Noncommercial license, which
permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is
non commercial and is otherwise in compliance with the licence.
TABLE 29 Associations found between mental health and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
EOC Knee PROMs 6-month
PASS
score
NS. Anxiety/
depression
worse outcome
Adjusted
ORtotal OKS (extremely anxious/depressed):
0.70 (95% CI 0.42 to 1.18)
Judge et al.141
EOC Knee PROMs 6-month
OKS
Anxiety/
depression
worse outcome
Linear model
coefficienttotal OKS (extremely anxious/depressed):
–2.21 (95% CI –4.34 to –0.09)
Judge et al.141
KAT Knee PROMs 12-month
OKS
Worse mental
health score
associated with
poor outcome
Linear model
coefficientSF-12 (10 units):
0.9 (95% CI 0.4 to 1.3)
Sánchez-Santos
et al.142
EPOS Hip PROMs 1- to 5-
year OHS
Lower SF-36
mental health
score associated
with poor
outcome
Δ linear model
coefficientSF-36 (10 units):
0.76 (95% CI 0.46 to 1.07)
Judge et al.139
EPOS,
EUROHIP,
EOC and
St Helier
Hip PROMs 12-month
OHS
Lower SF-36
mental health
score associated
with poor
outcome
Linear model
coefficientSF-36 (10 units):
0.76 (95% CI 0.18 to 1.33)
Judge et al.160
EPOS and
EUROHIP
Hip PROMs 12-month
OHS and
WOMAC
score
Lower SF-36
mental health
score associated
with poor
outcome
Linear model
coefficientSF-36 (10 units):
0.59 (95% CI 0.24 to 0.94)
Judge et al.161
NS, not significant.
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Clinical, surgical and drug predictors
Introduction
Surgical variables are not usually included in models assessing lower limb joint replacement. We considered
clinical examination findings, that is, the presence of fixed flexion deformity, joint deformity (valgus, varus,
no deformity) and presence of anterior cruciate ligaments (ACLs) and posterior cruciate ligaments. We also
considered variables extrinsic to the patient, that is grade of operating surgeon (consultant, associate
specialist staff, registrar and senior house officer) and the grade of senior surgeon present at the operation
(consultant, associate specialist staff and registrar).142 Furthermore, information about the surgical
approach (anterolateral and posterior) and patient position (supine and lateral) was also collected.139
Findings
Knee
Clinical variables were included in a general linear model to predict OKS patient outcome.142 We found
better outcomes in patients with fixed flexion deformity than in those with no deformity (linear model
coefficient 1.5, 95% CI 0.6 to 2.4). In addition, we found better outcomes in patients with varus deformity
than in those with no deformity and those with an absent preoperative ACL than in those with an intact
ACL (linear model coefficient 1.5, 95% CI 0.0 to 3.0).
Hip
In EUROHIP, we observed increasing differences between the 12-month follow-up and baseline scores from
K/L grade 2 to K/L grade 4, that is, the median WOMAC score for K/L grade 2 was 29.7 units (95% CI 22.6
to 36.8 units), K/L grade 3 was 34.4 units (95% CI 31.3 to 37.4 units) and K/L grade 4 was 38.5 units (95%
CI 35.4 to 41.7 units); differences among groups were statistically significant (p = 0.03). Although this effect
seems to increase also from grade 2 to grade 0, the absolute numbers of patients in groups 0 and 1 (six and
five patients, respectively) did not let us affirm that K/L grade was a U-shaped curve, with group 2 being the
worst. We also analysed K/L grade in patients from four cohorts, being K/L grades 1 and 2 versus K/L grade 4,
and found this not to be statistically significant, that is 0.43 units (95% CI –2.75 to 3.62 units) and 0.86 units
(95% CI –4.73 to 6.44 units), respectively (Table 30). We observed better outcomes in hip replacement
associated with a larger offset size (offset of ≥ 44 mm).
Change among femoral offset size categories had a small statistically significant difference in the
postoperative OHS achieved (Figure 26). We found a significant interaction between offset size and sex,
with the effect limited to women.139
We also identified the effect of surgical approach as significant, with the posterior approach having better
outcomes than anterolateral; that is, there is a difference in the OHS at 12 months of 2.2 units (95% CI
1.1 to 3.30 units).139 This result was very similar to those presented by Judge et al.;161 that is, the difference
at 12 months for the OHS was 2.42 units (95% CI 0.44 to 4.39 units).
Finally, we found that patients from GPRD receiving hormone replacement therapy had a lower risk of
joint (hip and knee replacements) revision surgery after 6 months (adjusted HR 0.62, 95% CI 0.41 to 0.94)
and after 12 months (adjusted HR 0.48, 95% CI 0.29 to 0.78)175 (Figure 27 and see Table 30).
Conclusion
Clinical factors have demonstrated their importance in TKR as predictors of OKS outcomes.142 Among
them, we identified fixed flexion deformity, preoperative valgus/varus deformity and preoperative damaged
ACL. We unveiled an association between femoral offset size and THR, with femoral offsets > 44 mm
related to better outcomes,139,161 although this finding may happen only in women.139 In addition, we
discovered that a posterior approach may have better outcomes than an anterolateral approach.139,161
Furthermore, K/L status was not a good predictor of the outcome.30,160
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Conclusion
We have identified a number of predictors of outcome for both THR and TKR. With the exception of
baseline Oxford score, the majority of the predictors have statistically significant, but clinically small, effects
in isolation. We have identified that the predictors of PROMs may be different from the predictors of
revision and complications of surgery, this was best evidenced by the data relating to age and sex. We
found that increasing age was associated with a lower risk of knee and hip revision,97 whereas in knee
studies younger patients had a higher likelihood of improvement and the older patients a worse
outcome.142 Furthermore, men had a higher risk of TKR revision,97 whereas women had worse PROMs after
TKR.141 Therefore, in order to understand the risks and benefits of lower limb arthroplasty, results from
PROMs outcomes would complement those obtained from revision studies.
TABLE 30 Associations found between surgical and drug variables and postoperative score
Cohort Hip/knee
PROMs/
revision Outcome
Association
found For example Reference
KAT Knee PROMs 12-month
OKS
Fixed flexion
deformity, varus
deformity, absent
preoperative ACL
were associated
with better
outcome
Linear model
coefficientfixed flexion deformity:
1.5 (95% CI 0.6 to 2.4)
Sánchez-Santos
et al.142
Linear model
coefficientno valgus/varus deformity:
–1.6 (95% CI –3.0 to –0.3)
Linear model
coefficientpreoperative ACL absent: 1.5
(95% CI 0.0 to 3.0)
EUROHIP Hip PROMs 12-month
WOMAC
score
K/L grade change
increases from
2 to 4
K/L grade 2 worse outcome;
p= 0.03
Judge et al.30
EPOS,
EUROHIP,
EOC and
St Helier
Hip PROMs 12-month
OHS
NS K/L grade Linear model coefficient(K/L 1):
0.43 (95% CI to 2.75 to 3.62)
Judge et al.160
Linear model coefficient(K/L 2):
0.86 (95% CI –4.73 to 6.44)
EPOS Hip PROMs 1- to 5-year
OHS
Femoral offset size
larger = better
outcome
Δ linear model
coefficient(offset): 0.17
(95% CI 0.06 to 0.28)
Judge et al.139
EPOS
and
EUROHIP
Hip PROMs 12-month
OHS and
WOMAC
score
Femoral offset size
larger = better
outcome
Linear model coefficient(offset):
0.18 (95% CI 0.03 to 0.32)
Judge et al.161
EPOS Hip PROMs 12-month
OHS
Posterior
approach = better
outcome
Linear model coefficient:
2.2 (95% CI 1.1 to 3.3)
Judge et al.139
EPOS
and
EUROHIP
Hip PROMs 12-month
OHS and
WOMAC
score
Posterior
approach = better
outcome
Linear model coefficient:
2.42 (95% CI 0.44 to 4.39)
Judge et al.161
GPRD Hip and
knee
Revision 10-year
implant
survival
HRT reduces
revision rates
HRHRT≥6 months: 0.62
(95% CI 0.41 to 0.94)
Prieto-
Alhambra
et al.175
HRT, hormone replacement therapy; NS, not significant.
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When comparing predictors of THR and TKR, we found that the results were broadly similar for the
majority of the risk factors assessed. We therefore surmise that the features of patients affecting TKR and
THR outcomes would be similar.
Having identified a number of predictors of outcome, it is now important to combine them into a model to
assess their independence and to search for interactions. This will be described in the next section.
Developing a predictive model
Statistical tool for predicting poor outcomes following total hip or knee
replacement surgeries
The final work of work package 2 was to combine the identified risk factors to develop a prognostic tool to
predict poor outcome following TKR and THR surgeries. We published a number of studies and combined
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FIGURE 27 Kaplan–Meier estimates of probability of revision surgery according to hormone replacement therapy
use. Reproduced from Annals of the Rheumatic Diseases, Hormone replacement therapy and mid-term implant
survival following knee or hip arthroplasty for osteoarthritis: a population-based cohort study, Prieto-Alhambra D,
Javaid MK, Judge A, Maskell J, Cooper C, Arden NK, COASt Study Group. vol. 74, pp. 557–63, 2015, with permission
from BMJ Publishing Group Ltd.175 HRT, hormone replacement therapy.
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FIGURE 26 Change in OHS over time, layered by femoral component offset (mm offset) categories, from Judge
et al.139 This is an open-access article distributed under the terms of the Creative Commons Attribution
Noncommercial license, which permits use, distribution, and reproduction in any medium, provided the original
work is properly cited, the use is non commercial and is otherwise in compliance with the licence.
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them into the statistical tools (for both hip and knee) for each surgery category. The papers are currently
under internal review and waiting for external validation in the pragmatic cohort study Clinical Outcomes in
Arthroplasty Study (COASt). Although the previous research provides information on different type of
predictors, it is important to understand how the interplay of these predictors can play a role in the
development of poor functional and pain outcome after THR/TKR.
We aimed to combine risk factors into clinically meaningful tools for stratifying patients for THR and TKR
surgeries. For this purpose we collected and used the data from EPOS, EUROHIP and KAT.
Hip predictive tool
The work for the development of the prognostic tool to predict the outcome following THR was done and
summarised in the article by Judge et al.,138 as described in the next section.
Patient-reported outcomes following primary hip replacement surgery: development
and internal validation of a prognostic tool138
Following identification and confirmation of risk factors within this work package we aimed to develop a
clinical risk prediction tool for both hip and knee arthroplasty patients. Such tools will be beneficial for
clinical decision-making and patients’ expectation of their surgery.
The recent literature describes combining of data from multiple risk factors and, thus, including the broad
range of predictors in a prognostic model.80,81 This includes patient-related risk factors such as age, sex,
education, obesity and mental health status; clinical predictors such as preoperative level of pain and
function, indication for surgery, coexisting conditions and radiographic (grade) variables; and surgery-related
risk factors, such as femoral component offset. In this work we aimed to develop a similar prognostic model
allowing inclusion of a number of risk factors to predict pain and function following hip replacement surgery.
We collected data from prospective cohorts of patients receiving primary THR for OA: EUROHIP and EPOS.
From EUROHIP we used the data from 845 patients and from EPOS we used the data from 1247 patients.
By combining the data from these large cohorts we took into account a comprehensive range of both
already-investigated risk factors and novel predictors.
As OHS was one of the predictors included for the analysis, we collected OHS questionnaires
preoperatively and 1 year postoperatively. OHS was used as a primary outcome measure. In the EUROHIP
cohort, outcome measures were predominantly collected via WOMAC, in contrast to EPOS, which
collected OHS. To derive OHSs from WOMAC we used the truncated regression model for 110 patients in
whom both OHS and WOMAC data are complete. Using this model we could predict WOMAC score at
baseline (R2 = 75.5%) and at 1 year (R2 = 63.4%).
Predictor variables we included in this work are represented in Table 31.
In the EPOS study, patients completed the SF-36. The SF-36 is an instrument that measures quality of life
in eight domains. One of these domains is the mental health component, which we have selected for this
work. In SF-36 the lowest score, 0, is indicative of the worst possible health and the highest score, 100,
of the best possible health. We obtained the fixed flexion range of motion variable in degrees from the
Charnley Modification of D’Aubigné–Postel Grade questionnaire.176 From comorbidities we collected
information on coexistent diseases, such as DVT, PE, urinary tract infection, other musculoskeletal
disorders, neurological, renal, cardiovascular, respiratory or hepatic disease or treatment for other medical
conditions. We have also collected detailed intraoperative information: grade of operating surgeon and
patient position. From the implant information we obtained and used data such as implant material
(stainless steel or ceramic), femoral head size in millimetres and the femoral component size (offset).
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TABLE 31 List of predictors available within the EUROHIP and EPOS cohorts, and distribution of the extent of
missing data in each study
Variable
Cohort, data available (%)
EUROHIP (n= 845) EPOS (n= 1247)
Patient variables
Preoperative and 12-month follow-up OHSa 100 100
Age (years) 99 99
Sex 95 100
BMI (kg/m2) 92 95
Employment/occupation 98 100
Education 88 0
Mental healthb 98 68
ASA grade 87 0
Years of hip pain 99 0
Care for someone else 99 0
Fixed flexion 0 92
Preoperative expectations 100 0
Preoperative comorbidity 0 69
Preoperative medication use 100 0
Analgesic/NSAIDs 99 92
Radiographic variables
K/L grade 93 0
Pattern of OA 87 0
Prosthesis type 97 0
Number of joints OA 100 0
Number of joints surgery 100 0
Number of sites osteophytes 85 0
Surgical variables
Grade of operator 0 100
Surgical approach 0 73
Patient’s position 0 100
Femoral component size (mm offset) 0 100
Femoral head 0 100
Head size 0 100
Duration of operation 0 95
NSAID, non-steroidal anti-inflammatory drug.
a The WOMAC score from EUROHIP was used.
b The EQ-5D anxiety/depression score was used in EUROHIP and the SF-36 mental component summary score was used
in EPOS.
Note
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
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From the EUROHIP cohort we obtained data on home circumstances, employment, education, duration
of pain in the affected hip, the number of preoperative expectations of surgery162 and other joints affected
by OA, as well as other surgeries in other joints. Medications (prior to surgery) that were considered relevant
to the study included analgesic/non-steroidal anti-inflammatory drugs (NSAIDs), bisphosphonates,
medications for heart disease, anticoagulants, antidepressants, bronchodilators and antidiabetic drugs. We
obtained EQ-5D scores for the patient’s health state today, mobility, self-care, usual activities and pain and
anxiety. We obtained the data collected from baseline radiographs of the pelvis taken in the anteroposterior
view. Radiographic variables included the standard K/L grade (0–4)162,176–179 and the intra-articular pattern
of disease distribution (superolateral, superomedial, medial or concentric). Osteophyte size in the
superior–femoral, superior–acetabular, inferior–femoral and inferior–acetabular regions was recorded. For
osteophytes with moderate sizes, we created an ordinal variable of the number of sites. From intraoperative
data we also obtained records from surgical teams on patients’ height and weight, prosthesis type and ASA
status, the last being a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe
systemic disease that is a constant threat to life).
Methodology for combining variables
Because cohorts contained a different set of confounders, combining the two studies resulted in a high
proportion of missing data. Appendix 3 shows the variables available in all cohorts.
Previously methodology has been developed to combine data from multiple sources.80,81,178,179 For instance,
Heymans et al.178 described the method multivariate imputation by chained equations (MICE), based on a
Bayesian approach,176 in which data from three controlled trials were combined to identify risk factors of
chronic low back pain. Jackson et al.80 used the multiple imputation methods within Bayesian graphical
modelling and described the associations between low birthweight and air pollution, thus incorporating
adjustments for crucial confounders that were not available within the individual data set. These two
approaches have been further compared in both simulation180 and cases studies.181 It was concluded that,
even when the proportion of missing data is high, the performance of both approaches is similar.
Moreover, they both correct most of the bias with a non-hierarchical (simple) data structure.
In our work we used MICE to combine the data sources as we were more familiar with this methodology,
it is easier to implement in standard statistical software and it takes less time to run the models.
Use of the multiple imputation method allows the assumption that the data are missing at random. This is
plausible, as the reason behind the missing data is that not all covariates were collected in each study.178
At first, we created 25 copies of the data set. In each copy missing values were replaced by imputed
values,176,182,183 with 20 cycles of regression switching. Imputations were made by drawing from the
posterior predictive distribution of each variable that required imputation. We included all of the covariates
together with the outcome variable (12-month postoperative OHS) in the imputation model, as this carries
information about the missing values of predictors.176 Prior to imputation we transformed continuous
variables so that they were approximately normally distributed. For the imputation of continuous variables
we used the linear regression method, whereas for categorical variables we used logistic, ordinal and
multinomial regression. At the second stage we fitted a statistical model to each of the imputed data sets
separately. The results were then averaged to obtain a single estimate of the association. We calculated
standard errors using Rubin’s rule, as it accounts for the variability between results of imputed data sets
and reflects the uncertainty associated with imputing missing data.176
Although the methodology we used has been tested and used before and proved to be transparent, and it
is relatively easy to implement within the standard statistical software, its use required us to make the
assumption that data were missing at random. This was plausible in the context of this study because the
reason for the missing data was that the variables were not collected. This was further supported by
inclusion of a wide range of covariates to ensure that sufficient predictors were included to recover missing
data for missing information. We are aware, however, that there were too many missed data in this study.
Even if the missing at random assumption is valid, with increased proportion of missing variables the
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reliability of the regression coefficient may diminish.182 However, we are reassured by the previous
simulations and case studies in which the methods have been shown to be effective, even with extreme
numbers (> 90%) of missing data.180,181
Statistical methods used
For statistical analysis we used Stata version 12.1 (StataCorp LP, College Station, TX, USA). We used
analysis of covariance (ANCOVA) to identify predictors of the 12-month follow-up OHS, adjusting for
preoperative OHS. In order to model non-linear relationships for continuous variables we used linear
splines. We use MICE in order to combine data from two studies and adjust for a wider range of
variables.80,81 In the imputation model we included all of the listed covariates together with the outcome
variable (12-month postoperative OHS). Before imputation we log-transformed continuous variables so that
they were approximately normally distributed. We created 25 imputed data sets for missing data by using
MICE in Stata. The final regression model included all predictor variables and was fitted to each imputed
data set. This was then averaged for overall estimated associations. We applied the automatic backward
selection per 200 bootstrap samples of imputed data sets. The variables retained were those consistently
selected for at least 70% of the time.
We assessed the performance of the tool by using the calibration and discrimination methods.184,185 By
calibration we could judge how close the predicted OHS was to the observed OHS for each tenth of
predicted score in 10 equally sized groups. By discrimination we assessed the measure of variation and for
this we used R2. In total, 200 bootstrap samples with replacement and combined with multiple imputations
were used to estimate overoptimism in the predictive ability of the model, and obtain bias-corrected
estimates of R2. We compared R2 from models developed in 200 bootstrap samples with R2 in the same
models applied to the original sample. As previously described in this chapter, a change in OHS by fewer
than 5 units is described as clinically not significant. We used this knowledge to finally test the ability of
the predictive tool to identify patients with the worst possible scores after their THR (i.e. identify the
patients with < 5-unit changes in OHS). We then used a logistic regression model and assessed the
discriminatory ability of the tool by calculating the area under the ROC curve.
Results
From the selected patients, only 63.7% in EUROHIP and 87.1% in EPOS had completed both a baseline
and 1-year follow-up OHS. We observed discrepancies between the patients who did not answer the
1-year follow-up questionnaire and those who responded (Table 32). In the EUROHIP cohort, responders
had better baseline pain and function and EQ-5D mental health scores, lower educational level and higher
levels of obesity as well as greater ASA scores. In the EPOS study we found differences in younger
responders and also in those employed and with a better preoperative SF-36 score.
The mean age of patients in EUROHIP was 65.7 years (SD 10.6 years) and 68 years (SD 10.7 years) in
EPOS. There were 55.2% and 62.8% women in EUROHIP and EPOS, respectively. BMI was similar across
the two cohorts, with a mean BMI of 27.8 kg/m2 (SD 4.4 kg/m2) in EUROHIP and 27.3 kg/m2 (SD 4.9 kg/m2)
in EPOS.
Table 33 displays the predictors that have been found statistically significant.
For example, higher baseline OHS (better pain and function) was associated with an increased follow-up
OHS, which is indicative of better pain and function outcomes. The effect of age was non-linear and there
was a threshold effect. Patients aged > 75 years had worse outcomes. Worse outcomes were also observed
in patients with an increased BMI, lower levels of education and lower baseline SF-36 scores. The pattern
of OA was found to be an important predictor of outcome as a radiographic variable. Patients with
superomedial, medial or concentric OA had worse outcomes than those with a superolateral pattern of
disease or with no reduction in joint space. Worse outcomes were also linked with having had previous
surgeries in other joints and having had arthritis in other joints. A posterior surgical approach and femoral
component offset of ≥ 44 mm were associated with significantly better outcomes.
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Internal validation and model performance
To validate the model internally we used bootstrapping to the imputed data sets. To ensure that the risk
factors are replicated in other external validation studies we ensured that all predictors identified were
those consistently selected across the 200 bootstrap resamples at least 70% of the time. The performance
of the model was assessed by calibration and discrimination (see Table 34). Calibration of the predicted
12-month postoperative OHS was good, except in the lowest deciles of OHS, in which case the model
overestimated the predicted score. Calibration of this predicted change in OHS was very good across all
deciles of change in OHS. The model showed a discriminatory ability with a bias-corrected R2 of 23.1%.
We assessed the performance of the model and found the calibration of the predicted 12-month OHS to
be good. The exception was the lowest deciles of OHS, where we found that the developed model
overestimated the predicted score. The performance of the model is described in Table 34.
We also calculated the predicted the absolute change in OHS by subtracting the predicted 12-month score
from the observed preoperative score. It was observed that the calibration of this absolute predicted change
was very good. Importantly, the model also showed good discriminatory ability, with a bias-corrected R2
of 23.1%.
TABLE 32 Clinical baseline data between responders and non-responders
Variables
Cohort
EUROHIP EPOS
Responders
(n= 908)
Non-responders
(n= 419)
Responders
(n= 987)
Non-responders
(n= 437)
ASA grade, n (%)
Fit and healthy 123 (15.5) 86 (22.5)
Asymptomatic no restriction 505 (63.7) 214 (56.0)
Symptomatic minimal 160 (20.2) 77 (20.2)
Severe restriction 5 (0.6) 5 (1.3)
K/L grade, n (%)
0 6 (0.7) 0 (–)
1 5 (0.6) 1 (0.4)
2 26 (3.2) 6 (2.4)
3 394 (49.2) 116 (46.4)
4 370 (46.2) 127 (50.8)
Number of coexisting diseases,
n (%)
0 136 (31) 295 (30)
1 147 (33) 351 (35)
2 99 (22) 216 (22)
3 43 (10) 97 (10)
4 16 (4) 31 (3)
WOMAC score OHS
Pain score, mean (SD) 54.5 (17.6) 57.7 (18.1) 16.1 (8.2) 16.5 (7.6)
Note
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
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Development of a risk prediction tool
We have developed a web-based tool that can be used to inform patients of the likely outcomes following
their surgery. This web-based tool (Figure 28) uses the predictive equation:
OHS12 months = ½2:23 × OHSbaselineð10 unitsÞ + ½0:26 × age<75 yearsð10 unitsÞ− ½2:00 × age≥75 yearsð10 unitsÞ
− ½0:66 × BMIð5 unitsÞ + (2:08 × educationcollege/university)
+ ½0:59 × mental healthð10 unitsÞ− (1:44 × OA patternsuperomedial/medical/concentric)
– (1:72 × OA patternno reduction)− (1:11 × OA joints)− (0:78 × surgery joints)
+(2:42 × posterior surgical approach) + (0:18 × femoral component size).
(1)
We tested the ability of the tool to identify the patients with the worst possible outcomes of surgery. The
worst outcomes are defined as those THR patients whose preoperative score does not improve for at least
5 units over the 12 months. For 89 patients who met the criteria of the worst possible outcome, the
discriminatory ability of the tool was good, with an area under the ROC curve of 0.78 (95% CI 0.73 to
0.82) (Figure 29). The tool had a sensitivity of 72% and a specificity of 73%. The calibration was also
reasonable, as indicated by the Hosmer–Lemeshow p-value of 0.13.
TABLE 33 Results of linear regression (ANCOVA) model to identify predictors of OHS at 12 months’ follow-up
Variable % included Coefficient (95%) p-value
Patient variables
Baseline total OHS (10 units) 100.00 2.23 (1.68 to 2.79) < 0.001
Age < 75 years (per 10 years) 75.00 0.26 (–0.19 to 0.71) 0.252
Age ≥ 75 years (per 10 years) 82.50 –2.00 (–3.55 to –0.45) 0.011
BMI (kg/m2) (5 units) 90.00 –0.66 (–1.10 to –0.22) 0.003
Education
None 0
College/university 100.00 2.08 (0.59 to 3.57) 0.006
SF-36 mental component summary score preoperative (10 units) 100.00 0.59 (0.24 to 0.94) 0.001
Radiographic variables
Pattern of OA
Superolateral 0
Superomedial/medial/concentric 89.00 –1.44 (–2.79 to –0.09) 0.037
No reduction 2.50 –1.72 (–4.80 to 1.35) 0.272
Number of joints with OA 100.00 –1.11 (–1.48 to –0.74) < 0.001
Number of joints with surgery 85.00 –0.78 (–1.50 to –0.06) 0.034
Surgical variables
Surgical approach
Anterolateral 0
Posterior 100.00 2.42 (0.44 to 4.39) 0.017
Femoral component size (mm offset) 82.50 0.18 (0.03 to 0.32) 0.016
Notes
Variables included in the final regression model are those that are retained in at least 70% of the 200 bootstrap backward
selection regression models. Age is represented as a linear spline, with a knot at 75 years of age.
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TABLE 34 Results of calibration and discrimination of the predictive model
Calibration
OHS
12 months Change
Observed Predicted Ratio Observed Predicted Ratio
Deciles
1 26.78 31.79 0.84 10.53 11.49 0.92
2 33.88 34.90 0.97 15.42 16.36 0.94
3 35.85 36.30 0.99 18.25 19.08 0.96
4 38.19 37.50 1.02 20.74 20.95 0.99
5 39.55 38.49 1.03 22.77 22.51 1.01
6 41.02 39.41 1.04 23.00 24.02 0.96
7 42.14 40.36 1.04 26.16 25.54 1.02
8 42.74 41.53 1.03 27.98 27.20 1.03
9 43.67 42.90 1.02 29.42 29.00 1.01
10 44.57 45.22 0.99 33.79 31.97 1.06
Discrimination (%)
R2 24.00
Optimism 0.80
Corrected R2 23.10
FIGURE 28 Example of a web-based calculator displaying the predictive tool based on the patient’s individual
preoperative characteristics.
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Main findings
Our study found that predictors associated with worse outcomes were old age, worse preoperative mental
health score, higher BMI and the lower education attainment. Better preoperative pain and function were
associated with better postoperative pain and function, and vice versa, patients with worse preoperative
pain and function were observed to obtain the greatest symptomatic improvement (greatest change)
between baseline and follow-ups described in previous literature.52,186 As for the surgical factors, much less
is described previously in the literature of their association with patient-reported outcomes of THR. In this
work we confirmed that the larger femoral component was associated with a better THR outcome.
A new finding was observed with radiographic variables. Specifically, the pattern of joint space narrowing was
found to be a strong predictor: patients with a medial, superomedial or concentric pattern of OA, as identified
on a radiograph, had worse outcomes, as opposed to those with a superolateral pattern or with no intra-
articular space. This observation applies only to patients with OA, as patients with other types of arthritis (such as
RA) were not included in the analysis. The results can be explained by the likelihood that the superolateral
pattern of disease developed as a result of subtle local mechanical factors such as abnormalities of acetabulum
or the femoral head, that is acetabular dysplasia and cam-type femoroacetabular impingement.33 It was
previously suggested that these types of mechanical risk factors are associated with superolateral disease.27,48
Superomedial, medial and concentric patterns of OA are more commonly observed in women, with the
presence of Heberden’s nodes47 and are generally bilateral.49 Therefore, the observed relationship between the
pattern of OA and the outcome may be because of patients with mechanical disease having better pain and
functional outcomes.
No associations were found between the radiographic severity of disease and the surgery outcome using
K/L grade. This may be explained by the existing of other confounding factors in the model, that is, other
markers of radiographic severity of disease.
We conclude that the tool developed within this work package to predict THR outcomes had calibration
and discriminatory ability. The tool has promising potential to inform patients and their clinicians of the
outcomes and help them with making the decision regarding whether or not to select patients for THR.
The tool predicts the outcomes 12 months postoperatively and provides the absolute change in OHS
expressed as a percentage. The performance of the tool to identify patients with the worst outcome
following THR was also good. We tested the model for internal validation but future work will be done to
provide external validation in the prospective cohort of pragmatic setting of NHS patients.
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FIGURE 29 The ROC curve showing discriminatory ability of the model to identify those patients with the worst
outcome (change in OHS of 5 units or fewer).
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Knee predictive tool
The work for the development of the prognostic tool to predict the outcome following TKR was done and
summarised in the manuscript by Sanchez-Santos et al.,142 as described in the next section.
A clinical tool for the prediction of patient-reported outcomes after knee
replacement surgery: a prospective cohort study142
To combine previously described risk factors into a prognostic tool to predict outcomes 12 months after
TKA we used the data from the KAT cohort.187,188 KAT is a pragmatic, partial factorial, unblinded
randomised controlled trial (RCT). In total, 2352 participants were recruited through a random sample to
KAT between July 1999 and January 2003, and then stratified by surgeon by sex, age and site of disease.
The trial contains information on patients receiving primary TKR surgeries across 34 centres in the UK. One
hundred patients who received UKR withdrew from the trial before the procedure or died were excluded from
the analysis. From the remaining 2252 patients with primary TKR, 1649 agreed to complete both baseline and
postoperative questionnaires. All TKR types were included whether or not a metal-backed tibial component,
patellar resurfacing and a mobile bearing were used. Patients had completed questionnaires pre- and
postoperatively (at 3 months, 1 year and annually after their surgery). The primary outcome measure for our
analysis was 12-month postoperative OKS. Predictor variables collected for this work are summarised in Table 35.
Statistical methods used
For statistical analysis we used Stata version 12.1. We compared patient characteristics in responders and
non-responders with preoperative and 12-month postoperative questionnaires. This helped with
determining selection (response) bias. We assessed the relationship between the potential predictors on
two outcomes: continuous 12-month postoperative OKS and change between pre- and postoperative OKS.
For continuous 12-month postoperative OKS we used general linear models to identify risk factors. We
assessed the linearity of continuous variables with the outcome by the fractional polynomials and the
collinearity between variables by variance inflation factor (VIF). Owing to the heteroscedasticity of the
variance of residuals, robust standard errors were used to estimate the sandwich variance estimator. We
used the chained equations to generate 40 imputed data sets to investigate the effects of missing data.
We used all potential predictors (including outcome) and combined estimated parameters by using Rubin’s
rule. Afterwards we selected 200 bootstrap samples with replacement from these 40 imputed data sets.
We applied automatic backward selection within each bootstrap sample (significance level of 0.157). Age
and sex were force entered into all models. All variables appearing for > 70% of the time were then used
in the final regression model.
For change in the OKS, for identified predictors we used the repeated measures linear regression in which
pre- and postoperative OKSs were included as an outcome. In order to describe the change in the
outcome, we included the interaction term between each potential risk factor and time point.
Results
Descriptive statistics
Descriptive statistics and comparison of responders (patients who completed both pre- and postoperative
questionnaires) compared with non-responders is summarised in Table 36.
As Table 36 shows, responders have a better (higher) baseline OKS and SF-12 mental health score than
non-responders. Responders seem to have a higher preoperative OKS and better preoperative SF-12
mental health score than non-responders. Responders also tend to have a higher ASA grade and had a
less damaged preoperative posterior cruciate ligament than non-responders. The percentage of missing
data for the majority of predictors was < 10%. A high percentage of missing data (> 30%) was mainly
observed for socioeconomic status and grade of senior surgeon.
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TABLE 35 List of prognostic variables available for analysis in KAT trial
Variable Additional information
Patients’ characteristic
Age From 32 to 93 years
Sex Male/female
Marital status 1. Married
2. Single
3. Widowed/divorced
BMI Weight/height2 (kg/m2)
Preoperative OKS 0 (worst) to 48 (best)
Preoperative SF-12 mental component summary score Maximum score of 75.3
IMD 200453 Score ranged from 2.1 (least deprived) to 79.3 (most deprived)
Clinical factors
Disease type OA or RA
Disease side 1. One knee
2. Both knees
3. General
ASA grade Grades 1 to 3–4 (grades 3 and 4 were collapsed)
Previous knee surgery Yes or no
Previous contralateral TKR Yes or no
Other condition affecting mobility Yes or no
Surgical factors
Fixed flexion deformity Yes or no
Knee deformity 1. Valgus
2. Varus
3. No deformity
State of ACL 1. Intact
2. Damaged
3. Absent
State of posterior cruciate ligament 1. Intact
2. Recessed/damaged
3. Divided
Grade of operator 1. Consultant
2. Associate specialist staff
3. Specialist registrar
4. Senior house officer
Grade of senior surgeon 1. Consultant
2. Associate specialist staff
3. Specialist registrar
Note
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
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TABLE 36 Descriptive statistics and comparison of potential predictors between responders and non-responders
Variables Responders (N= 1649) Non-responders (N= 603) p-value
Patients’ characteristic
Preoperative OKS (units), mean (SD) 18.3 (7.5) 17.0 (7.7) < 0.001
Age (years), mean (SD) 70.4 (8.1) 71.1 (8.9) 0.053
Sex, n (%)
Female 921 (55.9) 350 (58.0) 0.353
Male 728 (44.2) 253 (42.0)
Marital status, n (%)
Married 1082 (66.0) 376 (65.4) 0.348
Single 65 (4.0) 31 (5.4)
Widowed/divorced 492 (30.0) 168 (29.2)
BMI (kg/m2), mean (SD) 29.7 (5.4) 29.6 (5.3) 0.925
Preoperative SF-12, mean (SD) 50.2 (11.5) 48.6 (11.7) < 0.01
IMD 200453 score, medium (IQR) 15.6 (9.6–25.5) 14.5 (8.9–24.9) 0.273
Clinical factors
Disease type, n (%)
OA 1561 (95.3) 541 (94.6) 0.492
RA 77 (4.7) 31 (5.4)
Disease side, n (%)
One knee 432 (26.4) 137 (24.0) 0.521
Both knees 642 (39.2) 232 (40.6)
General 564 (34.4) 203 (35.5)
ASA grade, n (%)
Fit and healthy 277 (17.5) 89 (15.8) < 0.05
Asymptomatic no restriction 991 (62.8) 329 (58.5)
Symptomatic minimal/severe restriction 311 (19.7) 144 (25.6)
Previous knee surgery, n (%)
No 1039 (63.4) 381 (66.6) 0.172
Yes 599 (36.6) 191 (33.4)
Previous contralateral TKR, n (%)
No 1422 (86.8) 494 (86.4) 0.785
Yes 216 (13.2) 78 (13.6)
Other condition affecting mobility, n (%)
No 1408 (86.1) 474 (83.5) 0.121
Yes 227 (13.9) 94 (16.6)
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From the initial 19 variables we had used in the backward regression model, we identified 12 variables as
predictors of 12-month postoperative OKS (Table 37).
The worst functional and pain outcomes were identified in association with the following predictors:
worse preoperative OKS, worse SF-12 mental health status, ASA grade 3 or 4, presence of other conditions
affecting patient’s mobility and having had previous knee surgery. From surgical factors, the presence of a
fixed flexion deformity as well as preoperative varus deformity and absence of ACL as opposed to intact
ACL were found to be strongly associated with a better postoperative outcome. We found a significant
interaction between age and sex (p < 0.001) and included this in the model. From the age variable we
found that patients aged < 60 and > 80 years had a worse pain and function outcome. The effect
of age also varied by sex: women aged < 60 years had a better outcome than men, and women aged
> 80 years had a worse outcome than men. We found no difference across sex on the outcome in the age
group between 60 and 80 years.
TABLE 36 Descriptive statistics and comparison of potential predictors between responders and non-responders
(continued )
Variables Responders (N= 1649) Non-responders (N= 603) p-value
Surgical factors
Preoperative fixed flexion deformity, n (%)
No 690 (42.6) 257 (45.3) 0.272
Yes 930 (57.4) 311 (54.8)
Preoperative valgus/varus deformity, n (%)
Varus 1006 (63.0) 334 (60.7) 0.434
Valgus 325 (20.3) 111 (20.2)
No deformity 267 (16.7) 105 (19.1)
Preoperative ACL, n (%)
Intact 1054 (65.4) 362 (64.3) 0.694
Damaged 379 (23.5) 131 (23.3)
Absent 179 (11.1) 70 (12.4)
Preoperative posterior cruciate ligament, n (%)
Intact 1302 (81.1) 433 (77.3) < 0.05
Recessed/damaged 144 (9.0) 72 (12.9)
Divided 160 (10.0) 55 (9.8)
Grade of operator, n (%)
Consultant 968 (59.1) 357 (61.9) 0.376
Associate specialist staff 216 (13.2) 80 (13.9)
Specialist registrar 432 (26.4) 131 (22.7)
Senior house officer 22 (1.3) 9 (1.6)
Grade of senior surgeon, n (%)
Consultant 829 (72.0) 289 (71.4) 0.647
Associate specialist staff 185 (16.1) 72 (17.8)
Specialist registrar 138 (12.0) 44 (10.9)
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TABLE 37 Identification of the 12-month postoperative OKS for the total sample (general linear model)
Predictor variables (reference category)
Overall (n= 1649)
% retained in final model Coefficient (95% CI) p-value
Age (years)
(< 60)
60–69 100 0.7 (–1.5 to 3.0) 0.524
70–79 100 1.1 (–1.2 to 3.3) 0.354
≥ 80 100 –2.8 (–5.6 to 0.1) 0.059
Sex
(Female)
Male 100 –4.6 (–7.7 to –1.4) 0.004
Age × sex 78.0% (61.5% to 98.5%) 0.001
Log-preoperative total OKS 100 5.6 (4.4 to 6.7) 0.000
IMD 200453 score (10 units) 96 –0.5 (–0.9 to –0.1) 0.009
BMI (kg/m2) (10 units) 97 –1.5 (–2.4 to –0.6) 0.001
SF-12 mental component summary score (10 units) 98 0.9 (0.4 to 1.3) 0.000
ASA
(Fit and healthy)
Asymptomatic no restriction 52.5 –1.0 (–2.2 to 0.2) 0.097
Symptomatic minimal/severe restriction 96.5 –2.6 (–4.1 to –1.1) 0.001
Other condition affecting mobility
(No)
Yes 99.5 –2.9 (–4.3 to –1.6) 0.000
Previous knee surgery
(No)
Yes 100 –1.7 (–2.6 to –0.7) 0.000
Fixed flexion deformity
(No)
Yes 96.5 1.5 (0.6 to 2.4) 0.002
Preoperative valgus/varus deformity
(Varus)
No deformity 85.5 –1.6 (–3.0 to –0.3) 0.014
Valgus 12.0 –0.1 (–1.3 to 1.1) 0.865
Preoperative ACL
(Intact)
Damaged 77.0 0.8 (–0.2 to 1.8) 0.108
Absent 82.5 1.5 (0.0 to 3.0) 0.047
R2 20.9%
Optimism 0.67
Bias-corrected R2 20.2%
Note
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
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Internal validation and model performance
For the internal validation we used 200 bootstrap samples with replacement in the combination of multiple
imputations and assessed predictive ability for bias-corrected estimates. We examined the discrimination
(R2-statistic) and calibration to assess predictive ability. In the final predictive model the R2 was 20.2%. In
total, 14.3% of the variability of outcome was explained by age, sex and preoperative risk factors. With the
inclusion of other patient characteristics the variability was 16.6%, and with the inclusion of clinical and
surgical variables the variance reached 18.9% and 20.2%, respectively. We found that the model calibration
was good, with close agreement between predicted and observed values of 12-month postoperative OKS.
Main findings
Although the association between outcome of TKR and several potential determinants has been previously
established,189,190 we aimed to identify surgical variables as novel predictors of pain and functional outcome
at 12 months postoperatively following knee replacement surgery. From surgical factors it was found that
the presence of fixed flexion deformity and preoperative varus deformity and absence of ACL were
associated with better postoperative outcome. Preoperative deformity of fixed flexion leads to significant
changes in the biomechanics of the knee, subsequently leading to a debilitating condition. The surgery aims
to correct the knee malalignment and fixed flexion deformity, thus improving biomechanics. Hence, this
may be the cause of the improvement in pain and function. Severe deformity and absence of the ACL may
also result in more severe joint damage and may manifest as severe symptoms of OA. The discriminatory
ability of the model was also improved by inclusion of these surgical predictors in the model compared with
the model with only patient characteristics. From patient risk factors such as age and sex, we identified
that younger women had a better outcome than men, but in the older age group men performed better.
The worst outcomes were associated with the lowest baseline OKS, low socioeconomic determinants, high
BMI, worse mental health (as indicated by SF-12 score), worse ASA grade, history of previous knee surgery
and the presence of other conditions impacting on mobility. From radiographic variables, patients with
more severe disease achieve a greater degree of improvement after the knee replacement.
This work offers clinicians and patients a tool to predict outcomes 12 months after TKA. The tool can be
used to decide whether or not patients should be selected for surgery. Potentially modifiable risk factors
(such as BMI and mental health) can be improved before surgery, whereas factors such as age and sex will
simply help to inform the decision of whether or not an operation is sensible. We have validated the tool
internally and the next step would be to develop a web-based calculator, similar to the hip predictive tool,
which would enable clinicians and patients to predict outcome after their knee surgery. The external
validation of the tool is also required. This would be carried out in the prospective cohort of patients in the
pragmatic NHS setting.
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Chapter 4 Work package 3: economic evaluation
This chapter will evaluate the cost-effectiveness of implementation of the predictive tools designed inwork package 2.
Introduction
Hip and knee arthroplasties (THRs and TKRs, respectively) are regarded as one of the most successful
interventions in orthopaedics because they have been able to reduce pain, and improve joint function and
patient quality of life.191,192 Moreover, these benefits are achieved at a cost that makes the intervention
largely worthwhile. In fact, THRs are considered highly cost-effective,134 not only in the UK but also in
many other countries.193,194 According to an article published in The Lancet in 2007, THR has been given
the title of ‘operation of the century’.195
Despite the clinical success and established value for money of THRs and TKRs, the National Institute for
Health and Care Excellence (NICE) continues to explore the clinical effectiveness and cost-effectiveness of
these interventions. In particular, additional collection and analysis of long-term outcomes following
arthroplasties has been motivated.196 Given the large and growing number of procedures being performed,
the important portion of the health budget that they consume and the increasing number of data available
to assess their clinical effectiveness and cost-effectiveness, it is expected that economic evaluations of these
procedures will continue to be performed. Future assessments can be expected to explore cost-effectiveness
at higher levels of detail, such as the impact of different elements of the surgical process (e.g. fixation type,
prosthesis brand and model) or cost-effectiveness stratified by patient subgroups (e.g. according to sex, age,
BMI and comorbidities).
In addition, although procedures have become increasingly advanced,195 there is evidence showing that a
number of patients undergoing THRs achieve little or no improvement in terms of mobility or are not
satisfied with the results.197–199 In a study based on 1100 randomly selected THR patients from five different
regions in the UK, dating back to 2002, 11% of patients were found to be dissatisfied with the procedure
at 1 year, whereas only 2.6% had had a revision replacement by then,35 indicating that the need for
revision is not an indicator of patient satisfaction.
If potential poor or unsatisfactory outcomes following THR could be predicted, then these patients could
be treated in some other way that benefited them the most, without the health-care system having to
incur costs that could otherwise serve those same patients or others more efficiently. There has been work
linking age, sex, marital status, comorbidity and the physical status ASA score to THR outcome,197 whereas
anxiety/depression198 and socioeconomic factors such as education and employment199 have also been
found to be associated with patient outcomes and satisfaction.
An outcome prediction tool has been developed under work package 2 of this programme to identify,
preoperatively, patients with poor outcome after THR and TKR. It is important to ascertain whether or not
the implementation of the tools would be worth it in terms of its additional costs and benefits. It is
possible that the tool could effectively identify patients who would not have a satisfactory or very good
outcome after surgery, yet its potential higher benefits may be lower than the health benefits displaced
elsewhere in the system by directing resources to implement it. In short, it needs to be considered whether
or not the outcome prediction tool would be a cost-effective use of resources for the UK health-care
system. This work package provides such an economic evaluation of the tool.
To that aim, we developed a lifetime Markov model featuring two unique elements: it starts at the
orthopaedic surgeon’s assessment and it distinguishes between two outcome categories after primary and
revision procedures. To facilitate populating this and other economic models with health utility estimates,
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we compared the performance of several econometric models mapping OHS on to the EQ-5D index. All
models reported high predictive power. Transition probabilities for the model were obtained from expert
elicitation, the NHS PROMs initiative and the EPOS and KAT studies. The NHS PROMs, EPOS and KAT were
also used to estimate health utilities. Procedure costs and primary care costs were obtained from NHS
and CPRD data, respectively. An important contribution of this research was the estimation of a model
predicting surgery outcome category based on resource use.
Data sources about the outcomes of THRs and TKRs for UK patients (such as the PROMs), together with
other large patient-level data sets (such as the CPRD) made available by this programme grant, offered our
research a unique opportunity to estimate the majority of the model’s input parameters from patient-level
data. Most economic evaluations have to rely on data from small RCTs or observational cohorts, and more
often than not some input parameters are also obtained from previously published sources. We strived
to make this economic evaluation one populated mainly with data obtained from large representative
patient-level routinely collected data sets about the current practice of THRs and TKRs in the UK. Therefore,
results benefit from the highest levels of confidence, as well as extraordinary validity for UK decision-makers,
health-care professionals and patients.
Much is known about the cost-effectiveness of THRs and TKRs, but little about predicting unsatisfactory
outcomes. This knowledge gap is substantially reduced by the findings from this research, although ample
scope remains for future research. There are many implications of our results, both for current policy and
for future research.
Methods for total hip replacement
Economic model
Most economic evaluations of THRs have been performed based on Markov models, very appropriate
given the chronic nature of the disease and the ability to represent disease progression within OA using
discrete health states. In fact, one specific model structure, shown in Appendix 4, has been previously used
in six studies.200–205
Although a patient-level simulation model would have provided greater power to identify variability
between patients, and allowed for analysis at a more detailed level that would require patient-level data
on both costs and outcomes, that is often not available. As will be explained in detail in the section on
model inputs, we had access to nationally representative routinely collected patient-level data on primary
care resource use on the one hand, and secondary care together with outcomes on the other. However,
these two data sets were not linked and, therefore, a patient-level simulation could not be populated with
the required data.
We therefore developed an extended Markov model, which, as shown in Figure 30, begins at a stage of
surgical assessment as opposed to the primary THR, as most other models do. From surgical assessment,
patients may be referred to either the waiting list for a primary THR or to any of two non-surgical health
states: risk factor modification or long-term medical management. Patients referred for a consultation
with an orthopaedic surgeon would be likely candidates for arthroplasty because they would have been
checked and perhaps even treated by other health-care professionals before they were seen by the
surgeon. Some of those patients consulting with the surgeon would incidentally present conditions that
could compromise the outcome of the replacement surgery. When any of these or other relevant risk
factors are present, they would need to be dealt with before the patient could be put on the waiting
list for THR. These patients would therefore be referred to the appropriate risk factor modification
programme, where they would remain until they were found to be fit for surgery at a later reassessment.
Meanwhile, they would also have their hip pain treated, commonly with painkillers and/or physiotherapy.
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Some other patients may have been referred for the surgical consultation only for the surgeon to diagnose
that their hip problem, for example, was not related to the hip (problems with the spine, for instance, are
known to cause pain in the hip region) or was not an orthopaedic problem. These, as well as those patients
who are found by the orthopaedic surgeon not to be candidates for a THR for any other reason, and the
patients who despite being candidates decide that they are not willing to go through surgery, would be
referred back to primary or secondary care for long-term medical management of their condition. After
being reassessed, some of these patients may eventually be found fit and willing to receive a THR.
As the second defining feature of this Markov model is the distinction between surgery outcomes, the
states that patients may find themselves in after a primary THR are categorised according to a combination
of a measure of their postoperative pain and mobility functions together with their satisfaction. After a
primary THR in our model, patients may be in a state of good outcome (in which they would be mostly
free from pain and satisfied with surgery results) or in a state of poor outcome (in which pain and
functional limitations persist on patients generally dissatisfied with the results of the operation). Making
such a distinction also allows for different consumption levels of health-care resources by the two
outcome categories.
The distinction between good and poor outcomes after surgery is not exclusive to the primary operation.
THR patients who require a revision face the same possible outcomes (i.e. some will do better than others):
some will be satisfied whereas others will not, and those who feel better because pain was reduced and
mobility increased are more likely to be satisfied. The same distinction between outcome categories used
after primary THR was therefore applied in the Markov model following the revision operation, such that a
(potentially different) threshold in the OHS can be used to differentiate good from poor outcomes anchored
in post-revision satisfaction. Figure 30 illustrates the model schema in a slightly simplified form by combining
under ‘primary THR’ and ‘revision THR’ the first year after the operation, which the economic model actually
treated as two separate health states, one for each outcome category. The model showing all health states
and transition probabilities is shown in Appendix 5.
The model was conceived to operate with yearly cycles and for as long as patients remain alive.
Patient subgroups
The economic model was populated with data corresponding to different patient subgroups. Patient
cohorts were selected according to sex and age. The impact of these factors on THR revision rates, as well
as their proven effect on the likelihood of achieving a clinically significant physical functioning improvement
Primary
THR
Revision
THR
Deatha
Good
outcome
Good
outcome
Poor
outcome
Poor
outcome
Surgical
assessment
Reassessment
Reassessment
Risk factor
modification
Long-term
medical
management
FIGURE 30 Markov model for the cost-effectiveness of an outcome prediction tool for THR. a, Transitions from
each health state to the absorbing state of death.
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after arthroplasty,143 justifies exploring, separately, cost-effectiveness of the prediction tool by these
subgroups. Using a combination of sex and four different starting ages (45, 60, 70 and 80 years) produced
a total of eight groups. The starting age of 45 years was selected because, even though THRs and TKRs are
sometimes performed on younger patients, it is only after 45 years of age that sufficient numbers of
patients are found from which to draw reliable data inputs to populate the model. A cohort entering the
economic model would be, for example, 45-year-old women, and then a separate analysis would be
performed for 60-year-old women. This would also be the case for the remaining two subgroups of women
and the four equivalent male subgroups. Model input parameters were estimated from data about patients
aged 45–60 years for the model cohorts with a starting age of 45 years, about patients aged 60–70 years
for the model cohorts with a starting age of 60 years, and so on. For the purpose of populating the model,
nevertheless, whenever data for an input parameter were not available for a specific subgroup, a common
value was applied to several or all subgroups.
We were also interested in performing the analysis controlling for BMI. BMI thresholds have been applied
by some PCTs for patients’ assessment and eligibility for joint replacement surgery.206–209 However, it has
been found that BMI does not influence the ability of patients to benefit from THR.143 This contradiction
between the policy being implemented in some parts of England and the evidence already available
provides grounds for the inclusion of BMI in this evaluation. BMI was not available, however, in the main
sources of data used to populate the model and, therefore, its impact on the cost-effectiveness of the
prediction tool for THR was not analysed here.
Model inputs for total hip replacements
Transition probabilities for total hip replacement
Preoperative transitions
The first section of the model covering the states and transitions between the surgical consultation and
primary THR rendered this model not only novel but also contingent on information not systematically
collected before. This is because no data were found in the published literature that described referral
decisions by orthopaedic surgeons. In order to obtain estimates for these probabilities, we conducted a
systematic expert elicitation exercise to estimate mean referral rates as well as uncertainty around
those values.
We used an individual, direct method of expert judgement elicitation, which was a mathematical approach
that revealed experts’ answers as distributions. We presented experts with a set of questions about their
referral decisions of hypothetical THR patients. The histogram technique was employed, whereby a frequency
chart showing intervals for the range of answers were presented to experts, who were asked to specify their
relative subjective probabilities for each interval by placing a finite number of crosses throughout the grid.
We conducted a pilot exercise and then decided to run individual guided interviews with the seven selected
expert surgeons from hospitals in Southampton, Bournemouth, Oxford and Portsmouth. Responses from
these surgeons were analysed, with their responses aggregated. Appendix 6 details the individual responses.
The deterministic model was populated with the mean values obtained from the responses provided in
the expert elicitation. For the probabilistic sensitivity analysis (PSA), we assigned the corresponding beta
distribution if two conditions were met: (1) the resulting probability density function had to appropriately fit
the corresponding pooled probability distribution from experts’ responses; and (2) there was no significant
difference between the observed mean value and that generated by the inverse of the cumulative density
function evaluated at 0.5 (a difference > 0.05 was considered excessive). Table 38 shows the mean and SD,
as well as the distribution and its parameters, if applicable, used to populate preoperative transition
probabilities for the deterministic and probabilistic economic model.
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Postoperative transitions
Data for the breakdown of good and poor outcomes after primary THR were obtained from the NHS
PROMs initiative. The COASt project obtained, from the Health and Social Care Information Centre, the
non-identifiable HES and PROMs records of all patients who had a hip replacement operation and who
consented to participate in the PROMs initiative. Of a total of 171,881 PROMs records for the three fiscal
years between 2009 and 2012, only 128,084 were linkable with HES. After dropping records for other hip
replacement procedures, removing records from patients aged < 45 years and keeping only those with
non-missing postoperative OHS so that their outcome category could be determined, the data set of
primary THR by age and sex group comprised 68,156 interventions.
The outcomes of operations could all be classified as good or poor based on the set criteria. Thus, an OHS
below 38 units at 1 year after the primary surgery was considered a poor outcome. The percentage of
patients in each outcome category after primary THR, based on postoperative OHS reported in the HES
PROMs data from 2009 to 2012, allowed for an estimate of the probability of poor outcome by patient
group. As the split between good and poor outcome can naturally be considered binomial data, we fitted
a beta distribution to the probability of poor outcome immediately after a primary THR based on the
counts of good and poor outcomes within each patient subgroup, as reported in Table 39. Given the large
number of observations, uncertainty around these parameter values was quite low.
We used data collected preoperatively and annually during 5 years after a primary THR by the EPOS group
to estimate the probabilities of moving from each of the outcome categories in the first year to each
outcome category in year 2, and of moving between health states representing outcome categories during
TABLE 39 Probability of poor outcome after primary THR: deterministic and probabilistic parameters
Transition probability/patient subgroup (sex and age) Mean Distribution Alpha Beta
Men
45–59 years 0.298 Beta 1431 3370
60–69 years 0.262 Beta 2647 7546
70–79 years 0.310 Beta 3128 6974
≥ 80 years 0.398 Beta 1112 1682
Women
45–59 years 0.359 Beta 2253 4014
60–69 years 0.329 Beta 4399 8956
70–79 years 0.410 Beta 6099 8768
≥ 80 years 0.514 Beta 3015 2852
TABLE 38 Preoperative probabilities: deterministic and probabilistic parameters
Transition probability Mean SD Distribution Alpha Beta
Surgical assessment to risk factor modification 0.136 0.093 Beta 1.714 10.916
Surgical assessment to long-term medical management 0.167 0.208 Empirical
Risk factor modification to reassessment 0.679 0.285 Empirical
Reassessment after risk factor modification to THR 0.840 0.111 Beta 8.287 1.581
Long-term medical management to reassessment 0.106 0.066 Beta 2.208 18.598
Reassessment after long-term medical management to THR 0.315 0.300 Empirical
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the second and subsequent years after the primary. The EPOS data available to us on primary THR patients
included OHSs and other demographic information from a total of 1589 patients.
Table 40 reports the transition probabilities estimated from the sample for each patient subgroup as well
as the distribution parameters. Only one transition from each outcome category is reported as the other
will result from calculating one minus the probability of death, minus the probability of revision (reported
in the next section) and minus the probability reported in Table 40.
Using data from the EPOS trial, we extrapolated proportions of good and poor outcomes up to 10 years
after the primary THR by calculating the mean transition probability for remaining in each outcome
category between years 2 and 5 and applying it to the transitions between years 5 and 10. Table 41 shows
those mean probabilities and the parameters of the beta distributions calculated based on average counts.
Finally, yearly mortality rates from both model states were assumed to be the same all-cause sex- and
age-specific death rates used preoperatively.125
Revision rates were estimated for our two categories of outcome after THR. These rates were based on the
rates proposed by Kalairajah et al.210 for four groups, using 27, 33 and 41 as cut-off points on postoperative
OHS at 6 months after primary surgery based on a sample of over 15,000 THRs from the New Zealand Joint
Registry. Based on the overall proportion of patients classified as having poor and good outcomes in the
HES PROMs data set (45% and 55%, respectively), we chose to consider the three Kalairajah et al.’s groups
scoring up to 41 units as poor (42%) and those above 41 units as good (58%). We estimated instantaneous
revision rates (assuming the rate was constant over the 2 years) and then probabilities of revision at 1 year
for the two outcome categories. This is described in detail in Appendix 7. Table 42 shows the distribution
parameters of each revision rate for the PSA, which will be applied to all patient subgroups as the data were
not reported by sex and age groups.
The probabilities of good and poor outcome following a THR revision were estimated using HES PROMs
data, analogously to the approach taken for the probabilities following primary THRs. As the study
identifying cut-off points for outcome categories used data from primary THRs only,154 and it has not been
replicated on revision operations, we used the threshold identified for the second year (OHS 33) to classify
TABLE 40 Transition probabilities between outcome categories after primary THR from the first to second
postoperative years: deterministic and probabilistic parameters
Transition probability/patient subgroup (age, sex) Mean Distribution Alpha Beta
Good outcome year 1 to good outcome year 2
Men
45–69 years 0.929 Beta 131 10
≥ 70 years 0.987 Beta 156 2
Women
45–69 years 0.966 Beta 196 7
≥ 70 years 0.920 Beta 230 20
Poor outcome year 1 to poor outcome year 2
Men
45–69 years 0.444 Beta 24 30
≥ 70 years 0.472 Beta 17 19
Women
45–69 years 0.578 Beta 52 38
≥ 70 years 0.505 Beta 56 55
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our HES PROMs patient records into good or poor outcomes. We chose the lower second year cut-off
point as opposed to that for the first year after the operation because patients undergoing a revision THR
would have had problems with their primary prosthesis and are less likely to perform well than the broader
spectrum of patients undergoing a THR for the first time. The resulting transition probabilities are shown in
Table 43.
As in the case of primary THRs, our economic model required two sets of transition probabilities as the
cohort moves through the Markov model following a revision procedure. First, after their first year in good
or poor outcome immediately following the revision, patients who do not die would transit into good or
poor outcome at year 2, which are modelled as separate health states; and, second, patients in either
outcome category at year 2 or onwards may remain in the health state they are in or move to the other
one at each iteration.
Given that no other data were available with yearly follow-ups of revision THR patients, we used the same
data from EPOS primary THR records to produce estimates for the transition probabilities between outcome
categories after a revision, using 33 as the cut-off point for outcome classification at 1 year after revision
THR. Table 44 shows the estimated probabilities of the transition between good or poor outcomes during
TABLE 41 Transition probabilities between outcome categories from second year after a primary THR onwards:
deterministic and probabilistic parameters
Transition probability/patient subgroup (age, sex) Mean Distribution Alpha Beta
Good outcome to good outcome
Men
45–69 years 0.958 Beta 157.3 7.0
≥ 70 years 0.919 Beta 144.0 12.7
Women
45–69 years 0.945 Beta 223.7 13.0
≥ 70 years 0.899 Beta 239.7 27.0
Poor outcome to poor outcome
Men
45–69 years 0.682 Beta 18.3 8.7
≥ 70 years 0.492 Beta 8.3 8.7
Women
45–69 years 0.728 Beta 38.0 14.0
≥ 70 years 0.666 Beta 50.0 25.0
TABLE 42 Transition probabilities between outcome categories and revision THR: deterministic and probabilistic
parameters
Transition probability Mean Distribution Alpha Beta
Good outcome first year to revision THR 0.0026 Beta 22.2 8609.3
Poor outcome first year to revision THR 0.0130 Beta 93.4 7098.2
Good outcome year 2 and onwards to revision THR 0.0077 Beta 66.5 8565.0
Poor outcome year 2 and onwards to revision THR 0.0477 Beta 343.4 6848.2
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the first year following the revision to the same outcome category the second year after the procedure.
Table 45 shows the mean transition probabilities and distribution parameters entered in the model for the
transition of patients between outcome categories after the second year following the revision procedure.
Costs for total hip replacements
Resource use was obtained primarily from the CPRD, a database containing primary care data on
approximately 4.8 million patients from about 600 GP practices in the UK. The extract of the CPRD data
set employed for our analysis identified controls by matching sex, GP practice and age (±5 years) to each
case. Clinical factors, however, were expected to vary between cases and controls. We relied on the large
number of observations to balance out the differences in comorbidities, so that the effect of controls with
TABLE 43 Probability of poor outcome after revision THR: deterministic and probabilistic parameters
Transition probability/patient subgroup (sex and age) Mean Distribution Alpha Beta
Men
45–59 years 0.455 Beta 160 192
60–69 years 0.447 Beta 314 388
70–79 years 0.391 Beta 383 596
≥ 80 years 0.474 Beta 157 174
Women
45–59 years 0.510 Beta 255 245
60–69 years 0.476 Beta 390 429
70–79 years 0.450 Beta 492 601
≥ 80 years 0.500 Beta 272 272
TABLE 44 Transition probabilities between outcome categories after revision THR from first to second
postoperative years: deterministic and probabilistic parameters
Transition probability/patient subgroup (sex and age) Mean Distribution Alpha Beta
Good outcome year 1 to good outcome year 2
Men
45–69 years 0.902 Beta 148 16
≥ 70 years 0.954 Beta 167 8
Women
45–69 years 0.913 Beta 219 21
≥ 70 years 0.878 Beta 259 36
Poor outcome year 1 to poor outcome year 2
Men
45–69 years 0.581 Beta 18 13
≥ 70 years 0.579 Beta 11 8
Women
45–69 years 0.717 Beta 38 15
≥ 70 years 0.606 Beta 40 26
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more comorbidities and, hence, greater resource use than cases would be offset by the effect of those
with fewer comorbidities and, therefore, less use of resources. We calculated the mean quantity of each
resource used by sets of controls and subtracted this from the level reported by corresponding cases. We
interpreted this difference as the amount of resources used by each hip pain patient in excess of what
their controls, on average, demanded from the health-care system. The overall mean of these differences
was then an estimate of the resource use attributable to the hip problem. This approach also allowed us to
obtain an estimate of variability from the observed resource use attributable to hip pain.
As the analysis was performed from the perspective of the NHS, data on prices are those reported in the
Department of Health’s Publication of 2010–11 Reference Costs211 for inpatient events, the Personal Social
Services Research Unit’s Unit Costs of Health and Social Care 2011212 for primary care, and the British
National Formulary (BNF)213 for drug prices. The NHS reference costs correspond to the period 2011–12,214
Personal Social Services Research Unit’s unit costs are based on the period 2010–11 and the online version
of the BNF used was last updated in November 2011. All unit costs are therefore in 2011 GBP.
Preoperative costs
For the costs associated with all health states previous to a THR, records about both consultations and
prescriptions were considered. Consultation and medication costs were then added together and, thus, the
progression of estimated total costs attributable to hip pain used by patients during the 15 years prior to
their THR was produced, showing an expected upwards trend, especially in the 2 years prior to the primary
surgery. This growing estimated costs confirmed the increasing burden generated by unresolved hip pain
and problems experienced by patients who are referred for a THR. We used the estimates for the year
immediately prior to a THR to populate all preoperative states. Deterministic analysis was based on the
above mean values for costs attributable to hip problems. For PSA, a normal distribution was used to
model the uncertainty around the difference in resource use between the two groups. The process for
estimating these preoperative costs is discussed in more detail in Appendix 8. Table 46 shows the
estimated cost of all preoperative model health states by patient subgroup.
TABLE 45 Transition probabilities between outcome categories after second year following a revision THR
onwards: deterministic and probabilistic parameters
Transition probability/patient subgroup Mean Distribution Alpha Beta
Good outcome to good outcome
Men
45–69 years 0.958 Beta 157.3 7.0
≥ 70 years 0.919 Beta 144.0 12.7
Women
45–69 years 0.945 Beta 223.7 13.0
≥ 70 years 0.899 Beta 239.7 27.0
Poor outcome to poor outcome
Men
45–69 years 0.682 Beta 18.3 8.7
≥ 70 years 0.492 Beta 8.3 8.7
Women
45–69 years 0.728 Beta 38.0 14.0
≥ 70 years 0.666 Beta 50.0 25.0
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Primary total hip replacement costs
The cost of a primary THR was estimated separately for each patient subgroup based on Healthcare
Resource Group (HRG) assignment. In order to do this, we obtained the table of relative frequencies of
HRGs assigned by the payment by results system in the NHS to each THR reported in HES and eligible for
PROMs for fiscal year 2011–12 (N Gutacker, Centre for Health Economics, University of York, 2013,
personal communication). Based on these frequencies and the NHS reference costs by HRGs for the same
year,214 we calculated the mean cost for a primary THR by patient subgroup (Table 47).
Postoperative costs
To estimate postoperative primary health-care costs, we followed the same process used for preoperative
costs. However, the resulting costs pool together the costs associated with good and poor outcomes.
To produce separate estimates for the latter, we developed a model to predict outcome categories after
TABLE 46 Primary care costs associated to all preoperative states:a deterministic and probabilistic parameters
State/patient subgroup (sex and age) Mean cost (£) SD (£) Distribution
Men
45–59 years 98.00 200.35 Normal
60–69 years 98.20 209.08 Normal
70–79 years 87.60 219.69 Normal
≥ 80 years 101.10 222.50 Normal
Women
45–59 years 121.70 216.32 Normal
60–69 years 118.90 237.33 Normal
70–79 years 97.40 240.31 Normal
≥ 80 years 92.00 257.74 Normal
a Surgical assessment, risk factor modification, reassessment after risk factor modification, long-term medical management
and reassessment after long-term medical management. The cost of the consultation with the orthopaedic surgeon must
be added (£105) to states involving surgical assessment or reassessment in order to obtain total cost for the respective
health state.
TABLE 47 Cost of a primary THR to the NHS by patient subgroup
Patient subgroup (sex and age) Number of patients Mean cost (£) SD (£)
Men
45–59 years 4696 6069 249.40
60–69 years 7632 6102 233.50
70–79 years 7948 6186 182.00
≥ 80 years 2578 6352 143.00
Women
45–59 years 5121 6063 262.40
60–69 years 10,164 6083 208.60
70–79 years 12,838 6139 111.70
≥ 80 years 6043 6307 104.90
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surgery based on health-care resource use during the first year after the primary surgery. This was done
using data from the COASt cohort, described in Chapter 5, and Appendix 9 explains in detail the estimation
and use of the model. This model proved to be a unique and a valuable instrument, as the COASt cohort
appears to be the only data set with both postoperative outcome and resource use data available. The
connection between these was then used to estimate the outcome category of patients reported in the
CPRD who have a wealth of resource use data but no outcome measure available. The classification of
patients by outcome group using the model led to an estimated mean of £280 for likely poor-outcome
patients and £24 for likely good-outcome patients during the first year after the primary. The mean values
and distribution of costs for the first year after the operation added to the mean costs of surgery to produce
the total costs associated to the model states combining the primary THR and the first postoperative year in
good or poor outcome. These are shown in Table 48 with parameter distributions set to normal. As THR
costs were estimated regardless of surgery outcome, the slightly higher overall mean costs of poor
outcomes are explained by their higher primary care costs.
Costs for the second and subsequent years in either outcome category were estimated based on CPRD
records of resource use, as above, but with the application of an adjusted surgery outcome prediction
model. Once CPRD records were labelled as likely poor and likely good outcomes, records for years 2
through 10 after the primary surgery were pooled together, and mean values and distributions estimated
TABLE 48 Costs associated to primary THR and first year thereafter by outcome category: deterministic and
probabilistic parameters
State/patient subgroup (sex and age) Mean cost (£) SD (£) Distribution
Primary THR and first year in good outcome
Men
45–59 years 6070 123.50 Normal
60–69 years 6082 120.40 Normal
70–79 years 6143 134.90 Normal
≥ 80 years 6320 149.30 Normal
Women
45–59 years 6049 125.60 Normal
60–69 years 6054 140.10 Normal
70–79 years 6096 139.60 Normal
≥ 80 years 6250 153.30 Normal
Primary THR and first year in poor outcome
Men
45–59 years 6352 215.20 Normal
60–69 years 6379 227.30 Normal
70–79 years 6469 255.50 Normal
≥ 80 years 6637 222.60 Normal
Women
45–59 years 6376 242.50 Normal
60–69 years 6362 223.00 Normal
70–79 years 6421 228.80 Normal
≥ 80 years 6570 284.80 Normal
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to represent the yearly cost of primary care for patients 2 years and onwards after a THR. These values are
reported in Table 49 by patient subgroup.
Revision total hip replacement and postoperative costs
Parameters for the four revision and post-revision model states were estimated following the same process
as that of post-primary health states. Table 50 reports the mean and SDs of the costs associated to the
revision THR operation by patient subgroup.
For the costs of primary care provided to revision THR patients we used CPRD data. In order to distinguish
between primary care costs provided to good and poor outcome patients after a revision THR, we
employed the predictive model described previously using OHS 33 units as a threshold for outcome
categories and resource use data from primary surgery. Given the low number of revision cases further
divided after fitting the predictive model to the data, results for the primary care cost component could not
be presented for each of the eight patient subgroups and were instead produced in aggregate form for all
patients. Table 51 shows the mean cost associated to the model states combining group-specific revision
THR and common primary care costs for the first postoperative year in which the differences by outcome
categories are explained entirely by primary care costs associated to each group.
TABLE 49 Costs associated to second and subsequent years after THR in either outcome category states:
deterministic and probabilistic parameters
State/patient subgroup (sex and age) Mean cost (£) SD (£) Distribution
Second and subsequent year in good outcome
Men
45–59 years 21 183.30 Normal
60–69 years 19 191.50 Normal
70–79 years 5 213.80 Normal
≥ 80 years 34 250.60 Normal
Women
45–59 years 33 206.60 Normal
60–69 years 17 224.80 Normal
70–79 years 9 225.70 Normal
≥ 80 years –1 239.10 Normal
Second and subsequent year in poor outcome
Men
45–59 years 316 304.50 Normal
60–69 years 237 264.30 Normal
70–79 years 241 245.00 Normal
≥ 80 years 298 363.20 Normal
Women
45–59 years 314 295.70 Normal
60–69 years 285 285.60 Normal
70–79 years 255 296.80 Normal
≥ 80 years 253 355.90 Normal
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TABLE 51 Costs associated to revision THR followed by first year in either outcome category states: deterministic
and probabilistic parameters
State/patient subgroup (sex and age) Mean (£) SD (£) Distribution
Primary THR and first year in good outcome
Men
45–59 years 7937 38.00 Normal
60–69 years 8134 38.00 Normal
70–79 years 8183 38.00 Normal
≥ 80 years 8229 38.00 Normal
Women
45–59 years 7771 38.00 Normal
60–69 years 7948 38.00 Normal
70–79 years 8034 38.00 Normal
≥ 80 years 8039 38.00 Normal
Primary THR and first year in poor outcome
Men
45–59 years 8264 337.90 Normal
60–69 years 8460 337.90 Normal
70–79 years 8510 337.90 Normal
≥ 80 years 8555 337.90 Normal
Women
45–59 years 8098 337.90 Normal
60–69 years 8275 337.90 Normal
70–79 years 8361 337.90 Normal
≥ 80 years 8365 337.90 Normal
TABLE 50 Cost of a revision THR to the NHS by patient subgroup
Patient subgroup (sex and age) Number of patients Mean (£) SD (£)
Men
45–59 years 499 7899 885.30
60–69 years 835 8096 697.50
70–79 years 1247 8145 479.60
≥ 80 years 488 8191 941.60
Women
45–59 years 636 7733 777.50
60–69 years 1080 7910 664.60
70–79 years 1537 7996 458.90
≥ 80 years 885 8001 574.70
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For the model states representing each outcome category after a revision THR, Table 52 indicates the
mean and SD of primary care costs that, given the low number of CPRD observations, were applied to all
patient subgroups as well. These were estimated by pooling together all CPRD records for the years 2
through to 8.
Quality-adjusted life-years for total hip replacements
Mapping Oxford Hip Score to EuroQol-5 Dimensions
Since April 2009, NHS providers performing unilateral hip replacements have been required to collect both
EQ-5D scores and the OHS, a condition-specific outcome measure.144 Before this, however, EQ-5D was
not routinely collected from THR patients, whereas the OHS questionnaire was commonly collected and
regarded as an important indicator of the success of THR.145 The OHS consists of 12 patient-completed
statements covering pain, mobility and ability to carry out regular tasks. The current scoring system assigns
values between 0 and 4 to each item, higher scores corresponding to better outcomes. Individual scores
are summed, giving a total score ranging from 0 (worst) to 48 (best).145 The EQ-5D is a widely used generic
measure of health outcomes. It produces a summary index for each of the 243 descriptive health states by
applying a preference-based valuation derived from a sample of the general population.215
The ability to estimate EQ-5D scores based on the OHS would enable estimation of utility data for older
data sets for which OHSs were collected but EQ-5D scores were not. Older data sets are of key importance
given the need for long-term follow-up of hip replacement patients whose prostheses, in most cases, last
for many years without the need for replacement.
In order to estimate the summary EQ-5D index from OHS responses, we employed two known conversion
algorithm techniques: transfer-to-utility (TTU) regression and response mapping. The TTU regression
approach uses regression equations to predict the values of one outcome measure, using scores from a
second measure as regressor(s).216 We used three different TTU regression methods in this modelling
exercise: two are variations of the linear regression model, and the third is a two-part model combining a
binary outcome and a linear regression model. The first model regressed total OHSs on the EQ-5D summary
index using OLS. The second method employed responses to all 12 questions of the OHS questionnaire as
categorical regressors. The third was a two-part logit OLS model, whereby a first logit model would estimate
whether or not OHS responses are associated to an EQ-5D score of 1 unit, and if not a second OLS model
would predict the value (< 1 units). Meanwhile, response mapping seeks to predict the responses to each of
the five individual EQ-5D questions instead of predicting the summary score directly.217 A multinomial
logistic model was applied to do this. Each of these models is described in more detail in Appendix 10.
Data were obtained from the SWLEOC database. The full data comprised 3504 hip replacements, each with
preoperative and/or 6-month postoperative responses to the OHS and EQ-5D questionnaires, plus basic
demographic, socioeconomic and clinical information. All except two operations were performed between
2006 and 2008. All models were estimated on 1759 operations for which we had data on both pre- and
postoperative OHS and EQ-5D scores, sex, age and deprivation. As we were interested in cross-sectional
mapping, we pooled pre- and postoperative records together, providing 3518 outcome observations.
TABLE 52 Costs associated to second and subsequent years after THR in either outcome category states:
deterministic and probabilistic parameters
State/patient subgroup Mean cost (£) SD (£) Distribution
Second and subsequent year in good outcome
All patient subgroups 43 229.60 Normal
Second and subsequent year in poor outcome
All patient subgroups 261 242.20 Normal
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The simplest model, continuous OLS with total OHS as the only regressor, was statistically significant with
residuals approximately normally distributed. The categorical version of the linear regression model
including all OHS separate questions also reported residuals nearly normally distributed. However, it
produced some coefficients that were both statistically non-significant and inconsistent with the positive
relationship between OHS and EQ-5D; that is, they were either negative or did not follow an increasing
progression within the same question. This was fixed by pooling response levels together. For the two-part
approach, we estimated the first (logistic) part of the model and found that only 13 of the 48 regressors
were statistically significant. For the second part (categorical OLS) we estimated the model on observed
EQ-5D scores lower than 1 and included all OHS questions, as none could be excluded based on repetitive
likelihood ratio tests. We collapsed response levels using the same methods as with the categorical OLS
model. Again, we found that residuals were approximately normally distributed but with a high peak at
zero from perfectly fitted cases of observed EQ-5D equal to 1. For the response mapping approach we
found that all five multinomial models (one for each EQ-5D question) were statistically significant
(p < 0.001); however, many of the individual regressors were not. These results are also detailed further in
Appendix 10.
All selected variations of each model were internally validated and predictive power was highest for both
OLS models. In addition to assessing the models’ ability to predict the observed mean EQ-5D score, we
also calibrated them by recording prediction errors through the range of values of the dependent variable.
All models reported a high predictive power of the aggregate mean, although the level of precision was
not uniform across the full range of scores. Overall performance of the four models was within the range
of other reported mapping studies based on their root-mean-square errors of around 0.20.218
Preoperative quality-adjusted life-years
The HES PROMs data used to estimate the probabilities of good and poor outcome after a primary THR
were the most appropriate to estimate the HRQoL of patients before they undergo the operation given its
large number of observations and national representativeness. In order to fit a distribution to these health
utilities, which range from –0.5 to 1 quality-adjusted life-years (QALYs), disutilities (the distance in QALYs
between the recorded utility and its maximum value of 1) were calculated so that the range becomes
positive and bound by zero. As disutilities, a gamma distribution was fitted using the mean and SDs to
produce distribution parameters. Table 53 shows mean values and distribution parameters for disutilities
associated to all preoperative model states for each patient subgroup.
TABLE 53 Disutility associated to all preoperative states: deterministic and probabilistic parameters
State/patient subgroup (age, sex) Mean Distribution Alpha Beta
Men
45–59 years 0.615 Gamma 3.82 0.161
60–69 years 0.592 Gamma 3.68 0.161
70–79 years 0.597 Gamma 3.74 0.160
≥ 80 years 0.656 Gamma 4.33 0.151
Women
45–59 years 0.694 Gamma 4.61 0.151
60–69 years 0.653 Gamma 4.16 0.157
70–79 years 0.666 Gamma 4.32 0.154
≥ 80 years 0.724 Gamma 5.05 0.143
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Quality-adjusted life-years after primary total hip replacement
Patients undergoing a primary THR accrued health utilities depending on their outcome category. First, for
health utilities associated to model states including the operation, we considered the EQ-5D postoperative
summary scores by patient subgroups reported in the HES PROMs data set. We produced QALYs from the
latter by considering the progression of scores following a primary THR observed in EPOS because the
latter reported a measure at 3 months that helps better understand patients’ rate of improvement during
the first year after the primary surgery. Figure 31 shows estimated EQ-5D scores before, 3 months and
1 year after the operation mapped from the summary OHSs using the mapping method reported above.
As evidenced in this graph, poor outcomes not only improve less in the first 3 months than good
outcomes, but they also do not improve any more after that, on average, whereas good outcomes still
improve a bit more in the last 9 months of the first year after the THR. This progression was used to
estimate QALYs during the first year after the primary surgery using the HES PROMs data.
We applied the progression patterns to the data on pre- and postoperative EQ-5D summary scores
reported in the HES PROMs data set, to estimate QALYs associated to the first year after primary THR for
each patient subgroup by outcome category. We calculated disutilities and estimated the parameters for
the corresponding gamma distributions. Table 54 shows the mean value, as well as the parameters for the
gamma distributions, describing uncertainty around the mean value of the QALYs associated to the first
year after a primary THR for both good and poor outcome patients.
For the health states representing the second and subsequent years after the primary surgery in either outcome
category, we also benefited from the longer follow-up performed under EPOS and the representativeness in
the HES PROMs data when estimating the required QALY values. We estimated EQ-5D scores among patients
in the second and subsequent years after surgery based on the data in the EPOS and HES PROMs by combining
the yearly relationships found in the former with the point estimates, variability and representativeness of the
latter. Table 55 shows the mean values and distribution parameters for disutilities during the second and
subsequent years after the primary THR for each outcome category and by patient subgroup.
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FIGURE 31 Mean EQ-5D summary scores mapped from OHSs reported by EPOS patients.
WORK PACKAGE 3: ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
96
Quality-adjusted life-years after revision total hip replacement
Health utility estimates were obtained following an analogous procedure as that used for after a primary
THR. For the health states, including the revision procedure and the first year in either of the outcome
categories, QALYs were estimated based on pre- and postoperative EQ-5D summary scores from patients
undergoing a revision THR in HES PROMs combined with the estimated EQ-5D progression by EPOS
primary THR patients used in the previous section. We used the progression of scores after a primary
procedure because no data set was available containing follow-up HRQoL measures for revision THR
patients before and 1 year after the operation, as well as at a third point in between. Table 56 shows the
means and SDs of the EQ-5D summary scores of revision THR patients extracted from the HES PROMs
data set.
In order to estimate the QALYs associated to this first year after the revision THR, we connected the start
and end points reported in Table 56 using the differential progression by outcome category found for
primary patients. We estimated QALYs based on this progression, converted them into disutilities and
produced the mean values and gamma distribution parameters shown in Table 57.
The lack of follow-up data on sufficient revision THR patients meant that, for the model states representing
the second and subsequent years after their revision operation, we used the patterns of progression
observed in patients who underwent a primary surgery. Estimated EQ-5D summary scores, assumed to
TABLE 54 Disutility associated to primary THR and first postoperative year states: deterministic and probabilistic
parameters
State/patient subgroup (sex and age) Mean Distribution Alpha Beta
Primary THR and first year in poor outcome
Men
45–59 years 0.540 Gamma 4.20 0.129
60–69 years 0.485 Gamma 4.29 0.113
70–79 years 0.450 Gamma 4.37 0.103
≥ 80 years 0.457 Gamma 4.87 0.094
Women
45–59 years 0.536 Gamma 4.24 0.126
60–69 years 0.478 Gamma 4.22 0.113
70–79 years 0.454 Gamma 4.60 0.099
≥ 80 years 0.462 Gamma 4.40 0.105
Primary THR and first year in good outcome
Men
45–59 years 0.217 Gamma 2.14 0.101
60–69 years 0.212 Gamma 2.09 0.101
70–79 years 0.220 Gamma 2.39 0.092
≥ 80 years 0.247 Gamma 2.72 0.091
Women
45–59 years 0.248 Gamma 2.39 0.104
60–69 years 0.239 Gamma 2.45 0.098
70–79 years 0.245 Gamma 2.68 0.091
≥ 80 years 0.270 Gamma 2.98 0.091
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TABLE 56 The HES PROMs data: pre- and postoperative health utility estimates by patient subgroup and
outcome category
Patient subgroup (sex and age)
Health utility estimates
Preoperative
Postoperative
Poor outcome Good outcome
Mean SD Mean SD Mean SD
Men
45–59 years 0.338 0.353 0.367 0.284 0.811 0.194
60–69 years 0.355 0.349 0.395 0.290 0.840 0.169
70–79 years 0.406 0.329 0.459 0.276 0.824 0.173
≥ 80 years 0.358 0.319 0.496 0.241 0.790 0.193
Women
45–59 years 0.341 0.347 0.404 0.309 0.798 0.197
60–69 years 0.365 0.343 0.431 0.286 0.819 0.191
70–79 years 0.364 0.329 0.479 0.266 0.804 0.188
≥ 80 years 0.312 0.331 0.490 0.246 0.789 0.185
TABLE 55 Disutility associated to second and subsequent years after primary THR: deterministic and probabilistic
parameters
State/patient subgroup (sex and age) Mean Distribution Alpha Beta
Second and subsequent years after primary THR in poor outcome
Men
45–59 years 0.427 Gamma 10.42 0.041
60–69 years 0.398 Gamma 10.23 0.039
70–79 years 0.473 Gamma 15.95 0.030
≥ 80 years 0.471 Gamma 20.02 0.024
Women
45–59 years 0.489 Gamma 14.48 0.034
60–69 years 0.459 Gamma 13.92 0.033
70–79 years 0.405 Gamma 23.18 0.017
≥ 80 years 0.414 Gamma 29.39 0.014
Second and subsequent years after primary THR good outcome
Men
45–59 years 0.134 Gamma 1.97 0.068
60–69 years 0.128 Gamma 2.19 0.058
70–79 years 0.139 Gamma 2.12 0.065
≥ 80 years 0.160 Gamma 2.47 0.065
Women
45–59 years 0.139 Gamma 1.75 0.080
60–69 years 0.135 Gamma 1.81 0.074
70–79 years 0.185 Gamma 2.97 0.062
≥ 80 years 0.215 Gamma 4.13 0.052
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remain constant over the year, were converted into disutilities, and their mean values and gamma
distribution parameters estimated. These values are shown in Table 58.
Parameter values when using the prediction tool
As the economic evaluation compared current practice as described in the values and transition probabilities
above with the hypothetical scenario of implementing the outcome prediction tool estimated in Chapter 3, a
new set of model parameter values had to be estimated to populate the latter. Most model inputs remained
the same, but a few key ones that were directly associated with the implementation of the tool as a guide
for patient referral before the operation had to be adjusted. The probability of being referred for a THR
would be directly affected by the implementation of the tool, as would the probability of being referred to
risk factor modification because patients who are referred to that path are, in principle, considered suitable
for a THR. The probability of a patient going into long-term medical management will necessarily be
adjusted to compensate for the changes made to referrals for the previous two surgical pathways.
Data from 2092 patients were used to estimate the linear model predicting OHS at 1 year. We used the
estimating data set to explore the effects of using the prediction tool as the definitive guide to refer patients
to a THR (including risk factor modification) or to the long-term medical management state. Although not
applying the tool in fact led to all patients in the data set being referred for surgery, fitting the model to
TABLE 57 Disutility associated to revision THR and first postoperative year states: deterministic and probabilistic
parameters
State/patient subgroup (sex and age) Mean Distribution Alpha Beta
Revision THR and first year in poor outcome
Men
45–59 years 0.655 Gamma 6.24 0.105
60–69 years 0.627 Gamma 5.35 0.117
70–79 years 0.565 Gamma 4.90 0.115
≥ 80 years 0.535 Gamma 5.81 0.092
Women
45–59 years 0.616 Gamma 4.65 0.133
60–69 years 0.592 Gamma 5.06 0.117
70–79 years 0.549 Gamma 4.97 0.110
≥ 80 years 0.543 Gamma 5.75 0.094
Revision THR and first year in good outcome
Men
45–59 years 0.280 Gamma 2.41 0.116
60–69 years 0.259 Gamma 2.54 0.102
70–79 years 0.262 Gamma 2.50 0.105
≥ 80 years 0.297 Gamma 2.77 0.107
Women
45–59 years 0.294 Gamma 2.51 0.117
60–69 years 0.272 Gamma 2.22 0.122
70–79 years 0.288 Gamma 2.68 0.108
≥ 80 years 0.313 Gamma 3.01 0.104
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those same patients indicated that, if the threshold had been an OHS of 38 units, only 60% of patients
currently receiving a THR would have been referred for the operation (or risk factor modification) and the
remaining 40% would have been sent for long-term medical management instead.
Under current practice and according to our expert elicitation, 17% of patients are referred for long-term
medical management and 83% are considered suitable for a THR. These figures would change considerably
if the outcome prediction tool were to be applied. Table 59 shows the transition probabilities with the tool
being used.
TABLE 58 Disutility associated to second and subsequent years after revision THR: deterministic and probabilistic
parameters
State/patient subgroup (sex and age) Mean Distribution Alpha Beta
Second and subsequent years after revision THR in poor outcome
Men
45–59 years 0.531 Gamma 23.38 0.023
60–69 years 0.517 Gamma 23.20 0.022
70–79 years 0.541 Gamma 15.96 0.034
≥ 80 years 0.529 Gamma 19.80 0.027
Women
45–59 years 0.551 Gamma 20.05 0.027
60–69 years 0.529 Gamma 19.53 0.027
70–79 years 0.462 Gamma 45.08 0.010
≥ 80 years 0.454 Gamma 49.52 0.009
Second and subsequent years after revision THR good outcome
Men
45–59 years 0.217 Gamma 3.17 0.069
60–69 years 0.209 Gamma 3.17 0.066
70–79 years 0.190 Gamma 2.40 0.079
≥ 80 years 0.214 Gamma 3.16 0.068
Women
45–59 years 0.209 Gamma 2.49 0.084
60–69 years 0.196 Gamma 2.50 0.079
70–79 years 0.238 Gamma 4.06 0.059
≥ 80 years 0.255 Gamma 5.33 0.048
TABLE 59 Preoperative probabilities with the tool: deterministic and probabilistic parameters
Transition probability Mean SD Distribution Alpha Beta
Surgical assessment to risk factor modification 0.082 0.093 Empirical
Surgical assessment to long-term medical management 0.495 0.208 Beta 2.365 2.413
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The different probabilities of good and poor outcomes are the main reason why the tool is considered in
the first place; they will also be affected by its implementation, by definition leading to a smaller proportion
of poor outcomes. Table 60 shows the probability of poor outcome if the tool had been in place using a
threshold of an OHS of 38 units to refer patients.
Given that those patients having the operation are expected to perform well, and that there exists an
association between outcome and preoperative OHS as well as between OHS and EQ-5D, the QALYs
associated with all preoperative states but the surgical assessment would also be affected by the shuffling
of patients at this stage. Table 61 shows the mean disutilities and distribution parameters separately for
the two preoperative branches of the economic model.
Assumptions
Modelling assumptions
As with all models, the one presented here attempts to reflect the true care pathway of patients as they are
assessed for a THR, which most undergo, but it necessarily simplifies what in reality is a more complex
process. Our model, as any other, simplifies reality so that we can produce estimates for the cost-effectiveness
of the outcome prediction tool. This simplification is achieved by making a number of assumptions that can
make the model feasible.
First, this model assumes that the outcome prediction tool is capable of identifying potential poor surgical
outcomes before patients have the operation. In particular, we are assuming that the information in the
EPOS and EUROHIP data sets is representative of the equivalent characteristics and outcomes in the wider
population eligible to undergo THR in the UK. Second, we are assuming that all, or most, patients with an
OHS of ≥ 38 units the first year after their primary surgery are free from pain and major mobility limitations
as well as satisfied with the operation, and that the opposite is true for those who have a OHS of < 38 units.
Third, we assume that all patients found to be candidates for surgery, but presenting a risk factor that
should be dealt with before the operation, whether it is excessive weight, diabetes, high blood pressure or
something else, can all be grouped together into the risk factor modification state (in which most patients
would be expected to stay for only a short period). Similarly, we group a diverse set of patients into the
health state of long-term medical management. Fourth, we assume that probabilities of good and poor
outcomes are the same in the model whether the patient comes from the risk factor modification section or
from that of long-term medical management. Fifth, we do not allow for multiple revisions. And, sixth, we
assume that the tool would be used by orthopaedic surgeons.
TABLE 60 Probability of poor outcome after primary THR with the tool: deterministic and probabilistic parameters
Transition probability/patient subgroup (sex and age) Mean Distribution Alpha Beta
Men
45–59 years 0.168 Beta 22 109
60–69 years 0.165 Beta 38 192
70–79 years 0.133 Beta 23 150
≥ 80 years 0.237 Beta 9 29
Women
45–59 years 0.167 Beta 19 95
60–69 years 0.141 Beta 32 195
70–79 years 0.178 Beta 43 199
≥ 80 years 0.234 Beta 15 49
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Parameter assumptions
During the process of identifying parameter values to populate the economic model, a number of
assumptions were made, whether because of the simplification forced by the fact that we were modelling
a complex reality or because of limitations in the data available.
For transitions, first, although preoperative transition probabilities may vary between patient subgroups,
the values extracted from the expert elicitation exercise were assumed to apply to all patients regardless
of age or sex. Second, transitions between good and poor outcomes after year 2 post operation were
estimated based on follow-up questionnaires only up to year 5. Third, we assume that surgery outcome
after the primary has no bearing on surgery outcome after revision (as patients can move between
outcome categories after a primary). Fourth, we used the cut-off point derived for primary THRs to
categorise outcomes after revisions. Transition probabilities between outcome categories were also
assumed to be equivalent after primaries and after revisions when those calculated for the former were
applied to the latter. Fifth, and finally, we applied all-cause mortality rates from the general population.
For HRQoL values, first we assumed that the pattern of progression by outcome category during the first
year after the operation in EPOS is generalisable to the wider population. We also assumed that the
connection between OHSs in the first and second years is representative of the changes all or most
patients would experience. Second, we did not consider a utility decrement when assigning health utility
estimates to the good and poor outcome states where most patients would remain for long periods of
TABLE 61 Disutility associated to preoperative states with the tool: deterministic and probabilistic parameters
State/patient subgroup (sex and age) Mean Distribution Alpha Beta
Risk factor modification, and reassessment after risk factor modification
Men
45–59 years 0.497 Gamma 3.89 0.128
60–69 years 0.484 Gamma 3.76 0.129
70–79 years 0.490 Gamma 3.81 0.128
≥ 80 years 0.518 Gamma 4.01 0.129
Women
45–59 years 0.536 Gamma 3.84 0.139
60–69 years 0.511 Gamma 3.76 0.136
70–79 years 0.522 Gamma 3.87 0.135
≥ 80 years 0.539 Gamma 4.07 0.132
Long-term medical management and reassessment after long-term medical management
Men
45–59 years 0.954 Gamma 19.55 0.049
60–69 years 0.942 Gamma 20.99 0.045
70–79 years 0.933 Gamma 18.17 0.051
≥ 80 years 0.948 Gamma 21.10 0.045
Women
45–59 years 0.951 Gamma 19.39 0.049
60–69 years 0.946 Gamma 20.60 0.046
70–79 years 0.943 Gamma 18.44 0.051
≥ 80 years 0.957 Gamma 19.51 0.049
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time, until death in many cases. Third, we assumed that the progression of health utility estimated from
primary THR patients in EPOS was also applicable to revision THR patients. Fourth, and finally, we did not
consider any uncertainty around the time trade-off weights reported in the literature for the EQ-5D.215
Regarding assumptions about cost parameters, the first significant assumption was that there was no cost
to the risk factor modification state. Second, surgery costs were assumed to be the same regardless of
outcome category 1 year after the operation. Third, the costs of complications were not explicitly included.
And, fourth, in using preliminary results from the COASt cohort for sections of the cost estimation
exercise, we assumed that the cohort is representative of clinical practice and, more generally, of patients
in the UK.
The implications of these modelling and parameter assumptions, as well as related limitations, are discussed
at great length in Appendix 11.
Methods for total knee replacements
The economic evaluation of implementing the outcome prediction tool for TKRs followed the same
methodology as that applied to the economic analysis for the THR tool. Variations with regard to data
sources and methods specifically applied to the cost-effectiveness analysis for TKRs are detailed below.
Economic model for total knee replacements
The cost-effectiveness analysis was conducted following the same exact Markov model employed for hips
as the surgeons involved in consultation about the model structure agreed that it largely applied to both
THR and TKR. Figure 30 illustrates the simpler schema of the model for TKRs, whereas the full model
structure including the split of ‘primary TKR’ and ‘revision TKR’ each into two health states representing
the first year in a good or poor outcome would be exactly equivalent to that shown in Appendix 5
for THRs.
Model inputs
Transition probabilities for total knee replacements
For preoperative transitions, a similar expert elicitation exercise to that conducted for THRs was performed for
TKRs. Five expert orthopaedic surgeons, from three different hospitals, participated in the elicitation exercise.
An overwhelming agreement on distribution of probabilities of referral to risk modification state was observed,
whereas for long-term medical management and TKR expert opinion was very heterogeneous, probably
reflecting the different groups surgeons work with or the many factors that influence the decision to place
patients on the waiting list for a TKR (Figure 32). For the PSA, exactly as was done with THRs, some probability
distributions were used to estimate beta distribution parameters and in some other cases the empirical
distribution elicited from experts was used.
Before probabilities of good and poor outcomes after a primary or revision TKR for each patient subgroup
could be estimated from the HES PROMs data, a cut-off point for outcome categories had to be identified.
We chose a method to split outcome into categories based on patient satisfaction. This was extensively
discussed in the case of THRs, all of which applies to TKRs as well. The study by Judge et al.155 suggested a
cut-off point of an OKS of 30 units at 6 months as optimal as it maximised the sensitivity (77.8%) and
specificity (78.2%), identified via the 45-degree line on the ROC curve (AUC 0.85). However, this cut-off
point was estimated based on data from patients following a primary TKR, from a sample of 1784 patients
and using a threshold of 50 units out of a total possible score of 100 units in a VAS satisfaction question
answered by patients 6 months after their operation.
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
As we needed a cut-off point for outcome categories not only for primary but also for revision TKRs, and
as satisfaction after the latter is known to be significantly lower than after the former, we replicated the
method followed by Judge et al.155 on the HES PROMs data. This allowed us to estimate more robust
cut-off points derived from a much larger and representative sample, using satisfaction at 1 year following
surgery (which is the cycle length in our model) as the anchor, and identifying patients as ‘satisfied’ when
their answer to the question ‘How would you describe the results of your operation?’ was ‘excellent’, ‘very
good’ or ‘good’, leaving as dissatisfied those who answered ‘fair’ or ‘poor’. Data from 95,349 patients
undergoing a primary TKR were used to estimate a cut-off point after primaries, whereas data from 3068
patients who underwent a revision TKR were used to estimate a separate cut-off point following revisions.
The cut-off point in the OKS anchored in satisfaction 1 year after surgery was estimated to be 30 units for
primaries (sensitivity 80.7%, specificity 82.0%, AUC 0.89) and 24 units for revisions (sensitivity 77.9%,
specificity 78.6%, AUC 0.87) (Figure 33).
Based on the above cut-off points for outcome categorisation, the probabilities of good and poor
outcomes following primary and revision surgeries based on HES PROMs data are shown in Table 62 and
illustrated in Figure 34.
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The probabilities of a revision surgery after patients moved to either outcome category health state during the
first year after the primary or at ≥ 2 years were estimated based on the weighted average of annual revision
rates reported by the NJR219 for cemented, cementless and hybrid for all patients. For revisions at ≥ 2 years, the
annual reported revision rates for a first revision at years 2 through to 10 were averaged into one common
rate. The overall NJR rates were combined with the proportion of good and poor outcomes after TKR found in
the HES PROMs data set and the relative rates of revision between outcome groups reported by Rothwell et al.220
for THRs because no similar data have been found for TKRs. From Rothwell et al.‘s220 rates by outcome
groups, we considered poor outcomes those reporting a postoperative OHS of < 33 units, as that was the
closer cut-off point to the 30 units on the OKS identified in the HES PROMs data set. Estimated revision
rates by outcome groups for the first and subsequent years are shown in Tables 63 and 64.
Mortality rates during the first year after the primary were obtained from the NJR219 for each patient group.
For the transition probabilities between outcome groups, whether in the first or following years and after
primary or revision, we used the same values identified for THRs.
TABLE 62 Probability of each outcome group following surgery, by patient subgroup
Patient subgroup (sex and age)
Surgery
Primary Revision
Men
45–59 years 0.377 0.609
60–69 years 0.268 0.441
70–79 years 0.229 0.341
≥ 80 years 0.244 0.316
Women
45–59 years 0.416 0.534
60–69 years 0.312 0.400
70–79 years 0.306 0.418
≥ 80 years 0.337 0.395
M 45–59 years
W 45–59 years
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FIGURE 34 Percentage of good and poor outcome following primary TKR, by outcome groups. W, women; M, men.
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Costs for total knee replacements
For the model’s preoperative states leading to a primary TKR we used primary care costs from the CPRD,
for health states involving a surgical procedure we combined secondary care costs derived from HRGs and
primary care costs during the first year following the primary or revision operation, and for postoperative
costs we derived primary care costs from the CPRD, again from the second year after the operation
and beyond.
For the primary care costs derived from the CPRD, as with THRs, we estimated the excess resource use to
patients’ joint pain problems and arthroplasty by comparing cases with controls. Cases were patients with
a CPRD record of having undergone a TKR, whereas controls were those with no record of OA, knee pain
or arthroplasty ever in the system and of the same sex, similar age (±5 years) and attending the same GP
practice. We kept sets only with cases and at least one control, so that cases with no controls as well as
controls with no cases were excluded from our analysis. When data for more than one control were
available, resource use for controls was averaged and subtracted from the resource use by the case to
obtain an estimate of the excess resource use associated to OA, knee pain and TKR. We considered data
for up to 10 years before and 10 years after the first recorded primary TKR, and included years for which
patients were reported to be active in the GP practice for at least 6 months; otherwise records were
dropped. Consultations for the same health-care staff roles and as well as prescriptions for the same drugs
as those considered for THRs were included in the resource use analysis, with the addition of neuropathic
drugs [gabapentin (Neurontin, Pfizer Ltd) and pregabalin] that were considered common prescriptions for
TKR patients. The costs associated to consultations were obtained from the Personal Social Services
Research Unit report for 2014,221 whereas for prescriptions we applied the weighted average cost of daily
treatment to the excess number of treatment days per drug. The weighted average was calculated based
on the items dispensed by Pharmacy and Appliance Contractors in England during January 2015,222 current
unit prices for the NHS for those dispensed prescriptions223 and defined daily doses established by the
World Health Organization224 (or the BNF225 when information for a specific prescription did not appear in
the World Health Organization reference).
Primary care costs leading to the first primary TKR increased, on average, for all patient groups pooled
together, from nearly £60 excess costs per annum 10 years before the primary to slightly above £250
during the 365 days preceding the operation. As patients are assumed to enter the model during that year
before the operation, the values obtained per patient subgroup were applied to all preoperative health
states prior to the primary TKR. Table 65 reports the mean and CIs of preoperative excess costs for each
patient subgroup.
TABLE 63 Revision rates by outcome groups, first year after TKR
Outcome Revised Not revised Total Revision rates (%)
Poor 0.286 29.634 29.920 0.96
Good 0.108 69.972 70.080 0.15
Overall revision rates 0.394 99.606 100 0.39
TABLE 64 Revision rates by outcome groups, ≥ 2 years after TKR
Outcome Revised Not revised Total Revision rates (%)
Poor 1.710 28.210 29.920 5.71
Good 0.646 69.434 70.080 0.92
Overall revision rates 2.356 97.644 100 2.36
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The model states involving a primary or revision TKR were combined with a first year either in good or in
poor outcome following surgery based on the postoperative OKS of 30 units for primaries and of 24 units
for revisions (as explained in the previous section). The secondary care component of the costs associated
with these health states were obtained from the HRG associated with TKR. For primaries, we used the
mean elective inpatient unit cost for HRG codes relating to ‘major knee procedures for trauma’ and
‘intermediate knee procedures for trauma’, both categories 1 and 2 and with or without comorbidities and
complications. For revisions, we averaged the ‘major’ procedures only, in all cases as reported in the NHS
reference costs tables. The mean total cost of primaries was set to £5165, whereas that for revisions was
estimated to be £6022, and these costs were applied to all patient subgroups as the patient-level
estimation carried out for THRs showed no significant differences between costs for different patient
subgroups based on age, sex or outcome group following surgery.
For the primary care costs of patients following primary or revision surgery, we used the estimated excess
use of consultations and the CPRD-reported prescriptions to predict the outcome group. This was done
based on a model estimated from the COASt cohort of 483 patients, in which both OKSs and resource use
following primary knee replacement were available. A logit model was estimated for poor outcomes after
primary surgery in which patients scoring < 30 units at the 1-year follow-up were considered to have a
poor outcome. Sex, age, consultations with GPs, nurses or physiotherapists and prescriptions for all drug
groups included in the CPRD analysis were entered in the model. A manual backward stepwise selection
method was used to exclude variables that were not statistically significant, arriving at a model for poor
outcome after primary with GP consultations and prescription of opioid drugs as significant predictors.
This model, with 0.5 as the probability cut-off point, achieved a sensitivity of 12% and a specificity of
98%, with 80% correctly classified and an AUC of 68%, as illustrated in Figure 35.
The same method was applied to predict outcome after revision. The same estimating data set was used
but applying 24 units as the cut-off postoperative OKS for outcome groups. The resulting model included
not only GP visits and prescription of opioids but also sex as well as prescription of antidepressants and
neuropathic drugs. The model for poor outcomes after revision achieved a sensitivity of 13% and a
specificity of 99%, with 90% correctly predicted and an AUC of 78%.
The above models were applied to the CPRD data allowing the identification of patients as likely to have
good or poor outcomes, and their data extracted as input parameters for the corresponding model states.
The distribution of costs for the first year after a primary TKR by outcome group is shown in Figure 36. As
with THRs, there is a circular relationship because resource use is the main predictor of outcome category;
hence, costs will follow the pattern of high resource use equals poor outcome equals high cost. However,
TABLE 65 Excess primary care costs of TKR patients compared with controls (estimates from CPRD data)
Patient subgroup (sex and age) Observations Mean cost (£) Standard error (£) 95% CI (£)
Men
45–59 years 952 247.61 13.13 221.85 to 273.36
60–69 years 3164 231.84 7.40 217.33 to 246.34
70–79 years 3672 178.07 7.28 163.80 to 192.35
≥ 80 years 1274 182.46 12.75 157.44 to 207.48
Women
45–59 years 1222 332.65 13.77 305.63 to 359.68
60–69 years 3576 251.85 7.75 236.65 to 267.05
70–79 years 5192 209.27 6.24 197.03 to 221.51
≥ 80 years 2254 192.66 9.50 174.03 to 211.30
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only selected resource use variables are employed and, as Figure 36 shows, there is a clear overlap in the
curves, indicating that many patients likely to experience a poor outcome incur lower primary care costs
than those likely to experience a good outcome, thus breaking to a certain extent the circularity. Mean
primary care costs during the first year after primary TKR for each patient subgroup are reported in
Table 66.
The mean values for revisions are reported in Appendix 12 (see Table 122). For both primaries and revisions,
the connection between resource use and outcome category was maintained for the years following the
first after surgery and, accordingly, the same model applied. This was based on the fact that, as will be
shown in Quality-adjusted life-years for total knee replacements, no significant change was observed in
health utility between the first year and the next four, regardless of outcome category, after primary TKR.
This, together with the broad stability of total resource use observed in the CPRD from the second year
onwards, allowed us to obtain estimates of primary care costs for the good and poor outcome states
≥ 2 years following primaries and revisions by averaging the costs incurred in the years between the primary
and the first revision for the former, and between the first and second revision for the latter. These values
are reported in Appendix 12.
Quality-adjusted life-years for total knee replacements
Health utilities for all health states before primary TKR were derived from preoperative EQ-5D scores
reported in the HES PROMs data set. For this and all other health utilities, as was done with THRs, a PSA
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was performed by modelling the gamma distribution corresponding to the disutilities (the inverse of
QALYs), subsequently reconverted into QALYs. Regardless of outcome group after the primary operation,
mean health utility increased significantly with the operation, as shown in Figure 37.
For the first year following the primary surgery, we found that poor outcomes achieved the entirety of their
1-year change by the third month after their primary surgery, whereas good outcomes continue improving
after that time, achieving the first 85% of the total change in the first 3 months and the remainder in the
following 9 months. This progression was observed in 1500 patients from the KAT, with available EQ-5D
summary scores preoperatively and at 3 months and 1 year postoperatively. Figure 38 shows these findings
from the KAT data set. Based on the latter, the overall mean QALYs experienced by patients experiencing a
good or a poor outcome during the first year following the primary TKR were 0.742 and 0.449, respectively,
leading to a QALY gain of 0.281 for good outcomes and of 0.170 for poor outcomes.
TABLE 66 Mean primary care costs during first year after primary TKR
Patient subgroup (sex and age) Likely poor outcomes (£) Likely good outcomes (£)
Men
45–59 years 615.23 115.64
60–69 years 599.81 119.91
70–79 years 602.01 74.401
≥ 80 years 647.60 80.07
Women
45–59 years 757.77 148.75
60–69 years 653.98 108.32
70–79 years 603.89 79.94
≥ 80 years 555.03 75.71
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Data from the KAT also show that, for good outcomes, the mean EQ-5D summary score remains at the
same level during years 2 through to 5, whereas for poor outcomes there is a reduction of approximately
10% when pooling together those 4 years compared with the first after the primary surgery. Figure 39
shows this progression. Based on this, we maintained the health utility level achieved by good outcomes
after the first year for the health state comprising all subsequent unrevised years as a good outcome,
whereas for poor outcomes we reduced the level attained at year 1 by 10%, keeping the same SD for
uncertainty purposes. Given the lack of follow-up data on patients after a revision, we assumed this same
progression for the post-revision states of the model.
Parameter values when using the tool
Again, as with the model for THRs, the present model is assessing the cost-effectiveness of implementing
the TKR outcome prediction tool compared with current practice. Current practice has been described by
the model input parameters detailed above, whereas the hypothetical scenario of the prediction tool being
implemented would change some key parameters.
First, the prediction tool is assumed to be the ultimate guide for patient referral to TKR. Patients expected to
have a good outcome, that is to have an OKS of ≥ 30 units 1 year after their primary TKR in our base case,
would be considered candidates for the operation (TKR or risk factor management in the model), whereas the
rest would be placed in long-term medical management. After validating the outcome prediction tool in the
COASt cohort, it was shown that the tool would have instead kept 7% of those primary knee replacement
patients in a long-term medical management state, allowing the remaining 93% to be candidates for surgery.
Table 67 shows how these figures would change if the cut-off value for categorisation of outcomes is an OKS
as low as 24 units or as high as 34 units.
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Implementing the outcome prediction tool would therefore change all transition probabilities originating from
the consultation with the orthopaedic surgeon. Both TKR and risk factor management were adjusted by the
percentage drop reported above, and transition to long-term medical management adjusted accordingly.
Table 68 shows mean values for these transition probabilities as well as the distribution parameters for the
PSA. Under these circumstances, moreover, the probabilities of good and poor outcome after surgery are also
affected, the former upwards and the latter downwards, in accordance with the prediction tool’s sensitivity
and specificity. At an OKS of < 30 units, and based on the application of the tool to the COASt cohort, the
probabilities of poor outcome decreased to the levels shown in Table 69 for each patient subgroup.
Finally, preoperative QALYs would also be affected inasmuch as the health utilities of those patients kept
from a TKR referral would tend to be lower than the mean of all preoperative records. For those considered
candidates for a TKR, health utilities observed in the COASt cohort experienced only a non-significant
increase compared with the overall mean (equivalent to not using the tool). This can be explained by the
TABLE 67 Effect of implementing the outcome prediction tool for TKR on COASt cohort
OKS cut-off point for prediction tool (units) Candidate for TKR (%) No TKR (%)
24 99.67 0.33
26 99.17 0.83
28 97.84 2.16
30 93.37 6.63
32 87.56 12.44
34 75.79 24.21
TABLE 69 Probability of ‘poor’ outcome after primary THR, based on application of the outcome prediction tool on
the COASt cohort
Patient subgroup (sex and age) Mean Distribution Alpha Beta
Men
45–59 years 0.1494 Beta 13 74
60–69 years 0.1429 Beta 29 174
70–79 years 0.1891 Beta 38 163
≥ 80 years 0.1111 Beta 8 64
Women
45–59 years 0.1494 Beta 13 74
60–69 years 0.1429 Beta 29 174
70–79 years 0.1891 Beta 38 163
≥ 80 years 0.1111 Beta 8 64
TABLE 68 Probability of ‘poor’ outcome after primary TKR, based on application of the outcome prediction tool
Transition probability Mean SD Distribution Alpha Beta
Surgical assessment to risk factor modification 0.116 Empirical
Surgical assessment to long-term medical management 0.393 0.208 Beta 2.766 2.579
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
fact that only 6.6% of the sample would be removed; hence, we maintained the same values used for
current practice and obtained from the larger HES PROMs data set. For those 6.6% of patients who would
be held back and referred for long-term medical management, health utilities were significantly lower than
what was applied to current practice. Again, this can be explained by the fact that those patients expected
to have a postoperative OKS of < 30 units are likely to have a very low baseline OKS, as this was the main
predictor of the former. A mean disutility of 0.915 was used for all patient subgroups in this health state, as
this was estimated from the COASt cohort and its sample size was only 38 patients in total. However, given
this low and potentially unrealistic level of QALYs, this input parameter was chosen for one-way sensitivity
analysis to explore its effect on final results.
Assumptions
The assumptions made for this TKR model are exactly the same as those reported for the THR model.
Results
Total hip replacements
Expected (mean) results
Expected costs and QALYs over the lifetime of the cohorts entering the model were calculated for current
practice and the hypothetical scenario of implementing the outcome prediction tool with a predicted OHS
of 38 units as the threshold to direct patients to THR (> 38 units) or to long-term medical management
(< 38 units). The results for each patient subgroup, including the corresponding incremental costs and
QALYs (prediction tool minus current practice) and the corresponding ICERs are shown in Table 70.
As Table 71 shows, implementation of the outcome prediction tool is associated with lower costs as well
as lower QALY gains than current practice for all patient subgroups. As current lifetime costs for the
average patient assessed for a surgical intervention are between £6000 and £11,500 higher than lifetime
costs incurred by patients without a hip condition, and this for a gain of 4.5–14.5 QALYs, with values
mainly depending on age, implementing the outcome prediction tool would reduce such costs by
£1000–1500 but also reduce QALY gain by as much as 4 years in full health, or its equivalent.
TABLE 70 Deterministic cost-effectiveness results, by patient subgroup
Patient subgroup
(sex and age)
Current practice Prediction tool Incremental
ICER (£ per QALY lost)Costs (£) QALY Costs (£) QALY Costs (£) QALY
Women
45 years 11,562 14.52 10,437 10.87 –1125 –3.66 308
60 years 9282 11.08 7853 7.97 –1429 –3.11 460
70 years 7891 7.93 6199 5.56 –1692 –2.37 714
80 years 6520 4.75 4676 3.26 –1844 –1.49 1240
Men
45 years 10,086 14.61 9055 10.70 –1031 –3.92 263
60 years 8196 10.81 6890 7.64 –1306 –3.17 412
70 years 7062 7.64 5495 5.30 –1567 –2.34 669
80 years 5954 4.48 4367 3.07 –1587 –1.40 1130
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As a result, ICERs were estimated to be around £250–300 per QALY forgone for men or women assessed at
45 years of age, up to £1100–1200 per QALY lost for 80-year-old men or women considered for a THR. As
the prediction tool would reduce costs at the expense of QALYs gained, thus placing the cost-effectiveness
ratio in the south-west quadrant, only ICERs above £30,000 per QALY forgone might be considered
cost-effective under the assumption that the health-care system would be willing to reduce costs at the
expense of length and quality of life at the same rate that it is willing to adopt technologies that increase
QALYs at a positive cost. Hence, the above deterministic results suggest that the outcome prediction tool
would only be cost-effective if the health-care system was willing to exchange reduction in costs for
reduction in length and quality of life at a rate lower than the reported ICERs.
Scenario sensitivity analyses
We conducted one-way sensitivity analyses on the discount rate and on the health utility estimate applied to
long-term medical management, as this is the parameter value for which there were no highly representative
data and, therefore, the one subject to the largest uncertainty. We also performed a sensitivity analysis on
the cut-off point assumed by the outcome prediction tool to direct patients to THR or to long-term medical
management as the non-surgical alternative. The analyses were performed only on women entering the
model at 70 years of age to illustrate effects, because of the eight subgroups considered this is the largest
one receiving THRs in the UK.
The average health utility estimate for long-term medical management, when the prediction tool is
assumed to be in place, played an important part in the tool producing fewer QALYs than current practice.
Although its low value (around 0.05) was justified by the tool’s discriminatory raison d’être based primarily
on preoperative OHS, we performed sensitivity analysis on the QALY estimate associated to this state in
order to ascertain whether or not it affected results in any significant manner. As Table 71 shows, varying
the mean value of health utility assigned to this health state in five equal steps from the low 0.05 to the
same value applied to the simulation for current practice (0.334), increases the QALY gain when using the
tool, but not enough to reach the levels attained by current practice, ceteris paribus. The difference in
QALY gain is driven by the higher proportion of good outcomes in current practice and which, if the
prediction tool were implemented, would have been kept from surgery in long-term medical management
because of the tool’s imperfect specificity.
As is customary in economic evaluations and suggested in NICE’s Guide to the Methods of Technology
Appraisal,226 we performed sensitivity analysis by dropping the discount rate for both costs and benefits
from 3.5% to 1.5%. The results obtained when applying this lower rate did not affect results in any
significant way. Both incremental costs and QALYs were again in the negative range, with costs savings
slightly larger (£1712 instead of £1692) and QALYs lost increasing marginally, from 2.37 to 2.78. In
neither of the above two cases would the expected effects of changing original mean values be enough to
change the decision of not adopting the tool, unless the health service were willing to forgo QALYs for
savings at a rate of only £1600–1700 saved per QALY lost.
TABLE 71 Sensitivity analysis on health utility estimate for long-term medical management, women aged 70 years
Mean health utility estimate
Current practice Prediction tool Incremental
Costs (£) QALY Costs (£) QALY Costs (£) QALY
0.057 (base case) 7891 7.93 6199 5.56 –1692 –2.37
0.112 7891 7.93 6199 5.73 –1692 –2.20
0.167 7891 7.93 6199 5.91 –1692 –2.02
0.223 7891 7.93 6199 6.08 –1692 –1.85
0.278 7891 7.93 6199 6.26 –1692 –1.67
0.334 (current practice) 7891 7.93 6199 6.43 –1692 –1.50
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Arguably the parameter associated with the greatest uncertainty is the application of the outcome
prediction tool itself, as all results modelled here are, although based on the patient-level data used to
estimate the statistical tool, hypothetical. We therefore conducted a sensitivity analysis on the cut-off point
at which the outcome prediction tool would be used to direct patients into surgery, or not, to explore
potential effects on final results. By changing this cut-off point, five probabilities and a number of health
utility estimates would all change: the probabilities of being referred for a THR, for risk factor modification,
for long-term medical management, the probabilities of good and poor outcome, and the QALY estimate
for all preoperative states with the exception of surgical assessment. As the base-case analysis used an
OHS of 38 units as the reference cut-off point for the prediction tool, we adjusted the above model input
parameters accordingly for scenarios in which the tool would direct patients based on cut-off points of an
OHS of 32, 34, 36, 40 or 42 units. Table 72 shows the resulting total costs and QALYs of each alternative,
as well as the corresponding incremental differences and ICERs.
As expected, with changes to the parameters of the simulation under application of the prediction tool,
total costs and QALYs for current practice considering the cohort of 70-year-old women did not change,
but those for the tool did. As the tool becomes more lenient and directs patients with a predicted
postoperative OHS of < 38 units for a THR, savings with respect to current practice are reduced because
more patients ultimately have their hips replaced. Application of the tool thus calibrated would also mean
that the QALYs generated would approach those attained by current practice because more potential
good outcomes wrongly held back before in long-term medical management would now be put forward
for a THR, hence attaining the higher QALYs that the operation achieves on most patients. The opposite
effect was obtained when parameters were adjusted to a prediction tool that applied cut-off points of
> 38 units to decide which patients should receive a THR or not: more money would be saved, but more
QALYs would be forgone.
Probabilistic sensitivity analysis
We conducted a full PSA by allowing all parameter values to change stochastically and independently
based on their distribution. Figure 40 shows the results of running 1000 Monte Carlo simulations and
placing the corresponding incremental costs and QALYs on the cost-effectiveness plane for women and
men entering the model at 70 years of age. The vast majority of the simulations placed incremental
cost-effectiveness results on the south-west quadrant. More specifically, in 87% of cases for women and
88% of cases for men aged 70 years, implementing the tool was expected to cost less but also produce
fewer QALYs than current practice.
These Monte Carlo simulations produced a cost-effectiveness acceptability curve (CEAC), which is shown
in Figure 35 only for women entering the model at 70 years of age (there is no significant difference in
results by sex). The curves representing the probability that either current practice or the tool would be
deemed cost-effective at the various thresholds represented in the x-axis crossed at a point between £700
and £800 per QALY. This is consistent with the reported expected ICER of £714. This is shown in Figure 41
TABLE 72 Sensitivity analysis on the cut-off point applied by the outcome prediction tool, women aged 70 years
Cut-off point (OHS)
Current practice Prediction tool Incremental
ICER (£)Costs (£) QALY Costs (£) QALY Costs (£) QALY
32 units 7891 7.93 7630 7.02 –261 –0.91 288.72
34 units 7891 7.93 7394 6.67 –497 –1.26 394.74
36 units 7891 7.93 6896 6.18 –995 –1.75 569.83
38 units (base case) 7891 7.93 6199 5.56 –1692 –2.37 714.19
40 units 7891 7.93 5337 4.95 –2554 –2.97 858.80
42 units 7891 7.93 4648 4.58 –3243 –3.35 967.34
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by the decreasing probability of the outcome prediction tool being cost-effective as the threshold
increases, with this probability falling under that for current practice at a point exactly or near the ICER for
women entering the model at 70 years of age.
It is important to stress, however, that the range of willingness-to-pay thresholds within which
implementing the outcome prediction tool would be cost-effective refers actually to scenarios of cost
reduction and fewer QALYs generated with respect to current practice. This is effectively the range of
willingness-to-pay thresholds at which both alternatives produce net monetary losses, with the outcome
prediction tool generating lower net losses than current practice. It is, ultimately, a range of ‘willingness to
save’ resources at the expense of QALYs forgone. This is also shown for all patient subgroups, for which
we found no significant differences between sexes and a slight trend depending on age. The range of
willingness-to-pay thresholds at which the outcome prediction tool remains cost-effective increases as the
age of patients gets higher. Figure 41 shows this for female patient subgroups. In other words, if the
willingness to save resources at the expense of QALYs forgone progressively drops from £30,000 per
QALY, for example, implementing the outcome prediction tool would become cost-effective for older
patients first, and then gradually for younger cohorts.
Total knee replacements
Expected (mean) results
Similar to our findings with the tool for THRs, our cost-effectiveness analysis of the hypothetical scenario of
implementing the outcome prediction tool for TKRs would reduce costs to the NHS, but would also
decrease the QALYs that the TKRs achieve.
Table 73 shows current patients receiving a TKR cost the health-care system between £4000 and £14,000
over the course of their lives starting the year before they receive their primary TKR. The amount varies
slightly with sex, with women being somewhat more expensive, but greatly with age. This is to be
expected because we used a lifetime model, meaning that the younger patients are, the more likely they
are to receive an expensive revision joint replacement and the longer they live, hence using primary care
resources for longer time. For similar reasons, the mean number of QALYs associated with TKRs currently is
only marginally different between sexes but significantly so, depending on the age patients entered the
model. Although 45-year-old patients accrued, on average, between 12 and 13 QALYs after discounting
following their primary TKR, patients aged > 80 years would only accumulate about 4.5 QALYs.
TABLE 73 Deterministic cost-effectiveness results for TKRs, by patient subgroup
Patient subgroup (sex and age)
Current practice Prediction tool Incremental
ICER (£)Costs (£) QALY Costs (£) QALY Costs (£) QALY
Men
45 years 11,597 12.86 11,285 11.73 –312 –1.13 275
60 years 8083 9.94 7890 8.66 –193 –1.27 151
70 years 5914 7.30 5782 6.16 –132 –1.14 116
80 years 4270 4.49 4075 3.74 –195 –0.75 260
Women
45 years 14,972 12.56 14,460 11.76 –512 –0.80 637
60 years 10,147 10.03 9807 9.01 –340 –1.02 335
70 years 7479 7.43 7237 6.49 –242 –0.94 258
80 years 5152 4.57 4842 3.97 –310 –0.60 521
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Implementing the outcome prediction tool for TKRs developed as part of this project would keep a small
percentage of patients from being placed in the waiting list for surgery and keep them under long-term
non-surgical management. Our model suggests that this would reduce lifetime costs by £100–500, while
at the same time reducing the cumulative QALYs by 0.7 to 1.3. The impact of implementing the tool does
not vary significantly between sexes or with patients’ age. These potentially forgone results are consistent
with our observations about the improvement in pain and function that those who we have defined as
having ‘poor’ outcomes achieve despite not reaching the cut-off point of 30 units in their postoperative
OKS. This improvement, paired with their QALY gain, is forgone because of the application of a tool that
keeps the latter patients from surgery and, hence, from increasing their quality of life, even if by a lower
magnitude than those expected to reach the 30-unit cut-off point.
The above results place the deterministic cost-effectiveness ratio in the south-west quadrant of the
cost-effectiveness plane, as it did with THRs. Interpretation of the ICER in these circumstances, estimated at
between £100 and £700 per QALY, must be conducted with care, as it reflects not the additional cost per
additional QALY gained with the assessed intervention, but rather the costs saved by each additional QALY
forgone as a result of implementing the tool. The threshold band of £20,000–30,000 commonly applied
by NICE when recommending health-care interventions to be implemented by the NHS normally applies to
results in the north-east quadrant; therefore, the ICERs presented here must not be compared with this
threshold, as they are instead a measure of the impacts of disinvestment in the quality of life of patients
considered for TKR.
Scenario sensitivity analyses
As with our analysis of the THR tool, the single most uncertain model input parameter populating our
economic model is likely to be the quality of life associated to patients in long-term medical management
and subsequent reassessment health states of the model when the outcome prediction tool is modelled.
Although extracted from the validation of the tool on the COASt cohort and based on observed preoperative
health utility scores reported by patients, this value was only based on 38 observations and we found it to be
significantly low. We therefore conducted a one-way sensitivity analysis on this specific parameter, allowing it
to vary in equal steps from the value used in our base case (mean disutility 0.915 or 0.085 of a QALY) to the
value applied under current practice (disutility 0.620 or 0.380 of a QALY) for women entering the model
at 70 years of age, as was done with the analysis for THRs. Table 74 shows how, with costs unaffected,
increasing the health utility accrued by patients in long-term medical management and its reassessment up
to the same level used for current practice would reduce the QALYs forgone from approximately 0.9 to 0.3,
still keeping deterministic results in the south-west quadrant.
As the intervention being assessed in this analysis is the outcome prediction tool, a relevant sensitivity analysis
would be to vary the cut-off point at which the tool would ‘decide’ to allow patients to be referred for the
waiting list for TKR or keep them under long-term medical management. We performed this sensitivity
TABLE 74 Sensitivity analysis on health utility estimate for long-term medical management, women aged 70 years
Mean health utility estimate
Current practice Prediction tool Incremental
Costs (£) QALY Costs (£) QALY Costs (£) QALY
0.085 (base case) 7479 7.43 7237 6.49 –242 –0.94
0.144 7479 7.43 7237 6.63 –242 –0.80
0.203 7479 7.43 7237 6.76 –242 –0.67
0.262 7479 7.43 7237 6.90 –242 –0.53
0.321 7479 7.43 7237 7.04 –242 –0.40
0.380 (current practice) 7479 7.43 7237 7.17 –242 –0.26
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analysis based on the proportion of patients identified in the COASt cohort as being expected to be
candidates for TKR (expected to score above the predictive tool cut-off point) or not (expected to score less
than the cut-off level). As with THRs, however, the allocation of patients was the only parameter of the model
changed while all remaining transition probabilities, costs and QALYs per health state remained constant.
Again, for women entering the model at 70 years of age, Table 75 shows full deterministic results for all
patient subgroups at different cut-off levels of the expected postoperative OKS for the application of the tool.
As Table 75 shows, the higher the cut-off point, that is the more stringent the tool guiding the referral of
patients for TKR, the lower the number of patients getting a replacement, leading to lower costs but also
fewer QALYs were the tool to be implemented.
Probabilistic sensitivity analysis
We conducted a full PSA by running a Monte Carlo simulation of 1000 iterations, where input values for
each parameter feeding the economic model were independently drawn from their distributions based on
the observed heterogeneity of our patient-level data or the probability distributions obtained from the
expert elicitation exercise.
Figure 42 shows, for women entering the model at 70 years of age, how the small savings and levels of
QALY forgone estimated in the deterministic analysis become a cloud of possible results covering all four
quadrants of the cost-effectiveness plane, although concentrated mostly in the south-west quadrant
(52% of iterations). The spread of the cloud was largely similar for all patient subgroups, in all cases
therefore suggesting that, accounting for the uncertainty and heterogeneity of all model input parameters,
an outcome prediction tool such as the one assessed in this analysis is capable of saving funds for the
TABLE 75 Sensitivity analysis on the cut-off point applied by the outcome prediction tool, women aged 70 years
Cut-off point (OKS)
Current practice Prediction tool Incremental
ICER
(£ per QALY lost)Costs (£) QALY Cost (£) QALY Costs (£) QALY
24 units 7479 7.43 7328 6.69 –151 –0.74 202
26 units 7479 7.43 7321 6.67 –158 –0.76 208
28 units 7479 7.43 7302 6.63 –177 –0.80 221
30 units (base case) 7479 7.43 7237 6.49 –242 –0.94 258
32 units 7479 7.43 7153 6.32 –326 –1.12 291
34 units 7479 7.43 6983 5.95 –496 –1.48 335
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FIGURE 42 Results of the probabilistic sensitivity analysis in the cost-effectiveness plane for women aged 70 years.
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health-care system, although it may also prove more expensive in some cases, and that the tool can limit
the QALYs produced by TKRs but in some circumstances it can also increase them.
A PSA is often accompanied by a CEAC showing the likelihood of the intervention being cost-effective at
various thresholds, as was done with results for THRs. However, given that, again, results are mostly set in
the south-west quadrant of the cost-effectiveness plane, where, as we indicated above, the context
becomes one of disinvestment and where a cost-effectiveness threshold does not directly apply as it is
common employed, we do not show corresponding CEACs to avoid misleading messages.
Discussion
Main findings
No ground for rationing
The outcome prediction tool for THRs and TKRs developed under COASt would, as intended, reduce the
number and proportion of unsatisfactory and poor outcomes after the operation, saving NHS resources in
the process. However, the tool would do so at the cost of keeping a number of patients from surgery who
would have otherwise improved significantly in their OHS and HRQoL, meaning that the tool would also
produce fewer QALYs than current practice.
The highest savings per QALY forgone were reported by the oldest patient subgroups (men and women
aged ≥ 80 years) with an ICER around £1200 per QALY for THRs. We believe that this is probably an
overestimate of the cost-effectiveness of the tool based on having simulated its implementation through an
internal validation on patient-level data and no input from a surgeon. As a result, applied in reality, this tool
would probably ration joint replacements but to a lesser extent than our simulation did, thereby potentially
closing the gap of savings and of QALY losses. Nevertheless, even at the above possibly overestimated levels,
these results are unlikely to be deemed cost-effective for the NHS in England even assuming that the
£30,000 per QALY threshold currently used for more costly interventions that produce more QALYs were
applicable in a disinvestment scenario in which money is saved but QALYs are forgone. Keeping patients
from surgery, therefore, appears unlikely to be cost-effective for any tool applied to such a highly successful
operation, unless the tool is extremely sensitive and specific, to a level that the one assessed here appears
not to reach.
In this context, it seems highly unlikely that simple preoperative Oxford scores could direct patients more
efficiently than current practice, or even compared with the prediction tools assessed here. Nonetheless,
documents such as the 2010/11 South West London Effective Commissioning Initiative227 suggest that a
primary THR should be provided to patients as long as they have a preoperative OHS of < 26 units, or if
other criteria involving pain and functional limitation are met. Justification for this specific threshold is not
provided, other than a reference about patients with preoperative OHS of < 20 units achieving the greatest
benefit from THR,158 although this does not appear clearly stated in the publication and neither does the
publication address cost-effectiveness considerations behind the definition of a cut-off point to consider
THR. The same criterion was applied by the former Cheshire and Merseyside PCT,228 whereas Derby City
and Derbyshire specified a cut-off point of ≥ 30 units to fund a primary THR,229 again with no indication of
evidence to justify the specific OHS threshold and furthermore pointing in the opposite direction from the
South West London document, that is that THRs should be performed on patients who are not at their
worst in pain and mobility. The outcome prediction tools assessed in this evaluation considered not only
preoperative Oxford scores but also age, BMI and a number of environmental and surgical variables to
predict scores at 1 year after surgery. These prediction models are more comprehensive and appropriate
than using merely preoperative Oxford scores to guide the decision about performing a THR/TKR or not,
and it did not prove cost-effective. Using only preoperative scores would most likely be associated with even
higher net benefit losses than those found for the outcome prediction tool, which suggests that the
rationing policy based on Oxford scores should be stopped.
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New tool or new definition of outcome categories?
The prediction tools are simply not sensitive and specific enough, or, in other words, THRs and TKRs are
just remarkably effective interventions producing notable increases in the disease-specific outcome
measure as well as in a generic HRQoL one, even for patients labelled as having poor outcomes based on
a combination of satisfaction and Oxford scores.
One way forward is to work on improving the statistical tool. Other potential predictors of outcome
(such as the volume of operations performed in the hospital or the experience of the particular surgeon
performing the operation) have previously been found to be associated with outcome not only for hip
procedures,158,230 but also for arthroplasties of the knee,231 and could be included. More complete data not
requiring as much imputation of missing values could also be employed in the estimating sample to
produce a more accurate tool.
Improving the predictive power of the tool seems necessary for it to achieve better QALY results by keeping
from surgery only the small proportion of patients who would not improve, or would do so only slightly,
while sending all others achieving significant QALY gains through to surgery. The sensitivity analysis
conducted around the Oxford scores cut-off point at which the tools would direct patients to THR/TKR or
to long-term medical management showed that, regardless of the cut-off point, the prediction tools, as
developed, would not be able to achieve better QALY results than current practice. It is, therefore, not a
matter of calibrating the current prediction tool. A second approach to improve performance of the tool
could involve the adjustment of all model input parameters associated to what we termed good and poor
outcomes based on the OHS and OKS thresholds of 38 and 30 units, respectively, to reflect the various
thresholds identified by Arden et al.154 for specific patient subgroups based on sex, age, baseline OHS, BMI
and expectations.
Given the significant clinical effectiveness and cost-effectiveness of THRs and TKRs as they are performed in
the UK, we believe that a new description of the outcome group intended to be prevented is the optimal
way forward. Furthermore, we believe that this outcome group should be limited to those patients who do
not improve in their Oxford scores or EQ-5D, or who do so only very slightly. Using the postoperative OHS
and OKS thresholds of 38 and 30 units, respectively, to distinguish between two outcome categories and
employing an outcome prediction tool to prevent patients from falling into the lower scoring group is a
waste of potential significant improvements in HRQoL. The basis for this Oxford scores thresholds was
that they were found to be the level that best distinguishes between satisfied and unsatisfied total
replacement patients. Satisfaction does not, however, seem to be a valid proxy for HRQoL gain. The notable
improvement in EQ-5D summary score of those labelled as poor, and hence likely unsatisfied outcomes,
confirms this. If a new definition of the ‘poor’ outcome category could be identified such that it grouped
patients who do not or only hardly improve after the operation, and a prediction tool capable of accurately
identifying them can be developed, then THRs and TKRs could lead to better outcomes and lower costs.
The sooner, the better?
The model presented here incorporated a long-term medical management arm that essentially worked as a
surgery delay mechanism, which for a certain proportion of patients meant that they would not get a TJR
before they died. This was particularly important because, if the outcome prediction tools were to be
implemented, they would identify patients who are likely to perform poorly and those patients would be
kept from surgery precisely by placing them in this medical management state. The PROMs showed,
however, that waiting until the disease affects patients more severely tends to reduce their improvement.
For both good and poor outcomes the mean EQ-5D summary score increased significantly after surgery,
and it also showed that poor outcomes started at a lower EQ-5D score than good outcomes (0.18 vs. 0.35
for the lowest scoring patient subgroups in the case of THRs) and achieved a smaller improvement (0.25
vs. 0.44). Assuming that the disease progresses with time and, therefore, that the longer patients remain
without a replacement, the lower their Oxford scores and EQ-5D scores, would be a delay mechanism,
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such as the one implicitly put into place by the outcome prediction tools, which appears to potentially
reduce the ability of patients to improve. Field et al.158 have already suggested that delaying surgery could
make it more difficult for patients to achieve the best possible improvement. At least one economic
evaluation comparing THR against watchful waiting was structured assuming the exact opposite, that is
that patients were to remain in watchful waiting until their quality of life dropped to very low levels.202
Based on the above evidence, it would be important to perform similar assessments using as comparator a
watchful waiting alternative in which patients in need of a THR or TKR do not wait so long, perhaps until
their pain, mobility and quality of life began to decrease in a sustained manner but not beyond that point.
These findings must be handled with care, as they may be viewed as an indication for THR/TKR for all OA
patients early in their disease stage when it is also a fact that an important number of patients do perform
poorly after surgery. The complex prediction tools assessed in this study included a measure of disease
progression by incorporating preoperative Oxford scores as one of the predictors, and yet it lacked the
necessary accuracy to identify poor outcomes with sufficient sensitivity and specificity to make them
cost-effective interventions. Having a THR/TKR when patients are not at their worst may increase the
average improvement obtained, but that does not guarantee that poor outcomes will be reduced.
The improvement reported above and shared, albeit in different magnitudes, by the outcome category
groups we have called good and poor outcomes suggests that the term ‘poor’ lacks accuracy. A more
appropriate label for these groups would be better and worse outcomes. The timing of arthroplasty,
nonetheless, remains a complex and extremely policy-relevant question; but a question also that this study
did not attempt to answer, although it would hopefully contribute to future research.
Differentiated rates of revision
Our findings in this study support distinguishing between outcome categories when performing economic
evaluations for which the clearly different outcome groups are relevant. This is supported even further
by the revision rates reported by Rothwell et al.220 for the four different outcome groups suggested by
Kalairajah et al.,210 as the 2-year revision rate in patients with a postoperative OHS score < 27 units was
reported to be 7.6%, compared with 0.5% for those patients with a postoperative OHS score of > 41 units.
Although equivalent revision rates have not been calculated for the UK, it is sensible to expect a similar
pattern whereby worse outcomes have their replacements revised at a significantly higher rate than better
outcomes. Given the high cost of revision surgeries, this is yet another good reason to continue working on
the development of an outcome prediction tool because by accurately preventing worse outcomes after a
primary replacement, it would not only be preventing the higher primary costs during the lifetime of the
primary prosthesis, but it would also be preventing the much higher costs of a revision THR or TKR.
A large prosthesis market
In the case of THRs, over 100 different brands of acetabular cups and more than 140 brands of femoral
components were used in the UK during 2011.17 Equivalent figures for TKRs are similarly high. Furthermore,
these components of a TJRs can be fixed with cement, without cement or with a combination thereof
(hybrid), with an additional classification by head size (varying between 22 and 60mm) and bearing surface
(with different combinations of metal, ceramic and polyethylene) in the case of THRs. As a result, to speak of
a THR or a TKR in general terms, as we have done for this assessment, means that we did not make any
distinction between the significant number of combinations of components and types of each of these
interventions, all of which are associated with different prosthesis survival rates.17 We intended to incorporate
specific revision rates by fixation type that are reported to the NJR, but regrettably our request for the data
was denied.
Nevertheless, having access to these data is essential not only to refine economic evaluations such as this
one, but also to explore the effects that they may have on outcome after surgery. Again, for THRs, for
example, in its eighth annual report, the NJR reported that 935 different combinations of acetabular cups
and femoral components had been used in the 7-year period during which the registry had been collecting
data. Of those, at least 20 had been used on 2500 patients or more, reporting 5-year revision rates as far
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apart as 0.58% (95% CI 0.42% to 0.79%) for the Exeter V40 (Stryker UK Limited, Newbury, UK) with Elite
Plus Ogee (Depuy Synthes UK, Leeds, UK) (13,000 patients) and 3.6% (95% CI 2.72% to 4.76%) for the
SL-Plus Cementless Stem (Smith & Nephew, Watford, UK) with Exceed (Biomet UK Limited, Bridgend, UK)
(3500 patients).1 As NICE’s technology appraisal guidance 304 issued in 2014 recommends the use of
prostheses for primary THR as long as prostheses have rates (or projected rates) of revision of ≤ 5% at
10 years, research on the comparative performance of prosthesis brands is of paramount importance.233
The above evidence on differential survival of the prostheses and the significant difference in prosthesis
costs232 support further research specific by prosthesis type, something Pennington et al.234 have recently
started to address with a cost-effectiveness analysis of THR by fixation type in 2012.
Long-term follow-up
Finally, as joint replacements are interventions that impact patients for a long time and revision surgeries
have been found to be important drivers of cost-effectiveness,205 access to long-term follow-up data on
THR and TKR patients is essential. The Swedish Hip Arthroplasty Register has been following up patients
since the late 1970s and has also been collecting HRQoL data since 2002.235 This is a good example for the
UK to follow; the main commitment must be maintaining the collection of data over time regarding not
only the failure of prosthesis but also patient-reported outcomes, prosthesis types and brands, details
about the hospital where the procedure was performed as well as the surgeons involved and, crucially,
sociodemographic information about the patients.
Important additions to the information collected would be all likely determinants of outcome such as stage
of disease progression, diagnoses, coexistent conditions and previous treatment received. In terms of
health-care use, it would be important to achieve high degrees of effective linkage between the clinical
follow-up and hospital as well as primary care records before and after the operation. In the case of the
UK, this would mean building and maintaining links between an extended version of the PROMs initiative
with the records being collected by the NJR, the NHS hospital episode records, the NHS outpatient data
and the CPRD. Given that between 20% and 25% of THRs are performed privately, of which about half
are privately funded,1 links from the NJR data to the corresponding records in the private sector will
contribute to building a most complete database of relevant information about joint replacements in
the country.
Efforts made by the UK in the direction of improving the data collected to evaluate THRs and TKRs are
noteworthy. The establishment of the NJR in 2002 was a major first step, followed by including hip and
knee replacements as two of the four interventions for which PROMs are systematically collected as a
measure of treatment outcome and quality of care in the NHS. Although the national initiative only
involves one preoperative and one postoperative measure 6 months after surgery, the NJR has begun a
project extending the follow-up period for hip and knee replacement patients by sending PROM forms to
35,000 patients in England at 1, 3 and 5 years after surgery.236 These initiatives, combined with the
measures described above, will make an important contribution to building a solid body of data that,
available to researchers, will help shape policy on THR and joint replacement surgery for the benefit of
patients and the efficiency of the health-care system.
Strengths and limitations
In general, this research benefited from using the best available sources of data to populate a cost-effectiveness
model. First, the only source of data not based on patient-level records was the expert elicitation exercise,
which is comprehensively reported in the section dedicated to preoperative transition probabilities as inputs for
the hip and knee models. When expert opinion has been used in similar previous assessments, the details
about how the elicitation was conducted were not reported.83,237 For our economic evaluation, every step of the
process of collecting and synthesising experts’ judgement was described.
Apart from the expert judgements, all other sources of data consisted of patient-level data sets with the
most appropriate, representative and up-to-date information on the probabilities, health utility and resource
use associated with THRs in the UK, both before and after the operation. The HES PROMs data set,
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the CPRD, EPOS, KAT and the COASt cohort provide the best data on hip arthroplasty in the UK, and the
only model parameter estimated based on data from elsewhere was revision rates by outcome category,
which were published on data from New Zealand but ultimately adjusted to match the UK’s overall revision
rate and relative sizes of the outcome groups.
The level of detail provided by the above data sources allowed estimating model parameter values for
patient subgroups by age and sex. This not only made it possible to present results separately by these
subgroups, but critically it also allowed for adjusting all parameter values in the model so that not only
death rates but almost all other parameters changed in the simulation as patients became older. If results
are only as good as the data feeding the model, then those produced by this research are results in which
we can have great confidence.
However, no research is exempt from shortcomings. First of all, the interventions that were assessed with
our economic evaluations have not been implemented yet. Although the final work package of the COASt
research programme involves a validation of the prediction tool on the cohort of patients recruited from
Oxford and Southampton hospitals, our study was performed assuming that the results of the tool would
be those of its internal validation in the case of THRs and the actual validation for TKRs. Although an
internal validation would generally be associated with better results than external ones, the prediction tool
was estimated after merging large data sets and performing a substantial imputation of values that were
missing or simply not collected.
As reported in the section detailing the assumptions made surrounding the model’s structure and
parameterisation, there are a number of limitations that, although clinically feasible, constrain results.
Although the expert elicitation was conducted with a sound methodology and the frequency of convergent
results speak of understanding of the process by and agreement among surgeons, a validation of those
values at a national level would improve the model’s robustness. Revision rates by outcome groups were
adjusted from those reported on patients from New Zealand, while equivalent values can now be produced
for the UK thanks to the PROMs initiative. The lack of long-term follow-up of patients who do not receive a
THR and even of those who do have their hips replaced for both primary and revision operations forced us
to make a number of assumptions that, if replaced by evidence, would improve reliability of results. Further
research can focus on these limitations.
Research recommendations
Some of the former PCTs in England were using BMI thresholds for THR referrals, up until PCTs ceased to
exist with the introduction of the new structure of the health-care system in England in April of 2013.238 BMI
thresholds of 25 kg/m2,206,207 30 kg/m2207 and 35 kg/m2208,209 were defined as a basis to encourage weight
reduction before referral for THR. It is not clear whether or not the newly formed clinical commissioning
groups will continue applying these criteria to ration THRs but, as with OHS thresholds, they lack appropriate
economic evaluations. We originally intended to include BMI as one of the defining criteria for the patient
subgroups in our analysis, but were not able to do so because height and weight were available in only
about 40% of CPRD records. BMI was also unavailable in the HES PROMs data set, a limitation that
disappears if records are linked to the NJR as they do collect height and weight measures from hospitals
performing THRs. Although our economic evaluation focused on the application of an outcome prediction
tool and did not include BMI groups in the analysis, it did show that current practice of THRs in the UK is
remarkably cost-effective and, therefore, suggests that any rationing such as that possibly still in place based
on BMI must be carefully reviewed, as it may be denying a significant improvement in health to patients and
an opportunity to invest health-care resources in a very cost-effective manner.
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Chapter 5 Work package 4: external validation of
the tool
Work package 4 has been designed to test and externally validate the predictive tools, developed inwork package 2, in a pragmatic NHS setting of a prospective cohort of lower limb arthroplasty
patients (observational study COASt). We have obtained ethics approval to recruit 3200 hip and knee
arthroplasty patients to COASt across two NHS hospitals, and collected the data longitudinally. The study
assesses a strategy for predicting patients at risk of poor functional outcome following lower limb
joint arthroplasty.
Aim
The aims of this work package were to:
1. evaluate the practicality and effectiveness of the prediction tool generated in work package 2 in a large
pragmatic cohort study of hip and knee replacement surgeries
2. advise on improved design of future interventional clinical trials, which would aid improvement of the
outcomes following lower limb arthroplasties
3. further assess the ability of the tools developed in work package 2 to predict patients’ outcomes at an
early postoperative stage.
Background
Our work suggests that the postoperative patient-reported outcomes are dependent on preoperative
Oxford scores.139,141,155,160 Although routinely used in the selection of patients for joint replacement
surgeries, there is an increasing trend to utilise PROMs in a more meaningful way for patients and surgeons,
which would aid the selection process of patients for joint replacement surgeries. For patients, knowing
only by how many points surgery would change their score is not informative. A more meaningful way
would be to associate this score with a classification of poor or good outcomes. Within this programme, in
work package 2, we have carried out work to introduce cut-off points to identify patient satisfaction, which
would serve for a better understanding during clinical decision-making rather than a score on a continuous
scale.154,155 However, clinical applications of the thresholds are limited because of the combination of
preoperative predictors affecting the outcome of surgery.
Previously methodology has been developed to combine a wide range of predictors that can be included in
a statistical model to predict outcomes. In work package 2 we have included and investigated the effects of
the interplay of a wide range of risk factors as described in Chapter 3, using the Oxford scores as a primary
outcome. Not only we have confirmed previously described risk factors, but we have also identified the
interplay between these individual predictors, which have an important role in poor outcomes following hip
or knee replacement surgeries.138,142 Similarly, as part of this programme, we aimed to develop a prognostic
tool to predict outcomes following THR and TKR surgeries. Currently, there are two drafts describing hip
and knee predictive models. The knee model has been validated successfully using the COASt data set.
Indeed, external validation predicts 21% of the variance of the outcome. The knee manuscript is under
internal review before its submission to a peer-reviewed journal. The hip predictive model is currently
waiting for external validation with COASt.138,142 For work package 4 we have obtained ethics approval to
recruit and obtain the data from a new prospective observational study from patients receiving total hip and
knee replacement surgeries at two participating hospitals: the Nuffield Orthopaedic Centre (NOC) and
Southampton General Hospital.
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
In this work package we set out to validate the predictive tool developed in work package 2, which used
preoperative information including technical, patient and medical factors through the ROC curve analysis to
predict 12-month postoperative PROMs. We also aimed to collect the data to populate a cost-effectiveness
analysis of the implementation of the model in the current health-care system and thus complete work
package 3.
Description of the study
Study design
The Clinical Outcomes in Arthroplasty Study is a prospective, dual-centre longitudinal cohort study of
patients listed for hip and knee arthroplasties across two hospitals [the University Hospitals Southampton
NHS Foundation Trust (UHS) and NOC, which is the part of the Oxford University Hospitals NHS Trust
(OUH)]. The study collects baseline, intraoperative and follow-up information for up to 5 years after surgery.
It also collects patients’ preoperative, intraoperative and 1- and/or 2-year postoperative samples. The COASt
grant application was made to cover the costs for a 2-year follow-up. However, we believed that the
longitudinal collection of patients’ data would add great scientific value to the analysis in terms of long-term
prosthesis survival. Therefore, we obtained ethics approval to follow-up study participants for 5 years.
Important changes to the design of the study
The initial grant application for the programme was submitted to recruit 1600 patients across both
categories, hip and knee arthroplasties, as described in Sample size. However, the work carried out in work
package 2 demonstrated that patients undergoing TKR have different outcomes from those undergoing
THR, that is, outcome following TKR is poorer than that of THR.141,143 This resulted in a change to our
original plan and, hence, the subsequent increase in the recruitment up to 1600 patients in each category
(in total 3200 participants). We believed that this would enable us to have sufficient statistical power to
test the productivity of the predictive tools for hip and knee replacement surgeries separately. We have,
therefore, been granted an extension from NIHR to enable us to carry out this important work.
Owing to the number of the data collected during the study and the need to integrate them with the existing
information technology (IT) systems, we encountered unforeseen difficulties in the database development
and data extraction. There was an unexpected change in the core staff, specifically a high-grade database
manager. In addition, we experienced problems with incompatibilities and inconsistences within the NHS
systems from which we needed to obtain a substantial number of source data. We, thus, have been granted
a second extension of 9 months. Since we identified these problems, we had employed a number of staff
including a higher-grade database manager, study co-ordinator and several data assistants. We have made
substantial changes to the database design and have successfully overcome incompatibility issues.
Participating centres
Two hospitals have been participating in the study: Southampton General Hospital and NOC. There are three
subcohorts within the study: North COASt study (Oxford) (NCOASt), South COASt study (Southampton)
and Oxford Musculoskeletal Biobank (OMB). Patients recruited at the NOC under COASt ethics (Oxford)
constituted the NCOASt part of the study, and the patients recruited at the Southampton General Hospital
(SGH) constituted the South COASt part of the study. COASt also utilises the data and samples collected
by the OMB, under OMB ethics, which has also recruited patients listed for hip or knee arthroplasties at
the NOC.
At the beginning of work package 4, COASt had made a successful application to the OMB to access the
data and samples of patients who were listed for hip or knee arthroplasties at the NOC, signed the written
consent form and had met the COASt eligibility criteria. The OMB is a research tissue and data bank that
has been reviewed and approved by Oxford Research Ethics Committee C (reference number 09/H0606/11,
3 March 2009) and is regulated and licensed by the Human Tissue Authority (HTA) (licence number 12217).
As all questions in the pre- and postoperative questionnaires are mostly identical, the data collected from
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OMB and COASt are comparable. In addition to data, OMB also provides the study with long-term storage
sample capacity, as approved and governed by the HTA.
For a variety of trial management considerations, a subgroup of patients who were already recruited under
the OMB ethics was reconsented (converted) under COASt ethics and allocated to NCOASt. The breakdown
of patients groups is shown in the pie chart (Figure 43).
The majority of COASt eligible patients have been recruited under OMB ethics (2675 participants in
Oxford). In Oxford, the study recruited 295 NCOASt patients, of whom 156 were initially consented by the
OMB but were then reconsented into COASt at a later stage. In Southampton, where recruitment still
continues, the study has recruited 741 patients to date.
Clinical Outcomes in Arthroplasty Study team
Overall responsibility for the study falls to chief investigator who, in turn, delegates various responsibilities
to the team members. The principal investigator of the Oxford site is delegated to take up the
responsibilities to run the study in Oxford.
Recruitment and research visits are carried out by registered research nurses or physiotherapists. The study
manager and co-ordinator oversee overall monitoring of the recruitment, data collection and study milestones,
ensuring that the protocol is conducted in accordance with ethical and regulatory standards at all times.
The study has also been supported by the team of statisticians, a health economist, epidemiologist, database
manager, imaging research assistant and clerical and data entry assistants. Sample collection and management
have been delegated to a laboratory research assistant in Southampton, whereas in Oxford this has been
carried out by the OMB members.
Signature and delegation logs are regularly updated for each site, Oxford and Southampton. Although
patient recruitment and sample and data collection takes place at both centres, management, co-ordination
and data entry/validation are handled from Oxford.
The study milestones and the dissemination policy is supported by two committees: the Steering Committee
and the Data and Sample Access Committee (DSAC). Figure 44 shows the allocation of personnel at each
site of the study.
Study population
Patient inclusion and exclusion criteria
The broad inclusion criteria of COASt have allowed maximising the recruitment rate. All patients who have
been listed for hip and knee arthroplasties have been considered for the study. Inclusion and exclusion
criteria are shown in Table 76.
72%
20%
4%
4%
OMB eligible for COASt (n = 2675)
OMB converted to NCOASt (n = 156)
NCOASt only (n = 139)
SCOASt (n = 741)
FIGURE 43 Pie chart showing the breakdown of COASt eligible patients cohorts. SCOASt, South COASt Study.
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We have identified 10 procedures on the database to represent the preoperative assessments for eligibility
for COASt (Table 77). Actual surgery types performed within the COASt cohort are listed in Table 78.
Patient pathway
Consent and patient recruitment
All participants who are listed for hip and knee replacement surgeries are potentially eligible for inclusion
in the study. Once potential participants are identified, they are sent a recruitment pack, which includes
the patient information sheet (PIS), sample consent form and recruitment letter. Participant involvement in
this study does not normally provide direct personal benefits but such involvement facilitates future
research in this particular field and in the orthopaedic community.
Owing to their own time constraints, work and family commitments or any other reasons, some participants
have been unable to fully commit themselves to the study. However, they have supported the research by
allowing the study members to collect and use their data with their minimal participation. By adopting a
COASt team
Chief investigator
Principal investigator
• Research nurse
• Physiotherapist
• Data assistant
• Administrative
   assistant
• Data entry assistants
• Imaging research
   assistant
• Research nurse
• Laboratory research
   assistant
• Administrative assistant
Oxford Southampton
Study manager/study
co-ordinator
Statistician
Health economist
Epidemiologist
Database manager
Steering
Committee
DSAC
OMB
FIGURE 44 Showing personnel allocated to the study in Oxford and Southampton.
TABLE 76 Showing patient inclusion and exclusion criteria for COASt
Inclusion criteria Exclusion criteria
Aged > 18 years Unwilling or unable to give consent
On waiting list for hip or knee arthroplasty Charcot’s arthropathy or other severe neurological disorders
Consent competent and willing to consent Other severe neurological disorders
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minimally intrusive method we have accommodated a number of participants: we excluded their research
visits from the consent form; however, we retained consent on collecting data relevant to their surgeries
from medical records and, thus, enhanced the generalisability of the study results. In such cases we used
the specific consent form of minimum level of participation that permits team members to access and
gather information from participants’ medical records without the patients’ active participation.
Potential participants are normally identified by the orthopaedic team. They can be any patients who are
listed for knee or hip replacement surgeries at the NOC or SGH. The orthopaedic team identifies if patients
meet other inclusion criteria and then provides them with a recruitment pack containing the PIS, a sample
consent form and a recruitment letter. Depending on time and resources, the recruitment packs are either
given to participants on the day of their preassessment appointments or posted to them after their clinics.
After approximately 2 weeks, ensuring that the patient has had sufficient time for consideration,
a member of the COASt team contacts them to discuss the study in more detail, as specified in the PIS.
The COASt member takes a verbal consent during the telephone discussion. The verbal consent includes
an agreement that the participant is happy to receive the patient self-assessment booklet and the second
morning urine sample instruction sheet with a sample pot, when applicable. Written consent is taken at
the research appointment date, which is preliminarily agreed between the study member and the patient
over the telephone.
At the NOC, the majority of the patients listed for hip or knee replacement already complete the patient
self-assessment questionnaire (which is essentially similar to the questionnaire designed specifically for
COASt) for scheduled surgery as part of their routine care. This process ensures that the patients are not
overburdened and completing the questionnaire is not repeated specifically for the research. In this instance,
data are accessed either through the OMB or by the NCOASt directly from the NOC medical records.
TABLE 77 Detailing patient eligibility criteria by procedures for knee and hip category
Preoperative procedure knee Preoperative procedure hip
Hemiarthroplasty Hip resurfacing arthroplasty
Knee patellofemoral resurfacing THA
TKA THA revision
Knee patellofemoral resurfacing/TKA
TKA revision
Unicompartmental knee arthroplasty
Unicompartmental knee arthroplasty/TKA
TABLE 78 Detailing procedures performed in COASt cohort for knee and hip category
Knee procedure Hip procedure
Patellofemoral resurfacing Hip resurfacing arthroplasty
Primary TKA (primary TKA) Primary THA (primary THA)
Revision TKA (revision TKA) Revision THA (revision THA)
Unicompartmental knee arthroplasty Hip – other
Knee arthroscopy
Knee – other
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Once consent is taken, participants are assigned a site-specific screening number, which is then entered
into the screening log. In some cases, participants are listed for surgery for different joints (hip vs. knee
and left vs. right) at different time points. When the participant is willing for the research to collect data
relating to the second operation, second consent is taken. In this case a new study number is allocated.
This ensures the high quality of data collection and management. The screening log contains the details of
all participants, whether or not they have enrolled to the study. Patients who choose to opt out from the
research are flagged on the screening log.
Preoperative visits
After patients decide that they would like to take part in the study, they are contacted by a member of the
research team. At the research appointment, patients bring along a completed patient self-assessment for
inpatient surgery form. During the research appointment the patient signs the consent form, as described in
the section on consent. The following additional tests are undertaken: whole-body density [via dual-energy
X-ray absorptiometry (DEXA)], a physical assessment and blood and urine sample collection.
Inpatient data and sample collection
The COASt collects inpatient data and intraoperative samples with patients’ explicit consent.
Postoperative visits
Patients may also be invited to 1- or 2-year follow-up research appointments at their choice. These visits
may include a physical assessment, a DEXA scan, and blood and urine sample collection.
Follow-up
With patients’ consent, study personnel post follow-up questionnaires at 6 weeks and then annually for up
to 5 years postoperatively. The participants complete the questionnaires and return them in the prepaid
envelope provided.
Patient pathways at University Hospitals Southampton NHS Foundation
Trust and Nuffield Orthopaedic Centre
The patient pathway fundamentally differs between the two hospitals, which subsequently affected
recruitment rates across the two centres.
At the NOC, the study worked closely with the trust to combine the research documentation with the
extant NHS documentation, which was then adopted by the trust and subsequently used in patients’
routine care. The Oxford site then used the documentation for the collection of preoperative and inpatient
data. In particular, this includes preoperative booklets such as patient self-assessment for inpatient surgery,
procedure-specific physical assessment and admission, and inpatient and discharge information forms. As
the preoperative booklets have been incorporated into patients’ routine care, it significantly reduced the
overburdening of patients, leading to a very high rate of recruitment, with > 90% of patients approached
consenting to take part in the study; in contrast, in Southampton, a more conservative recruitment strategy
result in 40% of patients approached being recruited.
There are also slight differences in terms of the study milestones across the two centres. This has been
reflected in the recruitment process; as recruitment has proved to be very successful in Oxford, recruitment has
ceased at the NOC but it still continues at SGH. In addition to preoperative patients’ visits, in Southampton
patients are also invited in at 1 or 2 years after their surgery. These visits include a procedure-specific physical
assessment, blood and urine sample collection and a DEXA scan (Figure 45).
As previously described, the recruitment process has been more complex in Oxford. At the beginning of the
project, COASt had recruited patients under OMB ethics. A subset of OMB patients has been reconsented
to be followed up by COASt. This is because the OMB is restricted by its licence and generic ethics, which
does not currently permit research-specific procedures. We have amended the internal application to OMB
to request permission to follow up those patients recruited as part of the COASt–OMB collaboration.
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Figure 46 shows that some patients have remained under the OMB ethics (green box) whereas some of
the OMB patients (dark-green box under the green box, dotted line) have been reconsented into NCOASt
at the NOC; we had only invited patients for a preoperative physical assessment, preoperative sample
collection and a DEXA scan. Follow-up visits at the NOC were not carried out.
Patient pathway UHS
Consent
declined
Visit I 
Preoperative
data collection
Inpatient data
collection
Visits II or III
Postoperative data
collection
Patient follow-up
data collection
Participant listed for
arthroplasty by orthopaedic
surgeon
Patient sent 6-week, 
1-, 2-, 3-, 4- and 5-year
follow-up
questionnaires
Patient sent 6-week, 
1-, 2-, 3-, 4- and 5-year
follow-up
questionnaires
• Patient attends research
   appointment
• Baseline data collected, physical
   examination including the 
   collection of blood and urine 
   samples
Participant contacted by research nurse and
verbal consent obtained over telephone
Consent for
medical records
access only by
research team
Patient admitted to hospital for
 surgery
• Inpatient data collected
• Intraoperative samples and data
   collected
Patient information leaflet and
invitation letter sent by
orthopaedic team
Patient agrees to limited
participation in study
Participant verbally agrees to
fully participate in study
Consent and
baseline patient
self-assessment
booklet
completed
Patient attends follow-up research
appointments at 1 or 2 years 
postoperatively: DEXA, physical
assessment and blood and
urine collected
Inpatient data
collected
FIGURE 45 Recruitment process in SGH. The flow chart shows that the patient is either consented fully to the study
(right column) or with limited participation (left column of the flow chart). The right-hand side light-green boxes
depict the phase of data collection and follow-up visits.
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Patient pathway NOC
Participant listed for
arthroplasty by orthopaedic
surgeon
Patient sent 6-week, 
1-, 2-, 3-, 4- and 5-year
follow-up
questionnaires
Patient sent 6-week, 
1-, 2-, 3-, 4- and 5-year
follow-up
questionnaires
Patient sent 6-week, 
1-, 2-, 3-, 4- and 5-year
follow-up
questionnaires
• Patient attends research
   appointment
• Baseline data collected,
   physical examination
   including the collection
   of blood and urine samples
Participant contacted by research nurse and
verbal consent obtained over telephone
Consent for
medical
records access
only by
research team
Consent
declined
Patient admitted to
hospital for surgery
• Inpatient data collected
• Intraoperative samples 
   and data collected
Patient information leaflet and
invitation letter sent by
orthopaedic team
Visit
Preoperative data
collection
Patient agrees to limited
participation to study
NCOASt
Participant verbally agrees
to fully participate to study
NCOASt
Consent and
baseline patient
self-assessment
booklet
completed
Inpatient data
collection
Patient re-
consented by
COASt and
allocated to
NCOASt
Patient follow-up
data collection
Inpatient data
collected
Patient recruited
by OMB
FIGURE 46 Recruitment flow chart at the NOC. Three types of consents were taken: patients in the left-hand
column consent to limited participation to the study; patients in the right-hand column are fully consented to
participate in the study and are allocated to NCOASt; and patients in the middle column are recruited under OMB
ethics. The collection of baseline data and samples, and postoperative follow-up data for OMB happens similarly to
the NCOASt procedure; at some stage, some OMB patients are reconsented and followed up by NCOASt, and this
may happen at any stage. Hence, the flow is indicated by the dashed arrows. Light-green boxes indicate the stage
of the data collection and preoperative visit.
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Ethics
The study has been approved by the Oxford Research Ethics Committee A (reference number 10/H0604/91).
The sponsoring organisation of the study is the UHS. Although UHS is the sponsor for the study, the majority
of the co-ordination has been done in Oxford, where the study chief investigator is now based. Oxford has
considerable experience in setting up and running multicentre studies, is cognisant of the issues on research
governance and other frameworks, which are essential for conducting and maintaining clinical studies.
COASt has been conducted and maintained in accordance with International Conference of Harmonisation
Good Clinical Practice guidelines and is in compliance of other regulatory requirements and governing bodies.
Recruitment figures
Proposed sample size
The initial population sample size was calculated to test the predictive tool developed in work package 2.
This would have a sensitivity of at least 90% and a specificity of at least 75%. The power calculation was
based on having data for 1400 TJRs, which would result in there being 224 patients with which to
estimate sensitivity and 1176 patients with which to estimate specificity for hip arthroplasty patients. With
224 patients, a true sensitivity of 90% can be estimated to within 4% (95% CI 86% to 94%) and a true
sensitivity of 75% can be estimated to within 2.5% (95% CI 72.5% to 77.5%). The sample size doubled
in the course of the programme, as described in Important changes to the design of the study.
Actual recruitment figures
We have had an excellent rate of recruitment and went over the target by 15.96% from the proposed
sample size of 3200. Over-recruitment allowed us to maximise data collection, despite the loss of patients
during the long-term follow-up. The number of patients included in the study across both categories, hip
and knee, is illustrated in Figure 47.
As Figure 47 shows, the overall number of consented patients across the two centres is 3711 (2970 in
Oxford and 741 in Southampton).
A subset of patients was excluded during the course of the trial for the variety of reasons. For instance,
during the study some patients with progressive degenerative diseases, such as Parkinson’s disease and
multiple sclerosis, were recruited. Although not exhibiting severe symptoms at the time of the recruitment,
Consented 
(n = 3711)
Oxford 
(n = 2970)
Excluded 
(n = 60)
Excluded 
(n = 10)
• Withdrawn, n = 6
• Ineligible, n = 17
• Duplicated, n = 37
• Consent limited, n = 0
Southampton 
(n = 741)
Assessed 
(n = 2910)
Hip 
(n = 1469)
Hip 
(n = 412)
Knee 
(n = 1441)
Knee 
(n = 319)
Assessed 
(n = 731)
• Withdrawn, n = 0
• Ineligible, n = 4
• Duplicated, n = 0
• Consent limited, n = 6
FIGURE 47 Number of patients included in COASt.
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
133
because of the longitudinal nature of the study, it was expected that in these patients symptoms were likely
to deteriorate over time. Therefore, considering ethical implications, these participants have been excluded
from the study and flagged as ‘ineligible for COASt’. During the data cleaning and auditing, a small number
of patients in Oxford have been identified as duplicates. The errors have been rectified by flagging these
cases and removing them from the analysis. Only six patients have withdrawn their consent from the study
in Oxford. The minimum data set of withdrawn patients have been kept intact on the database for linkage
and auditing purposes. Six patients in Southampton have been recruited with an optional level of
participation (see Consent and patient recruitment) and marked as ‘consent limited’ on the database.
To summarise, 60 patients have been excluded from the study in Oxford either because they withdrew from
the study (six participants) or because they were ineligible (17 participants were diagnosed with severe
neurological disorders), or had been allocated duplicate study identification numbers (37 participants).
Ten patients were excluded from COASt because of the ineligibility criteria (four participants) and/or
because only limited consent was obtained (six patients). This left 2910 participants in Oxford and 731
participants in Southampton in whom data were collected pre- and postoperatively.
Retention has also been good and reached a rate of 87% at 1 year after surgery. The number of recruited
patients who returned 1-year follow-up booklets is shown in Tables 79 and 80. The tables list the
categories of actual surgeries that were used by COASt.
TABLE 79 Recruitment and figures and returned 1-year follow-up questionnaire for hip patients in COASt
Main group Subgroup
Oxford (n) Southampton (n) Total (n)
Yes Subgroup No Yes Subgroup No Yes Subgroup No
Patients assessed 1469 412 1881
Died before surgery 5 1 6
Had any surgeries vs.
waiting
1417 47 395 16 1812 63
Hip: othera 1 0 1
Hip: HRA 11 5 16
Hip: THA 1229 316 1545
Hip: THA revision 176 73 249
Knee: TKAb 0 1 1
Had COASt surgery
(either hip or knee)
1416 1 395 0 1811 1
Had COASt surgery on
assessed joint
1416 0 394 1 1810 1
Died without returning
6-week follow-up
questionnaire
16 3 19
Returned 6-week
follow-up questionnaire
590 790 355 37 945 827
Died without returning
1-year follow-up
questionnaire
5 1 6
Returned 1-year
follow-up forms
(including by telephone)c
1010 385 317 74 1327 459
HRA, hip resurfacing arthroplasty.
a Hip: other indicates that the surgery type is other than HRA, THA primary or revision.
b One patient was assessed for hip arthroplasty but the actual surgery performed was TKA.
c The number of returned follow-up questionnaires excludes those who are not yet due for sending 1-year follow-up booklet.
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Table 79 shows that 1881 hip patients in total (SGH and NOC) were included in the study. Of this cohort, six
patients died and 63 patients did not undergo surgery. Overall, 19 patients died in the 6 weeks after surgery
and six patients died before the end of the first year after their surgery. One patient in Southampton was
initially assessed for hip replacement surgery but actually underwent knee replacement surgery. Therefore,
in total, COASt followed up only 1327 patients at 1 year. This, however, does not reflect the true retention
rate because the number excludes those who had surgeries recently and who have not reached the 1-year
postoperative time point. Therefore, these patients have not yet been sent the 1-year follow-up booklets.
For the knee cohort, all patients who were listed for knee replacement surgery and were aged > 18 years,
consent competent and had not had severe neurological disorder were selected for the study (1760 patients
in total). Table 80 shows that 1760 patients have been assessed for knee replacement surgery. Of these,
four died before their surgery, 15 died in the 6 weeks after surgery and eight died before the end of the first
TABLE 80 Recruitment figures and returned 1-year follow-up questionnaire for knee patients in COASt
Main group Subgroup
Oxford (n) Southampton (n) Total (n)
Yes Subgroup No Yes Subgroup No Yes Subgroup No
Patients assessed 1441 319 1760
Died before surgery 2 2 4
Had any surgeries vs.
waiting
1358 81 303 14 1661 95
Hip: THAa 2 2 4
Knee: arthroscopy 18 0 18
Knee: otherb 1 1 2
Knee: patellofemoral
resurfacing
13 3 16
Knee: TKA 635 224 859
Knee: TKA revision 99 11 110
Knee: unicompartmental
knee arthroplasty
590 62 652
Had COASt surgery
(hip or knee)
1339 19 302 1 1641 20
Had COASt surgery on
assessed joint
1337 2 300 2 1637 4
Died without returning
6-week follow-up
questionnaire
14 1 15
Returned 6-week
follow-up questionnaire
560 751 277 24 837 775
Died without returning
1-year follow-up
questionnaire
5 3 8
Returned 1-year
follow-up questionnaire
(including by telephone)c
916 404 231 67 1147 471
a One patient was initially assessed for knee arthroplasty but the actual surgery performed was primary THA.
b Actual surgery type other than this specified on the database.
c The figure is not a true depiction of real success rate of 1-year follow-up as it includes patients who are still within 1 year
after their surgery.
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year after their surgery. In total, 95 patients have not had their surgery yet. Interestingly, four patients were
initially assessed for knee replacement but actually underwent primary total hip arthroscopy. Therefore, only
1637 patients were selected to be sent the 1-year follow-up booklet. Overall, 1147 patients have returned
the 1-year follow-up booklet or supplied the data over the telephone. This number, however, is not a true
reflection for the rate of 1-year follow-up success, as it excludes the patients who have not reached the
1-year postoperative time point.
Data, samples and radiographic variables
Data
The data have been collected in accordance with Good Clinical Practice and the Data Protection Act
1998.239 COASt data collection has gone though the appropriate approval processes. The data have been
collected either from participants’ hospital records or directly from participants. This includes:
l Baseline data – patient self-assessment for inpatient surgery and PROMs, both of which are completed
by patients, and procedure-specific physical assessment carried out by a qualified research nurse,
physiotherapist or podiatrist.
l Inpatient data – from participants’ medical notes various perioperative clinical information have been
extracted including radiographic variables and other clinical information relevant to the study, such as
intraoperative variables.
l Postoperative data – questionnaires completed by patients at 6 weeks and 1, 2, 3, 4 and 5 years after
their surgery. Follow-up questionnaires are posted to study participants. The completed booklet is then
returned in a stamped addressed envelope.
Radiographic variables
Radiographic variables such as radiographs and DEXA scans are collected pre- and postoperatively (DEXA
scans are carried out for the study at 1 and/or 2 years after surgery, as specified in COASt protocol).
Samples
The study team collected samples donated by participants. Participants’ specimens are allocated a unique
specimen number alongside their unique study number. All collected samples are processed and stored in
the OMB. This includes urine, blood and intraoperative biomaterial.
Urine samples are collected for future storage and deoxypyridinoline cross-link analysis. At visits a second
urine sample is collected. Blood samples are collected for storage and the serum is analysed for high-sensitivity
C-reactive protein (hsCRP) concentration. For this report we analysed blood samples for hsCRP to use as a
predictor for TJR outcome.
The COASt also collects intraoperative biomaterial such as femoral condyle, tibial plateau, meniscus,
ligament, synovium, synovial fluid, fat, femoral head, acetabular bone/cartilage, labrum, ligamentum teres,
synovium and synovial fluid.
Collection of samples will enable tests to be conducted and more extensive profiling to take place in the future.
It will also contribute significantly to clinical research in orthopaedics, rheumatology and musculoskeletal sciences.
Donated blood and urine speciments are centrifuged and aliquoted in several cryovials. This takes place
immediately after the collection. Samples that are not immediately analysed for deoxypyridinoline and
C-reactive protein are sent to the OMB for storage. Samples are analysed blind by the laboratory at SGH,
that is laboratory staff are not provided with sensitive patient information but only the study identifications.
Blood and urine sample types, number of aliquotes and tests that are carried out for the study are shown in
Table 81.
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All biological samples are collected and stored in accordance with the local trust guidelines and HTA.
Biomaterial for long storage is snap frozen and kept in the OMB, for testing, at –80 °C in a securely
monitored freezer.
If the results arising from sample testing generate any clinical concerns or queries, the case will be referred
to the principal investigator or chief investigator, who may in turn contact the patient’s GP/consultant to
inform them of the results.
Radiographic variables
Dual-energy X-ray absorptiometry scan
This is an additional test carried out by the study and was not included in the NIHR grant application. In
SGH and NOC we used densitometers Hologic Discovery QDR (Hologic, Bedford, MA, USA) and Hologic
Discovery A (Hologic, Bedford, MA, USA), respectively, for DEXA scans to measure bone mineral density
(BMD). The majority of DEXA scans are carried out at SGH and a relatively small number of successive
patients at the NOC. In SGH the scan is done preoperatively and at 1 or 2 years post surgery, whereas at
the NOC the scan was performed only before the patient’s surgery. BMD of the index joint will be used to
assess the quality of the bone into which the prosthesis is going to be implanted and will be used in future
research for assessing the risk of a poor PROMs outcome, postoperative osteoporosis fracture and the risk
of revision surgery. BMD measurements are made at the lumbar spine (L1–L4), hip, whole body and
proximal tibia/subchondral region, and an instant vertebral assessment has also been collected.
Radiographs
Patients’ preoperative radiographs of the index joint are obtained as a part of routine care by using a picture
archiving and communication system (PACS). Baseline radiographs are taken within the routine care in the
trusts for the majority of patients. These have been obtained by the study with patients’ consent. A small
minority of radiographs are taken out of the trust area and, therefore, are unavailable. Radiographic
variables have been taken mainly from the Digital Imaging and Communications in Medicine (DICOM)
format. DICOM format retains maximum image quality and accurate image size in order to be used for
assessing semiquantitative and quantitative morphology and OA variables for research purposes. When
DICOM was not available, Joint Photographic Experts Group (JPEG) images were used for baseline variables.
The radiographs used were clinical images taken during routine patient care and surgery preparation, and
were not standardised specifically for COASt. Therefore, the anteroposterior weight-bearing images that
were required for grading were not available for all patients. Radiographs were anonymised at the point
TABLE 81 Sample types and derived aliquots collected by COASt
Test Sample type Number of tubes
C-reactive protein Blood 1 × 5ml
DpD Urine 1 × 10ml
For samples for storage: extra blood maximum of 50ml allowed
C-reactive protein Blood for serum (gold) 1 × 6ml
C-reactive protein Blood for serum (red) 1 × 6ml
C-reactive protein Blood for plasma 1 × 6ml
DNA Blood 1 × 5ml
For samples on admission
DpD Urine 1 × 10ml
DNA, deoxyribonucleic acid; DpD, deoxypyridinoline.
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they were downloaded from the PACS, with all patient-identifiable information removed. Images were
saved in DICOM (.dcm) format in order to retain the best-quality imaging data.
Data storage and database
Database
All COASt data have been stored on servers located at the University of Oxford and managed by the Medical
Sciences Division IT. The patient-identifiable data have been collected and stored in two monitoring
databases (one for Oxford’s patients and one for Southampton’s patients) using Microsoft Access® databases
(2010, Microsoft Corporation, Redmond, WA, USA) located in high-compliance systems (HCSs). The other,
non-sensitive, data have been collected via a web interface developed in PHP and JavaScript accessible only
within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS),
and stored in a password-protected MySQL database (version 5.6.12; Cupertino, CA, USA).
Data security and confidentiality
Patient-identifiable data have been collected and stored in a password-protected HCS provided by the
Information Management Services Unit (IMSU) at NDORMS in Oxford to ensure patient data protection and
confidentiality. Only the NIHR Biomedical Research Unit IT manager, the database manager and approved
members from the study team have password-protected access to the patient-identifiable information, for
the purposes of patient follow-up, data validation and error checking. No sensitive data have gone outside
the HCSs. Each participant has been given a unique study-specific identifier used to identify them safely and
anonymously across the COASt databases. Password-protected access to the non-sensitive information has
been given to the database manager and approved study members for data checking and data entry
purposes, respectively.
Error checking and validation
A number of layers of data checking and validation have been implemented to allow only sensible data to be
entered into the databases. The NHS algorithm has been used to identify possible typing mistakes in the NHS
numbers. Lower and upper limits have been set in the database and interface for numeric fields in order to
accept only a range of possible answers according to the question being requested. When applicable, and
appropriate, for the question, a set of answers has been presented in the interface to facilitate data entry and
minimise human mistakes. Daily automated reviews of the data have been run overnight to identify any
outliers and, when present, automatic e-mails have been sent to the COASt team for further checking
and corrections.
Audit trail
The databases have recorded a full history of user access and user actions (i.e. data insertions, updates and
deletion). Audit tables in the databases have stored an original copy of any information that has been
entered, updated or deleted.
Backups
Backups of the databases have been performed regularly. The HCS Microsoft Access databases have been
backed up daily by the IMSU. The MySQL database has been dumped and stored daily on a dedicated
IMSU server at NDORMS. Only the NIHR Biomedical Research Unit IT manager and the COASt database
manager have authorised password-protected access to these data backups.
Safety reporting
Study-related risk assessments have been carried out and participants are informed of such risks, however
small, in PISs or in discussions, when necessary. Study safety reports are generated annually to Research
Ethics Committee and reported, as specified in the protocol.
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Patients and scientific community
Data sharing
Results deriving from work package 4 will be presented as publications in high-calibre journals, national and
international research meetings. We have a very strong track record of informing health policy nationally
and internationally, through organisations such as the European League Against Rheumatism, OARSI, World
Health Organization and the Institute of Fundraising. The intellectual property arising from the programme
is owned by the UHS. However, the trust had discussed the possibility of a future collaboration between
Southampton and Oxford around some potentially synergistic intellectual property, which is currently being
developed in Oxford and the outputs of the COASt.
We believe in the benefits of actively sharing the achievements of research with the public and the wider
scientific community. The results will be shared with the participants by posting newsletters detailing our latest
achievements and conclusions we have made so far. The templates of newsletters and any communication
will vary according to the phase of the study and the interpretations available at the time. We are planning to
design an external website for promoting use of COASt data and samples in order to maximise the study
potential and encourage collaborations with other scientific groups for the benefits of the public. For this
purpose we established the DSAC.
The DSAC facilitates the provision of access to the data set and samples collected. The DSAC operates
under its terms of reference and the protocol. The committee consists of several members of the local
research group, an independent chairperson and the patient representative from the patient and public
involvement (PPI). The committee ensures that the common principles on data and tissue policy are adhered
to, allows appropriate sharing of the study samples/data for scientific research with the participants’ privacy
and well-being protected within the scope of their informed consent, and ensures compliance with
regulatory requirements.
In order to access the COASt data and samples, a researcher sends a completed application form to the
DSAC. The applicants must be employees of a recognised academic institution, health service organisation
or commercial research organisation with experience in medical research with sufficient scientific merit.
Transfer of the data and samples outside the UK, within or outside the European Economic Area, requires
a full protocol that ensures conformity to UK legal, safety and ethical standards.
Patient and public involvement
We are committed to deliver credible data and results for the benefits of general public. At the same time
we ensure that the rights, safety and confidentiality of participants are respected and protected. Team
members involved in this research have been appropriately qualified by education, training and their
experience. In parallel, as described in our grant application, we have appointed the patient and public
representatives (PPRs) to represent patients’ rights from each participating centres.
At the beginning of work package 4 a PPR was appointed to the steering committee. At a later stage PPR
was involved in the dissemination strategy as a DSAC committee member, in which they supported the
study dissemination policy and ensured that the participants’ anonymity is observed while sharing the data
with other scientific groups.
The COASt PPR is a member of general public, works on voluntary basis and has interest in the topic we
research. The PPR’s contribution in the study involved:
l discussion on substantial amendments of the study
l data sharing and dissemination policy
l consultation on lay summaries.
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During the meetings, discussing COASt substantial amendments, the PPI had the opportunity to emphasise
a number of issues and, most importantly, effectively design the patient information leaflets. The leaflets
were designed to be well presented, informative and easy to understand, which certainly enhanced
recruitment success rates. There was a concern in the group that patients should not be overburdened
with different clinical studies that take place in local trusts. The PPR felt that, as a patient themselves, it is
important that patients are offered the opportunity to participate in as many observational studies as they
wish as long as they are happy to do so.
The PPR had more involvement in later stage of the study, especially during the dissemination phase, as
the DSAC member PPI had opportunity to review DSAC original documentation and share any suggestions
they had. Although previous meetings have happened face to face, meetings for the DSAC have been
carrying out remotely via teleconferences. The PPR has also been involved in consultation for lay summaries
such as designing newsletters and writing a lay summary for this report.
Although our PPR had involvement on a number of occasions, we fully understand that this involvement
could be expanded further. We would take the ideas forward and expand our relationships with the
public. In particular, the accent will be made on more active involvement at the initial stages, before grant
application, in which the ideas would be closely discussed with focus groups. Patients who have similar
interests in the study would have a clear vision of what patients would expect from the research and
whether or not the research would benefit patients. In the Research Ethics Committee application stage,
the focus groups would discuss the detailed patient pathway whether or not the research would affect
patients routine pathway, whether or not research would undertake suitable pathway to recruit optimum
number of patients, whether or not patients would have sufficient time for reading patient information
leaflets and other related documents and if the information provided in the leaflets and consent form is
easy to understand and sufficiently comprehensive. In the active phase, PPRs could review and comment
on proposed patient booklets and questionnaires, as well as data collection methods, potentially contribute
to the implementation of the results, and advise on different techniques and avenues for dissemination of
the results.
Statistical analysis (methods) and end points
This report describes the external validation of two prediction models for THR138 and TKR,142 using the
prospective COASt cohort. We also present results of the evaluation of the incremental value of additional
variables (radiographs and the K/L grade) on the work package 2 COASt knee and hip models.
Total knee replacement: Clinical Outcomes in Arthroplasty Study knee model
We developed a clinical risk prediction tool to predict the OKS at 12 months after undergoing TKR surgery.142
We used the data from 1649 patients enrolled in the KAT across 34 centres in the UK between July 1999
and January 2003. The presence of a fixed flexion deformity or other deformities (compared with no
deformity) and the absence of a preoperative ACL (rather than an intact ACL) were associated with a better
outcome. The clinical factors associated with a worse outcome were a worse ASA grade, the presence of
other conditions affecting mobility and previous knee surgery. A lower preoperative OKS, living in a poor
area, a high BMI and a worse SF-12 mental component summary score were also associated with a worse
outcome. The discrimination and calibration statistics were good. Patient characteristics explained 16.6% of
the outcome variability. The addition of clinical variables, then surgical variables increased the explained
outcome variance to 18.9% and 20.2%, respectively.
Total hip replacement: Clinical Outcomes in Arthroplasty Study hip model
We developed a clinical tool to predict patient-reported outcomes following primary hip replacement
surgery for OA using data from the Exeter Primary Outcome Study and EUROHIP.138 The OA pattern, one
of the radiographic variables, was an important determinant of outcome (i.e. patients with superolateral
disease had a better outcome). Arthritis and previous surgery on other joints led to a worse outcome.
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Among the surgical variables, a posterior surgical approach and a larger femoral component offset had a
better outcome. The patient factors of worse preoperative pain/function, increased age once > 75 years,
increased BMI, a lower educational attainment level and a worse preoperative SF-36 mental health score
also gave a worse outcome. These factors were operationalised into a clinical risk prediction tool. The tool
was well calibrated and discriminated well (R2 = 23.1%). The tool performed well in identifying the
patients with the worst outcomes (c-statistic = 0.77).
Assessment of Clinical Outcomes in Arthroplasty Study hip radiographs
Radiograph scoring methods
Two validated semiquantitative scoring methods were used to assess common features of OA visible on a
radiograph. The K/L score is a global grading system consisting of a combination of radiographic features
(osteophytes and joint space narrowing) in both the medial and lateral compartments.177,240 This score ranges
from 0, indicating no evidence of radiographic OA, to grade 4, which indicates severe radiographic OA.
The atlas developed by the OARSI was also utilised in order to score individual features and compartments
of radiographic OA.241 Osteophytes were scored based on size in four locations: inferior acetabular, inferior
femoral, superior acetabular and superior femoral. Joint space narrowing was graded in two locations:
superior and medial. The presence or absence of subchondral cysts and subchondral sclerosis was
also recorded.
Femoral head migration has been previously identified as an important predictor of outcome after hip
replacement surgery.137 As there is no single method for assessing this score, information from several
references were combined to replicate this measure and create a standardised, reproducible method of
assessment.242–246 Categories were selected to match the research by Dieppe et al.:137 superolateral,
superomedial, medial or concentric.
The following classifications were used to describe femoral head migration on the COASt images:
l superolateral – definite loss of joint space in the superolateral region of the joint leading to the
migration of the femoral head towards the lateral sourcil
l superomedial – definite loss of joint space in the superomedial region of the joint leading to the
migration of the femoral head towards the medial sourcil
l medial – inferomedial migration of the femoral head with associated medial and inferior joint
space loss
l concentric – joint space loss, which resulted in a relatively even width of the intra-articular joint space
between the femoral head and acetabulum superolaterally to medially
l none – no definite joint space loss, across a regional area, between the femoral head and acetabulum.
Radiograph scoring
Two readers with expertise in radiographic assessment of OA and joint morphology graded all COASt hip
radiographs. Preparation consisted of several weeks of intensive training, in which test sets of hip
radiographs were graded independently by each reader and then compared. Additional training and
adjudication of discrepancies identified from grading the test data set were provided by a consultant
rheumatologist with expertise in radiographic hip OA. Official reproducibility was evaluated using 50
radiographs randomly selected from a population-based cohort (the Chingford study247) reflecting the full
range of radiographic disease (as assessed by K/L grade). Each reader graded the full set of 50 radiographs
twice, approximately 2 weeks apart, in order to calculate both intra- and interobserver reproducibility.
Methods
We present a numerical description of the variables in the hip and the knee COASt data sets. For the
hip data set, we separately considered data from the patients who completed and returned all forms
(550 patients, forming the complete data set) and those who completed and returned, at minimum, the
1-year follow-up form (1098 patients, forming the incomplete data set). The two data sets were summarised
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to examine any pattern of missing data. Graphical methods were used to compare the outcome and
baseline OHS. The knee data set was also split into data from patients who completed and returned all forms
(608 patients) and data from those who completed and returned, at minimum, the 1-year follow-up form
(1025 records). However, the knee data set suffered from a substantial number of missing data. For example,
608 patients returned all the forms, but only 182 patients provided complete information on all the variables
that are required for validation of the knee model. Both the 608 and 1025 record data sets were also
summarised to examine the missing data patterns in the data sets.
The coefficient of determination (R2) was used to quantify the goodness of fit of both models. R2 is
computed by comparing the sum of squares from the regression line with the sum of squares from a
model defined by the null hypothesis. For external validation, the R2 of prediction is given as:
R2 = 1−∑
n
i=1(Yi− Y^ l)
2
∑ni=1(Yi − Y )
2
,
(2)
where Y is the arithmetic mean of the dependent variable in the data used to develop the model, Yi is the
predicted value and Y^ i is the observed value from the validation data set. An approximate approach is to
calculate the multiple R2 of Yi and Y^ i. We used this approximate approach as Y may not be readily
available in practice.
In addition to R2, the calibration of the hip and knee models on the COASt data sets was assessed at the
tenths of the predicted values, obtained from the developed models. The ratio of the mean of the observed
and predicted scores was compared within each tenth. A ratio close to 1 signified that the observed and
predicted scores were in agreement. We also plotted the observed and predicted scores. The calibration
slope was used to assess the degree of agreement between the observed outcomes and predicted values
(from the prediction models).
Although the hip and knee COASt data sets included complete data for most of the baseline variables, some
important variables had missing values. We used predictive mean matching to impute missing values in the
COASt data sets. This method is similar to regression, except, for each missing value, it randomly imputes a
value from a set of observed values whose predicted values are closest to the predicted value for the missing
value from the simulated regression model. We used single imputation to validate the predictive mean
matching. In single imputation, a single-imputed data set is taken from a multiply imputed data set. We
used the first imputed data set created from 10 multiply imputed data sets. Although single imputation is
not the most efficient method for variable selection in the presence of missing data, it maintains the
convenience of dealing with a single data set. It also avoids the inefficiency of the complete-case approach.
We assessed whether or not the hip and knee models could be improved by adding additional variables.
We evaluated the improvement after adding each new variable singly and jointly. We used bootstrapping
for internal validation, as it assesses and quantifies overfitting. We used 300 bootstrap samples to quantify
possible overfitting in the improved hip and knee models.
Results
Part 1: Clinical Outcomes in Arthroplasty Study hip model
Numerical description of the hip Clinical Outcomes in Arthroplasty Study data
Table 82 shows the characteristics of the COASt participants for all the variables that were required for
validating the COASt hip model. The data set included 550 complete records and 1098 incomplete
records. Patient factors included the baseline and outcome OHS values, age, BMI, the level of education
attained (education) and a surrogate for the SF-36 mental health score. Three radiographic variables were
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TABLE 82 Numerical description of the COASt variables and outcome used to validate the hip model
Variables and outcome
Data set
% missingComplete (N= 550) Entire (N= 1098)
Mean OHS (SD) at 12 months 41.06 (8.96) 41.20 (8.56) 5.7
Predictors
Mean baseline OHS (SD) 18.63 (8.05) 19.35 (6.70) 12.0
Mean age in year (SD) 68.23 (10.36) 67.97 (10.93) 0
Mean BMI (SD) 27.97 (3.88) 28.13 (5.00) 0
Education attainment, n (%) 24.4
None 192 (34.9) 320 (38.6)
O level 44 (8.0) 64 (7.7)
A level 38 (6.9) 26 (3.1)
Further education 117 (21.3) 161 (19.4)
Higher education 159 (28.9) 259 (31.2)
SF-36 (surrogate for mental health), n (%) 21.0
Yes 125 (22.7) 416 (48.0)
No 425 (77.3) 451 (52.0)
Superomedial, n (%) 48.9
None 49 (8.9) 50 (8.9)
Concentric 184 (33.5) 189 (33.7)
Medial 131 (23.8) 132 (23.5)
Superomedial 48 (8.7) 49 (8.7)
Superolateral 138 (25.1) 141 (25.1)
Arthritis, n (%) 23.0
Yes 396 (72.0) 603 (71.3)
No 154 (28.8) 243 (28.7)
Mean surgery (SD) 0.07 (0.26) 0.07 (0.26) 24.4
Posterior, n (%) 11.5
Hardinge 109 (19.8) 192 (19.8)
Posterior 440 (80.0) 779 (80.1)
Other 1 (0.2) 1 (0.1)
Mean stem size (SD) 40.25 (4.15) 40.25 (4.15) 11.6
New variables
Mean C-reactive protein (SD) 5.21 (7.77) 5.21 (7.77) 40.7
K/L grade, n (%) 48.9
0 3 (0.9) 3 (0.5)
1 5 (1.4) 5 (0.9)
2 28 (8.0) 29 (5.2)
3 135 (38.6) 136 (24.2)
4 179 (51.0 388 (69.2)
A level, advanced level; O level, ordinary level.
Complete data set, 550 records and entire data set, 1098 records.
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included: the OA pattern (superomedial), the presence of arthritis in other joints (arthritis) and surgery in
other joints (surgery). Two surgical variables were included: which posterior surgical approach was used
(posterior) and stem size. Model improvements were assessed by adding variables measuring the level of
C-reactive protein and the K/L grade.
The complete and incomplete data sets in Table 83 have similar distributions, as they had similar ranges,
means and SDs for each variable. The number of missing data in the radiographic variable superomedial
was high (48.91%). The two additional variables, C-reactive protein and K/L grade, also had a high
number of missing data (40.71% and 48.91%, respectively). It is therefore not surprising that these
variables had identical distributions in the complete and incomplete data sets.
We also compared additional general patient factors between the complete and incomplete data sets
(see Table 83). Apart from sex, the number of missing data was similar across all of the factors examined.
TABLE 83 Numerical description of the additional variables used that were not included in the COASt hip model
(complete and incomplete records)
Variable
Data set, n (%)
% missingComplete (N= 550) Entire (N= 1098)
Sex 0
Male 219 (39.8) 445 (40.5)
Female 331 (60.2) 653 (59.5)
Smoking 20.6
Yes 42 (7.6) 68 (6.2)
No 508 (92.4) 804 (73.2)
Alcoholism 20.8
Yes 7 (1.3) 12 (1.1)
No 543 (98.7) 858 (78.1)
Anxiety 21.7
Yes 68 (12.4) 101 (9.2)
No 482 (87.6) 759 (69.1)
Depression 21.04
Yes 97 (17.6) 153 (13.9)
No 453 (82.4) 714 (65.0)
Fractures 23.0
Yes 234 (42.6) 368 (33.5) 21.1
No 316 (57.5) 498 (45.4)
Back pain 22.0
Yes 219 (39.8) 367 (33.4)
No 331 (60.2) 489 (44.5)
OA 23.0
Yes 396 (72.0) 603 (54.9)
No 154 (28.0) 243 (22.1)
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TABLE 83 Numerical description of the additional variables used that were not included in the COASt hip model
(complete and incomplete records) (continued )
Variable
Data set, n (%)
% missingComplete (N= 550) Entire (N= 1098)
RA 22.4
Yes 38 (6.9) 55 (5.0)
No 512 (93.1) 797 (72.6)
Diabetes 20.8
Yes 38 (6.9) 66 (6.0)
No 512 (93.1) 804 (73.2)
Hypertension 21.9
Yes 239 (43.5) 367 (33.4)
No 311 (56.6) 491 (44.7)
Gout 21.7
Yes 36 (6.6) 58 (5.3)
No 514 (93.5) 802 (73.0)
Osteoporosis 23.5
Yes 47 (8.6) 73 (6.7)
No 503 (91.5) 767 (69.9)
High cholesterol 22.0
Yes 154 (28.0) 251 (22.9)
No 386 (70.2) 606 (55.2)
Bowel 21.6
Yes 147 (26.7) 251 (22.9)
No 403 (73.3) 610 (55.6)
Renal 21.1
Yes 31 (5.6) 45 (4.1)
No 519 (94.4) 821 (74.8)
Ethnicity 18.4
British 526 (95.6) 836 (76.1)
Irish 9 (1.6) 11 (1.0)
Any other white 10 (1.8) 12 (1.1)
White and black Caribbean 2 (0.2)
White and black African 14 (1.3)
White and Asian 1 (0.2) 13 (1.2)
Any other mixed background 2 (0.4) 5 (0.5)
Indian 2 (0.2)
Pakistani 1 (0.2) 1 (0.1)
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The numerical exploration of the arthritis and examination variables, questionnaire scores and 12-month
follow-up measures in the hip data set are presented in Appendix 13, Tables 105 and 106.
We imputed the incomplete data (1098 records) using MICE, as described in Methods. Figure 48 shows
the correlation matrix for the outcome variable and some of the continuous variables in the hip data set.
The correlations between the outcome and the surgery, stem size and C-reactive protein variables were
not significant (p = 0.313, 0.072 and 0.317, respectively) in the model using the complete data set;
however, these variables were significant in the model using the imputed data set. In the case of stem size,
this was explained by increasing statistical power, whereas for the other two variables, there were also
increases in the correlation coefficient suggesting an actual change in the association measured.
Statistical analysis of hip replacement surgery
We carried out model validation using both the complete and incomplete data sets. We used multiple
imputation to ‘fill in’ the missing observations in the incomplete data set, as discussed in Methods. The
rationale for using multiple imputation to fill in the missing data is not to gain power from having
increased sample size but to be able to show if there are systematic differences in the predictive
performances of the models validated using the complete and the completed data sets. We will expect
that if the assumption underlying the missing data is ‘true’, then the imputed data set should outperform
the complete data set in terms of predictive accuracy. Otherwise, the missing data have a distribution
different from the observed data.
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FIGURE 48 Correlation matrix plot for (a) the complete; and (b) imputed hip data sets. (continued )
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The model to predict the OHS at 12 months is defined as:
12-month OHS = 28:5 + patient factors + radiographic factors + surgical factors, (3)
where
Patient factors = ½(0:22 × baseline OHS)− (0:20 × age)− (0:13 × BMI)
+ (2:08 × college or university education)
+ (0:07 × SF-36 mental component summary score),
(4)
Radiographic factors = ½− (1:44 × OA pattern)− (1:11 × arthritis in other joints)
− (0:78 × surgery in other joints),
(5)
Surgical factors = f+ ½2:42 × posterior surgical approach) + 0:18 × stem size (mm offset)½ g. (6)
These variables were identified in the validation data set. The baseline OHS was computed after rescaling
the score to the range from 0 to 48. The outcome was computed using the same method. The SF-36
questionnaire was used to measure mental health in the model development data set. However, the
(b)
outcome_OHS
-10 20 50
r = 0.27
p < 0.001
r = 0.088
p = 0.003
30 40 50
r = 0.086
p = 0.004
r = 0.095
p = 0.002
0 1 2 3 4
r = 0.18
p < 0.001
baseline_OHS
r = 0.0098
p = 0.746
r = 0.11
p < 0.001
r = 0.12
p < 0.001
r = 0.037
p = 0.225
surgery
r = 0.012
p = 0.686
r = 0.018
p = 0.545
r = 0.23
p < 0.001
stem
r = 0.034
p = 0.263
r = 0.0067
p = 0.825
C_reactive_Protein
r = 0.013
p = 0.668
10 30 0.0 1.0 2.0 0 40 80
KL_grade
30
10
2.0
1.0
0.0
80
40
0
50
20
– 10
50
40
30
4
3
2
1
0
FIGURE 48 Correlation matrix plot for (a) the complete; and (b) imputed hip data sets.
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COASt did not collect this score. We used a surrogate score; a positive value was assigned if the patient
reported being treated for anxiety or depression, or if they scored 2 or 3 units on the mental health
component of the EQ-5D.
We assessed the performance of the model by evaluating calibration and discrimination (Table 84), as
described in the Methods section.
The distribution of the observed scores is not identical to the predicted scores, as can easily be seen in
Figure 49, which shows density plots of the observed and predicted scores using the complete records.
TABLE 84 Calibration and discrimination of the validated hip model using the complete data set
Tenths of the predicted OHS
OHS
Observed Predicted Observed : predicted
14.2–19.6 37.62 17.90 2.10
19.6–21.8 39.07 20.66 1.89
21.8–23.6 38.31 22.73 1.69
23.6–25.5 40.58 24.62 1.65
25.5–27 42.09 26.21 1.61
27–28.7 42.21 27.79 1.52
28.7–30.1 42.53 29.44 1.45
30.1–31.7 41.43 30.86 1.34
31.7–34.4 44.38 32.91 1.35
34.4–44.7 42.46 36.70 1.16
R2 0.042
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FIGURE 49 Density plot of the observed and predicted scores for the hip data using the complete data set.
(a) Observed OHS; and (b) predicted OHS.
WORK PACKAGE 4: EXTERNAL VALIDATION OF THE TOOL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
148
Figure 50 shows the baseline OHS and absolute change in OHS. We have computed the change in score
as a difference between observed and the baseline scores.
The model also had poor discriminatory ability (R2 = 4.2%), which was substantially less than that achieved in
the original model from work package 2. Model calibration was also generally unacceptable (see Table 84
and Figure 43), with the model generally predicting a worse outcome than seen in the observed data. This
was particularly true for the lowest deciles of outcome, for which the predicted scores were very substantially
less. These are the exact patients that we would want to model to predict accurately.
The calibration plot in Figure 51 graphically illustrates poor agreement between the observed OHS at
12 months and the predicted 12-month OHS from the prediction model.
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FIGURE 50 Histograms of the outcome using (a) baseline; and (b) absolute change in the OHS, using the complete
data set (550 records).
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FIGURE 51 Calibration plot of the validated hip model using the complete data set.
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Figure 52 shows the density plots of the observed and predicted scores using the complete records. The
distribution of the observed scores is bimodal, whereas the distribution of the predicted scores is unimodal.
We also examined the model performance using imputed data (1098 records). The discrimination and
calibration of the predicted model was worse than that using the complete data set. Table 85 shows the
observed and predicted OHSs at 12 months by tenths of predicted OHS. The R2 value of the model using
imputed data was 3.4%, which was smaller than that using the complete data set (4.2%). This result is
supported by the calibration plot in Figure 53.
TABLE 85 Calibration and discrimination of the validated hip model using the imputed data: validated COASt data
Tenths of the predicted OHS
OHS
Observed Predicted Observed : predicted
9.04–16.6 38.04 14.53 2.62
16.6–18.8 39.79 17.71 2.25
18.8–20.6 39.03 19.72 1.98
20.6–22.5 40.32 21.55 1.87
22.5–24.4 41.44 23.40 1.77
24.4–26.2 41.63 25.22 1.65
26.2–27.9 41.97 27.04 1.55
27.9–29.7 41.58 28.79 1.44
29.7–32.2 43.28 30.90 1.40
32.2–42.0 43.59 34.26 1.27
R2 0.034
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FIGURE 52 Density plot of the (a) observed; and (b) predicted scores for the hip data using the complete data set.
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Statistical analysis of the incremental value of the hip model predictors
We examined the performance of the hip prediction model by evaluating the improvement in its predictive
ability when additional predictors (listed below) that were not initially considered for inclusion in the model
were added:
1. C-reactive protein (mg/l) [bi_preop_crp_mg_lt]
2. K/L grades to assess OA severity [xr_preop_kellgren_and_lawrence].
We used the model based on the complete data set, as its validation performance was better than the
model based on the imputed data set.
An OLS regression was predicted to the COASt data set using variables identified as appropriate surrogates
for the variables in the original data. The C-reactive protein and K/L grades variables were added singly
and jointly to see if they would improve the model. Table 86 shows the uncorrected and corrected multiple
R2 values. The corrected R2 was based on 300 bootstrap samples used to estimate optimism because of
possible overfitting.
As noted from Figure 48a, the correlation between the C-reactive protein variable and the outcome was
not significant (r = 0.043, p = 0.317). It added noise and did not improve the model (corrected R2 = 0.108).
The K/L grades variable was significantly associated with the outcome variable and improved the model’s
predictive performance from 0.110 to 0.125. Adding both new variables did not improve the model’s
predictive ability further.
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FIGURE 53 Calibration plot of the validated hip model using the imputed data.
TABLE 86 Corrected and uncorrected R2 for the variables added to the COASt hip model
R2 Original variables C-reactive protein added K/L grades added
C-reactive protein and
K/L grades added
Uncorrected 0.144 0.144 0.164 0.164
Corrected 0.110 0.108 0.125 0.125
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
151
We therefore formally assessed a model that included the additional K/L grades variable:
Predicted OHS = 28:786 + patient factors + radiographic factors + surgical factors
+K/L grades,
(7)
where:
Patient factors = (0:284 × baseline OHS) + (0:013 × age)− (0:254 × BMI)
+ (0:418 × college or university education)
− (1:428 × surrogate for the SF-36mental component summary score),
(8)
Radiographic factors = (0:216 × OA pattern) + (0:270 × arthritis in other joints)
− (0:586 × surgery in other joints),
(9)
Surgical factors = (1:098 × posterior surgical approach)
+ 0:085 × stem size (mm offset)½  + 2:044 × (xr preop).
(10)
Table 87 shows the model calibration and discrimination. The R2 value (12.5%) showed a significant
improvement over the R2 from the validation process (4.2%), but was lower than the original R2 (23.1%).
In terms of calibration, the ratio of the observed and predicted scores within the tenth of the predicted
OHSs was close to 1 within each of the tenths, showing good agreement between the scores across all
tenths of predicted OHS. In general, this model did not improve the performance of the original model
developed by developed by Judge et al.138 Figure 54 shows the density plot of the predicted ‘improved’ hip
model. The distribution of the predicted scores behaved better than the predicted scores in Figure 52.
In terms of calibration, the ratio of the observed and predicted scores within the tenth of the predicted
OHSs was close to 1 within each of the tenths, showing good agreement between the scores across all
tenths of predicted OHS. In general, this model did not improve the performance of the original model
developed by Judge et al.138 Figure 54 shows the density plot of the predicted ‘improved’ hip model.
The distribution of the predicted scores behaved better than the predicted scores (see Figure 52).
Table 88 shows the associations between the outcome variable and the variables in the improved OHS
COASt model. The variables education attainment, superomedial, arthritis in other joints, stem size and
posterior surgical approach did not have significant effects at 0.157. Backward selection with a p-value
threshold of 0.157 was used to choose variables for this model.
TABLE 87 Calibration and discrimination of the improved model using the hip COASt data
Tenths of the predicted OHS
OHS
Observed Predicted Observed : predicted
31.2–36.3 34.16 34.54 0.99
36.3–38 35.92 37.20 0.97
38–39.1 38.23 38.51 0.99
39.1–40.3 40.95 39.71 1.03
40.3–41.2 40.89 40.77 1.00
41.2–42.2 43.01 41.65 1.03
42.2–43.2 43.40 42.68 1.02
43.2–44.2 42.67 43.67 0.98
44.2–45.5 44.42 44.80 0.99
45.5–49.7 46.66 46.97 0.99
R2 0.125
WORK PACKAGE 4: EXTERNAL VALIDATION OF THE TOOL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
152
Part 2: Clinical Outcomes in Arthroplasty Study knee model
Numerical description of the knee Clinical Outcomes in Arthroplasty Study data
Table 89 shows the variables that were required for validating the COASt knee model. The two incomplete
data sets contained 608 and 1025 records, and both suffered from a large number of missing data. The
patient factors included the baseline and outcome OKSs, age, sex, IMD 200453 score, BMI and a surrogate for
the SF-12 mental health score. Three clinical factors were included: (1) the presence of other conditions
affecting mobility; (2) a binary variable measuring whether or not knee surgery had previously occurred; and
(3) the ASA grade, which categorises patients as fit and healthy, asymptomatic on restriction or symptomatic
with minimal/severe restriction. The presence of other conditions affecting mobility was collected as a binary
variable that measured whether or not a patient suffered from RA, gout, inflammatory joint disease, avascular
necrosis, Paget’s disease, childhood conditions, multiple sclerosis, Parkinson’s, neurological problems, back
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FIGURE 54 Density plot of the predicted scores for the improved model using the hip data.
TABLE 88 Linear regression models for the OHS COASt data with one additional variable
Predictor variables
(reference category)
Overall Imputed
Complete case (n= 550) (standard error) Hip data (n= 1098) (standard error)
Intercept 28.79 36.31
Baseline (OHS) 0.28 (0.05)* 0.23 (0.03) *
Age (years) 0.01 (0.04) –0.04 (0.02)**
BMI (kg/m2) –0.25 (0.08)* –0.20 (0.05)*
Education 0.42 (0.22) 0.20 (0.15)
SF-36 mental health score –1.43 (0.87)** –1.67 (0.50)*
Superomediala 0.22 (0.29) 0.23 (0.19)
Arthritis in other joints 0.27 (0.80) –0.57 (0.54)
Surgery in other joints –0.59 (1.39) –1.61(0.91)**
Posterior 1.10 (0.88) 0.44 (0.61)
Stem size (mm offset) 0.09 (0.09) 0.11 (0.06)
K/L grade 2.04 (0.57)* 1.89 (0.37)*
*p < 0.001; **p< 0.157.
a OA pattern (superomedial, medial or concentric). A positive value indicates that the group has better postoperative
pain/function.
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TABLE 89 Numerical description of the COASt variables used to validate the knee model (incomplete data set,
608 records and the entire data set, 1025 records)a
Variable
Data set
Incomplete (N= 608) Entire (N= 1025)
Outcome
Incomplete
data set % missing
Entire data
set % missing
Mean OKS (SD) at 12 months 37.46 (9.74) 6.1 37.49 (9.64) 6.6
Predictors
Mean baseline OKS (SD) 20.31 (7.69) 3.1 9.33 (6.68) 7.8
Mean age in year (SD) 68.71 (9.12) 0 68.78 (9.36) 0
Sex, n (%) 0 0
Male 274 (45.1) 456 (44.5)
Female 334 (54.9) 569 (55.5)
Mean IMD 200453 score (SD) 11.62 (8.24) 0 11.88 (8.63) 0.3
Mean BMI (kg/m2) (SD) 30.52 (5.43) 0 30.34 (5.27) 0
SF-12 (surrogate for mental health), n (%) 2.3 11.6
Yes 141 (23.2) 381 (37.2)
No 453 (74.5) 525 (51.2)
ASA grade, n (%) 0.8 11.9
Fit 94 (15.5) 131 (12.8)
Asymptomatic 421 (69.2) 633 (61.8)
Symptomatic 88 (14.5) 88 (8.6)
Factors affecting mobility, n (%) 6.4 6.5
Yes 340 (55.9) 537 (52.4)
No 229 (37.7) 421 (41.1)
Previous knee surgery, n (%) 2.8 12.4
Yes 85 (14.0) 122 (11.9)
No 506 (83.2) 776 (75.7)
Fixed flexion deformity, n (%) 48.9 34.9
Yes 176 (29.0) 489 (47.7)
No 135 (22.2) 178 (17.4)
Preoperative deformity, n (%) 51.6 36.5
Normal 75 (12.3) 102 (10.0)
Valgus 93 (15.3) 105 (10.2)
Varus 126 (20.7) 444 (43.3)
ACL, n (%) 8.9 34.7
Intact 419 (68.9) 513 (50.1)
Damage 123 (20.2) 141 (13.8)
Absent 12 (2.0) 15 (1.5)
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pain, sciatica or joint contracture. Three surgical factors were also included in the model, measuring the
presence of a fixed flexion deformity, preoperative deformity (derived from the American Knee Society Score
Left Knee alignment and classified as normal, valgus or varus) and the state of the ACL (intact, damaged or
absent). The C-reactive protein variable was, again, used to assess possible model improvements.
We also explored additional general patient factors, shown in Table 90. Again, the COASt knee data set
with 1025 records had more missing data than the 608-record data set. Our numerical exploration of the
arthritis and examination variables, questionnaire scores and 12-month follow-up measures in the knee
data are presented in Appendix 13, Tables 107 and 108.
TABLE 89 Numerical description of the COASt variables used to validate the knee model (incomplete data set,
608 records and the entire data set, 1025 records)a (continued )
Variable
Data set
Incomplete (N= 608) Entire (N= 1025)
Outcome
Incomplete
data set % missing
Entire data
set % missing
New variable, n (%)
Mean C-reactive protein (mg/l) (SD) 6.13 (12.37) 25.7 5.90 (11.27) 37.6
a Comparing data sets with 608 and 1025 records in Table 123 shows that the severity of missingness was generally more
pronounced in the 1025 record data set than the 608 record data set. For example, 2.3% and 11.61% of the SF-12
mental component summary score variable data were missing in the 608- and 1025-record data sets, respectively. The
preoperative deformity variable had the most missing data (51.64%) in the 608-record data set. The C-reactive protein
variable had the most missing data (37.56%) in the 1025-record data set.
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
TABLE 90 Numerical description of the additional variables used that were not included in the COASt knee model
(incomplete data sets, 608 and 1025 records)
Variable
Data set, n (%)
Incomplete (N= 608) Entire (N= 1025)
Value % missing Value % missing
Smoking 0.2 9.3
Yes 38 (6.3) 59 (5.8)
No 569 (93.6) 871 (85.0)
Alcoholism 1.0 9.8
Yes 8 (1.3) 14 (1.4)
No 594 (97.7) 911 (88.9)
Anxiety 1.0 10.1
Yes 64 (10.5) 104 (10.2)
No 538 (88.5) 818 (79.8)
Depression 1.3 10.2
Yes 124 (20.4) 191 (18.6)
No 476 (78.3) 730 (71.2)
Fractures 1.2 10.0
Yes 264 (43.4) 392 (38.2)
No 337 (55.4) 531 (51.8)
continued
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TABLE 90 Numerical description of the additional variables used that were not included in the COASt knee model
(incomplete data sets, 608 and 1025 records) (continued )
Variable
Data set, n (%)
Incomplete (N= 608) Entire (N= 1025)
Value % missing Value % missing
Back pain 1.7 10.4
Yes 189 (31.1) 307 (30.0)
No 409 (67.3) 611 (59.6)
OA 4.6 13.1
Yes 413 (67.9) 644 (62.8)
No 167 (27.5) 247 (24.1)
RA 3.3 11.6
Yes 61 (10.0) 93 (9.1)
No 527 (86.7) 813 (79.3)
Diabetes 0.5 9.6
Yes 61 (10.0) 99 (9.7)
No 544 (89.5) 828 (80.8)
Hypertension 1.0 10.5
Yes 316 (52.0) 482 (47.0)
No 286 (47.0) 435 (42.4)
Gout 3.0 11.9
Yes 34 (5.6) 63 (6.2)
No 556 (91.5) 840 (82.0)
Osteoporosis 3.6 12.2
Yes 47 (78.3) 78 (7.6)
No 539 (88.7) 822 (80.2)
High cholesterol 2.6 11.5
Yes 189 (31.1) 292 (28.5)
No 403 (66.3) 615 (60)
Bowel 3.5 12.7
Yes 159 (26.2) 260 (25.4)
No 428 (70.4) 635 (62.0)
Renal 1.3 10.0
Yes 32 (5.3) 54 (5.3)
No 568 (93.4) 568 (55.4)
Ethnicity 2.1 8.0
British 581 (97.7) 895 (87.3)
Irish 5 (0.8) 6 (0.6)
Any other white 1 (0.2) 8 (0.8)
White and black Caribbean 1 (0.1)
White and black African 1 (0.1)
White and Asian 1 (0.2) 1 (0.1)
Any other mixed background 2 (0.3) 7 (0.7)
Indian 4 (0.7) 11 (1.1)
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We imputed the two data sets using MICE, as described in Methods. Figure 55 shows the correlation
matrix for the outcome variable and some of the continuous variables in the knee data set. The correlation
between the outcome and C-reactive protein variables was not significant using the 608-record data set,
but was significant using the 1025-record data set. This difference may have been caused by the high
degree of missingness in these variables. The correlations between the baseline OKS and IMD 200453
TABLE 90 Numerical description of the additional variables used that were not included in the COASt knee model
(incomplete data sets, 608 and 1025 records) (continued )
Variable
Data set, n (%)
Incomplete (N= 608) Entire (N= 1025)
Value % missing Value % missing
Pakistani 1 (0.1)
Bangladeshi 2 (0.2)
Any other Asian background 1 (0.2) 6 (0.6)
Caribbean 2 (0.2)
Chinese – 1 (0.1)
Any other ethnic group – 1 (0.1)
outcome_OKS
r = 0.34
p < 0.001
r = 0.026
p = 0.723
r = 0.22
p = 0.003
r = 0.19
p = 0.009
r = 0.034
p = 0.65
baseline_OKS
r = 0.033
p = 0.663
r = 0.23
p = 0.001
r = 0.11
p = 0.133
r = 0.047
p = 0.525
age
r = 0.26
p < 0.001
r = 0.048
p = 0.522
r = 0.088
p = 0.238
bmi
r = 0.18
p = 0.015
r = 0.066
p = 0.374
IMD
r = 0.12
p = 0.114
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FIGURE 55 Correlation matrix plot for the incomplete knee data sets with (a) 608 records; and (b) 1025 records.
(continued )
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score and C-reactive protein variables were also not significant using the 608-record data set, but were
significant using the 1025-record data set. This difference may have been caused by the degree of missing
data in the variables and, more importantly, by the distribution of the baseline OKS variable in the two
data sets (the baseline OKS variable was 20.31 units and 9.33 units for the 608- and 1025-record data
sets, respectively; see Tables 84 and 85).
Statistical analysis of knee replacement surgery
We validated the model using both incomplete knee data sets. To improve the statistical power of the
validation, we imputed the missing values using MICE and predictive mean matching.
The predicted 12-month OKS is:
Predicted 12-month OKS = 20:70 + patient factors + clinical factors + surgical factors, (11)
where:
Patients factors = 4:50 × (age 60−69 years) + 4:31 × (age 70−79 years) + 7:80
×(age ≥ 80 years)−4:57 × (sex) + 0:74 × (preoperative OKS)−0:05
×(IMD score)−0:15 × (BMI) + 0:09
×(SF-12 mental component summary score),
(12)
outcome_OKS
r = 0.33
p < 0.001
r = 0.032
p = 0.307
r = 0.21
p < 0.001
r = 0.13
p < 0.001
r = 0.17
p < 0.001
baseline_OKS
r = 0.038
p = 0.224
r = 0.22
p < 0.001
r = 0.12
p < 0.001
r = 0.15
p < 0.001
age
r = 0.21
p < 0.001
r = 0.092
p = 0.003
r = 0.031
p = 0.328
bmi
r = 0.15
p < 0.001
r = 0.056
p = 0.071
IMD
r = 0.015
p = 0.623
10 30 30 60 90 0 20 50
C_reactive_Protein
0
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FIGURE 55 Correlation matrix plot for the incomplete knee data sets with (a) 608 records; and (b) 1025 records.
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Clinical factors = 0:00 × (asymptomatic no restriction ASA grade)−2:60
×(symptomatic minimal/severe restriction ASA grade)−2:94
×(presence of other condition affecting mobility)−1:66
×(previous knee surgery),
(13)
Surgical factors = 1:50 × (presence of fixed flexion deformity)−1:65
×(no valgus/varus deformity) + 0:00 × (valgus deformity)
+1:50 × (absent preoperative ACL) + 0:00 × (damaged preoperative ACL).
(14)
Details of the model, including the variable interpretations, can be found in Sánchez-Santos et al.142
These variables were identified in the validation data set. We computed the baseline OKS using the
self-assessment questions sa_OKS_1 to sa_OKS_12. The model development data set had value ranges of
0 to 4 for these variables, whereas the COASt data set had value ranges of 1–5. We therefore rescaled the
composite score as 60 – (sa_OKS_1 +sa_OKS2 +. . .+ sa_OKS_12), allowing the score to lie in the range
0–48. We formed appropriate subvariables for the age category in the original model. The categorical
variable groups in the model were formed using the ‘factor’ function in the R statistical software package
(The R Foundation for Statistical Computing, Vienna, Austria) and included in the R base function
‘formula’. We gave the variable categories not included in the model zero coefficients during validation.
The SF-12 questionnaire score was used to measure mental health in the model development data set.
However, this score was not collected in COASt. We used a surrogate score that assigned a positive value
if a patient reported being treated for anxiety or depression, or scored 2 or 3 on the mental health
component of the EQ-5D.
The model performance was assessed using calibration and discrimination (Table 91), as described in the
methodology. Model calibration was generally poor and was worse in the lower deciles of the OKS. The
model had good discriminatory ability (R2 = 14.1%) as the original model had a discriminatory ability
of 20.2%.
TABLE 91 Calibration and discrimination of the validated knee model using the 608-record data set with imputed
data: validated COASt data
Tenths of the predicted OKS
OKS
Observed Predicted Observed : predicted
10.8–20.9 29.63 18.39 1.61
20.9–23.6 35.89 22.51 1.59
23.6–26.3 34.67 25.04 1.39
26.3–28.9 35.89 27.48 1.31
28.9–31 38.14 30.08 1.27
31–32.8 37.42 31.94 1.17
32.8–34.7 37.92 33.77 1.12
34.7–36.9 41.11 35.79 1.15
36.9–39.6 40.40 38.20 1.06
39.6–51 44.10 42.39 1.04
R2 0.141
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We also examined the model performance using the 1025-record data set (Table 92). The calibration and
the discrimination measures were poorer than the data set with 608 records.
The calibration plot in Figure 56 shows that the model performed better at the upper deciles. The model
had good discriminatory ability (R2 = 14.1%); however, this is still less than the original model (R2 = 20.2%).
As with the hip model, model calibration was also generally unacceptable, with the model generally
predicting a worse outcome than seen in the observed data. This was particularly true for the lowest deciles
of outcome, for which the predicted scores were very substantially less, and this is the area of greatest
interest.
Figure 57 shows the density plots of the observed and predicted knee data scores, which form a mixture
of two distributions with different variances.
TABLE 92 Calibration and discrimination of the validated knee model using the 1025-record data set with
imputed data
Tenths of the predicted OKS
OKS
Observed Predicted Observed : predicted
6.17–15 32.60 12.29 2.65
15–17.8 33.65 16.55 2.03
17.8–19.8 35.15 18.73 1.88
19.8–21.5 35.73 20.70 1.73
21.5–23 36.99 22.23 1.66
23–24.7 39.58 23.86 1.66
24.7–26.2 37.94 25.41 1.49
26.2–28.3 39.97 27.29 1.47
28.3–31.2 40.79 29.63 1.38
31.2–52.3 43.01 34.49 1.25
R2 0.103
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FIGURE 56 Calibration plot of the validated knee model using the 608-record data set.
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Figure 58 shows the baseline OKS and absolute change in OKS. We computed the change in score as a
difference between the observed and baseline scores.
Statistical analysis of the incremental value of a knee data set predictor
As the model performed better with the 608-record data set than with the 102-record data set, we used
the smaller data set to assess the possible benefits of adding an additional variable to the original knee
model. We examined the model performance by evaluating the improvement in model predictions after
adding the C-reactive protein variable (mg/l) [bi_preop_crp_mg_lt] as an additional predictor.
We predicted an OLS regression to the COASt knee data using the original variables and the C-reactive
protein variable. We calculated the corrected R2 value using 300 bootstrap samples estimating optimism
because of possible overfitting. Table 93, showing the corrected and uncorrected multiple R2 values, shows
that the addition of the C-reactive protein variable improved the model’s discrimination ability from 21.6%
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FIGURE 57 Density plot of the (a) observed; and (b) predicted OKS using the 608-record data set.
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FIGURE 58 Histograms of the (a) baseline; and (b) absolute change in the OKS, using the 608-record data set with
imputed data.
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to 23%. Both discrimination values were higher than those calculated for the original development data
set. Table 94 shows that the model was well calibrated, as the ratio of the observed and predicted scores
was close to 1 for all of the deciles. Figure 59 shows the density plot of the predicted scores for the
improved knee model.
The improved predicted OKS model is:
Improved predicted 12-month OKS = 40:95 + patient factors + clinical factors
+ surgical factors−0:090 × (C-reactive protein),
(15)
where:
Patient factors = −1:90 × (age 60−69 years)−1:95 × (age 70−79 years)−2:05
× (age ≥ 80 years) + 0:40 × (sex) + 0:34 × (preoperative OKS)−0:05
× (IMD score)−0:24 × (BMI)−1:71 × (SF-12 mental health score),
(16)
Clinical factors = −0:67 × (asymptomatic no restriction ASA grade)−1:90
× (symptomatic minimal/severe restriction ASA grade)−1:97
× (presence of other condition affection mobility)−2:28
× (previous knee surgery),
(17)
Surgical factors = −1:11 × (presence of fixed flexion deformity) + 2:59
× (no valgus/varus deformity) + 4:45 × (valgus deformity) + 0:77
× (absent preoperative ACL)−3:76 × (damaged preoperative ACL).
(18)
TABLE 93 Corrected and uncorrected R2 on adding the C-reactive protein variable to the COASt knee model
R2 Original variable C-reactive protein variable added
Uncorrected 0.259 0.277
Corrected 0.216 0.230
TABLE 94 Calibration and discrimination of the improved model using the knee COASt data
Tenths of the predicted values
Mean score
Observed Predicted Observed : predicted
17.6–31 26.71 28.51 0.94
31–33.3 33.02 32.29 1.02
33.3–34.9 33.14 34.12 0.97
34.9–36.5 36.85 35.89 1.03
36.5–37.6 37.69 36.98 1.02
37.6–39.1 39.03 38.33 1.02
39.1–40.6 41.43 39.71 1.04
40.6–41.9 41.52 41.29 1.01
41.9–43.7 41.75 42.83 0.98
43.7–52.4 44.43 45.62 0.97
R2 0.230
WORK PACKAGE 4: EXTERNAL VALIDATION OF THE TOOL
NIHR Journals Library www.journalslibrary.nihr.ac.uk
162
Appendix 13, Table 120, shows the association between the variables in the improved OKS COASt model
and the outcome. Sex and the IMD 200453 score did not have a significant effect at 0.157. Backward
selection with a p–value threshold of 0.157 was used to select the variables retained in the knee model.
Absolute differences between baseline and the 12-month
follow-up Oxford scores
Table 95 shows the (absolute) difference between the mean score at baseline and at the 12-month follow-up
for both the hip and the knee data sets. The average score showed improvement in the outcome of the
patients in the complete record data sets and the entire data sets. The baseline average score for the entire
knee data set is 9.33 units, which is far smaller than its counterparts in the complete-record data set
(20.31 units).
Patient expectation and outcome
Table 96 shows patients’ expectations and outcomes. For both the complete and the entire data sets,
and for the hip and the knee scores, patients were very satisfied with their outcomes. The percentage of
dissatisfied patients ranges between 1.8% and 2.0%.
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FIGURE 59 Density plot of the predicted scores for the improved knee model.
TABLE 95 Absolute difference between baseline and the 12-month scores for the OHS and OKS
OHS/OKS
Mean score
Absolute differenceBaseline 12-month follow-up
Complete OHS data with 550 records and OKS with 608 records
OHS 18.63 41.06 22.43
OKS 20.31 37.46 17.15
Entire data sets
OHS 19.35 41.20 21.85
OKS 9.33 37.49 28.16
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Discussion
This work package evaluated the performance of models produced in work package 2, designed to predict
PROMs following THR and TKR at 12 months. In order to do this, we recruited a large cohort of patients
from two hospitals with a wide variety of data and samples collected. This is the most comprehensive
cohort of arthroplasty patients collected to date. Neither model performed well in the validation cohort.
However, when the variables from the models were used to produce a new model within the validation
cohort, the performance improved, especially for the knee model. However, the models still did not reach
the same levels of performance as the development models. Both models performed poorly in the lower
deciles of outcome, which is unfortunately the area in which, for clinical utility, they would need to
perform well.
There are many reasons why the models did not perform well in the validation cohort, which include the
difference in patient characteristics, the different surgical techniques and the implants used in the
development and the validation cohorts, the degree of imputation used in both the development and
validation cohort, and the exact definition of the variables used in the development and validation cohorts.
When accessing the performance of the predictive model in a new cohort, it is extremely important to
evaluate the comparability of the two cohorts in question. The model can fail to perform well in a new
cohort because of limitations of the model itself or, more commonly, because of significant differences in
the new population. If the population is identical, then a poor performance would imply a failure of
validation of the model; however, if the population is significantly different, this could reflect a failure of
transportation. There are several important differences between the development and the validation cohorts
in the study. In the case of the hip replacement model, the developmental cohorts used were EUROHIP and
EPOS; EUROHIP is a pan-European cohort and EPOS was a RCT, both of which will introduce potential
issues related to case mix. Furthermore, the development cohorts were collected between 10 and 20 years
ago, when surgical implants and techniques were very different than those used today and will vary across
the contributing European sites in the EUROHIP cohort. In addition, patient selection has also changed, with
increasing provision of THRs to the older population with more comorbidities and also to younger, more
active patients. This is demonstrated by the validation cohort having a higher BMI, being older than the
EUROHIP cohort but younger than the EPOS cohort and having a higher proportion of patients with severe
radiographic OA (K/L grade 4). These factors would certainly mean that the development and validation
cohorts were very different in nature, which may explain some of the reduced performance of the model.
To produce the knee predictive model, we used the data from KAT, which was a RCT of knee replacement
and would have involved a different population from those attending the two hospitals through the NHS
system. This is demonstrated by the validation cohort being younger and including a lower proportion of
patients with a valgus deformity, a lower proportion of patients with an ASA grade of symptomatic and a
TABLE 96 Patient expectation and outcome
Joint
Data set, n (%)
Complete Entire
Hip 1. Very satisfied, 446 (79.2)
2. Somewhat satisfied, 62 (11.0)
3. Neither satisfied nor dissatisfied, 22 (3.9)
4. Somewhat dissatisfied, 22 (3.9)
5. Very dissatisfied, 11 (2.0)
1. Very satisfied, 773 (82.0)
2. Somewhat satisfied, 99 (10.5)
3. Neither satisfied nor dissatisfied, 21 (2.2)
4. Somewhat dissatisfied, 33 (3.5)
5. Very dissatisfied, 17 (1.8)
Knee 1. Very satisfied, 398 (75.0)
2. Somewhat satisfied, 64 (12.1)
3. Neither satisfied nor dissatisfied, 20 (3.8)
4. Somewhat dissatisfied, 39 (7.4)
5. Very dissatisfied, 10 (1.9)
1. Very satisfied, 654 (73.2)
2. Somewhat satisfied, 131 (14.7)
3. Neither satisfied nor dissatisfied, 33 (3.7)
4. Somewhat dissatisfied, 58 (6.5)
5. Very dissatisfied, 18 (2.0)
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lower proportion of patients having had previous knee surgery. Furthermore, because of the Oxford site’s
expertise in UKR, a large proportion of patients there underwent UKR, an operation often performed on
younger male patients with more mild OA. The same considerations of temporal changes, patient selection
and implant technology apply as they did with the THR.
Significant degrees of imputation were required for both the development and validation cohorts because
of missing data. This may have affected the performance of the model, as the imputation process may
have produced inaccurate distributions of missing variables. There were substantially more missing data in
the development cohorts than in the validation cohort. The most important issue to consider is the reason
for missing data. If data were missing completely at random or missing at random, then the imputation
would be relatively unbiased, but may still reduce the statistical power of the model. If, however, the
absence was related to any of the explanatory variables in the model or the outcome, the imputed data
could significantly affect the performance of the model. Although there were substantial missing data in
the EPOS and EUROHIP cohorts, this was generally because the variables were not collected and was
therefore these data were likely to be missing completely at random. However, in the case of some of the
main variables, up to 10% of missing data may have been missing not at random, which may have been
more problematic. Furthermore, in the validation cohort, the hip model performed less well than the knee
model and the development cohorts for the hip model were more reliant on imputation than the knee
model, supporting the potential role of imputation in explaining the poor performance of the model.
It was interesting to note that, in the validation cohort, the performance of the model was worse when
using the entire data set, which included substantial imputation, than when using the complete cohort set,
which relied less on imputed variables. Furthermore, slightly more variables were missing for the hip cohort
than for the knee cohort. Both of these facts support the role of imputation in the poor performance of
the models. We feel that the imputation in the developmental cohorts is probably the main factor in the
poor performance of the models.
Another potential issue was the use of surrogate variables in the validation cohort. In designing the
questionnaire for the validation cohort, we were mindful to use the most recent validated questionnaires to
measure the traits of interest. Unfortunately, many of the development cohorts used outdated or non-validated
questions and questionnaires and, as such, the two were not directly comparable between the two cohorts.
An example was the mental health score: the hip validation tool used the mental component summary score of
the SF-36 questionnaire, the knee validation tool used the SF-12 questionnaire and the validation cohort used a
surrogate variable using self-reported depression, anxiety or use of medications for anxiety and depression. For
the clinical variables identified in the development cohorts, there were few data available on the method of
collection and definitions used, meaning that there was significant potential for misclassification between the
development and validation cohorts.
It was somewhat disappointing to discover that the models in the validation cohorts performed particularly
poorly in the lower deciles of outcome of both THR and TKR. This is the area in which the tools will be
particularly useful if used to help patients and clinicians to make informed choices about the relative pros
and cons of surgery. The exact reason for this is uncertain; however, because of the paucity of patients
experiencing a poor outcome and the fact that some of these outcomes may be because of rare events
(such as surgical mishap or very individualised specific factors, such as chronic pain syndrome), it is not
surprising that they are difficult to predict. Hopefully when using the full data set of the validation cohort,
we may be able to improve prediction within these lower deciles.
The addition of highly sensitive C-reactive protein did not add to the performance of the hip model. It did,
however, add slightly to the performance of the knee model. This may reflect the greater range in inflammatory
processes present in those patients undergoing knee replacement for OA, which is traditionally thought to have
a higher inflammatory component than hip OA. The addition of radiographic severity, measured by the K/L
scale, did add significantly to the performance of the hip replacement model. Both of these results are
tantalising clues to the potential improvements in modelling that we may achieve in the future using the whole
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array of extra variables collected in the validation cohort. We are particularly interested in the role of vitamin D,
urine collagen cross-links and BMD as markers of bone health and metabolism. We are currently performing
these analyses and would hope to have provisional results in the near future. We will also run a complete new
model using the whole validation cohort data with the hope of identifying novel predictive markers but also of
improving the performance of the model. This would obviously require an external data set and we are in
provisional discussions with the Geneva Arthroplasty Registry, which does collect very similar data to the
validation cohort.
We also intend to follow the validation cohort going forward, to obtain annual follow-up scores for at
least 5 and, hopefully, 10 years with a view to having long-term PROMs and also revision and complication
rates. We feel this will significantly add to the current literature.
Conclusion
We demonstrated that the models produced in the development cohort did not perform well in the
validation cohort and feel that a combination of different variable definitions, the degree of imputation
used and the temporal changes in patient and implant selection would explain this. We hope that a new
bespoke model produced in this cohort and validated in a contemporary Geneva Arthroplasty Registry will
get around a number of these points and allow a model with much better performance to be produced.
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Chapter 6 Summary of the programme
The overall aim of this programme was to design and implement a strategy for predicting patients at riskof poor functional outcome following lower limb joint arthroplasty, for use within the NHS.
The programme was divided into four work packages. Each work package had its own aims and designs,
but all four were linked together to arrive to the final purpose of the programme. The schematic
representation of the programme is illustrated in Figure 60.
Work package 1
The aim of the work package was determined by the need to accurately quantify the rates of primary and
revision lower limb arthroplasties in the UK in order to allocate health resources effectively. In addition to
national data, it is important to explore data at a regional level. More important is the need to project
the number of procedures likely to be required in the future. Previous attempts at projections had not
accounted for the increase in age and levels of obesity in the population.
Our analysis using the CPRD database demonstrated that the rates for hip and knee arthroplasty have
increased substantially over this period, but with different trends. The rates of THR have increased steadily,
whereas the rates of TKR increased slowly initially but then rapidly since 2000, such that by 2006 the rates
of both procedures were very similar. Women were 67% more likely to have THR and 45% more likely to
have TKR performed than men.67 Trends in UKR have also increased over the last decade, and the ratio of
TKRs to UKRs fell from 250 : 1 in 1999 to 40 : 1 in 2006. The estimated numbers in 2006 were 74,800 for
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Lower limb arthroplasty: can we produce a tool to predict outcome and
failure and is it cost-effective?
• To describe the current and future need for primary and
   revision lower limb joint replacement surgery in the UK,
   using the general practice database
• To perform detailed health economic analyses of hip and 
   knee arthroplasty and arthroplasty failure using a large
   representative collection of cohorts
• To confirm the important operational, clinical and
   biological risk factors for poor outcomes and prosthesis failure
• To combine the risk factors, using decision analysis, to produce
   a clinically relevant instrument to predict poor outcome and
   replacement failure
• To establish a dual-site pragmatic prospective lower limb
   arthroplasty cohort and use the data to test and refine the
   practicality and effectiveness of the prediction instrument
FIGURE 60 Summary of programme. WP, work programme.
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TKRs and 1800 for UKRs, with UKRs being performed on a younger age group than TKRs. We produced
the lifetime risk of a TKR for 50-year-old men (8.1%) and women (10.8%), and THR for 50-year-old men
(7.1%) and women (11.6%), which are substantially below the estimated lifetime risk for hip and knee
OA. We feel that this is a valuable way of describing risk to patients.
Interrogating the CPRD data from 1991 to 2006, we found marked inter-regional differences in joint
replacement rates in the UK. These were higher for hips than for knees and have not narrowed over time
but, if anything, may have become more pronounced. The reason for these differences between the
regions cannot be explained using this data set, but requires urgent investigation. Potential explanations
include variation in medical indications and contraindications, personal and social perceptions of surgery,
and the availability of orthopaedic services, both NHS and private.
We have demonstrated that the rates of revision surgery are low compared with those for primary
operations but with very different temporal patterns. The rates of hip revision have remained essentially
stable for the last 10 years, whereas for knee revision, the rates have increased substantially. This may
partially reflect the recent increase in the rates of primary TKR but also the established techniques and
prostheses for THR. We have demonstrated that increasing BMI is a risk factor for revision surgery for both
the hip and knee. This is an important piece of information but it has to be considered along with the
effect of BMI on PROMs and also of complications, for which the adverse effects of obesity on outcome
are more obvious.
We have demonstrated that the numbers of THRs and TKRs performed are projected to increase
dramatically over the next 20 years. The different methodologies used give very different estimates. For
THR, we feel that the model using rates fixed at 2010 levels and varying BMI gives the most sensible
estimate, and this suggests a figure of 95,877 THRs, a 34% increase in the number of procedures from
2015 to 2035. For TKR, we feel that the rates in 2010 do not represent a balance between need and
provision, and that the rates will continue to rise. The real number required will therefore be greater than
the fixed rates and varying BMI model (118,666), but less than the estimates produced using the log-linear
model (1,219,362).
In this work package, we have estimated the current and future rates for lower limb arthroplasty, which
should aid in the long-term planning of health-care resources for the UK. The number of procedures
required will increase substantially over the next 20 years, especially those for revision arthroplasty. The
increase in rates is driven predominantly by the increasing age and obesity levels in the population. These
assumptions, particularly about rates of obesity, may be subject to change, particularly when considering
the current NHS focus on obesity. The projected rates of TKR are less certain than those of THR because of
the presumed need/provision gap.
In planning orthopaedic services, potentially one of the most cost-effective tools would be to stratify
patients for knee and hip replacement surgeries in order to avoid operations in those who would have a
poor outcome. This stratification necessitates the development of a statistical tool to predict poor outcomes
for surgeries. Work package 2 aimed to develop the predictive tools for knee and hip separately.
Work package 2
In this work package we describe the predictors for poor patient-reported outcomes at 12 months for
THR and TKR, and combine them into a statistical tool that could be used to identify patients with poor
outcomes before lower limb replacement surgeries.
As there was no existing definition of poor outcome using the Oxford scores, we used existing cohorts
from SWLEOC, with PROMs at 6, 12 and 24 months, to define values of the OHS and OKS that were
associated with patient satisfaction with the operation at 12 months. We used two different statistical
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methods to identify the cut-off points: the ROC curve and the 75th percentile approach. The values were
an OKS of 30 units for TKR and an OHS of 33 units for THR; however, a single score is not recommended
as stratified analyses demonstrated varying values depending on age, sex and baseline score.
Using the above methodology, we identified a number of predictors of outcome for both THR and TKR,
including preoperative Oxford scores, age, sex, BMI, deprivation index, indication for surgery, anxiety and
depression, and radiographic variables. With the exception of the baseline Oxford score, the majority of
the predictors were observed to have statistically significant, but clinically small, effects. Age had a variable
association with PROMs, with worse outcomes in the youngest and oldest patients, whereas younger age
was associated with a higher revision rate. Increasing BMI was associated with a higher rate of revision
and, although it was associated with a poorer PROM, the effect size was very small, suggesting that it
should not be a barrier to surgery. However, obese patients are at an increased risk of developing
postoperative DVT, PE, wound infection and urinary tract infection, which needs to be considered when
discussing the risks and benefits of surgery.
Preoperative pain/function was one of the strongest predictors of the outcome: better preoperative pain
and function was associated with better outcomes, and vice versa.32,44–47 Higher levels of deprivation were
associated with worse patient outcomes following TKR. Higher attained educational level was associated
with better postoperative reported outcomes following THR. Radiographic variables, specifically the pattern
of joint space narrowing, were found to be a strong predictor of outcome for THR; patients with a
superolateral pattern of joint space loss had better outcomes than those with medial, superomedial or
concentric patterns. However, no associations were found between the radiographic severity of disease
and the surgery outcome using K/L grade. Unfortunately, none of our extant TKR cohorts had routinely
collected preoperative radiographic variables to analyse.
We have demonstrated, for the first time, that the use of bisphosphonates reduces the risk of revision
knee and hip surgery by 46%.248 We have now validated these findings in a Danish registry. Furthermore,
hormone replacement therapy reduced the risk by 38% if used for at least 6 months postoperatively.175,249
In addition, we have described an increased postoperative risk of fracture, which is prevented by
bisphosphonate use.
Using our findings on predictors and previous literature reviews, we designed the predictive model for knee
and hip separately. For these statistical tools we performed internal validation to test their calibration and
discrimination ability. The hip predictive tool included age, sex, baseline OHS, BMI, education, SF-36, SF-36
mental component summary score, number of joints with OA, number of joints with surgery, radiographic
pattern of OA and two surgical variables (femoral offset size and surgical approach). The model performed
well with a corrected R2 of 23.1% and had good calibration with only slight overestimation of OHS in the
lowest decile of outcome. We developed a tool to predict the outcomes of THR at 12 months after surgery.
The tool provides the absolute change in OHS expressed as a percentage change.
The knee predictive tool included age, sex, baseline OKS, BMI, deprivation score, SF-12, SF-12 mental
component summary score, ASA grade, other conditions affecting mobility, previous knee surgery, fixed
flexion deformity, valgus/varus deformity at baseline and preoperative ACL state (intact yes/no). The model
performed less well than the hip model with a corrected R2 of 20.2%; however, it had good calibration.
Having identified a number of predictors of outcome of both THR and TKR, we produced predictive
models that were validated internally, but external validation of these predictive models is required in a
NHS setting. This required us to establish a new prospective cohort with extensive baseline phenotyping of
all patients (work package 4). We also need to assess the cost–utility of implementing this model in the
NHS (work package 3).
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Work package 3
Having developed an outcome prediction tool to preoperatively identify patients with poor outcomes after
their THR and TKR, it is important to ascertain whether or not implementing the tool will be cost-effective
in the health-care system and more importantly if it provides benefits to patients. In this work package we
provided an economic evaluation of the predictive tools.
We developed a lifetime Markov model featuring two unique elements: it starts at the orthopaedic
surgeon’s assessment and it distinguishes between two patient-reported outcome categories after primary
and revision procedures. Although these features are not unique to other disease areas and interventions,
they have not been combined in previous economic models of surgical interventions of OA patients. We
highlight the preoperative starting point of the model and the split of postoperative health states because
they allowed the analysis to focus on the hypothetical implementation of a prediction tool to guide the
decision for surgery as well as the reduction of poor surgical outcomes. Transition probabilities for the
model were obtained from expert elicitation, HES PROMs and the CPRD, EPOS, KAT and COASt cohorts
(work package 4). For most cohorts available to us, EQ-5D data were missing, but Oxford scores were
available. We therefore used several econometric models to map the OHS on to the EQ-5D index to enable
health utilities to be obtained from all cohorts. Procedure costs, as well as primary care costs, were
obtained from NHS and CPRD data, respectively. This research benefited from using the best available
sources of data to populate a cost-effectiveness model. The only source of data not based on patient-level
records was an expert elicitation exercise reported in a fully comprehensive manner. Apart from this, all
other sources of data consisted of patient-level data sets with the most appropriate, representative and
up-to-date information on the probabilities, health utility and resource use associated to THRs in the UK,
both before and after the operation.
The level of detail provided by the above data sources allowed the development of model parameter
values for patient subgroups by age and sex. This made it possible not only to present results separately by
these subgroups but, critically, also to adjust all parameter values in the model so that not only death rates
but almost all other parameters changed in the simulation as patients became older.
At 12 months post surgery, the EQ-5D scores increased substantially for both hip and knee replacement
operations (0.44 and 0.32 units, respectively). Even patients defined as having poor outcomes, using the
criteria defined in this programme, exhibited a substantial improvement in scores (0.28 and 0.19 units,
respectively). Thus, with the cost of surgery being £4000 and £6000, respectively, the operations are,
on average, clearly cost-effective interventions. This set a high hurdle for the predictive tool to be a
cost-effective tool. The outcome prediction tool for THRs and TKRs developed did, as intended, reduce
the number and proportion of unsatisfactory and poor outcomes after the operation, saving NHS resources
in the process. However, the tool would do so at the cost of keeping from surgery a number of patients
who would otherwise experience a significant improvement in OHS and HRQoL, meaning that the tool
would also produce fewer QALYs than current practice.
The highest savings per QALY forgone were reported from the oldest patient subgroups (men and women
aged ≥ 80 years), with a reported ICER around £1200 per QALY for THRs. This would probably not be a
cost-effective alternative for the NHS. Keeping patients from surgery, therefore, appears unlikely to be
cost-effective for any tool applied to such a highly successful operation, unless the tool is extremely
sensitive and specific, to a level that the one assessed here appears not to reach.
Our economic evaluation demonstrated that both THR and TKR are highly effective operations associated
with substantial health utility gain. Within the area of health care, these are achieved at a relatively low
cost, making this a cost-effective procedure. The predictive tool was effective in reducing subjects
experiencing a poor outcome, but as even these patients experienced health utility gain, it did so with an
associated overall utility loss. The Markov model produced will now be extremely useful for assessing the
impact of current local strategies aimed at restricting access to lower limb arthroplasty, including those
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based on BMI thresholds. It will also be essential for any improvements or novel predictive models
produced in work package 4 or by other researchers.
Work package 4
Work package 4 has been designed to evaluate and possible improve the predictive tools, developed in
work package 2, in a pragmatic NHS setting involving a prospective cohort of lower limb arthroplasty
patients. To do this, we aimed to recruit 3200 hip and knee arthroplasty patients across two NHS hospitals,
and extensively phenotype them preoperatively and follow them at 6 weeks and annually thereafter. We
recruited 3711 patients who were listed for knee and hip replacement surgeries across two NHS trusts:
OUH and UHS. This is the most comprehensive cohort of arthroplasty patients collected to date.
The cohort had good rates of recruitment and follow-up and confirmed the excellent patient-reported
outcomes of each operation: a THR preoperative OHS of 18.63 units (SD 8.05 units) and postoperative OHS
of 41.06 units (SD 8.96 units) with 92% satisfied, and a TKR preoperative OKS of 20.31 units (SD 7.69 units)
and postoperative OKS of 37.46 units (SD 9.74 units) with 87% satisfied. It provided essential data on health
resource use both pre- and postoperatively. The performance of the knee model was modest (R2 = 0.14)
and that of the hip model poor (R2 = 0.04). However, when the same variables were used to produce a
new model, the performance of the knee model improved (R2 = 0.216) compared with the development
model (R2 = ±0.202). Both models performed better in predicting good, rather than poor, outcomes. The
addition of radiographic OA severity improved the performance of the hip model (R2 = 0.125 vs. R2 = 0.110)
and hsCRP improved the performance of the knee model (R2 = 0.230 vs. R2 = 0.216).
There are many reasons why the models did not perform well in the validation cohort, which include the
difference in patient characteristics, the surgical techniques and the implants used in the development and
the validation cohorts, the degree of imputation used in both the development and validation cohort and
the exact definition of the variables used in the discovery and validation cohorts.
When assessing the performance of the predictive model in a new cohort, it is extremely important to
evaluate the comparability of the two cohorts in question. The model can fail to perform well in a new
cohort because of limitations of the model itself or more commonly because of significant differences in the
new population. There are several important differences between the development and the validation
cohorts in the study. In the case of the hip replacement model, the developmental cohorts used were
EUROHIP and EPOS: EUROHIP is a pan-European cohort and EPOS was a RCT, both of which will introduce
potential issues related to case mix. Furthermore, the development cohorts were collected between 10 and
20 years ago, when surgical implants and techniques were very different from those used today, and will vary
across the contributing European sites in the EUROHIP cohort. In addition, patient selection has also changed,
with increasing provision of THRs in the older population with more comorbidities and also in younger, more
active, patients. This is demonstrated by the validation cohort having a higher BMI, being older than the
EUROHIP cohort but younger than the EPOS cohort and having a higher proportion of patients with severe
radiographic OA (K/L grade 4). These factors would certainly mean that the development and validation
cohorts were very different in nature, which may explain some of the reduced performance of the model.
To produce the knee predictive model, we used the data from KAT, which was a RCT of knee replacement
and involved a different population from those attending the two hospitals through the NHS system.
This is demonstrated by the validation cohort being younger and including a lower proportion of patients
with a valgus deformity, a lower proportion of patients with an ASA grade of symptomatic and a lower
proportion of patients having had previous knee surgery. Furthermore, because of its expertise in UKR, a
large proportion of patients at the Oxford site underwent UKR, an operation often performed on younger
male patients with more mild OA. The same considerations of temporal changes, patient selection and
implant technology applies as it did with the THR.
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Significant degrees of imputation were required for both the development and validation cohorts because
of missing data, especially in the development cohorts. Although there were a substantial number of
missing data in the EPOS and EUROHIP cohorts, this was generally a result of variables not being collected
and data were therefore likely to be missing completely at random. In the validation cohort, the hip model
performed less well than the knee model and the development cohorts for the hip model were more
reliant on imputation that the knee model, supporting the potential role of imputation in explaining the
poor performance of the model.
Furthermore, in the validation cohort, the performance of the model was worse when using the entire
data set, which included more imputation, than when using the complete cohort set, which relied less on
imputed variables. Both of these support the role of imputation in the poor performance of the models.
We feel that the imputation in the developmental cohorts is probably the main factor in the poor
performance of the models.
The addition of hsCRP improved the performance of the knee model (R2 = 0.230 vs. R2 = 0.216), but not
the hip model. This may reflect the greater range in inflammatory processes present in those patients
undergoing knee replacement for OA, which is traditionally thought to have a higher inflammatory
component than hip OA. The addition of radiographic severity, measured by the K/L scale, did add
significantly to the performance of the hip replacement model (R2 = 0.125 vs. R2 = 0.110). Both of these
results are tantalising clues to the potential improvements in modelling that we may achieve in the future
using the whole array of extra variables collected in the validation cohort. We are particularly interested in
the role of vitamin D, urine collagen crosslinks and BMD as markers of bone health and metabolism. We
are currently performing these analyses and would hope to have provisional results in the near future. We
will also run a completely new model using the whole validation cohort data with the hope of identifying
novel predictive markers but also of improving the performance of the model. This would obviously require
an external data set and we are in provisional discussions with the Geneva Arthroplasty Registry, which
does collect very similar data to the validation cohort.
Research implications
There are several areas of future research that would build on the results of this programme to:
l develop and test a potential postoperative prediction model as possibly useful in reducing risk of
poor outcome
l use the COASt cohort as an opportunistic resource to test policy
l use prediction models to explore patients who have a good outcome after THR and TKR
l produce explore novel potential predictors of PROMs following THR and TKR in the validation cohort
(BMD, vitamin D, bone markers, better phenotyping of mental status, etc.)
l produce a new bespoke model in the validation cohort with external validation in a contemporary
Geneva Arthroplasty Registry
l follow the validation cohort going forward to obtain annual follow-up scores for at least 5 and,
hopefully, 10 years with a view to having long-term PROMs and also revision and complication rates
l use the Markov model to explore the economic effects of new therapeutic (e.g. postoperative
bisphosphonates) and care delivery interventions (e.g. BMI restriction criteria)
l perform a RCT of postoperative bisphosphonate use to reduce fracture and revision rates.
Conclusions
This programme has described the number of hip and knee replacement operations performed and
projected to be performed in the future, which will help in planning services. It has defined a poor outcome
using PROMs and identified a number of important predictors of PROMs. Increased BMI is statistically
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significantly associated with a worse PROM; however, the effect size is small and almost certainly not
clinically significant. It is, however, associated with an increased risk of revision surgery and postoperative
complications, which need to be considered in making a decision to operate. We have demonstrated and
validated that bisphosphonates reduce postoperative fractures and the need for revision surgery, which
warrants further investigation.
Both hip and knee surgery are cost-effective procedures, and, although we have produced a predictive
tool for outcome, it would not be cost-effective to implement in its current form. Further work is being
performed to refine and improve the predictive tools using extensive and novel risk factors. They will also
prove to be very useful as part of patient decision aids in the future. The Markov model produced will
prove extremely useful for assessment of any future therapeutic or health-care delivery interventions.
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Appendix 1 Read codes
General Practice Research Database medical codes
TABLE 97 Medical diagnosis codes for hip osteoarthritis
medcode readcode readterm
1104 N053512 Hip OA NOS
2209 N05z511 Hip OA NOS
6812 N05zJ00 OA NOS, of hip
NOS, not otherwise specified.
TABLE 98 Medical diagnosis codes for knee osteoarthritis
medcode readcode readterm
665 N05z611 Knee OA NOS
2487 N05zL00 OA NOS, of knee
NOS, not otherwise specified.
TABLE 99 Medical diagnosis codes for hip replacement
medcode readcode readterm
394 7K22z00 Total prosthetic replacement of hip joint NOS
2224 7K20.1G THR – total prosthetic replacement of hip joint using cement
5481 7K20.00 Total prosthetic replacement of hip joint using cement
2734 7K22.12 THR – other total prosthetic replacement of hip joint
9762 7K22.00 Other total prosthetic replacement of hip joint
33439 7K22000 Primary total prosthetic replacement of hip joint NEC
589 7K21.17 THR – total prosthetic replacement hip joint without cement
18442 7K21.00 Total prosthetic replacement of hip joint not using cement
16671 7K20.13 Charnley total replacement of hip joint using cement
10856 7K20000 Primary cemented THR
28468 7K20.14 Exeter total replacement of hip joint using cement
17860 7K20.11 Arthroplasty of hip joint using cement
47483 7K21000 Primary uncemented THR
38001 7K20y00 Total prosthetic replacement of hip joint using cement NOS
10348 7K20300 Primary hybrid total replacement of hip joint NEC
47812 7K20z00 Total prosthetic replacement of hip joint using cement NOS
37631 7K22y00 Other specified total prosthetic replacement of hip joint
29977 7K20.1E Stanmore total replacement of hip joint using cement
continued
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TABLE 99 Medical diagnosis codes for hip replacement (continued )
medcode readcode readterm
38332 7K20.17 Furlong total replacement of hip joint using cement
38347 7K21z00 Total prosthetic replacement hip joint not using cement NOS
52714 7K20011 Charnley cemented THR
6013 7K20.1C Muller total replacement of hip joint using cement
36590 7K20.18 Howse total replacement of hip joint using cement
47735 7K21.12 Furlong total replacement of hip joint not using cement
48220 7K22100 Conversion to total prosthetic replacement of hip joint NEC
71351 7K20.12 Aufranc total replacement of hip joint using cement
31843 7K20100 Conversion to cemented THR
47715 7K20.1B Monk total replacement of hip joint using cement
34997 7K20.1A McKee total replacement of hip joint using cement
10341 7K21y00 Total prosthetic replacement hip joint not using cement NOS
62092 7K20.1F Turner total replacement of hip joint using cement
62133 7K20400 Conversion to hybrid THR NEC
52901 7K20.16 Freeman total replacement of hip joint using cement
50624 7K21100 Conversion to uncemented THR
67778 7K20x00 Conversion from cemented THR
56215 7K20.19 Ilch total replacement of hip joint using cement
66139 7K20.15 Farrer total replacement of hip joint using cement
73951 7K21.16 Ring total replacement of hip joint not using cement
51519 7K21.15 Monk total replacement of hip joint not using cement
53109 7K21.11 Freeman total replacement of hip joint not using cement
67306 7K20600 Conversion from hybrid total prosthetic hip joint replacement NEC
94273 7K20.1D Pretoria total replacement of hip joint using cement
96435 7K21.13 Lord total replacement of hip joint not using cement
2032 7K22200 Revision of total prosthetic replacement of hip joint NEC
8895 7K20200 Revision cemented THR
29101 7K21200 Revision uncemented THR
38942 7K23200 Revision cemented hemiarthroplasty of hip
41370 7K22300 Attention to THR NEC
41184 7K24200 Revision uncemented hemiarthroplasty of hip
36700 7K20x11 Removal previous cemented total prosthetic replacement hip joint
28784 7K69100 Revision of resurfacing arthroplasty
55662 7K20500 Revision of hybrid THR NEC
38791 7K22x00 Conversion from previous total prosthetic replacement hip joint NEC
45930 7K68300 Conversion to excision arthroplasty
66363 7K22211 Revision of hybrid THR NEC
97176 7K22112 Conversion to hybrid THR NEC
99651 7K22x12 Conversion from hybrid total prosthetic hip joint replacement NEC
NEC, not elsewhere classified; NOS, not otherwise specified.
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TABLE 100 Medical diagnosis codes for knee replacement
medcode readcode readterm
5362 7K30.1V TKR – total prosthetic replacement of knee joint using cement
3414 7K30.00 Total prosthetic replacement of knee joint using cement
673 7K32z00 Other total prosthetic replacement of knee joint NOS
3973 7K32.12 TKR – other total prosthetic replacement of knee joint
8555 7K32.00 Other total prosthetic replacement of knee joint
28048 7K32000 Primary TKR NEC
11847 7K32200 Revision of TKR NEC
20746 7K30000 Primary cemented TKR
17471 7K31.00 Total prosthetic replacement of knee joint not using cement
9877 7K31.12 TKR – total prosthetic replacement knee joint without cement
10553 7K30200 Revision cemented TKR
11225 7K37.00 Cemented UKR
10372 7K30y00 Total prosthetic replacement of knee joint using cement NOS
8006 7K30z00 Total prosthetic replacement of knee joint using cement NOS
9817 7K38.00 Uncemented UKR
36343 7K37000 Primary cemented UKR
49053 7K31000 Primary uncemented TKR
54343 7K38000 Primary uncemented UKR
41545 7K31200 Revision uncemented TKR
37979 7K32y00 Other total prosthetic replacement of knee joint NOS
58612 7K31z00 Total prosthetic replacement knee joint not using cement NOS
55470 7K39.00 Hybrid UKR
54756 7K32400 Attention to TKR NEC
37950 7K39000 Primary hybrid UKR
46475 7K30.16 Charnley total replacement of knee joint using cement
61687 7K30.13 Attenborough total replacement of knee joint using cement
50829 7K31y00 Total prosthetic replacement knee joint not using cement NOS
48815 7K32x11 Removal previous total prosthetic replacement knee joint NEC
93344 7K30.11 Anametric total replacement of knee joint using cement
38740 7K30x11 Removal previous cemented total prosthetic replacement knee
44775 7K30.18 Denham total replacement of knee joint using cement
54860 7K30.19 Freeman total replacement of knee joint using cement
55991 7K30.1P Sheehan total replacement of knee joint using cement
42259 7K32211 Revision hybrid TKR NEC
62757 7K32100 Conversion to TKR NEC
66156 7k32200 Revision of total knee replacement NEC
44926 7K30.1R Stanmore total replacement of knee joint using cement
83544 7K32011 Primary hybrid TKR NEC
47301 7K30.1N Polycentric total replacement of knee joint using cement
continued
DOI: 10.3310/pgfar05120 PROGRAMME GRANTS FOR APPLIED RESEARCH 2017 VOL. 5 NO. 12
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Arden et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
199
TABLE 100 Medical diagnosis codes for knee replacement (continued )
medcode readcode readterm
49813 7K30.17 Deane total replacement of knee joint using cement
69999 7K30100 Conversion to cemented TKR
41820 7K32x00 Conversion from TKR NEC
63086 7K30.1T Uci total replacement of knee joint using cement
49716 7K30.1S Swanson total replacement of knee joint using cement
58980 7K37200 Revision cemented UKR
92246 7K30.1H Liverpool total replacement of knee joint using cement
38073 7K39200 Revision hybrid UKR
47223 7K32411 Attention to hybrid TKR NEC
61288 7K38200 Revision uncemented UKR
63802 7K30.1A Geomedic total replacement of knee joint using cement
66707 7K30.1E Herbert total replacement of knee joint using cement
70507 7K30.1Q Shiers total replacement of knee joint using cement
71456 7K30.15 Cavendish total replacement of knee joint using cement
73075 7K30x00 Conversion from cemented TKR
93435 7K32112 Conversion to hybrid TKR NEC
97341 7K31x00 Conversion from uncemented TKR
97400 7K37x00 Conversion from cemented UKR
99912 7K30.1I Manchester total replacement of knee joint using cement
28784 7K69100 Revision of resurfacing arthroplasty
45930 7K68300 Conversion to excision arthroplasty
NEC, not elsewhere classified; NOS, not otherwise specified.
TABLE 101 Medical diagnosis codes for hip pain
medcode readcode readterm
286 N094K12 Hip pain
1330 N094512 Hip joint pain
33407 N094K00 Arthralgia of hip
TABLE 102 Medical diagnosis codes for knee pain
medcode readcode readterm
9517 1M10.00 Knee pain
554 N094611 Knee joint pain
6044 N094M00 Arthralgia of knee
6166 N094W00 Anterior knee pain
10389 1M12.00 Anterior knee pain
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TABLE 103 Medical diagnosis codes for hip arthritis
medcode readcode readterm
7334 N06z511 Hip arthritis NOS
17561 N010511 Hip pyogenic arthritis
66483 N01zH00 Infective arthritis NOS, of hip
NOS, not otherwise specified.
TABLE 104 Medical diagnosis codes for knee arthritis
medcode readcode readterm
2852 N06z611 Knee arthritis NOS
62037 N03xB00 Arthritis associated with other disease, knee
56895 N01zK00 Infective arthritis NOS, of knee
NOS, not otherwise specified.
TABLE 105 Medical diagnosis codes for degeneration of the knee
medcode readcode readterm
17176 N072100 Degenerative lesion of articular cartilage of knee
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Appendix 2 Statistical methods
Predictors of outcomes of total knee replacement surgery141
Statistical methods: ANCOVA was used to identify predictors of the 6-month follow-up OKS, adjusting
for preoperative OKS. A multivariable model was fitted including all predictor variables. Analyses were
repeated for the total OKSs, pain scores and function scores separately. Regression diagnostics were
checked to ensure that the assumptions underlying the linear regression model (ANCOVA) were met. As
there was evidence of heteroscedasticity (variance of the residuals is non-constant), robust standard errors
were used with the sandwich variance estimator. Performance of the predictive model was assessed in
terms of calibration and discrimination.
The ROC curve analyses were used to identify cut-off points for the 6-month follow-up OKS associated
with satisfaction with surgery. Logistic regression modelling was used to identify predictors of the 6-month
PASS score. Calibration was assessed using a Hosmer–Lemeshow goodness-of-fit test. Discrimination was
assessed by calculating the area under the ROC curve. Regression diagnostics were checked to ensure that
the assumptions underlying the logistic regression model were met.
A population-based survival analysis describing the association
of body mass index on time to revision for total hip and knee
replacements: results from the UK general practice
research database97
Statistical methods: we used competing risks regression methods of Fine and Gray.250 Proportionality of
hazards assumptions was assessed by examining complementary log–log plots of the cumulative incidence.
As a sensitivity analysis we modelled the same data using a standard Cox regression analysis.
The association of patient characteristics and surgical variables
on symptoms of pain and function over 5 years following
primary hip replacement surgery: a prospective cohort study139
Statistical methods: a repeated measures linear regression model was fitted when the outcomes were
the OHS. A generalised estimating equation was used to account for clustering within the data using an
exchangeable correlation matrix. Fractional polynomial regression modelling was used to explore evidence
of non-linear relationships for continuous variables.
Body mass index is not a clinically meaningful predictor of
patient-reported outcomes of primary hip replacement surgery:
prospective cohort study160
Statistical methods: linear regression modelling is used adjusting for the baseline OHS and confounding
factors. A repeated measures linear regression model is fitted, in which the outcome is the pre- and
postoperative OHS, and an interaction term fitted between BMI and time, to describe the change in OHS
over time within BMI categories, adjusting for confounding factors.
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Bisphosphonate use and risk of postoperative fracture among patients
undergoing a total knee replacement for knee osteoarthritis:
a propensity score analysis251
Statistical methods: univariable and multivariable Cox regression models were used. The proportional
hazards assumption was checked using the Schoenfeld residuals formal test and the smoothing splines in
time plots. The linearity of quantitative covariates was assessed by inspection of the Martingale’s residuals
plots. Delta beta plots were used to look for possible influential cases.
Preoperative expectation predicts 12-month postoperative outcome
among patients undergoing primary total hip replacement in
European orthopaedic centres162
Statistical methods: ordered logistic regression modelling was used.
The effect of body mass index on the risk of postoperative complications
during the 6 months following total hip replacement or total knee
replacement surgery77
Statistical methods: for each operation (THR or TKR), logistic regression methods were used to assess
whether or not the likelihood of experiencing each outcome varied by BMI category. Robust standard
errors adjusting for clustering of patients within GP practices were used. Adjustment was made for
potential confounding variables.
Association between bisphosphonate use and implant survival after
primary total arthroplasty of the knee or hip: population-based
retrospective cohort study248
Statistical methods: we used propensity score adjustment to reduce the effects of confounding by
indication. The propensity score for bisphosphonate use represents the probability that a patient is
prescribed bisphosphonate treatment, and was estimated for the whole study population by multivariate
logistic regression modelling.
Patient-reported outcomes 1 year after primary hip replacement in a
European Collaborative Cohort30
Statistical methods: a random-effects logistic regression model was fitted that controlled for evidence of
clustering across countries. Multivariable analyses were then fitted to obtain adjusted ORs. Wald’s tests
were used to explore linear trends.
Clinical tool to identify patients who are most likely to achieve long-term
improvement in physical function after total hip arthroplasty143
Statistical methods: logistic regression modelling was used to identify predictors of functional improvement.
Univariable models explored the association between each of the predictor variables and the outcome. Linearity
was assessed using likelihood ratio tests comparing a model with a categorical variable to one with the variable
as a score. To avoid overfitting the model, 10 times as many outcome events as predictor variables (more
specifically, degrees of freedom) are required, restricting the regression model to six degrees of freedom.
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Regression diagnostics were checked to ensure that the assumptions underlying the logistic regression model
were met.
A clinical tool for the prediction of patient-reported outcomes
after knee replacement surgery: a prospective cohort study142
Statistical methods: general linear models were used to identify risk factors on postoperative OKS.
Linearity of continuous variables with the outcome was assessed using fractional polynomials and collinearity
between variables was assessed by the VIF. Because the variance of the residuals is non-constant (evidence
of heteroscedasticity), robust standard errors were used with the sandwich variance estimator.
Patient-reported outcomes following primary hip replacement surgery:
development and internal validation of a prognostic tool138
Statistical methods: ANCOVA was used to identify predictors of the 12-month follow-up OHS, adjusting
for preoperative OHS. Linear splines were used to model non-linear relationships for continuous variables.
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Appendix 3 Variable list
TABLE 106 Variable list of THR in different cohorts
Variable
Available,
n (%)
Categories (for binary/
categorical) data
Cohort
EPOS
(n= 1366)
EUROHIP
(n= 888)
St Helier
(n= 787)
SWLEOC
(n= 1598)
Patient ID 4639 (100) 100 100 100 100
Study ID 4639 (100) EPOS (n= 1366), EUROHIP
(n = 888), St Helier
(n = 787) and SWLEOC
(n = 1598)
100 100 100 100
OHS preoperative 4639 (100) 100 100 100 100
OHS 12 months 4413 (95) 93 96 89 100
PASS score: quality of life 4413 (95) Not satisfied (score of < 36)
(n = 1003) and satisfied
(score of ≥ 36) (n= 3410)
93 96 89 100
Age at operation 4618 (100) 99 99 100 100
Sex: 1= female, 0=male 4585 (99) 0 (n= 1772) and 1
(n = 2813)
100 95 100 100
BMI 2892 (62) 93 92 59 21
Weight (kg) 2495 (54) 98 93 0 21
Height (cm) 2440 (53) 94 92 0 21
Living alone 886 (19) Spouse/partner (n= 619),
somebody else (n= 50) and
alone (n= 217)
0 100 0 0
Caring for someone else 875 (19) No (n= 718) and yes
(n = 157)
0 99 0 0
Employment 872 (19) Employed (n = 216), retired
(n = 507), unemployed
(n = 25), retired early
(n = 66) and housework
(n = 58)
0 98 0 0
Employed 2781 (60) Unemployed (n= 2208)
and employed (n= 573)
100 98 0 34
Occupation 1366 (29) Heavy manual (n= 40),
light manual (n= 87),
office/professional
(n = 106), housewife
(n = 175) and unemployed/
retired (n= 958)
100 0 0 0
EQ-5D anxiety/depression
preoperative
2418 (52) None (n= 1327), moderate
(n = 975) and extreme
(n = 116)
0 99 0 96
Hospital Anxiety and
Depression Scale score
118 (2.5) 0 13
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TABLE 106 Variable list of THR in different cohorts (continued )
Variable
Available,
n (%)
Categories (for binary/
categorical) data
Cohort
EPOS
(n= 1366)
EUROHIP
(n= 888)
St Helier
(n= 787)
SWLEOC
(n= 1598)
SF-36 mental component
summary score
preoperative
916 (20) 67 0 0 0
ASA grade 1151 (25) Grade1 (n= 183), grade 2
(n= 763), grade 3
(n= 200) and grade 4
(n= 5)
0 88 0 23
School education 781 (17) Postgraduate (n= 28),
graduate (n= 91), college
(n= 244) and none
(n= 418)
0 88 0 0
College education 781 (17) None (n= 418) and
college/university (n= 363)
0 88 0 0
Years of hip pain 1044 (23) < 1 (n = 121), 1–2
(n= 317), 3–5 (n = 305)
and 6–8 (n= 301)
0 99 21 0
Fixed flexion 1254 (27) 0 (n = 643), 0–9 (n= 131),
10–19 (n= 275), 20–29
(n= 127), 30–59 (n= 68)
and ≥ 60 (n= 10)
92 0 0 0
Preoperative expectation:
care_self
888 (19) 0 (n = 831) and 1 (n = 57) 0 100 0 0
Preoperative expectation:
less_pain
1050 (23) No (n = 722) and yes
(n= 328)
0 100 21 0
Preoperative expectation:
care_others
888 (19) 0 (n = 864) and 1 (n = 24) 0 100 0 0
Preoperative expectation:
housework
888 (19) No (n = 677) and yes
(n= 211)
0 100 0 0
Preoperative expectation:
work
888 (19) 0 (n = 831) and 1 (n = 57) 0 100 0 0
Preoperative expectation:
shopping
888 (19) 0 (n = 804) and 1 (n = 84) 0 100 0 0
Preoperative expectation:
walk_normally
888 (19) No (n = 564) and yes
(n= 324)
0 100 0 0
Preoperative expectation:
as_much_as_possible
888 (19) 0 (n = 832) and 1 (n = 56) 0 100 0 0
Preoperative expectation:
drive
888 (19) 0 (n = 847) and 1 (n = 41) 0 100 0 0
Preoperative expectation:
garden
888 (19) No (n = 727) and yes
(n= 161)
0 100 0 0
Preoperative expectation:
holiday
888 (19) No (n = 866) and yes
(n= 22)
0 100 0 0
Preoperative expectation:
Activities of Daily Living
1049 (23) No (n = 758) and yes
(n= 291)
0 100 20 0
Preoperative expectation:
exercise_leisure
888 (19) No (n = 708) and yes
(n= 180)
0 100 0 0
Preoperative comorbidity:
dvt
947 (20) No (n = 881) and yes
(n= 66)
69 0 0 0
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TABLE 106 Variable list of THR in different cohorts (continued )
Variable
Available,
n (%)
Categories (for binary/
categorical) data
Cohort
EPOS
(n= 1366)
EUROHIP
(n= 888)
St Helier
(n= 787)
SWLEOC
(n= 1598)
Preoperative comorbidity:
pulmo
945 (20) No (n= 915) and yes
(n = 30)
69 0 0 0
Preoperative comorbidity:
uti
948 (20) No (n= 884) and yes
(n = 64)
69 0 0 0
Preoperative comorbidity:
muscu
948 (20) No (n= 606) and yes
(n = 342)
69 0 0 0
Preoperative comorbidity:
neuro
945 (20) No (n= 887) and yes
(n = 58)
69 0 0 0
Preoperative comorbidity:
respi
945 (20) No (n= 828) and yes
(n = 117)
69 0 0 0
Preoperative comorbidity:
cardi
945 (20) No (n= 559) and yes
(n = 386)
69 0 0 0
Preoperative comorbidity:
renal
945 (20) No (n= 924) and yes
(n = 21)
69 0 0 0
Preoperative comorbidity:
hepat
943 (20) No (n= 937) and yes
(n = 6)
69 0 0 0
Number of comorbidities 948 (20) 0 (n= 198), 1 (n = 489),
2 (n= 199), 3 (n = 47),
4 (n= 13) and 5 (n = 2)
69 0 0 0
Medication use:
bisphosphonates
888 (19) 0 (n= 873) and 1 (n = 15) 0 100 0 0
Medication use:
anticoagulant
888 (19) 0 (n= 831) and 1 (n = 57) 0 100 0 0
Medication use:
antidepressants
888 (19) No (n= 818) and yes
(n = 70)
0 100 0 0
Medication use:
bronchodilators
888 (19) 0 (n= 849) and 1 (n = 39) 0 100 0 0
Medication use:
antidiabetic
888 (19) 0 (n= 833) and 1 (n = 55) 0 100 0 0
Medication use: analgesic
NSAIDs
2079 (45) No (n= 446) and yes
(n = 1633)
99 81 0 0
Medication use: heart 720 (16) No (n= 258) and yes
(n = 462)
0 81 0 0
K/L grade preoperative 823 (18) K/L grade 0–2 (n= 123),
K/L grade 3 (n= 273) and
K/L grade 4 (n= 427)
0 93 0 0
Pattern of OA 771 (17) No reduction of joint space
(n = 36), superolateral
(n = 335) and
superomedial/medial/
concentric (n= 400)
0 87 0 0
Hypertrophic 779 (17) None (n= 662), hyper
(n = 45) and atrophic
(n = 72)
0 88 0 0
Prosthesis type 2223 (48) Hybrid (n= 354), cemented
(n = 1556) and
uncemented (n= 313)
100 97 0 0
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TABLE 106 Variable list of THR in different cohorts (continued )
Variable
Available,
n (%)
Categories (for binary/
categorical) data
Cohort
EPOS
(n= 1366)
EUROHIP
(n= 888)
St Helier
(n= 787)
SWLEOC
(n= 1598)
Superior acetabular
osteophyte
803 (17) 0 (n = 49), 1 (n= 243),
2 (n = 319), 3 (n = 162),
7 (n = 8), 8 (n= 12) and
9 (n = 10)
0 90 0 0
Superior femoral
osteophyte
803 (17) 0 (n = 87), 1 (n= 217),
2 (n = 269), 3 (n = 193),
7 (n = 10), 8 (n= 17) and
9 (n = 10)
0 90 0 0
Inferior acetabular
osteophyte
803 (17) 0 (n = 106), 1 (n = 197),
2 (n = 264), 3 (n = 192),
7 (n = 12), 8 (n= 22) and
9 (n = 10)
0 90 0 0
Inferior femoral
osteophyte
803 (17) 0 (n = 122), 1 (n = 270),
2 (n = 232), 3 (n = 135),
7 (n = 11), 8 (n= 23) and
9 (n = 10)
0 90 0 0
Acetabular sclerosis 803 (17) 0 (n = 319), 1 (n = 74),
2 (n = 376), 7 (n = 18),
8 (n = 6) and 9 (n= 10)
0 90 0 0
Acetabular cysts 803 (17) 0 (n = 442), 1 (n = 332),
7 (n = 14), 8 (n= 5) and
9 (n = 10)
0 90 0 0
Acetabular attrition 802 (17) 0 (n = 637), 1 (n = 140),
7 (n = 11), 8 (n= 4) and
9 (n = 10)
0 90 0 0
Femoral sclerosis 801 (17) 0 (n = 409), 1 (n = 43),
2 (n = 313), 7 (n = 18),
8 (n = 8) and 9 (n= 10)
0 90 0 0
Femoral cysts 801 (17) 0 (n = 336), 1 (n = 434),
7 (n = 14), 8 (n= 7) and
9 (n = 10)
0 90 0 0
Femoral attrition 800 (17) 0 (n = 526), 1 (n = 248),
7 (n = 11), 8 (n= 5) and
9 (n = 10)
0 90 0 0
Superior joint space 801 (17) 0 (n = 155), 1 (n = 82),
2 (n = 259), 3 (n = 282),
7 (n = 9), 8 (n= 4) and
9 (n = 10)
0 90 0 0
Medial joint space 800 (17) 0 (n = 287), 1 (n = 155),
2 (n = 218), 3 (n = 115),
7 (n = 9), 8 (n= 6) and
9 (n = 10)
0 90 0 0
Chondrocalcinosis 799 (17) 0 (n = 771), 1 (n = 6),
7 (n = 8), 8 (n= 4) and
9 (n = 10)
0 90 0 0
Number of joints with OA 884 (19) 0 100 0 0
Number of joints with
surgery
884 (19) 0 (n = 494), 1 (n = 272),
2 (n = 88), 3 (n= 25) and
4 (n = 5)
0 100 0 0
Lower back/foot/ankle
OA
881 (19) 0 (n = 635) and 1 (n = 246) 0 99 0 0
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TABLE 106 Variable list of THR in different cohorts (continued )
Variable
Available,
n (%)
Categories (for binary/
categorical) data
Cohort
EPOS
(n= 1366)
EUROHIP
(n= 888)
St Helier
(n= 787)
SWLEOC
(n= 1598)
Lower back/foot/ankle
surgery
884 (19) 0 (n= 797) and 1 (n = 87) 0 100 0 0
Grade of operator 1361 (29) Consultant, locum
consultant, associated
specialist/staff (n= 865) and
fellow, senior registrar,
registrar, locum registrar
(n= 496)
100 0 0 0
Surgical approach 985 (21) Anterolateral (n= 641) and
posterior (n= 344)
72 0 0 0
Patient’s position 1359 (29) Supine (n = 225) and
lateral (n= 1134)
99 0 0 0
Lavage system
(acetabular)
1334 (29) No (n= 47) and yes
(n = 1287)
98 0 0 0
Cement pressurisation
(acetabular)
1355 (29) No (n= 265) and yes
(n = 1090)
99 0 0 0
Cement pressurisations
(femur)
1350 (29) No (n= 13) and yes
(n = 1337)
99 0 0 0
Stem size (mm offset) 1363 (29) 31 (n= 64), 38 (n= 576),
44 (n= 695) and 50
(n = 28)
100 0 0 0
Femoral head 1362 (29) Stainless steel (n= 1250)
and ceramic – zirconia/
alumina (n= 112)
100 0 0 0
Head size 1366 (29) 22 (n= 243), 26 (n= 507)
and 28 (n = 616)
100 0 0 0
Duration of operation
(minutes)
1308 (28) 96 0 0 0
Type of polythene 1363 (29) UHMWPE (n= 809) and
duration (n= 554)
100 0 0 0
Acetabular cup
inclination (degrees)
923 (20) 68 0 0 0
Acetabular cup version
(degrees)
923 (20) 68 0 0 0
Hip dislocation 923 (20) No (n= 903) and yes
(n = 20)
68 0 0 0
IMD 200453 deprivation
score
1575 (34) 0 0 0 99
Marital status 301 (6) Divorced (n = 2), married
(n = 288), single (n= 7)
and widow (n = 4)
0 0 0 19
ID, identification number; UHMWPE, ultra high-molecular-weight polyethylene.
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
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Appendix 4 Hip replacement model by
Briggs et al.200
This popular model shown in Figure 61 was first published by Briggs et al.200 in 1998. One other studymade a slight change, keeping the same structure shown in the figure but substituting ‘death’ for
‘non-operative management’, allowing transitions to death from all states.252
Primary THR
Successful primary
Revision THR
Death
Successful revision
FIGURE 61 Hip replacement model used by six economic evaluations and first reported by Briggs A, Sculpher M,
Britton A, Murray D, Fitzpatrick R. The costs and benefits of primary total hip replacement. How likely are new
prostheses to be cost-effective? Int J Technol Assess Health Care vol. 14, issue 4, pp. 743–61200 reproduced
with permission.
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Appendix 5 Full total hip replacement economic
model schema
Primary
THR and
good
Primary
THR and
poor
Revision
THR and
good
Revision
THR and
poor
Deatha
Reassessment
Good
outcome
after primary
Poor
outcome
after primary
Good
outcome
after revision
Poor
outcome
after revision
Reassessment
Surgical
assessment
Risk factor
modification
Long-term
medical
management
FIGURE 62 Full THR economic model schema. Boxes, hexagons and oval represent health states. Arrows represent
possible transitions between health states. Death can occur following any other health state in the model.
a, Transitions from each health state to the absorbing state of death. Reproduced with permission from
Pinedo-Villanueva.253
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Appendix 6 Expert elicitation
Estimates of seven probabilities were informed using expert elicitation. Table 107 shows the derivedmean probabilities for the proportions of patients referred to primary THR, risk factor modification and
long-term medical management. As transitions from the first health state in the model (surgical
assessment) lead to the above three alternatives or to death (which we obtained from UK ONS life
tables125), and all of these must add up to 1, we omitted the transition least agreed on, from surgical
assessment to the waiting list for a THR, and let it instead be equal to the difference between one and the
sum of all other probabilities.
Table 108 shows the probability of referral from risk factor modification to reassessment and, specifically,
for those reassessed, the probability of being referred to the waiting list for a primary THR. Table 109
shows the individual and pooled mean and SD of the derived transition probabilities between long-term
medical management and reassessment, and from the latter to a primary THR.
TABLE 107 Expert opinion on patient referral from surgical assessment
Interviewed expert
Probability of referral from initial surgical assessment, mean (SD)
To waiting list for ‘THR’
To ‘risk factor
modification’
To ‘long-term medical
management’
Expert 1 0.32 (0.088) 0.04 (0.038) 0.65 (0.060)
Expert 2 0.31 (0.099) 0.12 (0.055) 0.20 (0.072)
Expert 3 0.73 (0.034) 0.15 (0.036) 0.08 (0.025)
Expert 4 0.84 (0.060) 0.02 (0.025) 0.08 (0.039)
Expert 5 0.91 (0.033) 0.06 (0.021) 0.02 (0.024)
Expert 6 0.69 (0.049) 0.12 (0.043) 0.04 (0.027)
Expert 7 0.59 (0.066) 0.31 (0.065) 0.11 (0.059)
Linear pool of experts 0.63 (0.227) 0.14 (0.093) 0.17 (0.208)
TABLE 108 Expert opinion on reassessment after risk factor modification
Interviewed expert
Probability of referral from risk factor modification, mean (SD)
To reassessment after 1 year If reassessed, to THR
Expert 1 0.75 (0.063) 0.97 (0.025)
Expert 2 0.56 (0.110) 0.85 (0.062)
Expert 3 0.84 (0.037) 0.88 (0.025)
Expert 4 0.89 (0.055) 0.87 (0.057)
Expert 5 0.05 (0.038) 0.63 (0.055)
Expert 6 0.79 (0.047) 0.79 (0.041)
Expert 7 0.87 (0.067) 0.90 (0.051)
Linear pool of experts 0.68 (0.286) 0.84 (0.111)
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TABLE 109 Expert opinion on reassessment after long-term medical management
Interviewed expert
Probability of referral from medical management, mean (SD)
To reassessment after 1 year If reassessed, to THR
Expert 1 0.03 (0.036) 0.50 (0.011)
Expert 2 0.16 (0.076) 0.54 (0.094)
Expert 3 0.12 (0.029) 0.15 (0.039)
Expert 4 0.13 (0.062) 0.07 (0.053)
Expert 5 0.14 (0.035) 0.85 (0.031)
Expert 6 0.05 (0.042) 0.05 (0.034)
Expert 7 0.10 (0.475) 0.05 (0.031)
Linear pool of experts 0.11 (0.066) 0.31 (0.300)
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Appendix 7 Estimating 2-year revision rates by
Kalairajah outcome classification using data from the
New Zealand Joint Registry
Revision rates by categories of outcome based on postoperative OHS have been reported to date onlyby Rothwell et al.,220 based on a sample of over 15,000 THRs from the New Zealand Joint Registry.
The authors found that lower postoperative OHSs were strongly associated with higher revision rates at
2 years after the primary surgery. Revision rates were calculated for the four groups proposed by Kalairajah
et al.210 using 27, 33 and 41 units as cut-off points on postoperative OHS at 6 months after primary
surgery. Table 110 reproduces the number of patients who had their primary surgeries revised within
2 years, the total number of patients by group and the corresponding 2-year revision rate, as reported by
Rothwell et al.220
We used the figures in Table 110 to produce estimated revision rates for our two categories of outcome
after THR. As we are using a postoperative OHS of 38 units to classify patients into poor and good outcomes
1 year after the primary surgery, Kalairajah et al.’s210 cut-off points of 34 or 41 units for the OHS could be
used to recategorise the four groups into two. Based on the overall proportion of patients classified as having
poor and good outcomes in the HES PROMs data set (45% and 55%, respectively), we chose to consider
the two Kalairajah et al.’s210 groups with scores up to 41 units as having a poor outcome (42%) and those
above 41 units as having a good outcome (58%). Poor outcomes (OHS ≤ 41 units) were hence associated
with a 2-year revision rate of 2.35% and good outcomes (OHS > 41 units) with 0.48%. The relative risk of
revision thus indicates that patients with an OHS of ≤ 41 units at 6 months after their primary operation are
4.93 times more likely to have a revision in 2 years than patients scoring > 41 units.
In order to produce separate revision rates for good and poor outcomes during the first year after the
primary surgery, we used the figures in Table 110 to produce instantaneous revision rates (assuming the
rate was constant over the 2 years) and then probabilities of revision at 1 year for the two outcome
categories. The 1-year probability of revision for the group scoring ≤ 41 units on the OHS was 1.18% and
that of the patients scoring above 41 units was 0.24%. The relative risk of revision at 1 year was therefore
4.96%, all based on data from the sample of New Zealand THR patients used by Rothwell et al.220
As a similar relative risk of revision by poor to good outcomes is not available for THR patients in the UK,
we used this relative risk to produce revision rates stratified by outcome categories based on overall
revision rates reported by the NJR and the proportion of good and poor outcomes found in the HES
PROMs data set.
TABLE 110 Number and rates of revision at 2 years based on New Zealand Joint Registry dataa
Group (OHS) Patients Revised Revision rate (%)
< 27 units 944 72 7.6
27–33 units 1452 32 2.2
34–41 units 4170 50 1.2
> 41 units 9257 44 0.5
a Data obtained from Rothwell et al.220
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Appendix 8 Estimating primary care costs
attributable to hip pain
As the CPRD stores a consultation as an event performed by a specific GP practice staff, we included onlyevents performed by health-care professionals such as GPs, nurses, physiotherapists or alternative
practitioners who would be directly involved in providing care to patients. To capture the use of medication, we
searched the CPRD extract for 25 different drugs, identified and grouped into six categories: antidepressants,
NSAIDs, opioid analgesics, non-opioid analgesics, laxatives and ulcer prevention medication. The mean number
of consultations for each set of controls was calculated and subtracted from the number reported for their
respective case. This was done for each health-care professional and type of event, and for each year. The
difference was assumed to be an estimate of the number of consultations the case had with the specific
health-care professional because of his or her hip problem.
Figure 63 shows the distribution of the number of day visits to GPs attributable to hip pain by the 21,572
cases included in the data set during the year prior to their operation. THR patients used, on average, an
estimated 1.8 extra GP day visits during the year immediately before their operation compared with similar
patients who did not have their hip replaced, suffer from OA or even suffer from hip pain. As Figure 63
shows, however, for many of these patients the number of extra visits to their GP was much higher,
while for others it was considerably lower. This was a natural and expected result. Our assumption that
comorbidities would balance between the two groups (cases and controls) refers to the aggregate level,
given the matching process and the large number of observations. For individual sets of matched patients,
however, no such balance was expected, as is confirmed by our results. The difference between cases and
controls was not only because the former had OA and the latter did not, and other conditions must have
been present in different rates between the two groups.
The use of medication associated with hip pain was estimated in the same manner as consultations. Mean
prescriptions units were subsequently calculated for each set of controls and this value subtracted from
that of the cases to obtain an estimate of the number of prescriptions associated with hip pain. For most
drugs, the resulting difference was zero for the majority of patients in all preoperative years, whereas for
paracetamol, for example, cases reported being prescribed 119 units more than their controls. As in the
case of consultations, there were patients on the THR waiting list who were prescribed many more tablets
Pe
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FIGURE 63 Estimated GP day visits because of hip pain by THR patients during the year prior to surgery, patients
aged > 45 years in the CPRD.
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than the mean of 119 units, and there were also many controls who, on average, were prescribed more
tablets than the patients awaiting the operation. To estimate medication costs, the number of units
attributable to hip pain was estimated as described above for the 272 different CPRD codes associated to
the 25 included drugs and then multiplied by their unit cost, as reported in the BNF.213
Consultation and medication costs were then added together and, thus, the progression of total costs
attributable to hip pain incurred by patients during the 15 years before their THR could be estimated. The
growing estimated costs confirmed the increasing burden generated by unresolved hip pain and problems
experienced by patients who are referred for a THR, who markedly demand many more health-care
resources during the year immediately prior to their operation. It is also notable that the relative weight of
prescription as a portion of total costs increase much more rapidly than that of consultations as patients
approach a THR, going from 20% to 27% to 36% at 8, 5 and 1 year before surgery, respectively. This
indicates that patients are not able to successfully manage their pain through more consultations with
health-care professionals and have to recourse to more medication until their hip is replaced.
We used the estimates for the year immediately prior to a THR to populate all preoperative states.
Deterministic analysis was based on the above mean values for costs attributable to hip problems. For PSA,
a normal distribution was used to model the uncertainty around the difference in resource use between
the two groups.
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Appendix 9 Logit model to predict surgery
outcome
To produce separate estimates by outcome category, we developed a model to predict surgery outcomebased on health-care resource use during the first year after the primary surgery, as collected from the
COASt cohort. Table 111 shows how patients experiencing poor outcomes (i.e. those with a postoperative
OHS < 38 units) reported more visits to health-care professionals and were more likely to be prescribed
painkillers. Using these data, we estimated a logit model to predict poor outcome, as defined in this study.
All resource use variables in the 1-year postoperative follow-up form used in the COASt cohort were
originally included in the model, together with age and sex. Age and sex, as well as the number of nurse
and physiotherapy visits, and drugs other than opioids and paracetamol were not statistically significant
predictors of poor outcome. As Table 112 shows, a model explaining 24% of the variance of outcome
category was estimated from a three-level categorical variable counting GP visits (zero being the base
case), whether or not patients were taking paracetamol and the number of opioid drugs taken. As we
lacked an external data set for validation, we fitted the model to the same estimation data set obtaining
the ROC curve shown in Figure 64, which reported an AUC of 0.80. At certain cut-off points, the model
was able to predict between 70% and 80% of both good and poor outcomes correctly.
As the predictors of poor surgery outcome were measures of resource use also available in the CPRD, we
fitted the above model to CPRD’s postoperative data to predict the outcome category that patients would
have most likely been classified into based on their patterns of resource use. We fitted the model to
data from the first postoperative year after the primary because this, combined with the cost of surgery
previously reported, produced overall costs associated with each model state covering primary THR and the
first year in either outcome category.
TABLE 111 Use of resources by outcome category, COASt cohort patients
Variable name All patients
Outcome
Missing OHSGood Poor
Patients, n (%) 329 (100) 276 (84) 38 (12) 15 (5)
Female, n (%) 198 (60) 166 (60) 22 (58) 10 (71)
Age (years), mean (SD) 68 (10.4) 68 (10.3) 71 (8.0) 67 (15.8)
BMI (kg/m2), mean (SD) 28 (4.9) 28 (4.9) 30 (4.7) 27 (4.7)
OHS, mean (SD) 42 (8.0) 44 (4.1) 24 (6.1) –
EQ-5D, mean (SD) 0.82 (0.253) 0.88 (0.185) 0.40 (0.288) 0.75 (0.238)
Satisfied with outcome, n (%) 298 (92) 266 (96) 19 (50) 13 (87)
Do not smoke, n (%) 307 (94) 258 (93) 35 (92) 14 (93)
Visits to GP ≥ 2, n (%) 46 (14) 28 (10) 16 (42) 2 (13)
Visits to NHS physiotherapist ≥ 1, n (%) 89 (27) 66 (24) 17 (45) 6 (40)
Visits to NHS nurse ≥ 1, n (%) 32 (10) 24 (9) 6 (16) 2 (13)
Taking any non-opioid drugs, n (%) 50 (15) 28 (10) 17 (45) 5 (33)
Taking any NSAIDs, n (%) 39 (12) 28 (10) 8 (21) 3 (20)
Taking any opioid drugs, n (%) 59 (18) 39 (14) 15 (39) 5 (33)
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Predictors in the CPRD were equivalent to those used to estimate the model in the COASt cohort.
The model was estimated based on the number of visits to the GP specifically because of problems with
the hip and, even though the CPRD collects the number of GP visits regardless of reason, we used the
reported number of visits after subtracting the mean visits in controls as an approximation for visits
because of hip problems. When fitting the model, we used the combined number of consultations,
whether at surgery or night visits. Any presentation of paracetamol was regarded as valid for the binary
predictor, and the number of opioid drugs was a straightforward count, also regardless of presentation,
from any of the drugs included in the analysis and classified as opioid.
Those patients for whom the model estimated a probability > 0.4 of being classified as poor outcome were
considered likely poor outcomes, and the rest were labelled as likely good outcomes.
TABLE 112 Surgery outcome predictive model at 1 year: logit regression for poor outcome, estimated on COASt
cohort data
Predictor Coefficient p-value 95% CI
Number of GP visits, 1–4 2.120 0.000 1.446 to 2.794
Number of GP visits, ≥ 5 2.468 0.003 0.851 to 4.085
Paracetamol 1.062 0.010 0.256 to 1.868
Number of opioid drugs 1.113 0.002 0.421 to 1.804
Constant –2.569 0.000 –3.066 to –2.071
n= 314
Pseudo R2= 0.241
Se
n
si
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ty
0.00 0.25 0.50 0.75 1.00
1 – specificity
Area under ROC curve = 0.8021
0.00
0.25
0.75
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0.50
FIGURE 64 Receiver operating characteristic curve for the model predicting surgery outcome category.
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Appendix 10 Mapping the Oxford Hip Score onto
the EuroQol-5 Dimensions
Transfer to utility
The first model regressed total OHS onto the EQ-5D summary index using OLS. This model is described by
Equation 19, where Ê is the expected EQ-5D summary score:
E^ = β0 + β1 × OHSi. (19)
Although total OHS is an aggregation of twelve categorical responses, we treated it as a continuous variable
under the assumption that it indicates levels of severity of hip arthritis. At www.orthopaedicscore.com
(accessed 2015), ranges of OHSs are associated with different severity levels of the disease.
The second method employed responses to all 12 questions of the OHS questionnaire as categorical
regressors and is shown in Equation 20:
E^i = β0 +∑
12
j = 1β j × OHSi j, (20)
where j is each of the 12 questions in the OHS questionnaire. One area of concern when including each of
the 12 questions of the OHS as regressors is that some of them may be highly correlated, in which case
there would be an effect over the variance of coefficients.254 In order to explore the presence of multiple
collinearity between OHS questions, Stata’s collin command was used on each pair of questions to assess
their R2 value and the VIF between them. In both cases, the higher the values the greater the collinearity,
with VIFs above 10 and R2 close to 1 being reasons of concern. The highest VIF reported was between the
questions on description of pain and on pain interfering with work with a factor of 2.92, also showing the
highest R2 at 0.66. Even though the collin command runs a simple correlation and ignores the fact that
variables are categorical, running the correlation accounting for the categorical regressor hardly changes
the value of the R2. Results suggest that none of the correlations between OHS questions are close enough
to being nearly perfectly linear to cause concern when fitting a model that includes them all. The mean VIF
when including all 12 OHS questions was 2.96.
The third TTU regression method used was a two-part logit OLS model. Many patients report having no
problem in the five dimensions included in the EQ-5D after hip replacement, hence a high proportion of
postoperative responses have scores of one (full health). As OLS would not predict a discrete score of one,
we formulated this two-part model in order to be able to predict full-health states.
The first part employed a binary outcome logistic model to predict which patients would have an EQ-5D
score of 1, as shown in Equation 21:
yi* = β0 +∑
12
j=1β j × OHSi j
pi(EQ5D = 1) =
exp(yi*)
1 + exp(yi*)
E^if=1 if pi(EQ5D = 1) ≥ 0:5<1 if pi(EQ5D = 1) < 0:5,
(21)
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where y* is an unobserved latent variable indicating the log of odds of the EQ-5D score being equal to 1.
We then converted this value into a probability using the exponential function, which determined if a score
of 1 was to be recorded as the expected EQ-5D summary score for the selected observation. The second
part used linear OLS regression to estimate EQ-5D values for those patients not predicted to score 1.
The underlying assumptions of the linear regression model were checked. Although there seemed to be
evidence of heteroscedasticity, a linear association between OHS and EQ-5D was confirmed by a fractional
polynomial plot and residuals were approximately normally distributed. For the categorical OLS and
two-part models, different variations were estimated and compared by excluding some or all response
categories of certain OHS questions. The best or more efficient variations of each class of model were
assessed by internal and external validation.
Potential limitations with the TTU regression approach have been documented.217 First, predicted values
may fall outside the range of possible EQ-5D scores (–0.594 to 1 unit). Second, the actual values are
unlikely to be matched by a linear regression. Third, regression methods have assumptions that need to
hold for a model’s estimations to be efficient, or at least unbiased, and these may not always be met.
Response mapping approach
Response mapping seeks to predict the responses to each of the five individual EQ-5D questions instead of
predicting the summary score directly.217 A logistic regression model can then be used to estimate probabilities
that each set of OHS responses would correspond to a response level of each EQ-5D question. The next step
would be to use a Monte Carlo simulation to assign response levels to each EQ-5D question by comparing
random numbers to these probabilities. In the original work by Gray et al.,217 the authors rightly used the
simulation procedure to generate a distribution and then assign the corresponding category, but reported only
a single simulation because, given their large sample size, differences were very small. Based on our sample
size, we also chose to assign health categories after one iteration only. The final index was then computed
using the UK’s EQ-5D tariff. However, this comes at a cost, as assigning a wrong predicted response in just
one of the EQ-5D dimensions would result in a significantly different fitted summary EQ-5D score.216
Responses to EQ-5D questions are ordered, which intuitively implies that the ordered logistic model would
be the most appropriate method to use. However, this requires the parallel regression assumption to hold.
A likelihood ratio test was used to assess if this assumption held but it did not, therefore a multinomial
logistic model was applied. Equation 22 was calculated for two of the three response categories of each
EQ-5D dimension, and the third was the reference case against which these probabilities were calculated:
pik =
exp(αk + ∑
12
j = 1
βk j × Xi j)
1 +∑3h = 2exp(αlt + ∑
12
j = 2
βh j × Xi j)
. (22)
Here, pik is the probability that respondent i will be assigned response category k (1, 2 or 3) for the two
non-reference categories (h). For the reference category, the numerator in Equation 22 becomes 1.
For all TTU regression and response mapping models we also ran variations that included additional
regressors (sex, age, age2 and deprivation converted into a categorical variable). As none of these
variations offered improved performance over the basic models, their results are not reported here.
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Data
Data were obtained from the SWLEOC database. The centre performs hip and knee replacement surgeries
for four acute NHS trusts in south-west London. The full data set comprised 3504 hip replacements each
with preoperative and/or 6-month postoperative responses to the OHS and EQ-5D questionnaires, plus basic
demographic, socioeconomic and clinical information. All except two operations were performed between
2006 and 2008. All models were estimated on 1759 operations, for which we had data on both pre- and
postoperative OHSs and EQ-5D scores, sex, age and deprivation. As we were interested in cross-sectional
mapping, we pooled pre- and postoperative records together, providing 3518 outcome observations.
We included primary and revision surgeries, as well as uni- and bilateral procedures. Multiple records for
the same patient were allowed, as long as each record described a separate procedure. As we had at least
two observations per patient (pre- and postoperative) our data set was clustered. We allowed for this using
Stata’s robust cluster command during model estimation to show robust standard errors.
We treated the functional relationship between the OHS and the EQ-5D as being essentially the same
regardless of circumstances and timing of data collection. Even though there could exist such a difference,
we considered it would not significantly affect the estimation of the mean score of the group. The data
were analysed using Stata/IC 11 statistical software.
Mapping results
The coefficients of the simplest model, continuous OLS with total OHS as the only regressor, are shown in
Table 113.
Table 114 shows coefficients for the categorical version of the linear regression and the two-part
approaches.
Performance assessment and validation
All selected variations of each model were internally validated. Table 115 shows summary performance
indicators for each model.
Given the lack of other data sets recording both OHS and EQ-5D, we performed the external validation
on 1616 observations from the subset of the original cohort of 3504 hip replacements that had not
been selected for the estimation sample. The validation sample comprised records with OHS and EQ-5D
responses for either the pre- or postoperative period, but not for both. Table 116 shows the performance
of the four models when fitted to the validation sample.
TABLE 113 Linear regression output from OLS continuous modela
Independent variables Coefficient Robust standard errorb 95% CI
Total OHS 0.0222 0.000 0.021 to 0.023
Constant –0.0697 0.010 –0.088 to –0.051
a For the number of observations n = 3518, F(1,1685) = 7704.93, Prob(F) = 0.000 and R2 = 0.672. Root-mean-square
error= 0.200.
b Standard error adjusted for 1686 clusters of patients.
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TABLE 114 Coefficients and p-values for OLS categorical and two-part models
OHS question: response level
OLS categorical
Two-part: logit
(first stage)
Two-part: OLS
(second stage)
Coefficient p> |t| Coefficient p> |t| Coefficient p> |t|
Description of pain: 0 Base case Base case Base case
Description of pain: 1 0.171 0.000 0.339 0.764 0.171 0.000
Description of pain: 2 0.146 0.000 0.460 0.669 0.150 0.000
Description of pain: 3 0.174 0.000 1.866 0.072 0.158 0.000
Description of pain: 4 0.212 0.000 3.035 0.003 0.162 0.000
Night pain: 0 Base case Excluded Base case
Night pain: 1 0.036 0.012 0.038 0.008
Night pain: 2 0.037 0.009 0.039 0.005
Night pain: 3 0.037 0.028 0.040 0.017
Night pain: 4 0.047 0.002 0.049 0.001
Sudden pain: 0 Base case Excluded Base case
Sudden pain: 1 0.004 0.837 0.013 0.456
Sudden pain: 2 0.027 0.089 0.039 0.014
Sudden pain: 3 0.034 0.071 0.052 0.007
Sudden pain: 4 0.044 0.011 0.052 0.003
Limping: 0 Base case Base case Base case
Limping: 1 0.045 0.000
Limping: 2 0.046 0.001 0.500 0.245 0.014 0.145
Limping: 3 0.045 0.001 0.929 0.003
Limping: 4 0.055 0.000 1.449 0.000
Walking duration: 0 Base case Excluded Base case
Walking duration: 1 0.006 0.738 0.009 0.624
Walking duration: 2 0.008 0.618 0.017 0.294
Walking duration: 3 0.031 0.050 0.048 0.004
Walking duration: 4 0.038 0.017 0.050 0.003
Climbing stairs: 0 Base case Base case Base case
Climbing stairs: 1 0.005 0.844
Climbing stairs: 2 0.039 0.009 0.046 0.063
Climbing stairs: 3 0.058 0.001 0.738 0.006 0.073 0.006
Climbing stairs: 4 0.085 0.000 0.072 0.008
Socks and stockings: 0 Base case Base case Base case
Socks and stockings: 1 0.042 0.005
Socks and stockings: 2 0.039 0.010 0.425 0.267 0.011 0.324
Socks and stockings: 3 0.055 0.001 0.946 0.005 0.018 0.143
Socks and stockings: 4 0.087 0.000 1.516 0.000 0.041 0.009
Pain from standing up from chair: 0 Base case Excluded Base case
Pain from standing up from chair: 1 0.072 0.004 0.076 0.001
Pain from standing up from chair: 2 0.101 0.000 0.107 0.000
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TABLE 114 Coefficients and p-values for OLS categorical and two-part models (continued )
OHS question: response level
OLS categorical
Two-part: logit
(first stage)
Two-part: OLS
(second stage)
Coefficient p> |t| Coefficient p> |t| Coefficient p> |t|
Pain from standing up from chair: 3 0.117 0.000 0.128 0.000
Pain from standing up from chair: 4 0.118 0.000 0.127 0.000
Car and public transport: 0 Base case Base case Base case
Car and public transport: 1
Car and public transport: 2 0.034 0.018 0.037 0.011
Car and public transport: 3
Car and public transport: 4 0.044 0.014 0.934 0.000
Washing and drying: 0 Base case Base case Base case
Washing and drying: 1
Washing and drying: 2 0.018 0.256 0.019 0.223
Washing and drying: 3 0.049 0.005 1.105 0.036 0.051 0.003
Washing and drying: 4 0.063 0.001 0.059 0.001
House shopping: 0 Base case Base case Base case
House shopping: 1 0.001 0.967
House shopping: 2 0.036 0.014 0.981 0.003 0.035 0.007
House shopping: 3 0.065 0.000 0.057 0.000
House shopping: 4 0.102 0.000 0.074 0.000
Pain interfering with work: 0 Base case Base case Base case
Pain interfering with work: 1 0.097 0.000 0.103 0.000
Pain interfering with work: 2 0.166 0.000 0.180 0.000
Pain interfering with work: 3 0.174 0.000 1.715 0.000 0.194 0.000
Pain interfering with work: 4 0.236 0.000 0.206 0.000
Constant –0.165 0.000 –9.816 0.000 –0.154 0.000
TABLE 115 Performance of models and internal validationa
Model:
regressors
Mean
fitted
EQ-5D
Difference
of means
(observed –
fitted)
Range
of fitted
EQ-5D
Range of
residuals
% within
0.10 utility
R2, EQ-5D
observed
vs. fitted
Root-mean-
square error,b
EQ-5D observed
vs. fitted
Continuous OLS:
total OHS
0.5750 0.0000 –0.070
to 0.995
–0.91 to
0.76
41.6 0.67 0.20
Categorical OLS:
all OHS questions
0.5750 0.0000 –0.165
to 0.967
–0.91 to
0.78
52.0 0.72 0.19
Two-part logit OLSc 0.5735 0.0015 –0.154
to 1.000
–1.11 to
0.82
51.5 0.70 0.19
Response mapping:
all OHS questions
0.5737 0.0013 –0.484
to 1.000
–0.98 to
1.03
49.0 0.57 0.23
a For the estimation sample n= 3518. Mean observed EQ-5D score was 0.575. The range of observed EQ-5D scores was
–0.594 to 1.
b Root-mean-square error of the regression.
c Logit stage used eight OHS questions and OLS used all OHS questions.
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Discussion
The present work shows that models estimated here have a high predictive power when mapping OHS
responses onto the summary EQ-5D score, and OHS changes onto EQ-5D change. Furthermore, it
demonstrates that all models employed here for score mapping are able to estimate the mean EQ-5D
index with a high level of precision. The simplest OLS continuous model achieved the closest estimation of
the mean EQ-5D score, whereas response mapping proved to be the only approach capable of estimating
individual scores well into the negative range and up to full health. An additional benefit of response
mapping is that it allows for the estimation of mean EQ-5D scores using different valuation tariffs. For all
models, predictive power varied considerably across the range of fitted EQ-5D scores with mean absolute
error for predicted low EQ-5D scores doubling that of higher fitted values, a tendency also found in a
previously published cross-walking study linking a condition-specific measure to a generic one. The OLS
categorical model reported lower predictive errors across the range of scores than the other models.
Overall performance of the four models was within range of other reported mapping studies, based on
their root-mean-square errors of around 0.20.
Results of the continuous OLS model indicate that, based on the data used, 67% of the variation in hip
patients’ EQ-5D scores is explained by their OHS. In other words, most of the variability in their HRQoL, as
measured by EQ-5D, is associated with the impact their hip problem has on the pain and limitations they
experience. We also found an association between severity of health problems and the models’ predictive
power of individual scores so that, in general, better health leads to lower predictive errors of EQ-5D score
mapping. This tendency, although explored by only a few authors in the past, has already been found in
studies cross-walking from disease-specific and generic measures onto the EQ-5D.
The mapping exercise benefited from pooling together pre- and postoperative responses to the
questionnaires, hence providing good power and the full range of scores for model estimation. We also
found a number of similarities between the EQ-5D and the OHS; for example, both ask about pain,
mobility and ability to perform tasks and functions. We felt that this was an extremely important factor in
the good performance of the mapping algorithms. Similar mapping exercises are likely to be sensitive to
similarities between instruments and it is very likely that mapping would perform poorly in cases where
instruments are very different.
TABLE 116 Performance of models and external validationa
Model:
regressors
Mean
fitted
EQ-5D
Difference
of means
(observed –
fitted)
Range
of fitted
EQ-5D
Range of
residuals
% within
0.10 utility
R2, EQ-5D
observed
vs. fitted
Root-mean-
square error,b
EQ-5D observed
vs. fitted
Continuous OLS:
total OHS
0.3805 –0.0005 –0.070
to 0.995
–0.78 to
0.67
25.4 0.56 0.23
Categorical OLS:
all OHS questions
0.3845 –0.0045 –0.165
to 0.967
–0.75 to
0.77
42.2 0.63 0.21
Two-part logit OLSc 0.3820 –0.0020 –0.154
to 1.000
–0.83 to
0.77
42.0 0.64 0.21
Response
mapping: all OHS
questions
0.3758 0.0042 –0.429
to 1.000
–0.91 to
1.07
44.4 0.45 0.26
a For the validation sample n= 1616. Mean observed EQ-5D score was 0.38. The range of observed EQ-5D scores was
–0.594 to 1.
b Root-mean-square error of the regression.
c Logit stage uses eight OHS questions and OLS uses all OHS questions.
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The mapping was performed using regression techniques that are very widely used and well understood,
which facilitated analysis and interpretation of results. There are some limitations, however, that should be
borne in mind when interpreting results. Although there is a substantial overlap between OHS and EQ-5D
questions, there is one exception. One of the EQ-5D’s dimensions explores anxiety/depression, which is not
covered in the OHS questionnaire; this limits the ability of the disease-specific measure to predict the scores
of the generic one. In addition, we would ideally like to have used a completely different data set for
external validation from that used for estimation. Our estimation and validation data sets are bound to have
shared many characteristics; nevertheless, the large sample size and wide distribution of scores support the
reliability of results. Although both the estimation and validation subsamples came from the same cohort,
their method of selection made the validation process more robust than if they had been selected randomly.
In most mapping studies, validation samples are built by randomly selecting cases from the same estimation
data set. By doing so, the validation may simply confirm that the selection was truly random instead of
actually testing whether or not results would vary on different data. Using a non-randomly selected
validation sample, we were able to test the validity of the mapping methods while controlling for the
equivalence effect of randomisation.
To conclude, the mapping methods tested here enable researchers, clinicians and policy-makers to obtain
reliable estimates of mean EQ-5D scores and mean changes thereof after THR when these are not directly
collected but responses to the OHS questionnaire are available. In Chapter 4, we report on the use of the
above mapping methods to produce utility estimates based on OHS measures collected in the absence of
EQ-5D data in order to populate our cost-effectiveness analysis. The models presented here report high
predictive power. It is important to stress that, if mapped scores are to be used as part of economic
evaluations, the uncertainty added by the mapping process must be properly incorporated into the analysis.
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Appendix 11 Model assumptions and limitations
As with all models, the one presented here attempts to reflect the true care pathway of patients as theyare assessed for a THR, which most undergo, but it necessarily simplifies what in reality is a more
complex process: patients’ conditions may evolve in ways that have not been simulated in our model or
health professionals or patients themselves may make decisions leading to a myriad of health states that are
not specifically included in our schema. Modellers face the inevitable trade-off of attempting to capture the
complexity of reality vis-à-vis building a manageable and parsimonious model that can be populated with
good-quality data and produce results that aid the decision-making process. As long as these necessary
simplifications do not contradict reality or produce misleading results, then the trade-off can only be
expressed and the likely limitations of the simplified models made explicit. The model presented here
captures the pathway of THR patients with greater detail and breadth than those used for previously
published economic evaluations of THRs; nevertheless, assumptions have necessarily been made.
Our model, as any other, simplifies reality so that we can produce estimates for the cost-effectiveness of
the outcome prediction tool. This simplification is achieved by making a number of assumptions that can
make the model feasible. It is important to make these assumptions explicit and to consider their possible
effects on final results.
First, this model assumes that the outcome prediction tool is capable of identifying potential poor surgical
outcomes before patients have the operation. The methods employed to produce the tool are rigorous
and appropriate, but they were applied to a set of patients that may or may not be representative of
the entire population. We are therefore assuming that the information in the EPOS and EUROHIP data sets
are representative of the equivalent characteristics and outcomes in the wider population susceptible of
undergoing a THR in the UK. Based on their large number of participants and on the fact that EPOS is a
UK-based study, and because EUROHIP is a multicentre study not only in the UK but also in other European
countries, we believe that the prediction tool built on such data is applicable to the wider UK context.
Outcome categories are a key element in this study; hence, an important assumption we are making is that
the way patients are classified in this model is valid and the most appropriate. We are assuming that all or
most patients with an OHS of ≥ 38 units at 1 year after their primary surgery are all free from pain and
major mobility limitations as well as satisfied with the operation, and that the opposite is true for those who
score < 38 units. This may not necessarily be so. First, the method used to identify the cut-off point was
anchored on satisfaction, which is a largely subjective concept. Second, satisfaction, and hence the cut-off
point for good and poor outcomes, may also vary with sex, age, BMI, expectations or severity of disease, to
name a few. In the study identifying this cut-off point on the postoperative OHS, the authors stratified their
results by sex, age and BMI tertiles, and baseline OHS, but the differences were not statistically significant
from the overall value. They also explored equivalent thresholds using the raw change in OHS after the
operation and the percentage of potential improvement achieved as outcome, and in both cases stratifying
by the above variables produced results whose difference to the overall values was not statistically
significant.154 We are, therefore, confident that an overall cut-off point is acceptable, as data appear to
suggest that the connection between a postoperative OHS and satisfaction is stable across different groups
of patients.
We also assume that all patients found to be candidates for surgery but presenting a risk factor that should
be dealt with before the operation, whether it is excessive weight, diabetes, blood pressure or something
else, can be grouped together and, therefore, the same costs, QALYs and transitions from the risk factor
modification state can be applied. This is probably not the case in real life. However, we are using this
health state essentially to introduce a delay into the path towards surgery, as attempts to modify risk factors
were reported by surgeons to be common when assessing patients considered for an arthroplasty. The risk
factor modification state (for which patients would be expected to stay for a short period in most cases)
is not intended to reflect the specificities of the risk factor modification treatment. In fact, the costs of
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modification of risk factors are not included in the costs associated with this state. In addition, although
HRQoL may differ depending on the type of risk factor patients have, we do not expect variations to be
significant, as EQ-5D is largely sensitive to mobility, pain and limitation to usual activities, which all patients
in the risk factor modification state would have in common as they have been found to be candidates for a
THR. We therefore believe that the heterogeneity of patients diverted to risk factor modification state
reflects clinical practice and that the variation in costs, QALYs and transition probabilities will be
appropriately incorporated into results via PSA.
We are also grouping a diverse set of patients into the health state of long-term medical management.
As above, we have given priority to what these patients have in common, namely their non-surgical
treatment, as opposed to their potentially different costs, QALYs and transition probabilities based on
what sets them apart. As health-care costs are expected to be driven by the non-surgical treatment
of their problem, and this will be largely similar for all, bringing such diverse groups of patients together is
warranted. QALYs, as explained above, are very much sensitive to hip pain and its consequences; hence,
however diverse these patients, they are all likely to have similar HRQoL. Transition probabilities, however,
may be different for patients in the long-term medical management state. One of the specific groups of
patients that will transit into this state is that composed of potential candidates for a THR who are not
willing to undergo the procedure. These patients, for example, are likely to be much more susceptible to
the effects of an outcome prediction tool than patients whose problem is not orthopaedic or hip related,
or simply those found unfit for surgery, all of whom will be in the long-term medical management state.
Nevertheless, the distribution of the probability of transition from this health state will capture some of the
variation within this group, which through PSA will allow results to incorporate this difference.
Another important assumption is that probabilities of good and poor outcomes are the same in the model
whether the patient comes from the risk factor modification section or from that of long-term medical
management. This is a clinically plausible assumption because long-term medical management patients,
who are ultimately referred for a primary arthroplasty, are likely to be very similar to those referred for a
THR from the risk factor modification state in all aspects relevant to surgery outcome.
The model presented here does not allow for multiple revisions. Although there are patients who undergo
more than two THRs in their lifetime, not only are they a very small proportion of all patients who receive
this operation but there are also no data available about the effect of surgical outcomes on a second or
later revision of the prosthesis.
Finally, we are ultimately assuming that the tool will be used by orthopaedic surgeons, when in reality it
would be very difficult to know whether or not the additional information it will provide will be taken into
consideration by surgeons, or even patients. It would be unrealistic to think that if the tool predicts that a
patient is likely to perform poorly, for example, that this information will supersede the surgeons’ criteria
when they would otherwise refer the patient for the operation, or vice versa. We therefore perform the
analysis comparing current practice against a hypothetical scenario in which the tool will dictate how
patients are referred after the surgical assessment as an extreme case. The results will therefore show
whether or not each unit of health benefit brought about by the strict use of this tool would require the
NHS to assume additional costs at a rate lower or higher than the opportunity cost within the health system.
Parameter assumptions
During the process of identifying parameter values to populate the economic model, a number of
assumptions were made, whether because of the simplification forced by the fact that we were modelling
a complex reality or because of limitations in the data available. In this section we discuss the assumptions
made on the various probabilities, costs and health utility estimates, their possible implications and
general feasibility.
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Although preoperative transition probabilities may vary between patient subgroups, the values extracted
from the expert elicitation exercise were assumed to apply to all patients regardless of age or sex. The
method of data collection posed an important limitation in this case. It would have been highly impractical
to ask the same questions to all experts about each specific patient subgroup, and they may have not
been able to provide different values for each group. Dividing the limited number of experts, to ask
different surgeons about different subgroups, was not feasible either. A common estimate for the mean
preoperative transition probabilities, therefore, may not capture the possible heterogeneity among groups.
By including surgeons who specialise in a particular type of patient, however, the uncertainty represented
in their answers was transferred to the pooled probability distributions, incorporating this heterogeneity
into the analysis, ultimately reflected in PSA results.
Transitions between good and poor outcomes > 2 years post operation were estimated based on follow-up
questionnaires only up to 5 years. Results from the EPOS records point to diminishing improvements over
the first 5 years and the extrapolation of estimated probabilities took the levels of each outcome category to
a plateau. It is possible, however, that, over time, and especially by 10 years after a primary THR, many of
those good outcomes worsen and the proportion of poor outcomes increases. We do not have data to
support this, yet it seems clinically plausible. We account for this with the distributions assigned to transition
probabilities linked to the number of patients involved in EPOS from whom probabilities were estimated
and that added some of this uncertainty into the results through PSA.
As patients transit the model from either outcome category after a primary THR to a revision THR and then
to an outcome category immediately after this, we are assuming that surgery outcome after the primary
surgery has no bearing on surgery outcome after revision. It may be possible that this is not the case, but
no data are available to confirm either hypothesis. However, our assumption is clinically plausible inasmuch
as this assumption implies that patients requiring a revision would be in a similar situation concerning
their prosthesis regardless of their state of origin when they transitioned into the revision THR state. Such
similarity would make them equally likely to perform well or poorly after the revision. In addition, although
good- and poor-outcome patients after the primary would not generate similar levels of HRQoL or costs to
the aggregate analysis, PSA did allow for variability such that these good- and poor-outcome patients after
the primary would not be so different in these regards either.
An important assumption was made when we used the cut-off point derived for primary THRs to categorise
outcomes after revisions. This was done because no similar cut-off point has been calculated for revision
THR patients. The resulting probabilities of good and poor outcomes are, nonetheless, acceptable as they
imply a slightly higher likelihood of performing poorly after a revision, which was consistently reported by
surgeons in the various rounds of consultations. Transition probabilities between outcome categories were
also assumed to be equivalent after primaries and after revisions when those calculated for the former were
applied to the latter. This was done because there are no data sets available with long-term follow-up of
revision THR patients. However, we considered it is very likely that these transition probabilities are indeed
similar because they describe patients’ response > 1 year following major surgery, which primary and
revision surgery both are. Assigning a distribution to these probabilities also reflects results accounting for
the uncertainty around their true value.
Finally, we applied all-cause mortality rates from the general population to patients with OA or other
conditions possibly leading to a THR assuming that such musculoskeletal problems do not affect their
chance of dying. In addition, mortality rates applied to the first year after surgery, whether primary or
revision, were those reported by the NJR, which describe only the risk of death without attempting to
identify whether or not surgery itself had any effect.17 We therefore assumed that those values were a true
reflection of death rates of patients undergoing a THR regardless of the reason, which is what the model
required. We further assumed that outcome at 1 year after surgery, again whether primary or revision, did
not have any bearing on mortality rates during that period.
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In regard to HRQoL values, it is important to note that both pre- and postoperative measures used for the
economic model were taken at roughly the same time with respect to the operation but not necessarily at
the same point in the progression of the disease. A recent study looking at the HES PROMs data from
2009–10, a subset of which we used to inform HRQoL parameters for our model, found that non-white
and more deprived patients tend to have joint replacement operations at a point when their OHS is lower
than their white and less deprived counterparts, suggesting that their disease had reached a more
advanced stage.255 We did not explore these inequalities here but, as the outcome prediction tool uses
preoperative OHS as the main predictor variable, it is likely that the tool already takes account of such
different disease stages regardless of patients’ race or deprivation level.
Regarding the use of the outcome prediction tool, inequalities in access to health services in general, to
appropriate referrals and to surgery itself may also have an impact on the tool’s effects. These inequalities
have already been identified in England based on sex, age, deprivation and ethnicity,256 but their possible
effects on the application of the outcome prediction tool are outside the scope of this research.
When estimating QALYs for the model’s health states, we assumed that the pattern of progression by
outcome category during the first year after the operation in EPOS is generalisable to the wider population.
We also assumed that the connection between OHS in the first and second years is representative of the
changes all or most patients would experience. Although this might not necessarily be strictly the case,
these assumptions are highly plausible as EPOS is a multicentre study whose main limitation is that the
prosthesis employed in the THR was of the Exeter brand. The most frequently used stem in cemented THRs
in England and Wales, used in more than 60% of the interventions performed in 2011, is in fact the Exeter
V40 (Stryker Corporation, Kalamazoo, MI, USA), with the second most common prosthesis being used in
< 20% of arthroplasties;17 hence data from only THRs performed using Exeter prostheses are likely to
be generalisable. In addition, although assumptions were made about the patterns of quality of life
progression, these were applied to the HES PROMs data set, a highly representative source from which
data were ultimately extracted.
The health states of good and poor outcome after primary or revision surgery are the states in which most
patients would remain for long periods of time, until death in many cases. We did not consider a utility
decrement when assigning health utility estimates to these states, which resulted in patients dying
while still at high HRQoL levels, especially in the case of good outcomes. This is a potentially unfitting
assumption, but it also becomes irrelevant in this analysis because results from the model employing the
outcome prediction tool are compared with current practice. In addition, if a decrement was to be applied
on the grounds of ageing, it would affect good and poor outcomes equally and for both comparators,
and hence such effects would essentially cancel each other out. Therefore, final utility estimates from
each separate model should not be considered an accurate estimation of health utilities obtained with or
without the intervention, and should only be analysed with respect to one another.
Because of the lack of data sets with follow-up information on revision THR patients, we assumed that the
progression of health utility estimated from primary THR patients in EPOS was also applicable to revision
THR patients. Although primary and revision patients may evolve differently during the first few months
after their operation, applying these patterns to observed pre- and postoperative scores reported by the
highly representative HES PROMs meant that the estimation of the parameters would still be highly
accurate. The reason for this is that the progression patterns applied only described how patients move
from their preoperative to their postoperative scores and not the scores themselves. Health utility estimates
for the model states describing the second and subsequent years after revision THR were also affected by
our assumption that the connection between OHS at years 1 and 2 after primary is the same as that after
a revision operation. Again, in the absence of data describing how revision patients evolve from years 1 to
2 after a revision, the best approximation available was those observed in primary patients, which is what
we used to populate the model.
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When estimating parameter distributions to characterise uncertainty around health utility estimates, we
assumed the time trade-off weights reported in the literature for the EQ-5D215 without considering any
uncertainty around such valuation. Although these values are commonly used when performing economic
evaluations, it is important to acknowledge that other valuation methods exist that could ultimately
produce different health utility estimates.
Regarding assumptions about cost parameters, the costs for the risk factor modification state considered only
reported primary care consultations and prescriptions by patients before their THR. It did not include the cost
of the risk factor modification programme itself because these vary according to the type of problem needing
to be addressed (e.g. weight reduction or blood pressure) and, to date, we have no reliable data on the use
of these programmes by THR patients before the operation. Moreover, the inclusion in the model of separate
states for risk factor modification and long-term medical management was primarily justified by the intention
to include a non-surgical treatment alternative as well as the reality of delayed primaries because of risk
factor management. We did not expect costs of the risk factor modification programmes to have any
significant effect on overall results.
Surgery costs, on the other hand, were explicitly included because they are the most resource-intensive
state of the economic model and, furthermore, they were assumed to be the same regardless of outcome
category 1 year after the operation. We had no reason to believe that there would be an association
between the HRG assigned to the operation, whether primary or revision surgery, and surgical outcome
1 year later.
Costs of complications were not explicitly included but, in many cases, they were already part of the cost
estimations. Perioperative complications were considered in HRG reference costs, and primary care resource
use resulting from complications was also part of the CPRD data used to produce cost estimates. However,
surgical complications such as DVT, PE, fracture and the more recently explored associations between THR
and myocardial infarction257 or stroke258 were excluded from the analysis. As this economic evaluation
assesses the implementation of an outcome prediction tool after THR, the effect of costs associated to
complications would be relevant only inasmuch as the tool changes the proportion of patients going into
surgery and these complications appear in statistically different rates between the outcome categories
considered. As we lack data on the differential incidence of complications between good- and poor-outcome
patients as defined here, and the rate of complications such as DVT and PE reported in other economic
evaluations of THR is as low as 1%,252 these were not incorporated into the analysis.
In using preliminary results from the COASt cohort for sections of the cost estimation exercise, we assumed
that the cohort is representative of clinical practice and, more generally, of patients in the UK. More
specifically, we assumed that the list of medications used after a THR as well as the pattern of resource use
and its relationship with surgery outcome observed in the COASt cohort is similar to the overall pattern and
connection in the country as a whole.
We assumed that estimating the surgery outcome predictive model at an OHS threshold of 33 units on
resource use data collected in COASt for the first year after a primary was a valid approximation of the
coefficients and statistical significance that would have been obtained had the model been estimated from
resource use collected during the second year. This was a necessary assumption, given the lack of data
on resource use collected during the second postoperative year from THR patients with an available OHS.
It is also a feasible assumption considering that, if resource use is associated with the level of pain and
limitations as measured by the OHS, then the timing of the measure should be irrelevant and the resulting
coefficients would represent the number of consultations and prescriptions associated with the groups
scoring above or below the new threshold.
Regarding the application of the outcome prediction tool, we indicated that it would have the effect of
lowering the probabilities of being referred for a THR, whether directly or through risk factor modification,
and that the transition probability to long-term medical management would increase because patients not
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referred for a THR would be treated non-surgically. We assumed that the tool would not have any direct
effect over the referral pattern of patients originally sent for long-term medical management because
those patients had, by definition, not been considered for the operation because their problem would not
be solved by the THR, they were unfit for surgery or they did not want to have it. None of these situations
would feasibly be affected by the output of the outcome prediction tool.
Finally, we assumed that there was no correlation between model parameters within each model
considering current practice or the application of the outcome prediction tool. The distinction is made
because the difference between the two models is, in fact, that they are populated by a different set of
probabilities and HRQoL measures that are associated with whether or not the tool is used. Any correlation
among parameters beyond the changing patterns because of implementing the prediction tool was not
considered in the economic model.
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Appendix 12 Primary care costs for total
knee replacements
TABLE 117 Mean primary care costs during first year after revision TKR
Patient subgroup (sex and age) ‘Likely poor’ outcomes (£) ‘Likely good’ outcomes (£)
Men
45–59 years 919.38 170.66
60–69 years 810.50 178.78
70–79 years 730.61 142.98
≥ 80 years 701.47 148.52
Women
45–59 years 919.38 177.52
60–69 years 810.50 144.60
70–79 years 730.61 113.33
≥ 80 years 701.47 115.18
TABLE 118 Mean primary care costs during year 2 and onwards after primary TKR
Patient subgroup (sex and age) ‘Likely poor’ outcomes (£) ‘Likely good’ outcomes (£)
Men
45–59 years 724.25 90.77
60–69 years 701.86 69.09
70–79 years 662.30 59.53
≥ 80 years 672.77 53.03
Women
45–59 years 760.91 124.05
60–69 years 718.00 91.40
70–79 years 665.88 65.90
≥ 80 years 646.93 59.42
TABLE 119 Mean primary care costs during year 2 and onwards after revision TKR
Patient subgroup ‘Likely poor’ outcomes (£) ‘Likely good’ outcomes (£)
All subgroups 923.23 101.94
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Appendix 13 External validation of the model
TABLE 120 Linear regression models for the OKS COASt data with one additional variable. Text in square brackets
in column 1 refers to the reference category for categorical variables. Brackets in columns 2 and 3 are SD
Predictor variables (reference category) Overall, complete case (n= 182) Imputed knee data (n= 608)
Intercept 41.25 40.95
Age (years)
[< 60]
60–69 –4.80 (1.93)* –1.90 (1.08)****
70 to 79 –4.27 (2.02)* –1.95 (1.11)****
≥ 80 –4.03 (2.84)**** –2.05 (1.43)****
Sex
[Female]
Male 1.36 (1.35) 0.40 (0.72)
Preoperative total OKS 0.33 (0.09)*** 0.34 (0.05)***
IMD 200453 score –0.09 (0.07) –0.05 (0.04)
BMI (kg/m2) –0.20 (0.14) –0.24 (0.07)***
SF-12 mental component summary score –2.58 (1.55)**** –1.71 (0.85)*
ASA
[Fit and healthy]
Asymptomatic no restriction 1.22 (1.76) –0.67 (1.00)
Symptomatic minimal/severe restriction 0.17 (2.50) –1.90 (1.33)****
Other condition affecting mobility
[No]
Yes –2.11 (1.30)**** –1.97 (0.72)**
Previous knee surgery
[No]
Yes –6.13 (1.89)** –2.28 (1.04)*
Fixed flexion deformity
[No]
Yes –0.26 (1.32) –1.11 (0.70)****
Preoperative valgus/varus deformity
[Varus]
No deformity 2.10 (1.66) 2.59 (0.91)**
Valgus 3.40 (1.57)* 4.45 (0.88)***
continued
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TABLE 121 Additional variables not included in the COASt hip model, based on the complete (550 records) and
incomplete (1098 records) data sets
Variables (type)
Data set
Complete Incomplete
Frequency % missing Frequency
Arthritis variables: previous treatments
Medication steroids (binary) Yes, n= 840; no, n= 466 37.43 Yes, n= 98; no, n = 589
Intra-articular steroid injection (binary) Yes, n= 93); no, n= 457 22.59 Yes, n= 151; no, n= 699
Intra-articular hyaluronic acid injection
(binary)
Yes, n= 4; no, n= 546 23.77 Yes, n= 6; no, n = 831
Soft tissue injection (binary) Yes, n= 8; no, n= 542 51.28 Yes, n= 8; no, n = 527
Infection treatment (binary) Yes, n= 1; no, n= 549 22.59 Yes, n= 7; no, n = 843
Arthritis variables: duration of suffering
Suffered in days 0 100
Suffered in weeks 0 100
Suffered in months Mean 6.79, SD 2.33;
missing, 76.91%
83.97 Mean 6.90, SD 2.38
Suffered in years Mean 5.13, SD 6.47;
missing, 18.73%
35.06 Mean 5.96, SD 7.87
Procedure and operations
Arthroscopy (binary) Yes, n= 6; no, n= 544 23.22 Yes, n= 10; no, n = 833
Radiography (binary) Yes, n= 492; no, n= 58 22.68 Yes, n= 751; no, n= 98
TABLE 120 Linear regression models for the OKS COASt data with one additional variable. Text in square brackets
in column 1 refers to the reference category for categorical variables. Brackets in columns 2 and 3 are SD
(continued )
Predictor variables (reference category) Overall, complete case (n= 182) Imputed knee data (n= 608)
Preoperative ACL
[Intact]
Damaged 2.27 (1.71) 0.77 (0.84)
Absent –7.68 (4.87)**** –3.77 (2.35)****
C-reactive protein –0.04 (0.05) –0.09 (0.02)***
*p< 0.05; **p< 0.01; ***p< 0.001; ****p< 0.157.
Coefficient: the regression coefficient represents the difference in 12-month OKS compared with the reference group.
A positive value indicates that the group has better postoperative pain/function.
ASA status: a standard measure of fitness for surgery, scored from 1 (normal, healthy) to 4 (severe systemic disease that is a
constant threat to life).
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TABLE 121 Additional variables not included in the COASt hip model, based on the complete (550 records) and
incomplete (1098 records) data sets (continued )
Variables (type)
Data set
Complete Incomplete
Frequency % missing Frequency
Examination
‘Get up and go’ test (categorical) Grade 1: 41 39.16 Grade 1: 48
Grade 2: 242 Grade 2: 295
Grade 3: 185 Grade 3: 223
Grade 4: 51 Grade 4: 63
Grade 5: 24 Grade 5: 31
Grade 6: 7 Grade 6: 8
‘Get up and go’ test in seconds
(continuous)
Mean 16.42, SD 9.69 43.26 Mean 15.85, SD 8.39
Handgrip strength: first right hand try
(continuous)
Mean 27.97, SD 10.57 37.98 Mean 27.91, SD 10.73
Handgrip strength: second right hand try
(continuous)
Mean 27.26, SD 10.70 38.07 Mean 27.25, SD 11.01
Handgrip strength: third right hand try
(continuous)
Mean 27.07, SD 10.57 38.07 Mean 27.19, SD 10.95
Handgrip strength: first left hand try
(continuous)
Mean 26.36, SD 10.77 37.98 Mean 26.29, SD 11.07
Handgrip strength: second left hand try
(continuous)
Mean 25.92, SD 10.55 38.25 Mean 26.03, SD 10.79
Handgrip strength: third left hand try
(continuous)
Mean 25.60, SD 10.38 38.34 Mean 25.81, SD 10.72
Right hip trochanteric bursitis (continuous) Mean 0.32, SD 0.47 56.74 Mean 0.30, SD 0.46
Left hip trochanteric bursitis (continuous) Mean 0.34, SD 0.47 63.57 Mean 0.28, SD 0.45
Right hip Trendelenburg sign (continuous) Mean 0.50, SD 0.50 61.66 Mean 0.41, SD 0.49
Left hip Trendelenburg sign (continuous) Mean 0.54, SD 0.50 68.03 Mean 0.43, SD 0.50
Charnley ABC categories259 l Single hip affected: 250
l Both hips affected: 188
l Multiple arthritis or
medial infirmity: 112
36.16 l Single hip affected: 312
l Both hips affected: 249
l Multiple arthritis or
medial infirmity: 140
Right hip internal rotation (continuous) Mean 14.72, SD 7.97 52.28 Mean 15.37, SD 7.98
Left hip internal rotation (continuous) Mean 15.36, SD 8.91 63.12 Mean 15.85, SD 8.43
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TABLE 122 Additional variables not included in the COASt hip model, based on the complete (550 records) and
incomplete (1098 records) data sets
Variables (type)
Data set
Complete, with missingness in some
variables Incomplete
Frequency % missing Frequency
Health resources use
Service GP Yes, n= 495; no, n= 46; missing, 1.64% 22.68 Yes, n= 773; no, n = 76
Service GP NHS Mean 3.57, SD 2.65; missing, 20.73% 38.07 Mean 3.57, SD 2.79
Service HDOC Yes, n= 410; no, n= 106; missing, 6.18% 26.41 Yes, n= 657; no, n = 151
Service HDOC NHS Mean 1.90, SD 1.44; missing, 33.82% 47.18 Mean 1.96, SD 1.40
Service physiotherapist Yes, n= 220; no, n= 297; missing, 6.0% 26.69 Yes, n= 334; no, n = 471
Service physiotherapist NHS Mean 3.27, SD 2.53; missing, 67.09% 75.50 Mean 3.44, SD 2.71
Service nurse Yes, n= 106; no, n= 373; missing, 12.91% 31.06 Yes, n= 173; no, n = 576
Service nurse NHS Mean 2.28, SD 2.22; missing, 84.55% 88.07 Mean 3.11, SD 5.56
Service alternative practitioner Yes, n= 89; no, n = 440; missing, 3.82% 23.77 Yes, n= 129; no, n = 708
Service A&E Yes, n= 58; no, n = 480; missing, 2.18% 22.77 Yes, n= 97; no, n = 751
Home care Yes, n= 11; no, n = 530; missing, 1.64% 22.31 Yes, n= 18; no, n = 835
Questionnaire scores
Pain detected: seven items
used to form the scores –
questions range from 0 to 5
Mean 8.90, SD 6.27 31.24 Mean 9.05, SD 6.39
Self-assessed EQ-5D Mean 9.34, SD 1.40 12.02 Mean 14.11, SD 1.97
Postoperative EQ-5D Mean 6.49, SD 1.90 3.28 Mean 6.50, SD 1.85
Intermittent and constant OA
pain: five items used to form
the scores. Questions range
from 0 to 4
Mean 1.56, SD 3.75 4.19 Mean 1.31, SD 3.45
12-month follow-up
Patient expectation and
outcome
1. Very satisfied: 446
2. Somewhat satisfied: 62
3. Neither satisfied or dissatisfied: 22
4. Somewhat dissatisfied: 22
5. Very dissatisfied: 11
1. Very satisfied: 773
2. Somewhat satisfied: 99
3. Neither satisfied or
dissatisfied: 21
4. Somewhat
dissatisfied: 33
5. Very dissatisfied: 17
A&E, accident and emergency department; HDOC, hospital doctor.
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TABLE 123 Additional variables not included in the COASt knee model, based on the 608- and 1025-record
incomplete data sets
Variables (type)
Data set
Incomplete with 608 records Incomplete with 1025 records
% missing Frequency % missing Frequency
Arthritis variables: previous treatments
Medication steroids (binary) 25.33 Yes, n= 84; no, n = 370 31.22 Yes, n= 128; no, n= 577
Intra-articular steroid injection (binary) 1.81 Yes, n= 142; no, n= 455 11.32 Yes, n= 218; no, n= 691
Intra-articular hyaluronic acid
injection (binary)
4.28 Yes, n= 7; no, n= 575 13.66 Yes, n= 9; no, n= 876
Soft tissue injection (binary) 4.11 Yes, n= 14; no, n = 569 13.76 Yes, n= 23; no, n = 861
Infection treatment (binary) 2.63 Yes, n= 7; no, n= 585 12.49 Yes, n= 12; no, n = 885
Arthritis variables: duration of suffering
Suffered in days 99.84 – 99.71 –
Suffered in weeks 99.51 – 99.61 –
Suffered in months 89.15 Mean 6.82, SD 2.58 90.93 Mean 6.67, SD 2.62
Suffered in years 13.65 Mean 8.45, SD 9.04 22.54 Mean 8.44, SD 8.93
Procedure and operations
Arthroscopy (binary) 2.80 Yes, n= 85; no, n = 506 12.39 Yes, n= 122; no, n= 776
Radiography (binary) 2.30 Yes, n= 516; no, n= 78 12.20 Yes, n= 773; no, n= 127
Examination
‘Get up and go’ test (categorical) 6.09 Grade 1: 56 32.29 Grade 1: 71
Grade 2: 286 Grade 2: 354
Grade 3: 163 Grade 3: 187
Grade 4: 44 Grade 4: 56
Grade 5: 19 Grade 5: 23
Grade 6: 3 Grade 6: 3
‘Get up and go’ test in seconds
(continuous)
23.52 Mean 14.17, SD 6.07 43.42 Mean 14.21, SD 6.35
Handgrip strength: first right hand
try (continuous)
5.76 Mean 28.33, SD 10.72 31.90 Mean 28.08, SD 10.80
Handgrip strength: second right
hand try (continuous)
6.42 Mean 27.61, SD 10.84 32.29 Mean 27.44, SD 10.99
Handgrip strength: third right hand
try (continuous)
6.42 Mean 27.17, SD 10.91 32.29 Mean 27.09, SD 11.07
Handgrip strength: first left hand try
(continuous)
5.59 Mean 26.49, SD 11.06 31.90 Mean 26.16, SD 11.17
Handgrip strength: second left hand
try (continuous)
6.58 Mean 26.31, SD 10.80 32.49 Mean 26.03, SD 10.95
Handgrip strength: third left hand
try (continuous)
6.74 Mean 25.95, SD 10.60 32.68 Mean 25.74, SD 10.75
Knee effusion (binary) 40.46 Yes, n= 101; no, n= 261 57.37 Yes, n= 124; no, n= 313
Knee fixed flexion deformity
(continuous)
48.85 Mean 13.48, SD 64.99 62.63 Mean 11.81, SD 58.71
Charnley ABC (continuous) 50.66 Mean 2.04, SD 0.71 63.51 Mean 2.08, SD 0.72
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TABLE 124 Additional variables not included in the COASt Knee model, using the 608- and 1025-record data sets
Variables (type)
Data set
Incomplete with 608 records Incomplete with 1025 records
% missing Frequency % missing Frequency
Health resources use
Service GP 2.30 Yes, n= 530; no, n = 64 12.20 Yes, n= 806; no, n= 94
Service GP NHS 23.19 Mean 3.71, SD 2.88 31.81 Mean 3.85, SD 3.30
Service HDOC 6.58 Yes, n= 472; no, n = 96 15.42 Yes, n= 723; no, n= 144
Service HDOC NHS 29.93 Mean 2.30, SD 2.56 36.88 Mean 2.27, SD 2.27
Service physiotherapist 8.39 Yes, n= 221; no, n = 336 18.05 Yes, n= 336; no, n= 504
Service physiotherapist NHS 69.74 Mean 3.95, SD 4.43 72.59 Mean 3.76, SD 4.21
Service nurse 11.02 Yes, n= 123; no, n = 418 21.56 Yes, n= 183; no, n= 621
Service nurse NHS 83.55 Mean 3.30, SD 3.78 85.56 Mean 3.23, SD 3.61
Service alternative
practitioner
4.93 Yes, n= 69; no, n= 509 14.05 Yes, n= 99; no, n = 782
Service A&E 4.93 Yes, n= 71; no, n= 507 14.34 Yes, n= 99; no, n = 779
Home care 3.95 Yes, n= 16; no, n= 568 13.66 Yes, n= 18; no, n = 867
Questionnaire scores
Pain detected: seven items
used to form the scores –
questions range from 0 to 5
14.15 Mean 10.50, SD 6.33 24.20 Mean 10.47, SD 6.39
Self-assessed EQ-5D 3.29 Mean 8.86, SD 1.37 7.81 Mean 13.71, SD 1.67
Postoperative EQ-5D 3.29 Mean 6.85, SD 1.90 3.90 Mean 6.91, SD 1.90
Intermittent and constant
OA pain: five items used to
form the scores – questions
range from 0 to 4
4.11 Mean 2.24, SD 4.18 4.00 Mean 2.14, SD 4.06
12-month follow-up
Patient expectation and
outcome
12.67 1. Very satisfied: 398
2. Somewhat satisfied: 64
3. Neither satisfied or
dissatisfied: 20
4. Somewhat dissatisfied: 39
5. Very dissatisfied: 10
12.78 1. Very satisfied: 654
2. Somewhat satisfied: 131
3. Neither satisfied or
dissatisfied: 33
4. Somewhat
dissatisfied: 58
5. Very dissatisfied: 18
A&E, accident and emergency; HDOC, hospital doctor.
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